<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">This document is a summary of the European Public Beurances (EPAR) which is discussed as the Committee on Humanities (CHMP) carried out in order to obtain recommendations concerning the application of the drug.</seg>
<seg id="2">"if you require any further information about your disease or treatment, please read the package passing (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="3">"if you wish further information regarding the basis of the CHMP recommendations, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as 5 mg, 10 mg, 15 mg and 30 mg of tablets, as a 10 mg, 15 mg and 30 mg of melting tablets (tablets that can be absorbed in the mouth) as a solution to insertion (1 mg / ml) and as an injection solution (7.5 mg / ml)."</seg>
<seg id="5">"B. wirres thinking and speaking, hallucinations (hearing or vision of things that are not present), mistrust and insanity; • Bipolar disorder, in which the patients have manic episodes (periods) alternately with periods of normal mood."</seg>
<seg id="6">"Abilify is used to treat medium to severe manic episodes, and for the prevention of manic episodes in patients who used in the past on the drug."</seg>
<seg id="7">The injectsolution will be used for fast control of fueled unrest or behavioural disorders when the orale ingesting of the drug is not possible.</seg>
<seg id="8">"in both conditions, the solution can be used or the melting-coated patients may be used in patients with the swallow of tablets difficulties."</seg>
<seg id="9">"in patients who want to take other medicines, which are just as advertised, should be adapted as the dose of furnishings."</seg>
<seg id="10">"this affects the signal transmission between brain cells by" neurotransmitters "," i.e. chemical substances that enable communication of nerve cells. "</seg>
<seg id="11">Aripipraatom also works primarily as "participatory Agonist" for the receptors for the neurotransmitters Dopamine and 5-Hydroxytryptamin (also Serotonin).</seg>
<seg id="12">"this means that Aripiprazas 5-Hydroxytryptamin and Dopamine, but in a slight extent than the neurotransmitters used to activate the receptors."</seg>
<seg id="13">"da Dopamine and 5-Hydroxytryptamin in schizophrenia and bipolarer disturbance play a role to normalize the activity of the brain, reducing psychotic or manic symptoms and their react is prevented."</seg>
<seg id="14">"the effectiveness of furnishings, to prevent the re-operation of symptoms, was examined in three studies above up to one year."</seg>
<seg id="15">"the effectiveness of the injection solution was compared in two studies at 805 patients with schizophrenia or similar diseases, which suffered at meatched unrest, over a period of two hours with a placebo."</seg>
<seg id="16">"in another study, Abilify over twelve weeks at 347 patients with Haloperidol, in a different study the effectiveness of Abilify and placebo, reacting to 160 patients, where the manic symptoms have already been stabilized with Abilify."</seg>
<seg id="17">"the effectiveness of Abilify injection solution was compared to a study of 301 patients with bipolarer disorder, which suffered an uninterrupted unrest, compared to Lorazepam (another antipsychotikum) and placebo over a period of two hours."</seg>
<seg id="18">"in all studies, the changes in symptoms of patients were examined using a standard scale for bipolar disorder or the number of patients who were addressed to the treatment."</seg>
<seg id="19">"the company also led studies to investigate how the body carries the melting tablets, and the solution to take resorously."</seg>
<seg id="20">"in the two studies with the injection solution shown patients, the Abilify in cans of 5,25 mg, 19,mg or 15 mg received, a significant stronger decrease in symptoms were given unrest than the patients who received a placebo."</seg>
<seg id="21">With the application for the treatment of bipolar disorder decreased asbilify in four of the five Kurzzeiting studies manic symptoms more effective than placebo.</seg>
<seg id="22">"Abilify by more than 74 weeks, more effective than placebo the react manic episodes of previously treated patients and if it was given in addition to an existing treatment."</seg>
<seg id="23">Abilify injections in 10- or 15-mg doses reduced also more effective than placebo the symptoms gested unrest and were similarly effective as Lorazepam.</seg>
<seg id="24">"the most common side effects of furniture fy (observed at 1-10 of 100 patients) are extrapyramidale interference (unfolding), headache (abstention), fatigue and exhaustion, resting, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomoeness, insomo</seg>
<seg id="25">The Committee on Humancision (CHMP) is to conclude that the benefits of furniture in the treatment of schizophrenia and the prevention of a new manic episode in patients who had predominantly manic episodes and in those of the manic episodes on the treatment with Aripianonymously spoke to the risks.</seg>
<seg id="26">"in addition, the Committee came to the result that the benefits of the injectarian solution in patients with schizophrenia or in patients with manic episodes, if a orale therapy is not suitable, compared to the risks."</seg>
<seg id="27">June 2004 the European Commission to meet Otsuka Pharmaceutical Europe Ltd. a licence for the Independence of Abilify in the entire European Union.</seg>
<seg id="28">ABILIFY is shown for the treatment of moderate to severe manic episodes of Bipolar disorder and for the prevention of a new manic episode in patients who had predominantly manic episodes and their manic episodes on the treatment with Aripianonymanspoken (see section 5.1).</seg>
<seg id="29">The recommended initial dose for ABILIFY is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily independently of the meals.</seg>
<seg id="30">Increased efficiency at doses over a daily dose of 15 mg was not proven although individual patients can benefit from a higher dose.</seg>
<seg id="31">The recommended initial dose for ABILIFY is 15 mg once daily, regardless of meals as Monotherapy or Combinations therapy (see section 5.1). "</seg>
<seg id="32">The effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar-I- disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">"with regard to the greater sensitivity of this patient group, a lower initiator should be considered as clinical factors to justify this (see section 4.4)."</seg>
<seg id="34">If the CYP3A4-Induction is set out of the combination therapy should be reduced to the recommended dose (see Section 4.5).</seg>
<seg id="35">The appearance of supreme behavior belongs to psychotic diseases and affective disorders and was reported in some cases after the beginning or after a change of anti-psychotic therapy.</seg>
<seg id="36">Results of an epidemiological study showed that it was no elevated to patients with bipolarer disturbance with Aripidalene in comparison to other antipsychotic medicines.</seg>
<seg id="37">"Aripianium should be used with caution in patients with well-known kardiovascular diseases (myokardincolored or condemic reduction, floppy disease, conditions, which are used for Hypotony (dehydration drugs) or hypertoner (including akzelerated medicines) or hypertoner (including akzelerated and maligne form)."</seg>
<seg id="38">"3 Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports about during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="39">"if at one with ABILIFY treated patients signs and symptoms of a smoothdyskinesthesia, should be considered to reduce the dose or to break the treatment."</seg>
<seg id="40">"when a patient sign and symptoms developed to interpret or unclear high fever without an additional clinical manifestation of mns, all antipsychotic medicines, including ABILIFY."</seg>
<seg id="41">"therefore, Aripianium should be in case of patients with Krampfanes in the Anamnese or in the conditions that have been applied with caution."</seg>
<seg id="42">"56 - 99 years old) with arias in patients with psychosis who have been associated with Alzheimer's disease, patients who have been treated with Aripigenberg, a elevated point in comparison to placebo."</seg>
<seg id="43">"however, there was in one of these studies, a study with fixed dosage, a significant relationship between the dosage and the advocate for unwanted vascular events with Ariium-treated patients."</seg>
<seg id="44">"hyperglycemic, in some cases extremely and associated with Ketoaziar or hyperosmolarem Koma or death, was reported in patients who have been treated with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="45">There is no precise risk assessment for hyperglycemic-related events with ABILIFY and other atypical antipsychotic drugs treated patients who allow direct comparisons.</seg>
<seg id="46">"polydipsy, polyurie, polyphagie and weakness) are observed and patients with diabetes Mellitus or with risk factors for diabetes Mellitus should be monitored regularly in terms of deterioration of glucosity values."</seg>
<seg id="47">"a weight increases in general in schizophrenia patients and patients with bipolarer Manor, due to Komorbidding, the use of antipsychotic medicines that is known as a side effect, or an unhealthy lifestyle."</seg>
<seg id="48">"due to the primary effects of Aripigeness to the central nervous system, caution if Aripivbenzene in combination with alcohol or other centrally effective medicines (see Section 4.8)."</seg>
<seg id="49">"the H2-Antagonist is Famotidine, a magensäure blocker, reduces the Resorpation rate of Aripipraism, with this effect however as clinically not relevant."</seg>
<seg id="50">In a clinical study with healthy probankrolling increased a highly effective CYP2D6-Inhibitor (Chinidin) the AUC of Aripiprazum 107%, while the Cmax remained unchanged. "</seg>
<seg id="51">"it is expected that other highly effective increhibitors of CYP2D6, like fluoxetine and paroxetine, have similar effects and therefore should be made similar Dosisreductions."</seg>
<seg id="52">"with CYP2D6 'bad' (=" poor ") metabolism of CYP3A4 in higher plasma-centrations, compared to CYP2D6 extensiven metabolic."</seg>
<seg id="53">If you consider the joint gift from Ketoconazol or other highly effective CYP3A4-Inhibitors with ABILIFY should be considered the potential benefits for the patient.</seg>
<seg id="54">"other highly effective inhibitors of CYP3A4, such as Itraconazol and HIV Proteaseinhibitors, should probably have similar effects and therefore should be made similar Dosisreductions."</seg>
<seg id="55">"after placing the CYP2D6- or 3A4-Inhibitors, the dosage of ABILIFY should be raised to the Dosishheight before the beginning of the accompanying therapy."</seg>
<seg id="56">Diltiazem or Escitalopram) or CYP2D6 together with ABILIFY can be reached with an excessive increase of Aripiprazol- concentrations.</seg>
<seg id="57">In clinical studies doses of 10-30 mg arias per day showed no significant effect on the metabolism of CYP2D6 (Dextromethorphan / 3-method xymorphinan-ratio), 2C19 (omeprabenzene) and 3A4 (Dextromethorphan). "</seg>
<seg id="58">"the Patients should be advised to notify their doctor, if they are pregnant or to plan a pregnancy during the treatment with Aripianium."</seg>
<seg id="59">"due to the insufficient data base for the safety when people and due to the reproduction studies in the animal studies of animal studies, this medicine may not be applied in pregnancy, unless the potential benefits are justified clearly the potential risk for the fetus."</seg>
<seg id="60">"however, with other antipsychotic drugs should be warned against patients before, dangerous machines, including power vehicles, to use, until they are sure they have no negative impact."</seg>
<seg id="61">The following side effects appear more frequently (≥ 1 / 100) on as under placebo or were classified as possible medical-relevant effects (*).</seg>
<seg id="62">"the frequency of the effects listed below is defined according to the following criteria: often (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"schizophrenia - In a controlled long-term study over 52 weeks entered into patients who have been treated with Aripianonism, Akathisie, Akathisie, Dystony and Dyskinesia, compared to patients who have been treated with Haloperidol (57,3%)."</seg>
<seg id="64">In a placebo-controlled long-term study of more than 26 weeks the incidence of EPS 19% in patients under Aripigenberg treatment and 13.1% in patients under placebo.</seg>
<seg id="65">"in another controlled long-term study, over 26 weeks was the incidence of EPS 14.8% in patients who have been treated with Aripids, and 15.1% in patients under olanzapin therapy."</seg>
<seg id="66">Manic Episodes at Bipolar-I-disorder - In a controlled study over 12 weeks was the incidence of EPS 23,5% in patients under Aripig-ol- treatment and 53.3% in patients under Haloperidol treatment.</seg>
<seg id="67">"in a different study over 12 weeks, the incidence of EPS 26,6% in patients were under Aripianbenzene treatment and 17.6% for those under lithium treatment."</seg>
<seg id="68">In the long-term phase of over 26 weeks when a placebo-controlled trial was the incidence of EPS 18.2% for patients under Aripiprazol- treatment and 15.7% for patients treated patients.</seg>
<seg id="69">A comparison between the patient-groups under Aripigenberg and placebo where potentially clinically controlled changes of routinely controlled laboratory parameters recorded and no medically significant differences.</seg>
<seg id="70">"enhancements of the CPK (Kreatin-phosphokinase), in general temporarily and asymptomatic, have been observed at 3.5% of the patients treated with Aripiping-treated patients, compared to 2.0% of the patients treated with placebo."</seg>
<seg id="71">"to the side effects that can occur in connection with a anti-psychotic therapy, and over its appearance was also reported in the treatment with Aripigenic syndrome, Spätdyskinesia and scratches, hyperglycemic and diabetes Mellitus (see section 4.4)."</seg>
<seg id="72">In clinical trials and since the launch were unintentional or intentional attacks by Aripids alone in adult patients with estimated doses of up to 1260 mg and without death.</seg>
<seg id="73">"although there are no information about the effectiveness of a tick-dialysis at the treatment of an overdose with Aripianium; however, it is unlikely that hemoralysis in the treatment of an overdose of benefits is, since Aripiprabenzene has a high plasmapcase."</seg>
<seg id="74">It is assumed that the effectiveness of Aripianium in schizophrenia and Bipolar-I-disorder on the combination of a partial agonist on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">Aripivbenzene showed in vitro a high monkey to Dopamine D2- and DHT2a receptors and for Serotonin 5HT2c- and 5HT2c- and 5HT2c- and 5HT7- for alpha-1-adrenagen and to the Histamin-H1receptors.</seg>
<seg id="76">At gift of Aripids in doses of 0.5 to 30 mg once daily over 2 weeks to healthy probanden showed a dosages of 11C-Racloprid, a D2 / D3 receptors-Liganden, on Nucleus caudatus and on the Putname. "</seg>
<seg id="77">In three placebo-controlled short-time studies (4 to 6 weeks) at 1.228 schizophrenia patients with positive or negative symptoms showed Aripiping compared to placebo a statistically significant stronger improvement of the psychotic symptoms.</seg>
<seg id="78">In a Haloperidol-controlled study was 52 of the percentage of the Responsible patients who talk to the study of study; in both groups (Aripipraz77% and Haloperidol 73%).</seg>
<seg id="79">"current values from brass, which were defined as secondary studies, including PANSS and the Montgomery-Asberg- Depression rates, showed a significant stronger improvement than in Haloperidol."</seg>
<seg id="80">In a placebo-controlled study about 26 weeks in stabilized patients with chronic schizophrenia showed a significant greater reduction in the return rate that was at 34% in the Aripiping-group and at 57% below placebo.</seg>
<seg id="81">"in a high-gloss-controlled, multinational double blind study at schizophrenia on 26 weeks, the 314 patients embraced by at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of ca."</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of the Bipolar-I-disorder Aripiprazan opposite placebo excessive effectiveness in reducing manic symptoms over 3 weeks.</seg>
<seg id="83">In a placebo-controlled monotherapy trial over 3 weeks with fixed dosage with patients with a manic or mixed episode of the Bipolar-I-disorder in Arielbenzene compared to placebo no superior efficacy.</seg>
<seg id="84">"in two placeboarding and active monotherapy studies over 12 weeks in patients with a manic or mixed episode of a Bipolar-I disturbance, with or without psychotic membranes, Aripivein showed Aripivbenzene in week 3 and an integral effect, which was comparable with the lithium or Haloperidol in week 12."</seg>
<seg id="85">Aripigenes also pointed 12 a comparable stake in patients with symptomatic remission of the Manie on like lithium or Haloperidol.</seg>
<seg id="86">"in a placebo-controlled study about 6 weeks with patients with a manic or mixed episode, with or without psychotic characteristics, which are partly over 2 weeks not on lithium or Valproat-Monotherapy in therapeutic Serumpers, with suspicious effectiveness in reducing managerial symptoms compared to Monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks in manic patients, who had attained a remission to placebo with regard to the prevention of a bipolar backcase, mainly in prevention of an accident in the Manie."</seg>
<seg id="88">Based on in vitro-studies are the enzymes CYP3A4 and CYP2D6 for the Dehydrifting and hydroxying of Aripigenberg responsible for the N-Dealkyelling is catalyzed by CYP3A4 catalyzed.</seg>
<seg id="89">The mean elimination of resistance is approximately 75 hours for Aripivbenzene in extensiven metabolic by CYP2D6 and at approximate 146 hours at 'bad' (= "poor") metabolic over CYP2D6.</seg>
<seg id="90">"there are no differences in pharmaceuinetics between male and female healthy proportions, as well as shown by a pharmacocinetic examination of schizophrenia patients showed no gender-dependent effects."</seg>
<seg id="91">A pop-specific analysis for Pharmacoinetics have no indication of clinically significant differences with regard to ethnic affiliation or the impact of the bow to the pharmaceuinetics of Aripigenberg.</seg>
<seg id="92">The pharmaceuinetic properties of Aripipraylbenzene and Dehximo-Aripids were similar to patients with severe kidney efficiency compared to young healthy volunteers.</seg>
<seg id="93">"a single dose study in Probanden with different Lebanese Leberpants (Child-Pugh Class A, B and C) showed no significant effect with regard to the impairment of the liver tenants of class C, which is not sufficient to draw conclusions on their metabolic capacity."</seg>
<seg id="94">"based on conventional studies on safety issues, toxicity, toxicity, toxicity, genetoxicity, and to canogens potential, the preclinical data made no particular hazards for man."</seg>
<seg id="95">Toxicologically significant effects have been observed only in dosages or Expositions that significantly exceeded the maximum dosage or exposure to human beings that they have limited only limited or no meaning for clinical use.</seg>
<seg id="96">The effects covers a dosages-dependent-levelling-toxicity (Lipofuscin products) for rats and / or parenchantage (AUC) at the recommended Maximaldeller (AUC) at the recommended dosage / carcinoma of the mid-sized steady State Exposition (AUC) at the recommended maxim State Exposition (AUC) at the recommended Maximaldosis by humans).</seg>
<seg id="97">"in addition, a cholelithiasis was established as a result of suspicking of Sulphylbenzene in Hydroxy- Metabolism in the Galle from monkeys to repeated clinical dose (AUC) in recommended clinical dose or 16- up to 81multiple of the recommended Maximaldosis by humans based on mg / m2)."</seg>
<seg id="98">"however, those in human genes are found at the highest recommended daily dose of 30 mg concentrations of Hydroxy- Apids no more than 6% of concentrations that were observed in the study over 39 weeks in the genall of monkeys, and lie far below the limit values (6%) of the in vitro-solubility."</seg>
<seg id="99">"in rabbits, these effects were observed after dosages, which resulted in Expositions of the 3- and 11triple the middle steady state AUC at the recommended clinical Maximaldosis."</seg>
<seg id="100">"perforated views for the delivery of individual labels from aluminium in folding boxes with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="102">It is assumed that the effectiveness of Aripianium in schizophrenia and Bipolar-I-disorder on the combination of a partial agonist on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">22 In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks in maneurial phase over 74 weeks before Randomisation achieved a remission compared to placebo considering placebo with regard to the prevention of a bipolar backcase, predominantly in prevention of a reversal in the Manie. "</seg>
<seg id="104">"27 Spätdyskinesia: in clinical trials, one year or less daued, there were occasional reports about during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="105">It is assumed that the effectiveness of Aripianium in schizophrenia and Bipolar-I-disorder on the combination of a partial agonist on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">"34 In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks in manic patients, who had attained a remission to placebo with regard to the prevention of a bipolar backcase, mainly in prevention of an accident in the Manie."</seg>
<seg id="107">"39 Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="108">It is assumed that the effectiveness of Aripianium in schizophrenia and Bipolar-I-disorder on the combination of a partial agonist on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">"46 In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks in manic patients, who had attained a remission to placebo with regard to the prevention of a bipolar backcase, mainly in prevention of an accident in the Manie."</seg>
<seg id="110">The recommended initial dose for Aripigenberg is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily independently of the meals.</seg>
<seg id="111">Patients who have difficulties when swallow by ABILIFY tablets you can take the melting coated alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">The appearance of supreme behavior belongs to psychotic diseases and affective disorders was reported in some cases after the beginning or after the change of a anti-psychotic therapy, also in treatment with Aripianium (see section 4.8). "</seg>
<seg id="113">"Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="114">"clinical manifestations of a mns are high fever, reforming consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and heart rhythmia)."</seg>
<seg id="115">"a weight increases in general in schizophrenia patients and patients with bipolarer Manor, due to Komorbidding, the use of antipsychotic medicines that can be observed as a side-effect, or an unhealthy lifestyle."</seg>
<seg id="116">"the patient should be advised to notify their doctor, if they are pregnant or pregnant during the treatment with Aripipraene."</seg>
<seg id="117">The following side effects appear more frequently (≥ 1 / 100) on as placebo or were classified as possible medical effects of drug using (*).</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of the Bipolar-I-disorder Aripiprazan opposite placebo excessive effectiveness in reducing manic symptoms over 3 weeks.</seg>
<seg id="119">"58 In a placebo-controlled study about 6 weeks with patients with a manic or mixed episode, with or without psychotic characteristics, which are partly over 2 weeks not on lithium or Valproat-Monotherapy in therapeutic Serumpers, with suspicious effectiveness in reducing managri symptoms compared to Monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks in manic patients, who had attained a remission to placebo with regard to the prevention of a bipolar backcase, mainly in prevention of an accident in the Manie."</seg>
<seg id="121">"in rabbits, these effects have been according to dosages, which resulted in Expositions of the 3- and 11triple the middle steady state AUC at the recommended clinical clinical clinical trial."</seg>
<seg id="122">Patients who have difficulties when swallow by ABILIFY tablets you can take the melting coated alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">"Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="124">71 In a placebo-controlled study about 6 weeks with patients with a manic or mixed episode of a Bipolar Serotherapy with or without psychotic characteristics which are partly over 2 weeks not on lithium or Valproat-Monotherapy in therapeutic Serotherapy with suspicious symptoms compared to Monotherapy with lithium or Valproat.</seg>
<seg id="125">Patients who have difficulties when swallow by ABILIFY tablets you can take the melting coated alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">"Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="127">"84 In a placebo-controlled study about 6 weeks with patients with a manic or mixed episode, with or without psychotic characteristics, which are partly over 2 weeks not on lithium or Valproat-Monotherapy in therapeutic Serumpers, with suspicious effectiveness in reducing managerial symptoms compared to Monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg Fructose each ml 400 mg methyl per ml 1.8 mg methyl-4-hydroxybenzoat (E218) per ml 0,2 mg propyl-4-hydroxybenzoat (E2G) per ml.</seg>
<seg id="129">The recommended initial dose for ABILIFY is 15 mg once daily, regardless of meals as Monotherapy or Combinations therapy (see section 5.1). "</seg>
<seg id="130">"to the prevention of the reunification of manic episodes, in patients who have already received Aripianbenzene, should continue the therapy with the same dose."</seg>
<seg id="131">"Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="132">"hyperglycemic, in some cases extremely and associated with Ketoaziar or hyperosmolarem Koma or death, was reported in patients who have been treated with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="133">There is no precise risk assessment for hyperglycemic-related events with ABILIFY and other atypical antipsychotic drugs treated patients who allow direct comparisons.</seg>
<seg id="134">92 In a clinical study with healthy probances increased a highly effective CYP2D6-Inhibitor (Chinidin) the AUC of Aripiprazum 107%, while the Cmax remained unchanged. "</seg>
<seg id="135">Diltiazem or Escitalopram) or CYP2D6 together with ABILIFY can be reached with an excessive increase of Aripiprazol- concentrations.</seg>
<seg id="136">Manic Episodes at Bipolar-I-disorder - In a controlled study over 12 weeks was the incidence of EPS 23,5% in patients under Aripiprazol-</seg>
<seg id="137">It is assumed that the effectiveness of Aripianium in schizophrenia and Bipolar-I-disorder on the combination of a partial agonist on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"in a high-gloss-controlled, multinational double blind study at schizophrenia on 26 weeks, the 314 patients embraced by at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of ca."</seg>
<seg id="139">97 In a placebo-controlled monotherapy trial over 3 weeks with fixed dosage with patients with a manic or mixed episode of the Bipolar-I-disorder in Arielbenzene compared to placebo no superior efficacy.</seg>
<seg id="140">"in a relative Bible study, in which the pharmacoinetics of 30 mg arias in tablet form was compared to healthy probankers, the relation between the geometric Cmax midvalue of the solution and the value of tablets at 122% (N = 30)."</seg>
<seg id="141">99 outside was a cholelithiasis as a result of suspicking of Sulphylbenzene in the Galle from monkeys to repeatedoraler gifts (AUC) in recommended clinical dose or 16- up to 81multiple of the recommended Maximaldosis by humans based on mg / m2).</seg>
<seg id="142">"in rabbits, these effects were observed after dosages, which resulted in Expositions of the 3- and 11triple the middle steady state AUC at the recommended clinical Maximaldosis."</seg>
<seg id="143">ABILIFY injection solution is applied to rapid control of Agificity and halation disorders in patients with schizophrenia or in patients with manic episodes of the Bipolar-I disorder if a orale therapy is not appropriate.</seg>
<seg id="144">"as soon as it is clinically attached, the treatment should be stopped using Aripianium injection solution and will be started using the oral application of Aripianium."</seg>
<seg id="145">To minimize the resorption and minimise the variability to minimize an injection in the M. Deltoideus or deep into the gluteus-Maximus-Muscle under parasious regions recommended.</seg>
<seg id="146">A lower dose of 5,25 mg (0,7 ml) can be used depending on the individual clinical status taking into account the prescribed or acoustic therapy provided (see Section 4.5).</seg>
<seg id="147">"if a further oral treatment with Aripianonymously is, see the summary of the features of the drug by using ABILIFY tablets, ABILIFY Schmelzenge or ABILIFY solution."</seg>
<seg id="148">There are no studies on the effectiveness of Aripigenbenzene injection solution in patients with Agiedness and behavioural disorders that have been caused differently than by schizophrenia and manic episodes of the Bipolar-I disorder.</seg>
<seg id="149">"in case a parenteric therapy with Benzodiazepins in addition to the Azodiazeptic solution in addition to Aripivbenzene injection solution should be observed as necessary, should be observed in terms of extreme conditions or blood pressure. (see Section 4.5)."</seg>
<seg id="150">Studies on the safety and effectiveness of Aripigenbenzene injection solution are not available for patients with alcohol or drug use (by prescribed or illegal medicines).</seg>
<seg id="151">"Aripianium should be used with caution in patients with well-known kardiovascular diseases (myokardincolored or condemic reduction, floppy disease, conditions, which are used for Hypotony (dehydration drugs) or hypertoner (including akzelerated medicines) or hypertoner (including akzelerated and maligne form)."</seg>
<seg id="152">"Spätdyskinesia: in clinical trials, which were one year or less daued, there were occasional reports on during the treatment with Aripiprazforced Dyskinesia."</seg>
<seg id="153">"clinical manifestations of a mns are high fever, muscle mass, alternating consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and heart rhythmia)."</seg>
<seg id="154">"polydipsy, polyurie, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucosity values."</seg>
<seg id="155">"a weight increases in general in schizophrenia patients and patients with bipolarer Manor, due to Komorbidding, the use of antipsychotic medicines that is known as a side effect, or an unhealthy lifestyle."</seg>
<seg id="156">"nevertheless, the intensity of the Sedation was compared to the sole gift of Aripids in a study, in a study, in the healthy probanden Aripigenitaire (15 mg dose) as a maladdition intramuscular (15 mg dose) intramuscular (2 mg dose) intramuscular."</seg>
<seg id="157">"105 The H2-Antagonist is Famotidine, a magensäure blocker, reduces the Resorpation rate of Aripipraism, with this effect however as clinically not relevant."</seg>
<seg id="158">"with CYP2D6 'bad' (=" poor ") Metabolisierern can result in comparison to CYP2D6 extensiven metabolic from CYP3A4 in higher plasma-centric presses."</seg>
<seg id="159">"other highly effective inhibitors of CYP3A4, such as Itraconazol and HIV- Proteaseinhibitors, should probably have similar effects and therefore should be made similar Dosisreductions."</seg>
<seg id="160">"after placing the CYP2D6- or 3A4-Inhibitors, the dosage of ABILIFY should be raised to the Dosishheight before the beginning of the accompanying therapy."</seg>
<seg id="161">"106 Lorazepam (2 mg dose) intramuscular was given, the intensity of the Sedation was compared to the allest of some gift of Aripianium."</seg>
<seg id="162">The following side effects occurred in clinical trials with Aripigenbenzene injection solution more common (≥ 1 / 100) than under placebo or were classified as possible medical-relevant effects (*) (see Section 5.1):</seg>
<seg id="163">"the frequency of the effects listed below is defined according to the following criteria: often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects appear more frequently on (≥ 1 / 100) than under placebo or were classified in clinical trials with oral carriages as possible medical effects (*) classified as possible medical effects (*):</seg>
<seg id="165">In a placebo-controlled long-term study over 26 weeks amounted to EPS 19% in patients under Aripiprazol- treatment and 13.1% in patients under placebo.</seg>
<seg id="166">In a different study about 12 weeks the incidence of EPS 26.6% in patients under Aripiprazol- treatment and 17.6% for those under lithium treatment.</seg>
<seg id="167">In the long-term phase of over 26 weeks when a placebo-controlled trial was the incidence of EPS 18.2% for patients under Aripigenberg treatment and 15.7% for patients treated with placebo.</seg>
<seg id="168">A comparison between the patient-groups under Aripigenberg and placebo where potentially clinically controlled changes of routinely controlled laboratory parameters recorded and no medically significant differences.</seg>
<seg id="169">"enhancements of CPK (Kreatinphosphokinase), in general temporarily and asymptomatic, have been observed at 3.5% of the patients treated with Aripiping-treated patients, compared to 2.0% of the patients treated with placebo."</seg>
<seg id="170">"to the side effects that can occur in connection with a anti-psychotic therapy, and over its appearance also has been reported in the treatment with Aripigenic syndrome, Spätdyskinesia and scratches, hyperglycemic and diabetes mellitus (see section 4.4)."</seg>
<seg id="171">110 and behavioural disorders was the Aripiallbenzene injection solution with statistically significant greater improvements of Agificity / Verhaltends compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">In a placebo-controlled short-time study (24 h) with 291 patients with bipolarer disorder as well as Agitive and behavioural disorders associated with a statistically significant stronger improvement in comparison to placebo and similar to the Lorazepam- reference arm.</seg>
<seg id="173">The observed average improvement of the output value on the PANSS Excitement Component Score with the primary 2-hour endpoint was 5,8 for placebo, 9,6 for Lorazepam and 8,7 for Aripishades. "</seg>
<seg id="174">"in analyses of subgroups in patients with mixed episodes or patients suffering from heavy duty, a similar effectiveness has been observed due to the total population but a statistical signature could be established due to a reduced patient number."</seg>
<seg id="175">In three placebo-controlled short-time studies (4 to 6 weeks) at 1.228 schizophrenia patients with positive or negative symptoms showed arias (oral) compared to placebo a statistically significant improvement of the psychotic symptoms.</seg>
<seg id="176">In a Haloperidol-controlled study was 52 of the percentage of the Responsible patients who talk to the study of study; in both groups (Aripipraz77% (oral) and Haloperidol 73%).</seg>
<seg id="177">"current values from brass, which were defined as secondary studies, including PANSS and the Montgomery-Asberg-Depressions rates, showed a significant stronger improvement than in Haloperidol."</seg>
<seg id="178">In a placebo-controlled study about 26 weeks in stabilized patients with chronic schizophrenia showed a significant reduction in return rate that was at 34% in Aripiprazol- (oral) -group and at 57% below placebo.</seg>
<seg id="179">"in a high-gloss-controlled, multinational double blind study at schizophrenia on 26 weeks, the 314 patients embraced by at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of ca."</seg>
<seg id="180">111 In a placebo-controlled study about 6 weeks with patients with a manic or mixed episode of a Bipolar Serotherapy with or without psychotic characteristics which are partly over 2 weeks not on lithium or Valproat-Monotherapy in therapeutic Serotherapy with suspicious symptoms compared to Monotherapy with lithium or Valproat.</seg>
<seg id="181">"in a placebo-controlled trial over 26 weeks followed by a 74-week study extension in manic patients, who had attained a remission to placebo with regard to the prevention of a bipolar backcase, mainly in prevention of an accident in the Manie."</seg>
<seg id="182">The Aripiping AUC is in the first 2 hours after intramuscular injection 90% greater the AUC according to gift of the same dose as tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">In 2 studies with healthy probances the average time until reaching the maximum plasma pipulation at 1 to 3 hours of application.</seg>
<seg id="184">The gift of Aripianium injectarian solution was tolerated by rats and monkeys in no direct toxicity of a target (AUC), the 15- and 5 times over the maximum human therapeutic exposure of 30 mintramuscular systems. "</seg>
<seg id="185">"in studies on the production of intraverse application according to intravenous application, no security concerns according to maternal exposure, the 15- (rats) and 29 times (rabbit) over the maximum human therapeutic exposure of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripianium (oral), safety digestology, toxicity, toxicity, genetoxicity, and to canogens potential, the preclinical data made no particular hazards for man."</seg>
<seg id="187">Toxicologically significant effects have been observed only in dosages or Expositions that significantly exceeded the maximum dosage or exposure to human beings; thus they have limited limited or no meaning for clinical use.</seg>
<seg id="188">The effects covers a dosages-dependent-levelling-toxicity (Lipofuscin products) for rats and / or parenchymology (AUC) at the recommended maxim of 60 mg / kg / day (equivalent to the maximum number of medium-state exposure (AUC) at the recommended maximum-state exposure (AUC) at the recommended maxim (AUC) at the recommended Maximaldosis by humans).</seg>
<seg id="189">"in addition, a cholelithiasis was established as a result of suspicking of Sulphylbenzene in Hydroxy- Metabolism in the Galle from monkeys to repeatedoraler gifts (AUC) during the recommended clinical dose or 16- to 81-ply the recommended Maximaldosis by humans based on mg / m2)."</seg>
<seg id="190">"in rabbits, these effects were conducted according to dosages, which resulted in Expositions of the 3- and 11-triple of the mid-state-state AUC at the recommended clinical Maximaldosis."</seg>
<seg id="191">"Pharmacovigilance system The regulatory holder must ensure that before and during the product is marketed as the Pharmacovigilance system, as it is described in the version 1.0 of Module 1.8.1."</seg>
<seg id="192">"according to the" CHMP guideline for Medicinal products for human use "," the updated risk management plan must be submitted simultaneously with the next Periodic Safety Update Report (PSUR). "</seg>
<seg id="193">"furthermore, a current risk management plan must be submitted if new information is known to influence the current security data, the Pharmacovigilance plan or the measures to risk minimizing risk assessment or measures aimed at risk minimization."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablets EU / 1 / 04 / 276 / 004 56 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 x 1 tablets EU / 1 / 04 / 276 / 007 28 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 019 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the listed side effects you can considerably impairs or you notice side effects that are not indicated in this use of information, please inform your doctor or pharmacist."</seg>
<seg id="200">"it is used for the treatment of adults who suffer from a disease, which is characterized by symptoms like hearing, seeing or feeling of things that are not present, mistrust, wahning language, wirres behavior and despised mood."</seg>
<seg id="201">"ABILIFY is used in adults for treatment of a condition with excessive feeling, the feeling of excessive energy to have much less sleep than usual, very fast speech with quick changing ideas and sometimes strong stimulating."</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugar diseased) in the family beginner suffer inarbitrary, irregular muscle movements, especially in the face of heart or vessel disease, or cases of a heart or cardiovascular disease (transitoric attack / TIA), abnormal blood pressure."</seg>
<seg id="203">"if you suffer as an older patient (loss of memory or other intellectual skills), you should notify me or a pile of your doctor if you ever had a stroke or a temporary manoeuvre of the brain."</seg>
<seg id="204">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="205">"children and young people ABILIFY is not applicable to children and juveniles, as it was not examined by patients under 18 years of age."</seg>
<seg id="206">"at intake of ABILIFY with other medicines, Please inform your doctor or pharmacist if you use other medicines / apply or used especially if it is not prescription drugs."</seg>
<seg id="207">Medicines for the treatment of heart rhythmia antidepressants or herbal medicines used to treat depression and anxiety are used medicines to treat HIV infection antionvulva that are used to treat epilepsy</seg>
<seg id="208">"pregnancy and lactation, you should not take ABILIFY if you are pregnant, unless you have discussed this with your doctor."</seg>
<seg id="209">"transport and operation of machines you should not drive a car and do not operate tools or machines, until you know how ABILIFY with you."</seg>
<seg id="210">Please take this medicine only after consultation with your doctor if you are known that you suffer from a intolerance toward certain states.</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your physician before."</seg>
<seg id="213">If you have taken a larger amount of ABILIFY when you should notice that you have more ABILIFY tablets have taken care of your doctor (or if someone has taken differently some of your ABILIFY tablets), please contact your doctor immediately. "</seg>
<seg id="214">"if you have forgotten the intake of ABILIFY if you have forgotten a dose, take the forgotten dose as soon as you think, do not take a day the double dose."</seg>
<seg id="215">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable movements, headache, backless, backleness, sleeping problems, relaxation problems, wreaks, crying, citage, and blurred sight."</seg>
<seg id="216">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel very windy, especially when they arise from a underlying or sitting position, or they can determine a accelerated powder."</seg>
<seg id="217">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="218">Like ABILIFY looks and content of the pack ABILIFY 5 mg tablets are rectangular and blue with embossing of A-007 and 5 on one page.</seg>
<seg id="219">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="220">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your physician before."</seg>
<seg id="221">"like ABILIFY looks and content of the pack ABILIFY 10 mg tablets are rectangular and rosafarches, with embossing of A-008 and 10 on one page."</seg>
<seg id="222">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="223">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your physician before."</seg>
<seg id="224">"like ABILIFY looks and content of the pack ABILIFY 15 mg tablets are round and yellow, with embossing from A-009 and 15 on one page."</seg>
<seg id="225">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="226">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your physician before."</seg>
<seg id="227">"like ABILIFY looks and content of the pack ABILIFY 30 mg tablets are round and rosafarben, with embossing of A-011 and 30 on one page."</seg>
<seg id="228">"171 If you suffer as an older patient (loss of memory or other intellectual skills), you should notify me or a pile of your doctor if you ever had a stroke or a temporary manoeuvre of the brain."</seg>
<seg id="229">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="230">Important information on certain other parts of ABILIFY patients who are not allowed to take phenylalanine should be aware that ABILIFY Schmelzenge Aspartame as a source for phenylalanine.</seg>
<seg id="231">"immediately after opening the blister packs the tablet with dry hands, and place the melting tablets to the whole on the tongue."</seg>
<seg id="232">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your physician before."</seg>
<seg id="233">If you have taken a larger amount of ABILIFY when you should notice that you've taken more ABILIFY Schmelzenge (or if someone has taken differently some of your ABILIFY Schmelzenge), please contact your doctor immediately. "</seg>
<seg id="234">"calciumtrimetasilicate, croscaroma-sodium, silicone Cellulose, aspartame, aspartame, aspartame, aspartame, Aesulfam, aspartame, vinegame, iron acid, iron (III) - oxides (E172)."</seg>
<seg id="235">"like ABILIFY looks and content of the pack The ABILIFY 10 mg melting coated tablets are round and rosafarches, with embossing" A "on one side and" "10" on the other. "</seg>
<seg id="236">"177 If you suffer as a peer patient (loss of memory or other intellectual skills), you should notify me or a pile of your doctor if you ever had a stroke or a temporary manoeuvre of the brain."</seg>
<seg id="237">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="238">"calciumtrimetasilicate, croscaroma-sodium, silicone Cellulose, aspartame, aspartame, aspartame, aspartame, acesulum, iron (III) - hydroxid-oxid x H2O (E172)."</seg>
<seg id="239">"like ABILIFY looks and content of the pack The ABILIFY 15 mg melting coated tablets are round and yellow, with embossing" A "on one side and" 15 "on the other."</seg>
<seg id="240">"183 If you suffer as a peer patient (loss of memory or other intellectual skills), you should notify me or a pile of your doctor if you ever had a stroke or a temporary manoeuvre of the brain."</seg>
<seg id="241">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="242">"like ABILIFY looks and content of the pack The ABILIFY 30 mg melting coated tablets are round and rosafarches, with embossing" A "above" 643 "on one side and" 30 "on the other."</seg>
<seg id="243">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="244">"transport and operation of machines you should not drive a car and do not operate tools or machines, until you know how ABILIFY with you."</seg>
<seg id="245">190 Important information on certain other components of ABILIFY EBILIFY solution to take contains 200 mg Fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor has communicated you that you suffer from a intolerance towards certain states, contact your doctor before you take this medicine."</seg>
<seg id="247">The dose of ABILIFY solution to the one has to be measured with the spotted measurement or confessed 2 ml trop pipette that are contained in pack.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">If you have taken a larger amount of ABILIFY when you should notice that you have taken more ABILIFY solution to the entry (or if someone has taken another ABILIFY solution to the entry), please contact your doctor immediately. "</seg>
<seg id="250">"dinatriumedetate, Fructose, glycavities, methyl-4- hydroxybenzoat (E2G), prosodium-hydroxybenzoat (E2G), sodium-hydroxid, Sucrose-aromatic with other natural flavors."</seg>
<seg id="251">"how ABILIFY looks and content of the packet ABILIFY 1 mg / ml solution to inserting is a clear, colored liquid for bottles and 50 ml, 150 ml or 480 ml"</seg>
<seg id="252">"ABILIFY injection solution is used for rapid treatment of gested unrest and unquestionable behavior that can occur as symptoms of a disease, which are characterized by symptoms like: sound, reflective, reflective language, wirres behavior and despised mood."</seg>
<seg id="253">"people with this disease can also depressed to feel guilty, anxious or tense. excessive energy to have much less sleep than usual, very fast response with changing ideas and sometimes strong stimulating."</seg>
<seg id="254">"inform immediatly your doctor, if you are connected to muscle stiffness or rigidity with high fever, sweating, changing state of state or very fast or irregular heart attack."</seg>
<seg id="255">"when using ABILIFY with other medicines, Please inform your doctor or pharmacist if you use other medicines / apply or used especially if it is not prescription drugs."</seg>
<seg id="256">Medicines for the treatment of heart rhythmia antidepressants or herbal medicines used to treat depression and anxiety are used medicines to treat HIV infection antionvulva that are used to treat epilepsy.</seg>
<seg id="257">"196 pregnancy and lactation, you should not apply ABILIFY if you are pregnant, unless you have discussed this with your doctor."</seg>
<seg id="258">"transport and operation of machines you should not drive a car and do not operate tools or machines, if you feel like using ABILIFY injection solution."</seg>
<seg id="259">"if you have concerns that you get more ABILIFY injection solution than you need to do, please talk to your doctor or patches."</seg>
<seg id="260">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) by ABILIFY injection solution are fatigue, shaft, headache, unhelplessness, nausea, and vomiting."</seg>
<seg id="261">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel a changed blood pressure, especially when set up out of the song or sitting, or a fast powder, a drying feeling in the mouth or feel abbeaten."</seg>
<seg id="262">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable movements, headache, weariness, backleness, sleeping problems, relaxation problems, wreaks, crying, citage, and blurred sight."</seg>
<seg id="263">"if you need more information about your disease or treatment, please read the package passing (also part of the EPAR), or contact your doctor or pharmacist."</seg>
<seg id="264">Abraxane should be applied only under the supervision of a qualified oncologist in the application of cytostatika (deadly of cells) specialized departments.</seg>
<seg id="265">"at patients, certain side effects occur to the blood or the nervous system, the dose may be reduced or interrupted treatment."</seg>
<seg id="266">"(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu</seg>
<seg id="267">"the effectiveness of abraxane was studied in a main study, participated in the 460 women with metastatic breast cancer, of which approximately three quarters had previously been a anthracyclin."</seg>
<seg id="268">The effect of abraxane (in some gift or as Monotherapy) was compared with the conventional Paclitaxel contained drug (given in combination with other medicines for the reduction of side effects).</seg>
<seg id="269">"altogether spoke in the main study of 72 (31%) of the 229 with abraxane patients treated to the treatment, to 37 (16%) of the 225 Patients, the conventional Paclitaxel contained medicine."</seg>
<seg id="270">"seen only the patients who have been treated for the first time because of metastatic breast cancer, there were no difference between drugs and survival for the first time."</seg>
<seg id="271">"against the other hand, with Patients, which had previously received other treatments for their metastatic breast cancer, with regards to these indicators that abraxane effective as conventional Paclitaxel contained medicine was."</seg>
<seg id="272">"in addition, it must not be applied to patients who are silent or before the start of the treatment of low neutrality pay in the blood."</seg>
<seg id="273">"the Committee on Humancision (CHMP) set forth that abraxane in Patients, where the first treatment did not beat more effective than conventional Paclitaxel medicine, and that it must not be used in contrast to other Paclitaxel medicine, to reduce side effects."</seg>
<seg id="274">"January 2008, the European Commission granted abrasion BioScience Limited has permission for the Independence of abraxane throughout the European Union."</seg>
<seg id="275">Abraxane-Monotherapy is indians for the treatment of metastatic mammacros for metastatic disease and is not displayed for a standard anthracycline-contained therapy (see also section 4.4).</seg>
<seg id="276">In patients with severe neutropenie (neutrophiles) &lt; 0,50 x 109 / l over a period of one week or longer) or severe sensory Neuropathy during the abrasion treatment should be reduced to 220 mg / m2.</seg>
<seg id="277">"with sensoric Neuropathy degree 3 is the treatment to break down to degree 1 or 2, and at all subsequent cycles the dose must be reduced."</seg>
<seg id="278">There is currently no adequate data for the recommendation of dosage adjustment in patients with easy to even impairment of the liver function (see Section 4.4. and 5.2).</seg>
<seg id="279">There were no studies carried out with patients with imptigated kidney function and there is currently no adequate data on the recommendation of dosages in patients with impairment the kidney function (see Section 5.2).</seg>
<seg id="280">Abraxane is not recommended for use in children under 18 years of age due to non-sufficient data of inconceivable and effectiveness.</seg>
<seg id="281">Abraxane is a Albumin-bundy nanoparticel formulating from Paclitaxel which could have much other pharmacological characteristics as other formulations of Paclitaxel could (see section 5.1 and 5.2).</seg>
<seg id="282">"if an allergic reaction occurs, the medicine should be used immediately and a symptomatic treatment should be initiated and the patient must not be treated with Pacamaxel."</seg>
<seg id="283">"in the patients there should be no renewed abrasion treatment cycles, up to 1.5 x 109 / l increased again on &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver functioning (Bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with abrasion.</seg>
<seg id="285">"while a clearly with abrasiane in connection of cardiotoxicity has not been proven, kardials are not unusual, especially in patients with earlier anthracyclin treatment or impairflow heart or packed heart disease."</seg>
<seg id="286">"in case of patients after the gift of abrasion of abrasion, break and circulation, these can be treated with the usual anti-emetika and consistent means."</seg>
<seg id="287">"abraxane should not be used in pregnant or for women at childbearing age, which is not applied to effective contraception, except the treatment of the mother with Paclitaxel is unavoidable."</seg>
<seg id="288">Women at childbearing age should apply during and up to 1 month after treatment with abraxane a reliable contraction method.</seg>
<seg id="289">"male patients, which are treated with abraxane is advised, while and up to six months after the treatment of no child."</seg>
<seg id="290">"male patients should be advised before treatment over a sperm count, since the treatment with abraxane is the possibility of irreversible infertility."</seg>
<seg id="291">Abraxane can cause side effects such as fatigue (very often) and shrub (common) that can affect on the traffic and the ability to use machines.</seg>
<seg id="292">Below are the most common and most important incidents of side effects performed at 229 patients with metastatic colorPhase III study once every three weeks with 260 mg / m2 abraxane were treated.</seg>
<seg id="293">Neutropenie was the most striking important hämatological toxicity (at 79% of the patients) and was quick reversible and dosages; Leukopenie was reported at 71% of the patients.</seg>
<seg id="294">Anemia (HB &lt; 10 g / dl) was observed at 46% of the patients with abraxane patients and was severe in three cases (HB &lt; 8 g / dl).</seg>
<seg id="295">In table 1 the side-side effects listed in conjunction with the gift of abraxane as monotherapy with each dose and indication of studies in studies (N = 789).</seg>
<seg id="296">Very frequent (≥ 1 / 10); frequent (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 1,000); very rare (&lt; 1 / 10,000). "</seg>
<seg id="297">"occasionally: increased blood pressure, weight increases, increased lacunhydrogenase in the blood, increased blood sugar, increased blood sugar, increased phosphoror in the blood, reduced phosphor in the blood, reduced potassium in the blood of Hercerties:"</seg>
<seg id="298">"dysphagie, pulling, zinc, dry, painless chair, sosophagitis, pains in the substrates, orbital pain, rektale blood disorders of kidneys and urinary tract:"</seg>
<seg id="299">"pain in the breast Korean wall, weakness of musculature, Genickness, pains, pains, pain in the skeleton muscles, flanges, wears Very common:"</seg>
<seg id="300">Resignity 1 The frequency of hypersensitivity actions will be calculated based on a definitive event in a population of 789 patients</seg>
<seg id="301">"since these events have been reported on a voluntary basis during clinical practice, no estimates of the actual frequency is possible and there was no kallial connection with these events."</seg>
<seg id="302">Pacamaxel is an antimikrotubuli-drug which promotes the collateral of the micro-buli from the tubullies and the micro-buli stabilization by the imitation of their landolymerisation.</seg>
<seg id="303">"this stabilisation leads to an inhibiting of the normal dynamic reorganization of mikrotubulky network, which is essential for the vitational Interphase and the exotic cell functions."</seg>
<seg id="304">"it is known that Albums is conveyed in the transcytosis of Plasmakomponents into the endothelplers, and as part of in-vitro studies has been proven that the presence of Albums in the transportation of Paclitaxel is promoted by the endothelical cells."</seg>
<seg id="305">It is believed that this improved transendotresale transport by the gp-60-Albuminrezor is conveyed and due to the albombindingProteins (Eted protein acidic rich in cysteine) a Pacamaxel accumulation in the field of the tumor appearance.</seg>
<seg id="306">The application of abraxane for metastatic Mammakzinom is supported by data of 106 patients in two incomparable trials and 454 patients who have been treated in a randomised phase III comparison.</seg>
<seg id="307">"in a study, 43 patients were treated with metastatic Mammakzinom with abraxane, which was given in the form of an infusion about 30 minutes by a dosage of 175 mg / m2."</seg>
<seg id="308">In the second study a dose of 300 mg / m2 was used as infusion of 30 minutes to 63 patients with metastatic Mammakzinom.</seg>
<seg id="309">"this multicentric study was conducted in patients with metastatic Mamadiaxel 175 mg / m2 as a 3-hour infusion with prefabrication for the prevention of an allergic reaction (N = 225), or in the form of abraxane 260 mg / m2 as a 30-minute infusion (N = 229)."</seg>
<seg id="310">"when recording into the study, 64% of the patients had an implied general state (ECOG 1 or 2), 79% had visceral metastases and 76% had more than 3 metals."</seg>
<seg id="311">"14% of patients had previously made chemotherapy before, 27% had only a adjuvante chemotherapy, 40% only due to Metastasification and 19% due to Metastasification and for adjuvant treatment."</seg>
<seg id="312">"9 The results for the general response rate and time until progression of the disease and progression-free survival and survival for patients who receive the First-line therapy, are shown below."</seg>
<seg id="313">Neurotoxicity towards Paclitaxel was evaluated by improving a degree of patients who lived at a time during therapy a peripheral Neuropathy degree 3.</seg>
<seg id="314">The natural course of peripheral Neuropathy for sound toxicity due to the cumulative toxicity of abraxane after &gt; 6 treatments were not evaluated and is still unknown.</seg>
<seg id="315">The Pharmacoinetics of the overall Pacman litaxel to 30- and 180-minute infusion of abraxane with a dose of 80 to 375 mg / m2 was established in clinical studies.</seg>
<seg id="316">The ingredient exposure (AUC) increased from 2653 to 16736 ng.h / ml analogue to a dosage of 80 to 300 mg / m2.</seg>
<seg id="317">10 After intravenous gift of abraxane to patients with metastatic Mammakzinom in the recommended clinical dose of 260 mg / m2 the Paclitaxel Plasmaconcentric in multiphashic way.</seg>
<seg id="318">The medium distribution volume was 632 l / m2; the high distribution volume indicates a far-reaching extravagant distribution and / or soft connection of Paclitaxel.</seg>
<seg id="319">"in a study with patients with advanced solid tumors, the pharmacokinetic properties of Paclitaxel were compared to intravenous 30-minute infusion of 260 mg / m2 abrasion with values according to a 3-hour injection of 175 mg / m2."</seg>
<seg id="320">"the Clearance of Paclitaxel was higher (43%) than after a solution-made Paclitaxel injection, and also the distribution volume was with abraxane higher (53%)."</seg>
<seg id="321">In the published literature on in-vitro-studies of human Lebanikrosome and tissue layers is reported that Pacamaxel is primarily associated to 6α -Hydroxypacaxel and 6α -3 "-p-Dihydroxypaclaxel) metabolized.</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 abraxane in patients with metastatic colorcinoma amounted to 4% of the given total effect 6α -Hydroxypacliaxel and 3 "-p-Hydroxypactenaxel and 3" -p-Hydroxypaclaxel, which leads to a far-reaching non-renal Clearance. "</seg>
<seg id="323">"however, about patients aged over 75 years old are only a few data available, since only 3 patients of this age group took part in the pharmacocinetic analysis."</seg>
<seg id="324">The chemical and physical stability has been proven at 2 ° C - 8 ° C in original carton and before brightly light is protected over 8 hours.</seg>
<seg id="325">Pactaxel is an cytotality rate medicine and as well as with other potentially toxic substances should be realized when dealing with abraxane caution.</seg>
<seg id="326">Using a sterile sprayer slowly over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium-infusion solution in a abrasive bottle.</seg>
<seg id="327">"after complete delivery of the solution, the carrying bag should rest at least 5 minutes to ensure a good use of the solids."</seg>
<seg id="328">"then the shutters for at least 2 minutes slowly and carefully checked and / or inverted, until a complete remains of the pulse is done."</seg>
<seg id="329">"if susceptible or sinners are visible, the cross-bottle must once again be inverted to achieve a complete reset."</seg>
<seg id="330">The exact doscope of the 5-mg / ml Suspension will be calculated and the appropriate amount of relies abraxane in an empty, sterile PVC- or non-PVC infusion bag. "</seg>
<seg id="331">"Pharmacovigilance System The holder of approval for the Internet must ensure that the Pharmacovigilance system, as described in version 2.0 and is presented in Module 1.8.1. of the authorisation, and works before and while the medicine is put into traffic."</seg>
<seg id="332">"risk management plan the owner of the approval for the contract is obligated to perform the studies conducted in the Pharmacovigilance plan, as described in version 4 of the risk management plan (RMP), as well as all subsequent updates of the RMP, which are agreed with CHMP."</seg>
<seg id="333">"according to the CHMP directive on risk management systems for medicines to apply to the application, the updated RMP should be submitted simultaneously with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, a updates to date is available • If new information can be found on the current security specification, the Pharmacovigilance plan or risk minimization) • within 60 days of reaching an important milestones (Pharmacovigilance or risk management) • On request of the EMEA"</seg>
<seg id="335">"8 hours in the refrigerator, in the fridge, if they are kept in the carton, to protect the content from light."</seg>
<seg id="336">"abraxane is used to treat Mammakarcinoma when other therapies were tried, but not successful, and if you do not come for anthracycline-in therapies."</seg>
<seg id="337">Abraxane must not be used: • if you are oversensitive (allergic) against Paclitaxel or one of the other components of abraxane are • if you are silent when your white blood cells are lower (output for neutrophilology of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"special caution in the application of abraxane is required: • If you have an impacted Nierenfunction, if you suffer a sense feeling, prickling, prickling sense or muscle weakness, if you have severe Lebanese problems • if you have heart problems."</seg>
<seg id="339">"when applying abraxane with other medicines, Please inform the doctor if you apply other medicines or have recently applied, even if it might not cause prescription medicine, since this might cause a interaction with abraxane."</seg>
<seg id="340">Women at childbearing age should apply during and up to 1 month after treatment with abraxane a reliable contraction method.</seg>
<seg id="341">"in addition, they should be advised before treatment over a sperm count, since through the abrasion treatment the possibility of a lasting infertility."</seg>
<seg id="342">"transport and the use of machinery abraxane can cause side effects such as fatigue (very common) and shrine feeling (often), which can affect on the traffic and the ability to use machines."</seg>
<seg id="343">"if you also receive other medicines during your treatment, you should consult with regards to driving or use machines from your doctor."</seg>
<seg id="344">22 • Effect on the peripheral nerves (pains and numbness) • pains in one or more joints • pain in the muscles • nausea • eving • weakness and tiredness</seg>
<seg id="345">"the frequent side effects (at least 1 of 100 patients reported) are: • skin rash, dried ailments, piracy, irritation • inhibiting, poultry or suspicion • respiratory or soft parts, painters or soft parts, pains or wling tongue, oral mouth or wling tongue, Mundsoor • Sleeps."</seg>
<seg id="346">The rare side effects (at least 1 of 10.000 patients reported) are: • Luninfect • Hauling campaign on a different substance after irradiation • blood circulation</seg>
<seg id="347">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="348">"if they are not used immediately, it can be stored in the carrying bag up to 8 hours in the fridge (2 ° C - 8 ° C) if it is stored in the line-carton to protect the content from light."</seg>
<seg id="349">Any carrying bag contains 100 mg Paclitaxel. • After the reconstitution contains every ml of the suspension 5 mg Paclitaxel. • The other part is Albuminous resolution of man (includes sodium, sodium-caprylat and N Acetyltryptophan (Ph.Eur.)) "</seg>
<seg id="350">Precautions for the preparation and application Paclitaxel is an cytotality rate medicine and as well as with other potentially toxic substances should be realized when dealing with abraxane caution.</seg>
<seg id="351">Using a sterile sprayer should slowly be injected over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium-infusion solution in a abrasive bottle.</seg>
<seg id="352">"then the crossroads for at least 2 minutes slowly and cautious, and / or inverted until a complete remains of the pulse is done."</seg>
<seg id="353">This is necessary to calculate the exact doscope of the 5 mg / ml Suspension and the appropriate amount of reformed abraxane in an empty, sterile PVC-infusion bag type IV injected. "</seg>
<seg id="354">Parenteric medicines should be undered prior to the application of a viewing test on possible particles and discoloration when always allow the solution or mastery this.</seg>
<seg id="355">"stability unopened valves with abrasils are kept up to which on the packaging indicated date stable, if the crossroads in the envelon is kept to protect the content from light."</seg>
<seg id="356">The stability of the relies Suspension in the flow bottle After the first reconstitution should be filled immediately into an infusion bag.</seg>
<seg id="357">Member states must ensure that the owner of the approval will take care of the approval in dialysis centres and retail stores with the following information and materials:</seg>
<seg id="358">"• Training brochure, summary of the features of drug using (specialist information), labelling and packaging inspection. • With a clear picture of the correct cooling of the product accidentally for transport through the patients."</seg>
<seg id="359">"this means that Absinamed a biological medicine is similar, which is already approved in the European Union (EU) and contains the same ingredient (" "reference cisions"). "</seg>
<seg id="360">"it will be used in patients with normal blood flow, in connection with a blood transfusion to occur in connection with a blood transfusion of complications, if the intervention is not possible and where a bloodloss of 900 to 1 800 ml is expected."</seg>
<seg id="361">"the treatment with seabamed must be initiated under the supervision of a doctor, the experience in the treatment of patients with diseases whose medicine is indicated."</seg>
<seg id="362">"in patients with kidney problems and in patients who want to make their own blood-blood, is seamed to injected in a Vene."</seg>
<seg id="363">The injection can also be made by the patient or his supervisor if they have received an appropriate instruction.</seg>
<seg id="364">"in patients with chronic kidney efficiency, or patients who receive chemotherapy should always be in the recommended range (between 10 and 12 grams per Decilite in adults or between 9,5 and 11 g / dl in children)."</seg>
<seg id="365">"the iron values of all patients are required before the treatment to ensure that no iron lack consists, and iron supplements should be given during the entire treatment."</seg>
<seg id="366">"in patients who receive chemotherapy, or in patients with kidney problems can be caused by a ythropoietal lack or thus that the body does not sufficiently speak on the body's own ythropoietin."</seg>
<seg id="367">Erythropoietin will also be used before operations to increase the number of red blood cells and thus reduce the consequences of a blood loss.</seg>
<seg id="368">"it is produced by a cell, produced in which a gene (DNA) was transported to the formation of epetin alfa."</seg>
<seg id="369">Abseamed was compared with filing as an injection in a veins within the framework of a main study with 479 patients suffering from one by kidney problems caused by reference problems.</seg>
<seg id="370">All patients participating in this study was at least eight weeks old Eprex / Erypo in a Vene injected before they were either placed on seabamed or furthermore Eprex / Erypo.</seg>
<seg id="371">Main Indicator for the effectiveness was the change of hemogist values between the beginning of the study and the completion period in the weeks 25 to 29.</seg>
<seg id="372">"the company also laid out the results of a study in which the effects were carried out under the skin with those of Eprex / Erypo at 114 cancer patients, which were given chemotherapy."</seg>
<seg id="373">"in the study with patients who suffered on one by kidney problems caused by kidney problems, the hematglobinvalues of patients were provided on the same measure as with those patients who continue to be Eprex / Erypo."</seg>
<seg id="374">"compared to this, the patients still showed Eprex / Erypo, an increase of 0.063 g / dl of the output value of 12,0 g / dl."</seg>
<seg id="375">The most common side effect of Absinamed is an increase in blood pressure from occasionally to symptom of an encephalopathy (brain problems) such as sudden-related migrant headache and bness.</seg>
<seg id="376">Seabamed must not be used in patients who may possibly excessive (allergic) against epotin alfa or one of the other components.</seg>
<seg id="377">"seamed as injections under the skin is not recommended for treating kidney problems, as further studies are required to ensure that this is triggered by no allergic reactions."</seg>
<seg id="378">"the Committee on Humancision (CHMP) is to conclude that for abortion in accordance with the provisions of the European Union of evidence, the medicine is a comparable quality, safety and active profile such as Eprex / Erypo."</seg>
<seg id="379">"the company, the seashamed will provide for medical professional staff in all Member States information packages, including information on the security of the drug."</seg>
<seg id="380">"August 2007, the European Commission dedicated to the company Medice medicines Pütter GmbH & Co KG as a permit for inclusion in the entire European Union."</seg>
<seg id="381">"treatment of anemia and reduction of transfusion needs in adults with solid tumours, maligars or multiplom mythological status, which consists of chemotherapy and for which the risk of transfusion based on the general condition (e.g. kardiovascular status, pre-existing anemia in the beginning of chemotherapy)."</seg>
<seg id="382">"the treatment should only be performed in patients with moderate anemia (hemoglobin [HB] 10 - 13 g / dl), if blood-saving measures are not available or inadequate, in case of planned major operating terms that require a large blood volume, which require a large blood volume (4 or more units blood for men; 5 or more units blood for men)."</seg>
<seg id="383">"for reduction of stranbleness, Absinamed can be applied in front of a large selective orthopedic intervention in adults without iron lack, where a high risk of transfusion applications are expected."</seg>
<seg id="384">HB 10-13 g / dl) and a expected blood loss of 900-1800 ml are not able to participate in an autonomous blood program.</seg>
<seg id="385">The hemoglobin-destination Concentration is between 10 and 12 g / dl (6.2 - 7.5 mmol / l), except for paediatric patients where the hemoglobinocation between 9,5 and 11 g / dl (5,9 - 6,8 mmol / l). "</seg>
<seg id="386">"anarchic symptoms and folds may vary depending on age, gender and overall cranes, therefore the assessment of individual clinical trials and disease can be required by the physician."</seg>
<seg id="387">A rise in hematglobins around more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">Due to the variability between patients may occasionally be observed in a patient individual hemogybinaries via or under the hemoglobin audiences.</seg>
<seg id="389">Given this hemogybinaries should be tried over an appropriate dosismanagement management, the hemoglobin-target group of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l). "</seg>
<seg id="390">If the hemoglobin is worth more than 2 g / dl (1.25 mmol / l) per month (7.5 mmol / l) exceeds 25 g / dl (7,5 mmol / l) is the epotin-alfa dose by 25%.</seg>
<seg id="391">"patients should not be monitored, to ensure that epotin alfa is needed in the lowest possible dose which is required for controlling the anemia and the anarchic symptoms."</seg>
<seg id="392">The present clinical results suggest that patients with beginns very low HB-value (&lt; 6 g / dl or &lt; 3,75 mmol / l) possibly need higher cabs (HB &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">"the present clinical results suggest that patients with initial low HB-value (&lt; 6,8 g / dl or &lt; 4,25 mmol / l) possibly need higher cabs (HB &gt; 6,8 g / dl or &gt; 4,25 mmol / l)."</seg>
<seg id="394">"initial dose 50 i.E. / kg 3 times a week by intravenous application, if necessary with a derivatives of 25 i.e / kg (three times a week), until the desired target is achieved (this should be done in steps of at least 4 weeks)."</seg>
<seg id="395">"anarchic symptoms and - folds can be different depending on age, gender and overall cranes, therefore the assessment of individual clinical trials and disease can be required by the physician."</seg>
<seg id="396">Given this hemogybinaries should be tried over an appropriate dosismanagement management, the hemoglobin-target group of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l). "</seg>
<seg id="397">"patients should not be monitored, to ensure that epotin alfa is required in the lowest possible dose which is necessary for controlling the accumulation of symptoms."</seg>
<seg id="398">"if after 4 treatment weeks of hemogglove value is increased by at least 1 g / dl (0,62 mmol / l), or the reflector number of ≥ 40,000 cells / kg, the dose of 150 i.e / kg should be kept once a week or 450 i.E. / kg once a week."</seg>
<seg id="399">"if the hemogglobinanrose &lt; 1 g / dl (&lt; 0,62 mmol / l) and the reflective number &lt; 40,000 cells / µl should be raised to the output value, the dose should be raised to 300 i.e / kg three times a week."</seg>
<seg id="400">"if after another 4 treatment weeks with 300 i.e / kg three times a week of hemogglove value to ≥ 1 g / dl (≥ 0.62 mmol / l), or the reduction of ≥ 40,000 cells / µl should be maintained / kg three times a week."</seg>
<seg id="401">"is in contrast to the hemogglove value by &lt; 1 g / dl (&lt; 0,62 mmol / l) or the retikozytensionnumber of &lt; 40,000 cells / µl compared to the output value, is an appeal to the epotin-alfa therapy is unlikely and the treatment should be canceled."</seg>
<seg id="402">"patients with mild anemia (hematocrit 33 - 39%), which is necessary for a dosage of ≥ 4 hemispheres, should be seamed in a dose of 600 i.e / kg body weight twice weekly for 3 weeks before the operating procedure."</seg>
<seg id="403">"with the iron substitution should be as early as possible - for example, some weeks before the start of the autologists bleeding program - to be started before the beginning of the seated therapy of large iron reserves."</seg>
<seg id="404">"6 The recommended dosage is 600 i.E. / kg Epoettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="405">"this should be epetin alfa preoperatively 300 i.E. / kg at each 10 consecutive days before, on the day of the surgery, as well as 4 days immediately after."</seg>
<seg id="406">"alternatively, the injection at the end of the dialysis can be given over the hose of a Fistelnadel, followed by 10 ml isotonous cooking solution in order to rinse the hose and ensure an adequate injection of the drug in the cycle."</seg>
<seg id="407">Patients suffering from treatment with some Erythropoetin (Pure Red Cell Aplasia, PRCA) should not receive a seamed or another Erythropoetin (see section 4.4 - Erythroblastopenie). "</seg>
<seg id="408">"heart attack or stroke within one month before treatment, instabile Angina pectoris, elevated risk for deep Venenthrombs (e.g. anamnestable well-known thromboembolien)."</seg>
<seg id="409">"in patients, which are envisaged for a greater selective orthopedic intervention, is the application of epeptin alfa alfa, peripheral temperament, vascular disease of carotives or cerebrovascult disorder; in patients with recently replaceable heart attack or smebrovascult event."</seg>
<seg id="410">Erythroblastopenie (PRCA) Very rare has been reported on the appearance of an anti-mediated PRCA to Monate- up to years of treatment with subkutanem Erythropoetin.</seg>
<seg id="411">"in patients with sudden economic loss, defined as a reduction of hemogulbinvalues (1 - 2 g / dl per month), the reflective or vitamin-B12-lack, alarm or inflammation, loss or inflammation, blood loss and hammads)."</seg>
<seg id="412">"if the Reverulozych value, taking into account of anemia (i.e. the Reticulozyten" index "), the Thromatic cylinders or &lt; 0,5%), the thyroythropoetin-antibodies are determined and an examination of the bone-marks for diagnosis of a PRCA."</seg>
<seg id="413">The data on immunity with substitutes for substitutes in patients with a risk for an anti-inducted PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">8 For patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="415">In clinical trials a elevated mortal risk and risk for serious bardiovascular events were observed if Erythropoesis (ESA) with a tick-concentration of more than 12 g / dl (7,5 mmol / l) were given.</seg>
<seg id="416">Controlled clinical trials have demonstrated no significant benefits that is attributable to the gift of epoxetine symptoms when the hemogybinocation is required to control the control of accumulation symptoms and the avoidance of blood transfusions.</seg>
<seg id="417">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="418">In patients with chronic kidney efficiency and clinically corrosive coronary reduction or shrine efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="419">"after the time of this findings, by the treatment of anemia with epoxetine alfa, with adult efficiency, which are not yet dialysis, the progression of kidney efficiency is not accelerated."</seg>
<seg id="420">In tumour patients under chemotherapy ought to be considered for assessing the therapy of epetin alfa a 2 - 3-week delay between epetin-alfa-Gabe and the Erythropoetin answer to be taken into account (patients who may possibly be transfigured).</seg>
<seg id="421">"if the HB increase is greater than 2 g / dl (1.25 mmol / l) per month or a HB-value of 13 g / dl (8,1 mmol / l), the dose must keep the risk for possible thrombal events (see section 4.2 treatment of patients with chemotherapy conditionality, between 10 g / dl and 12 g / dl)."</seg>
<seg id="422">"the decision for the application recombinant Erythropoetine should be based on the benefit of the respective patients, which should also consider the specific clinical context."</seg>
<seg id="423">"in patients, which are intended for greater selective orthopedic surgery should be, if possible, prior to the beginning of epoxetine-alfa therapy the cause of anemia and treated accordingly."</seg>
<seg id="424">Patients suffering themselves to a greater selective orthopaedic surgery should be an appropriate tromboseprophylaxis as they have a elevated risk for thrombotic and vascular diseases, especially in a related cardiovascular disease. "</seg>
<seg id="425">"in addition, it cannot be excluded that in treatment with epetin alfa for patients with an output moglozing by &gt; 13 g / dl a elevated risk for postoperative thrombal / vascular events can exist."</seg>
<seg id="426">In several controlled studies for epoxetine was not proven that they can survive in tumour patients with symptomatic anemia and reduce the risk of tumor progression.</seg>
<seg id="427">"4 months in patients with metastatic breast cancer, which was given a chemotherapy if an hemoglobin-target group of 12 - 14 g / dl (7.5 - 8,7 mmol / l)"</seg>
<seg id="428">Will be epoxy alfa combined with Cicrid porin should be monitored in the blood level of Ciclosporin and the Ciclosporindosis of the rising hematoccia.</seg>
<seg id="429">From in-vitro-investigations on Tumoredom does not result in evidence of a interaction between epetin alfa and G-CSF or GM-CSF regarding hämatological differential or proliferation.</seg>
<seg id="430">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, arteries, hair-cymbs, bulb nicotics and 11 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="431">The most common side-effect during treatment with epetin alfa is a dosages-dependent increase in blood pressure or deterioration of an existing hypertension.</seg>
<seg id="432">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="433">Independent from the ythropoetin treatment it can come in surgical patients with cardiovascular disease after repeated blood pressure to thrombotic and vascular complications.</seg>
<seg id="434">The genealogical acquired epetin alfa is glycoded and related to the amino acids and carbohydrates in relation to endogenous humanythropoetin that was isolated from the urine of the patient.</seg>
<seg id="435">"it could be demonstrated with the help of cultures of human bone markings that epetin alfa specifically stimulates the Erythropoesis, and the luminosity is not influenced."</seg>
<seg id="436">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="437">"1895 patients with solid tumors (683 Mamzinome, 260 bronchial karzinoms, 174 gynecological tumors, 300 gastrointestinal tumors and 478 others) and 802 patients with Hemmoblastes."</seg>
<seg id="438">Survival and tumor are examined in five large controlled studies with a total of 2833 patients; four of these studies were double-thread placebenrolet studies and</seg>
<seg id="439">"in the open study, no difference in total survive between the patient combined with recombinant Erythropoetin treated patients and the control patient."</seg>
<seg id="440">"in these studies, in these studies show themselves with recombinant Erythropoetin treated patients with an anemia due to various more common malignous consistency, statistically significant higher mortality than with controls."</seg>
<seg id="441">The overall survival in the studies could not be explained by differences in the incidence of trombs and associated complications associated with recombinant Erythropoetin treated patients and with inspections.</seg>
<seg id="442">"there is a elevated risk for thromance Bolshevik events in tumour patients, which can be treated with recombinant Erythropoetin, and a negative impact on the overall survival cannot be excluded."</seg>
<seg id="443">"it is not clarified how far these results are treated to the application of recombinant Erythropoetin in tumour patients using chemotherapy with the aim to transfer a tick-glove under 13 g / dl, because too few patients were included with these characteristics in the supplied data."</seg>
<seg id="444">Epoxy-alfa-provisions after repeated intravenous application showed a half-value period of about 4 hours in healthy probances and a slightly extended half-time period of about 5 hours in patients with kidney efficiency.</seg>
<seg id="445">"according to subtle injections, the Serummirror of epotin alfa are much lower than the levels of servermirror, which will be achieved after intravenous injection."</seg>
<seg id="446">"there is no cumulation: the servings levels remain the same, regardless of whether they are determined 24 hours after the first gift or 24 hours after the last gift."</seg>
<seg id="447">(bone markfibrose is a known compilation of chronic kidney efficiency while people and could be attributed to a secondary hyperparathyreoidized or unknown factors.</seg>
<seg id="448">In a study in hematalytic patients who have been treated with epetin alfa was the incidence of bone markers with dialysis patients who have not been treated with epetin alfa.</seg>
<seg id="449">"14 In animal experimental studies with approximate the 20triple of the application for the use of people recommended weekchendosis led epetin alfa, to a delay of oscillation and to an increase in mortality mortality."</seg>
<seg id="450">These reports rely on in vitro Befences with cells from humanitarian tumor stubs that are known for the clinical situation but of unsecure Signifiano.</seg>
<seg id="451">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="452">"the syringes are provided with graduating and the filling volume is indicated by a sticky label, so that if necessary, the dimensions of partial quantities is possible."</seg>
<seg id="453">The treatment with seabamed must be initiated under the supervision of physicians to have the experience in treating patients with the above indications.</seg>
<seg id="454">"21 The recommended dosage is 600 i.E. / kg Epoettin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="455">23 For patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="456">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="457">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, bulky Thrombs, orphanic taps, bulb nicotics and 26 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="458">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="459">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="460">29 In animal experimental studies with approximate the 20t of the use of the wattendosis led epetin alfa to diminishing body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="461">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage is 600 i.E. / kg Epoettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="463">38 In case of patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="464">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="465">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, orphanic proudinal sex, bulb nicotics and 41 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="466">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="467">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="468">"44 In animal experimental studies with an approximate of the 20ivoendosis led epetin alfa to diminished body weight, to a delay of oscillation and to an increase in mortality mortality."</seg>
<seg id="469">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage is 600 i.E. / kg epotin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="471">53 In patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="472">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="473">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, orphanic taps, bulb nicotics and 56 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="474">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="475">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="476">"59 In animal experimental studies with nearly 20% of the 20ivoendosis led epetin alfa to diminished body weight, to a delay of oscillation and to an increase in mortality mortality."</seg>
<seg id="477">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="478">66 The recommended dosage is 600 i.E. / kg Epoettin alfa that should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0). "</seg>
<seg id="479">68 In patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="480">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="481">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, arteries, hair-cymbs, bulb nicotics and 71 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="482">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="483">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="484">74 In animal experimental studies with approximate the 20t of the 20iendosis led epetin alfa to diminished body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="485">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage is 600 i.E. / kg epotin alfa, once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="487">83 In patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="488">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="489">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, orphanic taps, bulb nicotics and 86 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="490">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="491">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="492">89 In animal experimental studies with an approximate maturity of the 20iendosis led epetin alfa to diminishing body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="493">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="494">"96 The recommended dosage is 600 i.E. / kg Epoettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="495">98 In patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="496">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="497">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, arteries, hair-cymbs, bulb nicotics and 101 blood circulation, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="498">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="499">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="500">"104 In animal experimental studies with approximate the 20t of the 20iendosis led epetin alfa to diminished body weight, to a delay of oscillation and to an increase in mortality mortality."</seg>
<seg id="501">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="502">111 The recommended dosage is 600 i.E. / kg Epoettin alfa that should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0). "</seg>
<seg id="503">113 In patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="504">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="505">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, orphanic taps, bulb nicotics, aninalthropoundry treatment, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="506">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="507">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="508">119 In animal experimental studies with approximate the 20t of the use of the weeketendosis led epetin alfa to diminishing body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="509">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="510">126 The recommended dosage is 600 i.E. / kg Epoettin alfa that should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0). "</seg>
<seg id="511">128 For patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="512">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="513">"about thrombotic, vascular events such as myocardiac scenic attacks, dyokardincolourless, guilloric attacks, limborous madness, orphanic empowerment, obinalthropoous treatment, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="514">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="515">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="516">134 In animal experimental studies with an approximate maturity of the 20iendosis led epetin alfa to diminishing body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="517">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="518">"141 The recommended dosage is 600 i.E. / kg Epoettin alfa, which should once a week over three weeks (day 21, 14 and 7) before the operating procedure and the day of the surgery (day 0)."</seg>
<seg id="519">143 For patients with chronic kidney efficiency should not exceed 4.2 recommended upper limit of hemoglobin audiences.</seg>
<seg id="520">The hemoglobinds should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in the blood pressure.</seg>
<seg id="521">"about thrombal, vascular events such as myocardiac disorders, dyokardincolourless, guesoric attacks, limborous madness, orphanic empowerment, obinalthropoous treatment, as well as patients among epythropoetin treatment, as well as patients among epetin alfa, reports."</seg>
<seg id="522">An increased incidence lical thrombovasculated events (see section 4.4 and section 4.8 - General) was observed in patients under the treatment with Erythropoetine.</seg>
<seg id="523">"389 patients with Hemmoblastomers (221 multiple myelome, 144 Non-Hodgkinome) and 332 patients with solid tumors (172 Mamzinczinome, 23 Bronze chizinome, 22 gastroozinome, 21 gastroochinale Karzinome and 30 more)."</seg>
<seg id="524">149 In animal experimental studies with approximate the 20t of the use of the weeketendosis led epetin alfa to diminishing body weight, to a delay of oscillation and to an increase in mortality mortality. "</seg>
<seg id="525">"as part of the outpatient application, the patient can store wastewamed once for a period of 3 days outside the cooling rankes and not over 25 ° C."</seg>
<seg id="526">"the holder of the approval of the approval has prior to the launch and in accordance with the relevant authorities of member states, medical professional staff in dialysis centres and retail stores, with the following information and materials: • Training broker with the following information and materials: • With unique representation of the product molding machine boxes for transporting the patient."</seg>
<seg id="527">"the holder of permission for the Inleiding has to ensure that it was implemented in version 3.0 and in Module 1.8.1. of the authorisation introduced by the pharmacovigilance system and is functioning, before the drug is being applied to traffic, and as long as it is applied to the transport of pharmaceuticals."</seg>
<seg id="528">"the holder of permission for the Inleiding plan specified in the Pharmacovigilance plan and additional measures for Pharmacovigilance, as in Version 5 of the authorisation listed on the Risk Management Plan (RMP), as well as according to any subsequent update of the Risk Management Plan."</seg>
<seg id="529">"a recent review should be made available in accordance with the" CHMP guideline for Medicinal products for human use "at the same time, with the next updated report on the unimaginable report on drug using (Periodic Safety Update Report, PSUR)."</seg>
<seg id="530">"in addition, a recent review should be submitted: • when receiving new information, the impact on the current safety standards (Safety Specification), the Pharmacovigilance or the measures for the risk of risks associated with regard to reaching an important (the Pharmacovigilance or risk reduction) milestones • by the EMEA"</seg>
<seg id="531">• within one month before your treatment have suffered a heart attack or a stroke. if you suffer from instabiler Angina Pectoris (for the first time) - the risk of a blood-ropeer in the veins (deep Venenthrombs) - if you have previously occurred such a bloody ropic.</seg>
<seg id="532">"you may have heavy blood circulation of the heart (coronare heart disease), the arteries of legs or arms (peripheral adjustment of the carotives) or brain (vascular disease), you have recently had a heart attack or stroke."</seg>
<seg id="533">"during the treatment with Abseamed, it can come back to a light dosages-dependent increase in blood vessels that will come back in further treatment."</seg>
<seg id="534">Your doctor will carry out regular blood tests to regularly check the number of blood vessels during the first 8 weeks of treatment.</seg>
<seg id="535">"iron-angel, resolution of the red blood cells (Hämolyse), blood loss, vitamin-B12- or folksric angel should be taken into account and before the start of therapy with deportations."</seg>
<seg id="536">Very rare has been reported on the appearance of an anticulary yythroblastopenie after monate- up to years of treatment with subkutanem (under the skin) Erythropoetin.</seg>
<seg id="537">"if you suffer from Erythroblastopenie, he will break your therapy with abyss and determine how your anemia is best handled."</seg>
<seg id="538">"therefore, Abseamed must be given by injections in a Vene (intravenous) if you are treated because of an anemia due to a kidney disease."</seg>
<seg id="539">At a high hemogglove value the risk of problems with the heart or blood vessels exist and the sterilience could be increased.</seg>
<seg id="540">"with an increased or ascending potassium, your doctor can consider a interruption of the treatment with wastewamed, until the potassium are again in the standardization range."</seg>
<seg id="541">"if you suffer from chronic kidney and clinically obvious coronary heart disease, your doctor will make sure your doctor will not exceed a certain value."</seg>
<seg id="542">"after the present findings, due to the treatment of blood poverty with seabamed with chronic kidney disease (kidney efficiency), which are not yet dialysis, the progression of kidney efficiency is not accelerated."</seg>
<seg id="543">A 2 - 3-week delay between epetin-alfa-gift and the desired effect should be taken into account for assessing the effectiveness of wastewamed.</seg>
<seg id="544">200 your doctor will be able to determine your values of the red blood-color (hemogglobin) and to adjust your abnormal dose accordingly to keep the risk of a bleaching education (thrombal event) as low as possible.</seg>
<seg id="545">"this risk should be weighed over from treatment with epetin alfa, especially if you have an elevated risk for thrombotic vascular events, e.g. if you have fettless (adipous) or if you have existed already thrombal vascular events (e.g. a deep Venenthrombbell or Lpulembolie)."</seg>
<seg id="546">"if you are cancer patients, remember that Abseamed like a growth factor for blood cells and under certain circumstances can influence the tumor negative."</seg>
<seg id="547">"if you are upcoming a greater orthopedic surgery, the treatment begins with wastewamed the cause of your anemia and treated accordingly."</seg>
<seg id="548">"if your values of the red blood color (hemoglobin) are too high, you should not receive seamed as a elevated risk for blood vessels after the operation."</seg>
<seg id="549">Please inform your doctor or pharmacist if you use other medicines / apply or used especially if it is not prescription drugs.</seg>
<seg id="550">"if you take Ciclosporin (means to suppression of the immune system) during your therapy with Absinamed, your doctor will arrange certain blood tests to measure the blood level of Ciclosporin."</seg>
<seg id="551">Laboratory examinations have no interaction between epetin alfa and G-CSF and GM-CSF (G-CSF and GM-CSF are means of building the immune system, for example by cancer chemotherapy or with HIV). "</seg>
<seg id="552">"depending on how your blood-poverty (anemia) talks on the treatment, the dose may be adjusted for about every four weeks until your condition is under control."</seg>
<seg id="553">Your doctor will then arrange regular blood tests to verify the treatment success and ensure that the medicine does not work properly and your hemogglove value does not exceeds any particular value.</seg>
<seg id="554">"once you are well set, you will receive regular doses from Abseamed between 25 and 50 i.E. / kg twice weekly, divided into two equal injections."</seg>
<seg id="555">Your doctor will then arrange regular blood tests to verify the treatment success and ensure that your hemogglove value does not exceeds a particular value.</seg>
<seg id="556">"depending on how the anemia talks on the treatment, the dose may be adjusted for about every four weeks until the condition is under control."</seg>
<seg id="557">"to ensure and secure, that the hemogglove value does not exceeds a certain value, the doctor will perform regular blood tests."</seg>
<seg id="558">"if it is necessary to shorten the treatment time before surgery, a dosage of 300 I.UE. / kg at 10 consecutive days before surgery, on the day of the surgery and another 4 days after the surgery."</seg>
<seg id="559">"however, you can also learn if your doctor keeps this for appropriate, also learn how to splash yourself under the skin."</seg>
<seg id="560">"heart, Herzincolouring, brain bleeding, stroke, arteries, arterial trombs, oscillosuses of the retina and bloodine in artificial kidneys were reported in patients under Erythropoetin treatment."</seg>
<seg id="561">Eyeblider and the lips (quincke-eyelet) and shock-allergic reactions with symptoms like tingling, redness, hump, and accelerated powder were reported in rare cases. "</seg>
<seg id="562">Erythroblastopenie means that no longer exists enough red blood cells in the bone marrow (see section "Special caution in the application of Abseamed is required).</seg>
<seg id="563">After repeated blood pressure it can come - independently of the treatment with wastseamed (thrombotic vascular events).</seg>
<seg id="564">The treatment with seabamed may go with an increased risk for blood circulation according to the operation (postoperative thrombal vascular events) when your starting-moglobinds is too high</seg>
<seg id="565">Please inform your doctor or pharmacist if one of the listed side effects can be affected considerably or if you notice side effects that are not indicated in this usage information.</seg>
<seg id="566">"when a syringe from the fridge was taken from the fridge and room temperature (up to 25 ° C), it must be used either within 3 days or be rejected."</seg>
<seg id="567">"Aclasta is used for the treatment of the following illnesses: • Osteoporosis (an illness, which makes the bones, both in women after the menopause and in men."</seg>
<seg id="568">"it is applied to patients with a high fractional risk (bone marquarries), including patients who suffered recently a lesser strokes like at the fall; • Morbus Paget of the bone, an illness, which changed the normal course of bone growth."</seg>
<seg id="569">"in addition, patients with Morbus Paget should take at least 500 mg of calcium twice daily for at least 10 days after the treatment; patients with hip abuse should be obtained before the first infusion of vitamin D (50 000 to 125 000 IE)."</seg>
<seg id="570">"administration of Paracetamol or Ibuprofen (means against inflammation) shortly after the application of Aclasta can be reduced in the three days after the infusion of symptoms, such as fever, muscle aches, gripping ache and headaches."</seg>
<seg id="571">For the treatment of the Morbus Paget may only be prescribed by doctors who have experience in treating this disease.</seg>
<seg id="572">"since the active ingredient in Aclasta dersame is as in zometa, a part of the data material for zometa was attracted by Aclasta."</seg>
<seg id="573">"in the first study, nearly 8 000 older women were involved with osteoporosis, and it was investigated the number of spine and hip refractures over a period of three years."</seg>
<seg id="574">"the second study included 2 127 men and women with osteoporosis over 50 years, which suffered recently a girder cast; it was examined the number of fractures over a period of up to five years."</seg>
<seg id="575">"with Morbus Paget, Aclasta was tested in two studies in a total of 357 patients and compared six months long with Risedronat (a different bisphosphate)."</seg>
<seg id="576">Main Indicator for the effectiveness was whether the salary of the alkaline Phosphatase in Serum (a enzyme) in the blood is realized or decreased by at least 75% compared to the output value.</seg>
<seg id="577">"in the study with older women, the risk of spinal fractures was reduced by patients under Aclasta (without other Osteoporosemediente) over a period of three years compared to the patients below placebo by 70%."</seg>
<seg id="578">"in comparison of all patients under Aclasta (with or without other Osteoporosemediente), with those under placebo, the risk of hip refractures has been reduced by 41%."</seg>
<seg id="579">In the study with men and women with hip powers 9% of patients under Aclasta a Frale (92 of 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">Most side effects of Aclasta appear within the first three days after infusion and are less frequent.</seg>
<seg id="581">Aclasta may not be used in patients who may possibly excessive (allergic) against Zoledronic acid or other bisphosphor or any of the other components.</seg>
<seg id="582">"as with all Bisphosphates are subject to patients with aspirated risk of kidney, reactions to the infusion set and Osteonekrose (Abdie of bone tissue) in the jaws."</seg>
<seg id="583">"the manufacturer of Aclasta provides clearing material for doctors ready to apply the Aclasta for the treatment of osteoporosis, which contains how the medicine is used, as well as similar material for patients, in which the side effects of drug are explained and pointed out when they should address the doctor."</seg>
<seg id="584">"April 2005, the European Commission granted the company Novartis Europharm Limited approving the approval of Aclasta in the entire European Union."</seg>
<seg id="585">Conditions ODER limitations regarding secure AND efficient use OF pharmaceuticals are implemented by THE member states • Terms and Conditions ODER limitations regarding secure AND efficient use OF THE medicines by using THE member states of ZU are implemented</seg>
<seg id="586">Treatment of osteoporosis in postmenoporosis women and in men with an increased risk for fractures, including patients with a recently built low-traumatic girdles. "</seg>
<seg id="587">The patient information package should be provided and the following core message applies: • The packagance of calcium and vitamin D, adequate physical activity, the non-smoking and a healthy diet • Major signs and symptoms for serious side effects • whann to access medical or nursing assistance. "</seg>
<seg id="588">Treatment of osteoporosis • in case of postmenoporosis • in men with an increased risk for fractures, including patients with a recently built low-traumatic girdles. "</seg>
<seg id="589">For the treatment of postmenopausal osteoporosis and the osteoporosis in men a intravenous infusion of 5 mg of Aclasta once every year.</seg>
<seg id="590">"in patients with a low-traumatic girder, the administration of infusion of Aclasta two or more weeks after the operative care of the hip performance is recommended (see Section 5.1)."</seg>
<seg id="591">For the treatment of the Morbus Paget should only be prescribed by doctors who have experience in the treatment of the Morbus Paget.</seg>
<seg id="592">After treatment of the Morbus Paget with Aclasta a long remission period was observed in patients who responded to the therapy (see Section 5.1).</seg>
<seg id="593">"in addition, it is very advisable to guarantee patients with Morbus Paget an adequate supply of calcium, according to twice a day at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see section 4.4)."</seg>
<seg id="594">"in patients with a recent low-traumatisfaction, a initiator of 50,000 to 12,000 i.E. oralem or intramuscular vitamin D is recommended before the first Aclasta infusion."</seg>
<seg id="595">"the frequency of symptoms which occur within the first three days after the administration of Aclasta, can be reduced by gift from Paracetamol or Ibuprofen shortly after the application of Aclasta."</seg>
<seg id="596">Patients with kidney function (see Section 4.4) In case of patients with a creatinin Clearance &lt; 35 ml / min will not be recommended Aclasta as a limited clinical experience for this patient group.</seg>
<seg id="597">"older patients (≥ 65 years) A Dosisadaption is not necessary, since the bioavailability, distribution and Elimination in elderly patients is similar to younger."</seg>
<seg id="598">"children and young people of Aclasta is not recommended for use in children and young people under 18 years, since data are missing for inconsistency and effectiveness."</seg>
<seg id="599">Aclasta is not recommended in patients with severe kidney efficiency (Kreatinin Clearance &lt; 35 ml / min) since this patient's population is limited only limited clinical experience.</seg>
<seg id="600">A pre-existing hypokalzemia is before the start of therapy with Aclasta by adequate supply of calcium and vitamin D (see section 4.3).</seg>
<seg id="601">"due to the rapid introduction of the effect of Zoledronic acid on the bone structure, a temporary anaemia can develop, whose maximum usually occurs within the first 10 days after the infusion of Aclasta (see section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable to guarantee patients with Morbus Paget an adequate supply of calcium, according to twice a day at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see section 4.2)."</seg>
<seg id="603">"cancers, chemotherapy, treatment with corticians, bad oral hygiene) should be used before an application of bisphosphates a dental examination with reasonable dental treatment."</seg>
<seg id="604">"for patients who need dental carriages, are no data available whether the interruption of the treatment with Bisphosphor is reduced the risk for osteonekrosen in the orthodontics."</seg>
<seg id="605">The clinical evaluation by the treating doctor should be the basis for the treatment plan of each patient and are based on an individual benefit risk assessment.</seg>
<seg id="606">"the frequency of symptoms which occur within the first three days after agreement of Aclasta, can be reduced by gift from Paracetamol or Ibuprofen shortly after application of Aclasta (see section 4.2)."</seg>
<seg id="607">"the frequency of as serious side-effect in cases of pre-hoped was increased by patients who received Aclasta (1,3%) in comparison to patients who received placebo (0,6%) (22 of 3.852)."</seg>
<seg id="608">In the osteoporose-studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]) was the total rigidity of prehoped between Aclasta (2,6%) and placebo (2,1%). "</seg>
<seg id="609">"very common (≥ 1 / 10), frequent (≥ 1 / 100, &lt; 1 / 10), occasional (≥ 1 / 1,000, &lt; 1 / 1.000), rare drug interactions are listed in chart 1."</seg>
<seg id="610">"Nierenfunctioning Zoledronic acid was associated with kidney function, which brought itself as acceptance of the kidney function (i.e., an increase in serum-creatinins) and in rare cases as an acoratory fail."</seg>
<seg id="611">The change in the Kreatinin Clearance (measured before administration) and the appearance of kidney failure were measured in a clinical study at Osteoporosis over three years compared between the Aclasta- and the placebo group.</seg>
<seg id="612">A temporary increase in the serum Kreatinins within 10 days after gift was observed at 1.8% of patients with Aclasta treated patients compared to 0.8% of the patients treated with placebo patients.</seg>
<seg id="613">"based on the evaluation of the laboratory findings, the temporary calcium values indicated below the normal oscillation range (less than 2,10 mmol / l), with 2,3% of the patients treated with Aclasta in the Morbus Paget studies treated with Aclasta in the Morbus Paget studies."</seg>
<seg id="614">All patients received sufficient amounts of vitamin D and calcium in the study for postmenopausal osteoporosis in the study on avoiding clinical fractures and in the Morbus Paget studies (see Section 4.2).</seg>
<seg id="615">"in the study on avoidance of clinical trials, the vitamin D mirror were not a regular basis, however, the majority of patients received an initial dose of vitamin D before the administration of Aclasta (see section 4.2)."</seg>
<seg id="616">"local reactions after administration of Zoledronic acid in a large clinical study was reported on local reactions to the infusion set, such as redness, swelling and / or pain, reported (0.7%)."</seg>
<seg id="617">"Osteonekrosen in the orthodontics, mainly in cancer patients, about Osteonekrosen (primary in the orthodontics) reported that were treated with Bisphosphates, including Zoledronic acid."</seg>
<seg id="618">"many of these patients had signs for local infections including Osteomyelitis, and most of the reports refers to cancer patients to dental patients or other dental veneers."</seg>
<seg id="619">7 study with 7.736 patients joined Osteonekoarthritis in the orthodonate area at one with Aclasta and with a placebo treated patients.</seg>
<seg id="620">"in case of overdose, which leads to a clinically relevant hypokalzemie, can be reached by gift of oral calcium and / or an intravenous infusion of calcium gluconat."</seg>
<seg id="621">Clinical effectiveness in the treatment of postmenopausal osteoporosis (PFT) The effectiveness and safety of Aclasta 5 mg once a year for 3 consecutive years (7.736 women aged between 65 and 89) and at least two light or a medium-medium-T-Score for shenkelhy ≤ -2.5 with or without signs of an existing spine perfoods.</seg>
<seg id="622">Effects on morphometric whirlpools of Aclasta sened significantly significantly over a period of three years as well as after a year the frequency of one or more new spine perfections (see table 2).</seg>
<seg id="623">Aclasta-treated patients of 75 years and older had an increase of 60% reduced risk for spinal diseases compared to placebo-patients (p &lt; 0,0001).</seg>
<seg id="624">"effects on girfraktures Aclasta pointed an equal effect over three years, which resulted in one by 41% (95% CI, 17% to 58%) reduced risk to hip refractures."</seg>
<seg id="625">"effect on the bone density (BMD) Aclasta increased the bone density at the handlebar acid, hips and at the distal radius compared to all times (6, 12, 24 and 36 months)."</seg>
<seg id="626">"9 increasing the bone density of the Lendiwirling column around 6,7%, the total hips by 6,0%, the shenkelhum 5.4% and the distal radius by 3.2%."</seg>
<seg id="627">"Knochenhistology In case of 152 postmenopausal osteoporotic patients, which were treated with Aclasta (N = 70) or placebo (N = 70), a year after the third annual dose of bone biopsies were taken from the pelvic."</seg>
<seg id="628">A microcomputer tomography (µCT) analysis showed with Aclasta treated patients compared to placebo an increase in traverse bone volumption and maintaining the traverse bone architecture.</seg>
<seg id="629">Bone-sales marker The knob-specific phosphatorial Phosphatase (B1NP) in Serum and the Beta-C-Telopeptid (b-CTx) in Serum were determined in sub-groups of 517 to 1.246 patients in periodic interactions.</seg>
<seg id="630">The treatment with an annual 5 mg dose of Aclasta reduced BSAP after 12 months significantly increased by 30% compared to the output level and was held at 28% below the starting point for 36 months.</seg>
<seg id="631">P1NP was significantly reduced by 61% below the starting point after 12 months and has been kept at 52% below the starting point for 36 months.</seg>
<seg id="632">B-CTx was significantly reduced by 61% below the output value after 12 months and was kept at 55% below the starting point for 36 months.</seg>
<seg id="633">"vitamin D mirror were not very routinely measured, but most of the patients received an initial impulse of vitamin D (50,000 to 125,000 i.E. oral or intramuscular) 2 weeks before the infusion."</seg>
<seg id="634">The total mortality lay at 10% (101 patients) in the group of Aclasta treated group compared to 13% (141 patients) in the placebo group.</seg>
<seg id="635">Effect on the bone mineral density (BMD) In the HORIZON-RFT-study increased the Aclasta treatment compared to placebo treatment the BMD at all times.</seg>
<seg id="636">The Aclasta treatment led more than 24 months compared to placebo treatment to an increase in BMD by 5.4% in total and around 4,3% at the skeleventh.</seg>
<seg id="637">"clinical effectiveness in men In the HORIZON-RFT-study, 508 men were randomized and in 185 patients the BMD was assessed after 24 months."</seg>
<seg id="638">The study was not designed to show a reduction in clinical factions in men; the frequency of clinical fractures was 7.5% at Aclasta-treated men compared to 8.7% on placebo.</seg>
<seg id="639">In another study in men (study CZOL446M2308) was once an annual convention of Aclasta compared to once weekly change of Alendronat based on the percentage change of the Lenawirbel BMD after 24 months compared to the starting value.</seg>
<seg id="640">Clinical effectiveness of the treatment at Morbus Paget's treatment at the age of 30 years with radiologized mordial Paget of the bone investigates (middle serum mirror of the alkaline Phosphatase according to the 2,6pm to 3.0triple-specific upper normal value for recording into the study).</seg>
<seg id="641">11 The effectiveness of an infusion of 5 mg Zoledronic acid compared to intake of 30 mg Risedronat once every day during 2 months was proven in two sixteen studies studies.</seg>
<seg id="642">"after 6 months, after 6 months a similar acceptance of pain relief and pain-influenced in comparison to the starting value for Aclasta and Risedronat was observed."</seg>
<seg id="643">Patients who were classified at the end of the Sixsmonatigen main study as the Responsider (on the therapy) were added to a follow-up phase.</seg>
<seg id="644">"of the 143 with Aclasta and the 107 with Risedronat treated patients, the therapeutic approach was treated at 141 of the patients with Aclasta, compared to 71 of the follow-up phase of 18 months after application."</seg>
<seg id="645">"unique and multiple 5 and 15 minutes to feed infusion of 2, 4, 8 and 16 mg Zoledronic acid at 64 patients with the following pharmacokinetic data which proved to be dosisindependently."</seg>
<seg id="646">"after that, the plasmasegel took rapidly starting to &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 h, followed by a long lasting phase very low concentration, no more than 0,1% of the maximum value."</seg>
<seg id="647">"rapid disappearance from the big cycle with half-value-times ½ α 0,24 and t ½ ß 1,87 hours, followed by a long Elimination phase with a temporal Elimination period t ½ of 146 hours."</seg>
<seg id="648">The early distribution phases (α and β, with the above mentioned ½ -values) we probably represent the fast Resorption in the bones and the expropriation over the kidneys. "</seg>
<seg id="649">"in the first 24 h, 39 ± 16% of the agreed dose were bound in the urine while the rest is mainly tied at bone tissue."</seg>
<seg id="650">"the total body Clearance is independent of the dose 5,04 ± 2,5 l / h and remains uninfluenced by gender, age, race or body weight."</seg>
<seg id="651">"an extension of the infusion period of 5 to 15 minutes led to the decrease of the Zoledroneous concentration by 30% at the end of infusion, but had no effect on the surface under the curve (plasma centration against time)."</seg>
<seg id="652">"decreased Clearance by cytochrom-P450-Enzymsystems metallized substances is unlikely, because Zoledronic acid is not metabolized because they are a watchful or no direct and / or irreversible, interdependent inhibitor of the P450-"</seg>
<seg id="653">Special patient groups (see Section 4.2) The renal Clearance of Zoledronic acid correlation with the Kreatinin Clearance, namely 75 ± 33% of the loans in the average 84 ± 29 ml / min (range 22 to 143 ml / min). "</seg>
<seg id="654">This results in fact that an easy (Clcr = 50- 80 ml / min) and a homogeneous kidney functioning up to 35 ml / min does not require a dosage adjustment of the Zoledronic acid.</seg>
<seg id="655">"for severe kidney-functioning (Kreatinin- Clearance &lt; 30 ml / min), only limited data are not limited to this population."</seg>
<seg id="656">Acute toxicity The highest not letal intravenous individual dose was with mice 10 mg / kg body weight and with rats ± 6 mg / kg body weight.</seg>
<seg id="657">"in studies of dogs, individual doses of 1,0 mg / kg (based on the AUC the 6500 of the recommended human therapeutic exposure), given over a period of 15 minutes, good and without a renal flow."</seg>
<seg id="658">"chronic and chronical toxicity In studies with intravenous application was arranged by doses of 0,6 mg / kg as 15-minute infusion in 3-day infusion in 3-day infusion in 3-day infusion in 3-day infusion (a cumulative dose, which is sufficient in Intervallen of 2- 3 weeks (a cumulative dose which corresponds to the 7triple of human therapeutic exposure, covered to the AUC, corresponds), well tolerated."</seg>
<seg id="659">"in long-term studies with repeated Examination, which exceeded the maximum of the intended Human exposure effects with other organs, including the Gastrosyinaltrakt and the liver, as well as on the intravenous inject."</seg>
<seg id="660">"the most common evidence of studies with repeated application was a longer primary Spongiosa in the metaphysical Spongiosa on animals in the growth phase, with almost all dosages, a evidence that reflects the pharmacological effect of substance."</seg>
<seg id="661">In rats you watched a teratogenic at doses from 0,2 mg / kg as outer and inner (visceral) abnormalities and such skeleton.</seg>
<seg id="662">At rabbits were no teratogenic effects or embryos effects observed though the maternal toxicity in 0,1 mg / kg as a result of the lowest serum lium mirror was pronounced.</seg>
<seg id="663">"if the medicine is not directly used, the user is responsible for the storage time after preparation and the conditions before the application; normally 24 h at 2 ° C to 8 ° C will not be exceeded."</seg>
<seg id="664">"Aclasta is supplied as a package containing a bottle as packing unit, or as a bunch of 5 packs, each one bottle is supplied."</seg>
<seg id="665">Treatment of osteoporosis in postmenoporosis women and in men with an increased risk for fractures, including patients with a recently built low-traumatic girdles. "</seg>
<seg id="666">The patient information package should be provided and the following core message applies: • The packagance of calcium and vitamin D, adequate physical activity, the non-smoking and a healthy diet 17 • Important signs and symptoms for serious side effects • whann to access medical or nursing assistance. "</seg>
<seg id="667">"July 2007, supplemented on 29 September 2006, in the module 1.8.1 of the authorisation described by the Pharmacovigilance System in force before and when it is marketed throughout the product."</seg>
<seg id="668">"Risko-Management plan the owner of the approval for the Independence is committed to the studies and the additional activities on Pharmacovigilance, which adopted in the Pharmacovigilance Plan (RMP) in Module 1.8.2 of the authorisation and of all the following through the CHMP authorised versions of the RMP."</seg>
<seg id="669">"according to the CHMP directive on risk management systems for human medicine, the revised RMP should be submitted together with the next" Periodic Safety Update Report (PSUR). "</seg>
<seg id="670">"a working copy should be submitted • If new information is known, which could influence the current statements on security, the Pharmacovigilance Plan or activities for minimization of risk assessment or risk minimization). • On request of the EMEA."</seg>
<seg id="671">"Zoledronic acid is a representative of a subclass class, called the Bisphosphor, and is used for treatment of osteoporosis in postmenoporosis in men and the Morbus Paget of the bone."</seg>
<seg id="672">"the blood flow of sex hormones, especially oestrogen, which are formed from androgen, play a role in the rather gradual loss of bone mass that is observed in men."</seg>
<seg id="673">"at the Morbus Paget, the bone structure is carried out quickly, and new bone material is structured as normal, which makes the bone material weaker than normal."</seg>
<seg id="674">"Aclasta works by making it again normalized, thereby a normal bone-building and thus gives rise to the bones again."</seg>
<seg id="675">"if you are in dental treatment or do not need dental surgery, please inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"for use of Aclasta with other medicines. please inform your doctor, pharmacist or nursing staff, if you use other medicines / apply or have recently taken / apply, even if it is not prescription medicine."</seg>
<seg id="677">"for your doctor it is particularly important to know if you take medicine, of which it is known that they compensate the kidneys."</seg>
<seg id="678">"with use of Aclasta, with food and drink, you are concerned that you can take enough fluid in accordance with the instructions of your doctor, before and after the treatment with Aclasta."</seg>
<seg id="679">"Osteoporose The usual dose is 5 mg once a year, which is given to you by your doctor or nursing staff as infusion in a Vene."</seg>
<seg id="680">"if you have recently broken the hips, it is recommended to make appointments of Aclasta two or more weeks after the operating supply of hip."</seg>
<seg id="681">Morbus Paget The usual dose is 5 mg that is given to you by your doctor or nursing staff as infusion in a Vene.</seg>
<seg id="682">"since Aclasta for a long time, you may possibly need a further dose only after one year or longer."</seg>
<seg id="683">"it is important to follow these instructions precisely, so that the calcium mirror in your blood is not too low in time after infusion."</seg>
<seg id="684">"at Morbus Paget can work Aclasta longer than a year, and your doctor will inform you when you need a renewed treatment."</seg>
<seg id="685">If the administration of Aclasta matches your contact with your doctor or hospital to arrange a new appointment.</seg>
<seg id="686">"before ending the therapy with Aclasta, you will be able to ending the treatment with Aclasta, please take your next physician first and discuss this with your doctor."</seg>
<seg id="687">"side effects in connection with the first infusion set very often on (with more than 30% of patients), are often less common after subsequent infusion."</seg>
<seg id="688">"fever and Schütz, muscle - or joint pain and headaches, come within the first three days after the administration of Aclasta."</seg>
<seg id="689">"currently, it is unclear whether Aclasta causes this irregular heart attack, but you should report it to your doctor if you notice such symptoms when you get Aclasta."</seg>
<seg id="690">"physical signs due to a low calcium concentration in the blood, such as muscle-mole or warns, especially in the area around the mouth."</seg>
<seg id="691">"flu, sleeplessness, fatigue, tiredness, tremness, melting, pannicious, mulateness, mulateness, mulateness, mulateness, melting, casual skin, common skin, affluctance, casual skin, common skin, affluctance, melting, affluctance, melting, affluctance, hormonal skin, affluctance, melting, affluctance, hormonal skin, affluctance, melting, melting, melting, horsore, horsantage, horsantage, and thirst."</seg>
<seg id="692">"lasting pain and / or not healing wounds in the mouth or at the jaws were reported above all in patients, which were treated with Bisphosphor because of other diseases."</seg>
<seg id="693">"about allergic reactions, including rare cases of respiratory problems, Nesselrash and angioars (such as swelling in the face, the tongue, or in Rachen), was reported."</seg>
<seg id="694">"please inform your doctor, pharmacist or nursing staff, if one of the listed side effects you can considerably impaired or you notice side effects that are not listed in this usage information."</seg>
<seg id="695">"if the medicine is not directly used, the user is responsible for the storage time and conditions up to the application; normally 24 h at 2 ° C to 8 ° C will not be exceeded."</seg>
<seg id="696">"in patients with a recently built low-traumatic girdles, the infusion of Aclasta two or more weeks after the operative care of the girdles."</seg>
<seg id="697">"before and after the administration of Aclasta, patients must be supplied sufficiently with fluid; this is especially important in patients who receive a diuretic therapy."</seg>
<seg id="698">"due to the rapid introduction of the effect of Zoledronic acid on the bone structure, a temporary, sometimes symptom-running, hypokalzemie develop, whose maximum usually occurs within the first 10 days after the infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable to guarantee patients with Morbus Paget an adequate supply of calcium, according to at least twice daily 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently built low-traumatic girder, a initial dose of 50.000 up to 125,000 I.E. oralem or intramuscular vitamin D recommended before the infusion of Aclasta."</seg>
<seg id="701">"if you require any further information about your disease or treatment, please read the package passing (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="702">ACOMPLIA is additionally applied to a diet and movement for the treatment of adult patients (body mass index - BMI) of 30 kg / m ² or above or • the overweight (BMI of 27 kg / m ² or above) and beyond.</seg>
<seg id="703">"furthermore, four studies conducted at over 7 000 patients in which ACOMPLIA was used as a supportive means for setting up the prey."</seg>
<seg id="704">"to the studies for setting up the prey, there was no uniform results, so that the effect of ACOMPLIA was difficult to assess this application area."</seg>
<seg id="705">Which risk is associated with ACOMPLIA? he had observed The most common side effects of ACOMPLIA who were observed during studies (observed in over 1 of 10 patients) were nausea (nausea) and infections of the upper breaths. ng The complete listing of the side effects associated with ACOMPLIA reported side effects is the package passing.</seg>
<seg id="706">It may also be used in patients who are suffering from an existing severe depression or treated with antidepressants since it can increase the risk of depression and among others with a small minority of patients suicians.</seg>
<seg id="707">Beware is offered in the current application of ACOMPLIA with medicines such as Ketoconazol or Itraconazol (medicine against fungal infections), Telithromycin or Clarithromycin (antibiotics). LN</seg>
<seg id="708">The Committee on Humancision (CHMP) to conclude that the effectiveness of ACOMPLIA in terms of weight reduction in patients with obesity or overweight</seg>
<seg id="709">Medicines is used for patients who need health and not from cosmetic reasons (through provision of clearing up for patients and doctors) and around the Arz</seg>
<seg id="710">It Additional to diet and exercise for treating a Adiposas (BMI ≥ 30 kg / m ²) or overweight patients (BMI &gt; 27 kg / m ²) which also have one or more risk factors (see Section 5.1).</seg>
<seg id="711">ACOMPLIA is not recommended for use in children and young people under 18 years of age on the basis of miscarriage of data and unthinkable.</seg>
<seg id="712">"La depressant diseases or voting changes with depressants symptoms were received at up to 10%, Suan exceeding in up to 1% of patients who received RimonBrabant (see section 4.8)."</seg>
<seg id="713">"and in depressants disturbances may not be applied, unless the benefits of treatment in the individual case weighs out the risk (see section 4.3 and 4.8)."</seg>
<seg id="714">"he also Also in patients, which - beside the Adiposas - no recognizable risks can occur without depressed reactions."</seg>
<seg id="715">"related or other closest people) are to point out that it is necessary to monitor the re-operation of such symptom and get immediately medical advice, when these symptoms arise."</seg>
<seg id="716">• Elder patients The effectiveness and unthinkable of RimonBrabant in the treatment of patients over 75 years were not sufficiently demonstrated.</seg>
<seg id="717">Patients with a kardiovascular event (myokardincolored or stroke etc.) before less than 6 months ago were elaborated by studies with RimonBrabant.</seg>
<seg id="718">"Rifampicin, phenytoin, Phenytoin, Phenobtoepin, Johannisamazepin, Johanniskraut) is assumed that the simultaneous gift of potent CYP3A4-Inductors is the plasma concentration of RimonBrabant"</seg>
<seg id="719">"SSE are overweight patients and patients with obesity, and furthermore at 3800 patients in other indications."</seg>
<seg id="720">"to The following table (table 1) shows the unwanted effects in placebocontrolunsupported studies in patients, which were treated to weight reduction and due to accompanying metabolic diseases."</seg>
<seg id="721">He significantly significantly higher than the corresponding placeborate (for unwanted effects ≥ 1%) or if they were clinically relevant (for unwanted effects &lt; 1%). ng At the evaluation of side effects are basically laid down the following skins:</seg>
<seg id="722">Very frequent (≥ 10%); frequent (≥ 1, &lt; 10%); occasionally (≥ 0,1, &lt; 1%); rarely (≥ 0.01, &lt; 0,1%); very t lä "</seg>
<seg id="723">"in a familiarity study, in which a limited number of persons declined by up to 300 mg, only light symptoms were observed."</seg>
<seg id="724">Patients had an BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and one at the same time an existing hypertone and / or dyestidemia.</seg>
<seg id="725">"N weight reduction after one year amounted to ACOMPLIA 20 mg 6,5 kg, related to the output value, compared to 1.6 kg for the placebo group (difference -4,9 kg CI95% -5.5; -4,4, p &lt; 0,001)."</seg>
<seg id="726">"the patients treated with ACOMPLIA 20 mg, and 1.2 kg in the placebo group (difference -3.8 kg; CI95% -4,4, -3.3; p &lt; 0,001)."</seg>
<seg id="727">After 2 years the difference in the total weight reduction between ACOMPLIA and placebo -4.7 kg (CI95% -5.5%; -3,4, p &lt; 0,001). "</seg>
<seg id="728">9 weight reduction and other risk factors in the studies in patients without diabetes in which a mixed population of patients with</seg>
<seg id="729">Under RimonBrabant 20 mg became an average waste of triglyceride of 6.6% (starting triglyceride 1,62 mmol / l) compared to an increase of 5,8%</seg>
<seg id="730">"in a second study in patients with a Adiposal type (Serenade), the absolute change in HbA1c value (with an output value of 7,9% for both groups) after 6 months -0.8 for RimonBrabant 20 mg and 0.3 under placebo"</seg>
<seg id="731">"the percentage of patients who reached a HbA1c- value of &lt; 7%, was 51% in the RimonBrabant Group and 35% in the placebo group."</seg>
<seg id="732">The difference between the medium weight change between the 20 mg- and the placebo group was at 3.8 kg (CI95% -5.5% -2.6 p &lt; 0,001). LN</seg>
<seg id="733">"improvement of the HbA1c-value in patients, the RimonBrabant 20 mg had taken approximately 50% by direct effects of RimonBrabant, and about 50% by the weight reduction of barbar. n eim Arz"</seg>
<seg id="734">2 hours reaches the steady State plasma cutting doors were reached after 13 days (Cmax = 196 ± 28,1 ng / ml; Cephalgh = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"the food: he received Probanden, received the RimonChicago or after a fat meal, in case of food supply a um 67% increased Cmax respectively by 48% increased ng AUC."</seg>
<seg id="736">Patients with black skin colour can have a up to 31% lower Cmax and one by 43% lower AUC as patients of other ethnic populations.</seg>
<seg id="737">N populationspocinetic analyses (age range 18- 81 years) is estimated that a 75- three-year patient is estimated at 21% higher Cmax and a around 27% higher AUC than a 40-year</seg>
<seg id="738">"5.3 preclinical data on safety, they were not observed in clinical trials which were not observed in clinical trials, but were evaluated in animals after exposure in human therapeutic sector, have been assessed as possibly relevant to the clinical application:"</seg>
<seg id="739">"in some, however, not in all cases the beginning of the convulsions seems to be associated with technological stress such as dealing with animals."</seg>
<seg id="740">"was given RimonBrabant over a longer period before the combination (9 weeks), which allowed a recovery from the initials effects of RimonBrabant, so no unwanted effects were observed on the fertilisation or cycles."</seg>
<seg id="741">The influence of RimonBrabant on the pre- and postnatal development was examined at the Ratte in doses of up to 10 mg / kg / day.</seg>
<seg id="742">"in a study on rats and postnatal development, an exposure of RimonBrabant in utero and by means of lactose no changes in learning or memory."</seg>
<seg id="743">Detailed information on this medicine is available on the website of the European medicines Agency (EMEA) http: / / www.emea.europa.eu / availability. itte n eim Arz</seg>
<seg id="744">"La On the packs of the drug, the name and address of the manufacturer, which are responsible for the release of the charms."</seg>
<seg id="745">"26 Heating psychiatric events such as depression or voting changes have been received in patients, the ACOMPLIA, reports (see)"</seg>
<seg id="746">"SSE If you are symptoms of depression (see below) during the treatment with ACOMPLIA, please contact your doctor and break the treatment."</seg>
<seg id="747">"shwindle-feeling, anxiety, anxiety, juckwise, fatigue, fatigue or inflammability, spache, spache, back pain and inflammation) on hands and feet, Hitzewallings, Sturz, gripping infectious."</seg>
<seg id="748">SSE please consult your doctor or pharmacist if one of the listed side effects may not be affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="749">"summary of the EPAR for the public, this document is a summary of the European Public Beurry report (EPAR), which explains how the Committee on Human Rights (CHMP) has been evaluated in order to obtain recommendations concerning the use of the drug."</seg>
<seg id="750">Actos is applied to the treatment of type-2 diabetes (also known as not insulindependent diabetes). • It can be used alone (Monotherapy) in patients (especially overweight patients) in which Metformin (a diabetesmedimedication) is not displayed. • It can be applied together with another Diabetesmedimedication (dual therapy).</seg>
<seg id="751">It can be used in addition to Metformin patients (especially overweight patients) which can not be satisfactory with Metformin alone in the highest tolerable dose.</seg>
<seg id="752">"in combination with a sulphylharness or insulin, the previous dose of the sulphylharnems or insulin can be retained by patients with hypoglycemic (low blood sugar); here should be reduced the dose of the sulphylharnems or the insulin."</seg>
<seg id="753">"this means that the body of your own insulin can be better tolerated and the blood sugar levels, which can also adjust type-2 diabetes."</seg>
<seg id="754">"with more than 1 400 patients the effectiveness of Actos in Tripletherapy, patients received a combination of metformin with a sulphylharness, in addition they received up to 3.5 years either Actos or placebo."</seg>
<seg id="755">"in studies, the concentration of a substance in the blood has been measured in the blood (glycoylified hematglobin, HbA1c) which shows how well the blood sugar is set."</seg>
<seg id="756">"Actos led to a reduction in HbA1c value, which makes blood sugar values in use of doses of 15 mg, 30 mg and 45 mg were cut."</seg>
<seg id="757">"at the end of the Tripleal study, the effect of additional gift from Actos to existing treatment with metformin and a sulphylharness in a reduction of HbA1c values by 0.94%, while the additional gift of placebo to a reduction of 0.35% led."</seg>
<seg id="758">"in a small study where the combination of Actos and insulin have been studied in addition to patients who took the Actos in addition to insulin, a reduction in HbA1c values of 0.7% after 6 months, compared to 0.14% in the patients, which were in addition placebo."</seg>
<seg id="759">"the most common side effects in connection with Actos were visible disorders, infections of the upper breaths (decreasing sensitivity), weight increases and hypolithesia (decreased sensitivity to irritation)."</seg>
<seg id="760">Actos may neither be used in patients who may react possibly sensitive (allergic) compared to Pioglitazone or one of the other components to be used in patients with liver problems, herring efficiency or diabetic ketoazibox (high concentration) - bags - in the blood). "</seg>
<seg id="761">It has been decided that Actos in the framework of a monotherapy (for the sole use) as an alternative to the standard treatment with metformin patients is to serve in which Metformatted is not indicated.</seg>
<seg id="762">"October 2000, the European Commission granted the company Takeda Europe R & D Centre Limited has permission for the approval of Actos in the entire European Union."</seg>
<seg id="763">"the tablets are white until white, round, weighed and wear on one side the markings" 15 "and on the other side the" "Actos". ""</seg>
<seg id="764">"Pioglitazon is also displayed for combination with insulin in patients with type 2 diabetes mellitus, whose blood sugar is inadequate at insulin and with which Metformations is inappropriate (see section 4.4)."</seg>
<seg id="765">"for use of Pioglitazone in patients under 18 years of age, no data is available, therefore the application in this age group is not recommended."</seg>
<seg id="766">"in patients suffering from the presence at least a risk factor (e.g. earlier Herziness or symptomatic coroneness) at risk, the doctor should start treatment with the lowest available dose and increase the dose."</seg>
<seg id="767">"patients should be observed at signs and symptoms of a heart efficiency, weight increases or ödeme to be observed especially those with reduced cardiology reserve."</seg>
<seg id="768">Patients should be observed at signs and symptoms of a heart efficiency and can be observed if Pioglitazone is applied in combination with insulin.</seg>
<seg id="769">A kardiovascular Outcome study with Pioglitazon in patients under 75 years of type 2 diabetes mellitus and preammatory illness was carried out.</seg>
<seg id="770">"in this study, an increase in reports about heart efficiency, which however did not lead to an increase in morality in the study."</seg>
<seg id="771">"in patients with increased stamina, ALT &gt; 2,5 x upper limit of the standard range) or with other signs of a liver disease may not be used."</seg>
<seg id="772">"if the ALT-Spiegel can be raised up to the 3-fold the upper limit of the standard division, the liver ymers are to control as soon as possible."</seg>
<seg id="773">"if a patient symptoms developed, which are developed on a hepatic dysfunction, such as unclarifying, fatigue, fatigue, appetite and / or darker resin, are the liver ymers."</seg>
<seg id="774">The decision whether the patient treatment should be continued with Pioglitazon should be guided until the foreseen of the laboratory parameters.</seg>
<seg id="775">"in clinical studies with Pioglitazone, a dosages-dependent weight increases, which can be seen by lipossessions and in some cases with a liquid quality."</seg>
<seg id="776">As a result of a hemispheres occurred under the therapy with Pioglitazone a low reduction of the middle hematglove values (relative reduction around 4%) and the hematocrits (relative reduction around 4,1%).</seg>
<seg id="777">Similar changes have been observed in comparative controlled studies with Pioglitazone in patients under Metformin (relative reduction of hematylharnstoff and insulin (relative reduction in hematylharnstoff and insulin (relative reduction in hematylharnstoff and insulin (relative reduction of hematoid to 1-2% and the hematocrits at 1-3.2%).</seg>
<seg id="778">"as a result of increased incidence in patients, Pioglitazon as orale two-combination therapy with a sulfur-combination therapy with insulin-combination therapy with insulin, the risk of a doscope-dependent hypoglycemic."</seg>
<seg id="779">"after the launch of the market launch under the treatment with Thiazolidindions, including Pioglitazon, about a occurrence or deterioration of a diabetic maculadems with a reduction of visual sharpity."</seg>
<seg id="780">"it is unclear whether there is a direct connection between the intake of Pioglitazon and the appearance of Makulaödemen, however, the possibility of a Makulaödems should be aware of the possibility of a Makulaödems; a suitable ophthalmological statement should be considered."</seg>
<seg id="781">"in a summary analysis of reports of unwanted events regarding bone marquitting from randomized, controlled, double clinical trials over a period of up to 3.5 years with more than 8.100 patients who have been treated with Pioglitazone."</seg>
<seg id="782">The calculated Fraum-Inzipped amounted to 1.9 fractures per 100 patient-years with Pioglitazon treated women and 1,1 fractures per 100 patient-years with women who have been treated with a comparative study.</seg>
<seg id="783">"in the proactive study, a study of 3,5 years for the study of kardiovascular events, compared with 23 / 905 (2.5%; 1.1 fractures per 100 patient years) with patients treated with a comparative study."</seg>
<seg id="784">"the patients should be aware of the possibility of pregnancy, and if a patient wishes a pregnancy or it occurs, the treatment is abide (see Section 4.6)."</seg>
<seg id="785">Studies on the investigation of interactions have shown that Pioglitazone does not have relevant effects on the Pharmacoinetics or Pharmacodynamics of Digoxin, Varprocoumon and Metformin. "</seg>
<seg id="786">"interactions with pharmaceuticals that are metabolized by these enzymes, e.g. orale contrazeptive, cymbumkanalblocker and HMGCoA-Reduction are not expected."</seg>
<seg id="787">The simultaneous application of Pioglitazon with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) result in an increase in the AUC from Pioglitazon around the 3-fold.</seg>
<seg id="788">Simultaneous application of Pioglitazon with Rifampicin (a cytochrom P450 2C8-Induction) result in a reduction in the AUC from Pioglitazon by 54%.</seg>
<seg id="789">This is due to it that under treatment with Pioglitazone which is diminished in the pregnancy of hyperinsulinemia and increased insulin to decrease the availability of the metabolic substrates for the killing growth.</seg>
<seg id="790">Very common &gt; 1 / 10; frequent &gt; 1 / 100; &lt; 1 / 10; occasionally &gt; 1 / 10000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual cases: unknown (from this data will not be estimated). "</seg>
<seg id="791">These lead to a temporary change of the turbine and the billing indexes of the lens as they can also be observed in other hypoglycemic drugs.</seg>
<seg id="792">"in clinical studies with Pioglitazon, ALT-Anstiege played over the triples of the standard area often equally at placebo, however rare than in comparison groups under metformin or Sulphylharnstoff."</seg>
<seg id="793">In a outcome study in patients with advanced advanced macrovasculosis's disease was the frequency of a heavy herd efficiency while Pioglitazon around 1.6% higher than under placebo when Pioglitazon bzw.</seg>
<seg id="794">"since the launch, it has been reported by means of Herziness efficiency under Pioglitazon, however, more frequently when Pioglitazone was used in combination with insulin and in patients with heart efficiency in the Anamnese."</seg>
<seg id="795">"it became a summary analysis of reports of unwanted events regarding bone marquarries from randomized, controlled, double clinical trials over a period of up to 3.5 years with more than 8.100 patients treated with Pioglitazon treated groups and over 7.400 patients in the groups involved in comparison-media treatment."</seg>
<seg id="796">"over a period of 3.5 years of ongoing proactive study, the fractures appeared at 44 / 870 (5,1%) of the patient with Pioglitazon treated patients with 23 / 905 (2.5%) in patients with a comparative study."</seg>
<seg id="797">"at intake of the maximum dose of 120 mg / day over four days, then 180 mg / day over seven days no symptoms occurred."</seg>
<seg id="798">Pioglitazon seems to have a activation of specific core recipe (peroxide) to work in the animal model to an increased insulin-sensitive sensitivity of liver, fat and skeleton muscle cells. "</seg>
<seg id="799">It could be shown that Pioglitazon reduces the Glucoseproduction in the liver and increases the peripheral gluten-valuation in case of insulinresistant.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclazide as Monotherapy has been continued over two years to investigate the time until leaving the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 treatments).</seg>
<seg id="801">"at the time after two years after the therapy, a blood sugar control (defined as HbA1c &lt; 8,0%) by Pioglitazon at 69% of the patients (compared to 50% of patients under Gliclazid)."</seg>
<seg id="802">"in a placebocontroluned study about 12 months, patients whose blood sugar were inadequate despite three intonatiful optimization phase with insulin, to Pioglitazone or placebo."</seg>
<seg id="803">"in patients under Pioglitazon reduced the medium sized HbA1c - value by 0.45%, compared to patients who continued only insulin; a reduction in insulin in the group has been observed."</seg>
<seg id="804">"in clinical studies over one year, under Pioglitazon consistently showed a statistically significant acceptance of the Albumin / Kreatinin-Quotions compared to the output values."</seg>
<seg id="805">The effect of Pioglitazon (Monotherapy with 45 mg versus placebo) was checked in a small, on 18 weeks by examining type-2 Diabetics. "</seg>
<seg id="806">In most clinical trials compared to placebo a reduction of the total plasma clash and the free fatty acids and a rise of HDL- cholesterol levels as well as little feet, but clinically not significantly increased LDL- cholesterol levels. "</seg>
<seg id="807">In clinical studies over a period of up to two years Pioglitazone compared to placebo, metformin or liclazid the overall plasticity and the free fatty acids, and increased the HDL cholesterol levels. "</seg>
<seg id="808">Compared to placebo under Pioglitazon was not determined statistically significant increase in the LDL cholesterol levels while under Metformin and Gliclazid diminished values were observed.</seg>
<seg id="809">"in a study of 20 weeks reduced pioglitazone not only the sober triglyceride, but also improved the postprandial elevated triglyceride mirror, this has an effect on the triglycavities and on the hepatic triglycavities synthesis."</seg>
<seg id="810">"in the proactive study, a kardiovascular Outcome study, 5238 patients were randomized with type 2 diabetes mellitus and advanced medical illness in groups, which has received a period of up to 3.5 years in addition to existing antidiabetic and kardiovascular therapy either Pioglitazone or placebo."</seg>
<seg id="811">"according to oral application Pioglitazon quickly resorated, whereby the peak of concentration in unchanged pioglitazone will usually be reached 2 hours after application."</seg>
<seg id="812">"based on this basis, the contribution of M-IV is based on the effectiveness of Pioglitazon, where the relative effectiveness of M-II is minimal."</seg>
<seg id="813">"in Interaction studies, Pioglitazon could not have relevant effect on the pharmacoinetics or pharmacodynamics of Digoxin, Varprocoumon and Metformin."</seg>
<seg id="814">Simultaneous application of Pioglitazon with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) or with Rifampicin (a cytochrom P450 2C8-Induction) (see Section 4.5).</seg>
<seg id="815">"after the application of radioactive markisen Pioglitazon, the marker became mainly found in the fur (55%), and to a lower extent in the Harn (45%)."</seg>
<seg id="816">"the middle plasma-Eliminationshalbumal time of unchanging pioglitazone is at the people 5-6 hours, and the whole active metaboo is at 16 - 23 hours."</seg>
<seg id="817">"the plasma concentration of Pioglitazon and his metaboo are lower in patients with reduced kidney function lower than with healthy proportions, whereby the mares of the oral Clearance of the parent company were similar."</seg>
<seg id="818">"in toxicological studies they appeared in mice, rats, dogs and monkeys agreement after repeated agreement of Plasmailed Plasmasts, anemia and reversible centric heart hyperhypertrophy."</seg>
<seg id="819">"this is due to that treatment with Pioglitazon which is diminished under the treatment of hyperinsulindemia, and increased insulin to decrease the availability of the metabolic substrates for the killing growth."</seg>
<seg id="820">In long-term studies (up to 2 years) were induced at the Ratte increased incidence of hyperplasia (with male and female rats) and tumors (at male Ratting) of the urgency epithelium.</seg>
<seg id="821">In an animal model of family meromatant Polyposis (FAP) conducted the treatment with two other Thiazolidindions to an increased frequency of colonizers.</seg>
<seg id="822">"the tablets are white to white, round, flat and wear on one side the markings" 30 "and on the other side the" "Actos". ""</seg>
<seg id="823">The calculated Fraum-Inzipped amounted to 1.9 fractures per 100 patient-years with Pioglitazon treated women and 1,1 fractures per 100 patient-years with women who have been treated with a comparative study.</seg>
<seg id="824">"in the proactive study, a study of 3,5 years for the study of kardiovascular events, compared with 23 / 905 (2.5%; 1.1 fractures per 100 patient years) with patients treated with a comparative study."</seg>
<seg id="825">"in a further study over two years, the effects of a combination therapy of metforman with Pioglitazon or Gliclazid were investigated."</seg>
<seg id="826">"in clinical studies over 1 year, under Pioglitazon consistently showed a statistically significant acceptance of the Albumin / Kreatinin-Quotions compared to the output values."</seg>
<seg id="827">"in a study of 20 weeks reduced pioglitazone not only the sober triglyceride, but also improved the postprandial elevated triglyceride mirror, this is both an effect on the tryglycoerid absorption as well as on the hepatic trygumerid synthesis."</seg>
<seg id="828">"although the study was consistent with regard to their primary endpoint, which presented a combination of the overall mortality, non-fatal coronarisation and Revascularisation of the Bannarisation and Revascularisation of the leg arteries, put the results close that with the intake of Pioglitazon are no kardiovascular long-term risk."</seg>
<seg id="829">"the tablets are white to white, round, flat and wear on one side the markings" 45 "and on the other side the" "Actos". ""</seg>
<seg id="830">"in a summary analysis of reports of unwanted events regarding bone marquitting from randomized, controlled, double clinical trials over a period of up to 3.5 years with more than 8.100 patients who received comparison to Pioglitazone, showed up an increased incidence of bone marquarries in women."</seg>
<seg id="831">"in the proactive study, a study of 3,5 years for the study of kardiovascular events, compared with 23 / 905 (2.5%; 1.1 fractures per 100 patient years) with patients treated with a comparative study."</seg>
<seg id="832">"in a study of 20 weeks reduced pioglitazone not only the sober triglyceride, but also improved the postprandial elevated triglyceride mirror, this has an effect on the triglycavities and on the hepatic triglycavities synthesis."</seg>
<seg id="833">"on the packing passing of the drug, the name and address of the manufacturer, which is responsible for the release of the batches."</seg>
<seg id="834">"the pharmaceutical companies will submit an additional 6 month period in September 2005 (PSUR) and then submit an annual PSURs, up to a different part of CHMP."</seg>
<seg id="835">It must be a recent risk management plan according to the CHMP guideline for Medicinal Products for Medicinal Products for Human Use.</seg>
<seg id="836">"if you are suffering in type 2 diabetes, Actos 15 mg tablets to control the control of your blood sugar, by bringing a better understanding of the body's body."</seg>
<seg id="837">"if you are known that you suffer from a sugar-bearer, please contact Actos 15mg tablets to your doctor."</seg>
<seg id="838">"please inform your doctor or pharmacist if you have further medicines or until recently taken, even if it is not prescription medicine."</seg>
<seg id="839">"if you use Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, liclazid, Tolbutamide), your doctor will inform you whether you need to reduce the dose of your medicine."</seg>
<seg id="840">"in some patients with long-term type 2 diabetes mellitus and heart disease, which were treated with Actos and insulin."</seg>
<seg id="841">"in clinical studies, in which Pioglitazone was compared with other oral antidiabetics or placebo (effective free tablets) compared to women (but not in men), the Pioglitazon took a higher number of bone marquarries."</seg>
<seg id="842">"if you have taken care about too many tablets, or if another or a child has taken your medicine, you must get in touch with a doctor or a pharmacist."</seg>
<seg id="843">"how Actos looks and content of the package Actos 15 mg tablets are white to white, round, vaulted tablets with the marking" "15" on one side and the "" Actos "on the other."</seg>
<seg id="844">"if you are suffering in type 2 diabetes, Actos 30 mg tablets to control the control of your blood sugar, by bringing a better understanding of the body's body."</seg>
<seg id="845">"if you are known that you suffer from a sugar-bearer, please contact Actos 30mg tablets to your doctor."</seg>
<seg id="846">"if you use Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, liclazid, Tolbutamide), your doctor will inform you whether you need to reduce the dose of your medicine."</seg>
<seg id="847">"61 Informing you as soon as possible your doctor, if you notice signs of a heart efficiency, such as unusual shorthness or fast weight increases or local swellings (ödeme)."</seg>
<seg id="848">"in clinical studies, in which Pioglitazone was compared with other oral antidiabetics or placebo (effective free tablets) compared to women (but not in men), the Pioglitazon took a higher number of bone marquarries."</seg>
<seg id="849">"how Actos looks and content of the package Actos 30 mg tablets are white to white, round, flat tablets with the marking" 30 "on one side and the" "Actos" on the other. "</seg>
<seg id="850">"if you are suffering in type 2 diabetes, Actos 45 mg tablets to control the control of your blood sugar, by bringing a better understanding of the body's body."</seg>
<seg id="851">"if you are known that you suffer from a sugar-bearer, please contact Actos 45mg tablets to your doctor."</seg>
<seg id="852">"if you use Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, liclazid, Tolbutamide), your doctor will inform you whether you need to reduce the dose of your medicine."</seg>
<seg id="853">"66 For some patients with long-term type 2 diabetes mellitus and heart disease, which were treated with Actos and insulin."</seg>
<seg id="854">"inform you as soon as possible your doctor, if you notice signs of a heart efficiency, such as unusual shorthness or fast weight increases or local swellings (ödeme)."</seg>
<seg id="855">"in clinical studies, in which Pioglitazone was compared with other oral antidiabetics or placebo (effective free tablets) compared to women (but not in men), the Pioglitazon took a higher number of bone marquarries."</seg>
<seg id="856">"67 If one of the listed side effects you can considerably impairs or you notice side effects that are not indicated in this use of information, please inform your doctor or pharmacist."</seg>
<seg id="857">"how Actos looks and content of the package Actos 45 mg tablets are white to white, round, flat tablets with the markings" 45 "on one side and the" "Actos" on the other. "</seg>
<seg id="858">This document is a summary of the European Public Beurances (EPAR) which explains how the Committee on Human Rights (CHMP) are discussed in order to obtain recommendations concerning the use of the drug.</seg>
<seg id="859">"if you need more information on your medical condition or treating your illness, please read the package passing (which is also part of the EPAR) or contact a doctor or pharmacist."</seg>
<seg id="860">"if you wish further information on the basis of the CHMP recommendations, please read the scientific discussion (which is also part of the EPAR)."</seg>
<seg id="861">Actraphane 10: solvent insulin 10% and Isophan insulin 30: solvent insulin 40% and Isophan insulin 40: solvent insulin 50% and Isophan insulin 50% and Isophan insulin 50%</seg>
<seg id="862">Actraphane is usually used once or twice a day when a quick initial effect can be desired together with a longer lasting effect.</seg>
<seg id="863">"(44-20) 74 18 84 00 fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.</seg>
<seg id="864">"Actraphane was not produced in a total of 294 patients with type-1 diabetes, where the pancreas cannot produce a insulin, and type-2 diabetes in which the body is unable to use the insulin effective."</seg>
<seg id="865">In the study after 12 weeks the concentration of a substance (glycoylified hematglobin (HbA1c) which shows how well the blood sugar is set.</seg>
<seg id="866">Actraphane led to a homologation of the HbA1c mirror that resulted in the blood sugar levels like strong as with any other human insulin.</seg>
<seg id="867">Actraphane should not be used in patients who may possibly excessive (allergic) on human insulin (rDNA) or one of the other components.</seg>
<seg id="868">"furthermore, the doses of Actraphane can possibly be adjusted if it is given together with a number of other medicines that can affect blood sugar (the full list is to be taken from the package passing)."</seg>
<seg id="869">The Committee on Humancision (CHMP) is to conclude that the benefits of Actraphane during the treatment of diabetes compared to the risks.</seg>
<seg id="870">October 2002 the European Commission granted the company Novo Nordisk A / S for approval by Actraphane in the entire European Union.</seg>
<seg id="871">"mixed-insulin products are usually used once or twice a day, if a quick initial effect can be desired together with a longer lasting effect."</seg>
<seg id="872">The injections must be left under the skin at least 6 seconds to ensure that the entire dose was injected.</seg>
<seg id="873">Patients whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly. "</seg>
<seg id="874">"any change with regard to strength, brand (manufacturers), Insulintyp (fast effective, biphashic, longitulin or Insulinanalogon) and / or manufacturing method (through recombination DNS to insulin origin) can result in that a change in dosage is required."</seg>
<seg id="875">"if the change to Actraphane is required when changing to Actraphane, it may be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="876">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="877">"traveling to travel across multiple times, the patient should be pointed to the Council of his doctor, since such trips can lead to be used or taken at meals at other times."</seg>
<seg id="878">The doctor must therefore consider possible interactions with therapy and his patients always ask for others by them.</seg>
<seg id="879">"4 Both hypoglycemic as well as hyperglycemic, which can occur in a non-sufficient diabetestherapy, increase the risk of abnormalities and fruit mitod in utero."</seg>
<seg id="880">Serious hypoglycemic bodies can lead to consciousness and / or scratches and with temporary or permanent disturbances of the brain function and even death.</seg>
<seg id="881">Disorders of the nervous system - peripheral Neuropathy A rapid improvement of blood sugar control may be associated with complaints which are known as acute paintonal Neuropathy and usually reversible.</seg>
<seg id="882">5 A intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="883">Diseases of the skin and the substrates - Lipodystrophie An of the injection point can be created when a lipodystrophy can arise if failed to switch to the injectors within the injection range.</seg>
<seg id="884">General diseases and complaints at the agreement of the agreement - Local oversensitivity reaction to the injection station During the Insulintherapy can occur local oversensitivity actions (redness, swelling, delling, pain and hematom at the injection point). "</seg>
<seg id="885">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="886">A hypoglycemic can still develop and develop: • Easy hypoglycemic bodies can be treated by orale states of glucose or sugar foods.</seg>
<seg id="887">"therefore, Diabetics should therefore always have trauma sweets, sweets, biscuits or sugar fruit juice in themselves. • Heavy hypoglycemic injection of glucagon (0.5 to 1,0 mg) is given by an intra-speculators or subkutaneous injection of glucagon (0,5 up to 1.0 mg), given by a fixed help of glucose, which is given intravenous by the doctor."</seg>
<seg id="888">"the effect starts within half an hour, the active member is reached within 2 to 8 hours, and the whole activity is up to 24 hours."</seg>
<seg id="889">Resorption The resorption profile is based in it that it is a mixture of insulin products with fast or consuming resorption.</seg>
<seg id="890">A number of spans (Hydrolyse-) places on the humaninsulinmolecule has been considered; none of the metabolic metaboo is active.</seg>
<seg id="891">"based on conventional studies on safety digestology, toxicity, toxicity, genotoxicity, to the carcinogens potential and for reproduction of production, let preclinical data do not recognise any particular hazards for man."</seg>
<seg id="892">"it is recommended - after the Actraphanions made from the refrigerator, the temperature of the insulin to increase room temperature (not over 25 ° C), before it is charged according to the instruction manual for the first use."</seg>
<seg id="893">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="894">The doctor must therefore consider possible interactions with therapy and his patients always ask for others by them.</seg>
<seg id="895">"12 Both hypoglycemic as well as hyperglycemic, which can occur in a non-sufficient diabetestherapy, increase the risk of abnormalities and fruit mitod in utero."</seg>
<seg id="896">13 An intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="897">The terminale half-time (t ½) is therefore rather a measure of elimination as a measure of Elimination per se from the insulin (insulin in the blood circulation one of only a few minutes).</seg>
<seg id="898">"it is recommended - after the Actraphanions made from the refrigerator, the temperature of the insulin to increase room temperature (not over 25 ° C), before it is charged according to the instruction manual for the first use."</seg>
<seg id="899">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="900">20 Soviet hypoglycemic as well as hyperglycemic drugs can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="901">21 An intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="902">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective function of the cartridge.</seg>
<seg id="904">It is recommended - after Actraphane Penfill from the refrigerator was taken from the refrigerator - the temperature of the insulin to the room temperature (not over 25 ° C) to increase in accordance with the instruction manual for the first use.</seg>
<seg id="905">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="906">28 Soviet hypoglycemic as well as hyperglycemic drugs can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="907">29 A intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="908">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="909">36 Both hypoglycemic as well as hyperglycemic drugs can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="910">37 An intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="911">44 soviet Hypoglycemic as well as hyperglycemic drugs that can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="912">45 A intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="913">"some patients, which were hypoglycemic reactions after a change of animal on human insulin, reported that the early warning symptom symptoms were less pronounced or different from the previous insulin."</seg>
<seg id="914">52 Soviet hypoglycemic as well as hyperglycemic drugs can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="915">53 A intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="916">Injections must be prepared before injections that the Dosislatency goes to zero and appears an insulin punch at the top of the injections.</seg>
<seg id="917">"59 patients, whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly."</seg>
<seg id="918">Both hypoglycemic as well as hyperglycemic drugs can occur in a non-sufficient diabetestherapy to increase the risk of abnormalities and fruit mitod in utero.</seg>
<seg id="919">A intensification of the insulin therapy with a deducted improvement of blood sugar can however be connected with a temporary deterioration of the diabetic Retinopathy.</seg>
<seg id="920">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="921">This manufacturing process may only be used together with products that are compatible with them and ensure a safe and effective function of production.</seg>
<seg id="922">"it is recommended - after Actraphane Novolet from the refrigerator was taken from the refrigerator, to increase the temperature of the insulin to room temperature (not over 25 ° C) before it is charged according to the instruction manual for the first use."</seg>
<seg id="923">"67 patients, whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly."</seg>
<seg id="924">75 patients whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly. "</seg>
<seg id="925">83 patients whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly. "</seg>
<seg id="926">91 patients whose blood sugar has improved significantly for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly. "</seg>
<seg id="927">"99 patients whose blood sugar has significantly improved for example by an intensive increulin therapy, the hypoglycemic symptoms can be altered and should be advised accordingly."</seg>
<seg id="928">"any alteration regarding strength, brand (manufacturers), Insulintyp (fast effective, biotic insulin, scientific insulin or Insulinanalogon) and / or manufacturing method (through recombinant DNA compared to insulin origin) can result in that a change in dosage is required."</seg>
<seg id="929">It is recommended - after Actraphane Innolet from the refrigerator was taken from the refrigerator - the temperature of the insulin to the room temperature (not over 25 ° C) to increase in accordance with the instruction manual for the first use.</seg>
<seg id="930">"it is recommended - after Actraphane FlexPen was taken from the fridge - the temperature of the insulin to the room temperature (not over 25 ° C), before it is charged according to the instruction manual for the first use."</seg>
<seg id="931">"on the packing passing of the drug, the name and address of the manufacturer, which is responsible for the release of the batches."</seg>
<seg id="932">"store in the fridge (2 ° C - 8 ° C) non-freezing the carrying bag in carton, to protect the content from light to upheaval: not in the fridge or over 25 ° C"</seg>
<seg id="933">Subkutane application Penfill cartridges are envisaged for the application with insulin objects of the instruction resustion packs of the instructions Actraphane 10 Penfill can only be used by one person</seg>
<seg id="934">"store in the fridge (2 ° C - 8 ° C) non-freezing the cartridge in carton, to protect the content from light to upheaval: not in the fridge or over 30 ° C"</seg>
<seg id="935">Subkutane application Penfill cartridges are envisaged for the application with insulin objects of the instruction resustion packs of the instructions Actraphane 20 Penfill can only be used by one person</seg>
<seg id="936">Subkutane application Penfill cartridges are envisaged for the application with insulin objects of the instruction resustion packs of the instructions Actraphane 30 Penfill can only be used by one person</seg>
<seg id="937">Subkutane application Penfill cartridges are intended for the application with insulin objects of the instruction resustion packs of the instructions Actraphane 40 Penfill can only be used by one person</seg>
<seg id="938">Subkutane application Penfill cartridges are envisaged for the application with insulin objects of the instruction resustion packs of Actraphane 50 Penfill should only be used by one person</seg>
<seg id="939">Subkutane application for use with Actraphane 10 Novolet are NovoFine injection moulding packing table with Actraphane 10 Novolet should only be used by one person</seg>
<seg id="940">"store in the fridge (2 ° C - 8 ° C) non-freezing in light after breakage: not in the fridge or over 30 ° C"</seg>
<seg id="941">Subkutane application for use with Actraphane 20 Novolet are NovoFine injection moulding packing table with Actraphane 20 Novolet should only be used by one person</seg>
<seg id="942">Subkutane application for use with Actraphane 30 Novolet are NovoFine injection moulding packaging. Actraphane 30 Novolet must be used only by one person</seg>
<seg id="943">Subkutane application for use with Actraphane 40 NovoLet's NovoFine injection packages provided by the instruction resustion packages Actraphane 40 NovoLet's only be used by one person</seg>
<seg id="944">Subkutane application for use with Actraphane 50 NovoLet's NovoFine injecting packaging for the instructions of the instructions of Actraphane 50 NovoLet one can only be used by one person</seg>
<seg id="945">Subkutane application for use with Actraphane 30 InnoLet's NovoFine S injecting packing of the instruction resustion Actraphane 30 InnoLet's only be used by one person</seg>
<seg id="946">This means that about half an hour after you have used it to sink your blood sugar and that the effect will be approximately 24 hours.</seg>
<seg id="947">► if you allergic (excessive) to this insulinproduct, metacresol or one of the other components (see section 7 More information). "</seg>
<seg id="948">Pay attention to the below 5 which side effects are possible? described symptoms of an allergy ► if you feel the first signs of a hypoglycemic (symptoms of a submering).</seg>
<seg id="949">"if your doctor has a change from an insulin or brand to another, it may have to be adapted to the dose by your physician."</seg>
<seg id="950">► How to check out the label whether it is about the right ink type; disinfect the rubber compounds with a medical virtualization.</seg>
<seg id="951">"if this is not completely worshipped, if you get the crossroads to your pharmacy, if it was not properly kept or frozen (see 6 How is Actraphane to preserve?) ► if there is not as accurate white and tracker."</seg>
<seg id="952">Use the injection technology that has been recommended to you your doctor or your diabetesberacy in the ► How to ensure the injections of a minimum of 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="953">"the warning of an undercarriage can suddenly occur, and can be: kold sweat, kold blossom, great hunger, suspicking, sensory, nervousness, nervousness, nervousness, nervousness, confusion, concentration of concentration."</seg>
<seg id="954">"tell your relatives, friends and close workmates that they will bring you in the case of a consciousness in the stable page and must immediately get a doctor."</seg>
<seg id="955">"they may not give you nothing to eat or drink, as you may not treat it. ► If a severe lower damage may not be treated or even to death ► If you had an undercarriage with awareness, or frequently up submissions, look for your doctor."</seg>
<seg id="956">"you can regain the consciousness faster, when you become familiar with the hormone glucagon of one person who is familiar with its gift, injected."</seg>
<seg id="957">"this can happen: • If you make too much insulin, if you eat too little or a meal • if you prefer more than otherwise physically."</seg>
<seg id="958">"amplified uredrank, Durst, appetite or fatigue, Benefulness or fatigue, smoked dry skin, mouth dry and fruity (according to Aceton) riechender breath."</seg>
<seg id="959">• You have forgotten an insulin object • repeated injected of less insulin than you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="960">If you often give too often an injection at the same place can be shrinking on this spot (Lipatrophie) or to increase (Lipohypertrophy).</seg>
<seg id="961">"if you notice depressions or distortions of your skin at the injection point, report your doctor or your diabetesberacy in this, as these reactions can worsen or influence your intuition if you want to injure in such a place."</seg>
<seg id="962">"if you immediately looking for a doctor on other parts of the body or if you suddenly feel uncomfortable and you suddenly feel uncomfortable, nausea, nausea, pinness, or you have the impression of being unconscious."</seg>
<seg id="963">You may have a very rare severe allergic reaction to Actraphor or one of its components (so-called systemic reaction).</seg>
<seg id="964">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="965">What Actraphane 30 contains - The ingredient is characterized by recombinant DNS technology (30% as solvent insulin and 70% as a soluophan insulin).</seg>
<seg id="966">"how Actraphane looks and content of the packet suspension, white, waking suspension in packs with 1 or 5 handles each 10 ml or a bunch of 5 ml bottles each 10 ml."</seg>
<seg id="967">Use the injection technology that has been recommended to you your doctor or your diabetesberacy in the ► How to ensure the injections of a minimum of 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="968">It is recommended - after it was taken from the refrigerator - the temperature of the carrying bag to increase room temperature before the insulin is charged in accordance with the instruction manual for the first use.</seg>
<seg id="969">"how Actraphane looks and content of the packet suspension, white, waking suspension in packs with 1 or 5 handles each 10 ml or a bunch of 5 ml bottles each 10 ml."</seg>
<seg id="970">► How to check out the label whether it is about the right ink type; check always the penis fill cartridge including the rubber cord (stops).</seg>
<seg id="971">Do not use them if any damage is visible or a gap between the rubber-mate and the white band of the label.</seg>
<seg id="972">"further information can be found in the instruction of your inulin object. ► Desinfy the rubber embraces with a medical virtualization. ► Benefits always for any injection a new injection, to avoid contamination."</seg>
<seg id="973">► in Insulininfusion pumps ► if the penis fill or the device that has left the penis fill (see 6 How it is not properly kept or frozen (see 6 How is Actraphane to preserve?) ► if there is not incomparably white and trübe.</seg>
<seg id="974">"if you are treated with Actraphane 10 Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="975">"before you use the cartridge into the insulin object system, you move at least 20 times between the positions a and b on and off (see picture) so that the glass ball moves from one end of the cartridge for another."</seg>
<seg id="976">Use the injection technology that has been recommended to you your doctor or your diabetesbery in your skin and ensure that the full dose of injections has been described under your skin and ensure that the full dose of injections was cut off after every injection of the injections of the injections and to worry and to worry and make Actraphane without extra-in injections.</seg>
<seg id="977">"183 Make your relatives, friends and close workmates that they bring you in case of a consciousness of consciousness into the stable page, and immediately need a doctor."</seg>
<seg id="978">• You have forgotten an insulin object • repeated injected of less insulin than you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="979">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="980">It is recommended - after it was taken from the refrigerator - the temperature of the penis fill cartridge based on room temperature before the insulin is provided in accordance with the instruction manual for the first use.</seg>
<seg id="981">Keep the cartridges always in the scope of carton if you do not use them to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - The ingredient is characterized by recombinant DNS technology (10% as solvent insulin and 90% as a soluophan insulin).</seg>
<seg id="983">"how Actraphane looks and content of the packet suspension is supplied as trendy, white, waking suspension in packs with 1, 5 or 10 cartridges of 3 ml each."</seg>
<seg id="984">"further information can be found in the instruction of your inulin object. ► Desinfy the rubber embraces with a medical virtualization. ► Benefits always for any injection a new injection, to avoid contamination."</seg>
<seg id="985">"if you are treated with Actraphane 20 Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="986">"189 Searing your relatives, friends and close workmates that they bring you in case of a consciousness of consciousness into the stable page and immediately need a doctor."</seg>
<seg id="987">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="988">191 survey you always use the cartridges always in carton if you do not use them to protect them from light.</seg>
<seg id="989">What Actraphane 20 contains - The ingredient is characterized by recombinant DNS technology (20% as solvent insulin and 80% as a soluophan insulin).</seg>
<seg id="990">"how Actraphane looks and content of the packet suspension is supplied as trendy, white, waking suspension in packs with 1, 5 or 10 cartridges of 3 ml each."</seg>
<seg id="991">"further information can be found in the instruction of your inulin object. ► Desinfy the rubber embraces with a medical virtualization. ► Benefits always for any injection a new injection, to avoid contamination."</seg>
<seg id="992">"if you are treated with Actraphane 30 Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="993">"195 Sagen you make your relatives, friends and close workmates that they will bring you in the case of a consciousness in the stable page and must immediately get a doctor."</seg>
<seg id="994">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="995">"197 always the cartridges always in carton, if you do not use them to protect them from light."</seg>
<seg id="996">"manufacturer The manufacturer can be identified by the Charge name, which is printed on the flap of the cartons and on the label,"</seg>
<seg id="997">"if at the second and third place of the batch combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerde, Denmark</seg>
<seg id="998">"if at the second and third place of the batch combination H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France."</seg>
<seg id="999">Further information can be found in the instruction of your insul. ► Desinect the rubber compounds with a medical virtualization. ► Benefits always for any injection a new injections to avoid contamination.</seg>
<seg id="1000">"if you are treated with Actraphane 40 Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="1001">201 Searing your relatives, friends and close workmates that they bring you in case of a state of consciousness into the stable page, and immediately need a doctor. "</seg>
<seg id="1002">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1003">203 Move the cartridges always in the envelope on if you do not use them to protect them from light.</seg>
<seg id="1004">What Actraphane 40 contains - The ingredient is characterized by recombinant DNS technology (40% as solvent insulin and 60% as a soluophan insulin).</seg>
<seg id="1005">Further information can be found in the instruction of your insul. ► Desinect the rubber compounds with a medical virtualization. ► Benefits always for any injection a new injections to avoid contamination.</seg>
<seg id="1006">"if you are treated with Actraphane 50 Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="1007">"before you use the penis fill cartridge in the insulin object system, move it at least 20 times between the positions a and b on and off (see picture) so that the glass ball moves from one end of the cartridge for another."</seg>
<seg id="1008">"207 Searing your relatives, friends and close workmates that they bring you in case of a consciousness of consciousness into the stable page, and immediately need a doctor."</seg>
<seg id="1009">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1010">209 Maintainer the cartridges always in carton if you do not use them to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - The ingredient is characterized by recombinant DNS technology (50% as solvent insulin and 50% as a soluophan insulin).</seg>
<seg id="1012">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1013">► How to check out the label whether it is about the right insul intyp and use for any injection a new injections to avoid contamination.</seg>
<seg id="1014">"► in Insulininfusion pumps, if the NovoLet's dropped, damaged or broken, is the danger of running insulin, if it was not properly kept or frozen (see 6 How is Actraphanium?) ► if there is not even incomparatively white and trübe."</seg>
<seg id="1015">"the warning of an undercarriage can suddenly occur, and can be: kold sweat, kold blossom, great hunger, suspicking, sensory, nervousness, nervousness, nervousness, nervousness, confusion, concentration of concentration."</seg>
<seg id="1016">"214 If one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this use of information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1017">"in use, Novolet prepens and those who are used shortly or may be managed as a substitute, are not in the fridge."</seg>
<seg id="1018">"it is recommended - after having taken from the fridge - the temperature of the Novolet prepens to increase room temperature, before the insulin is charged to the manual for the first use."</seg>
<seg id="1019">Let the closing flap of your NovoLet finished always set when NovoLet not in use is to protect the insulin before light.</seg>
<seg id="1020">"how Actraphane looks and content of the packet suspension is supplied as trendy, white, waking suspension in packs with 5 or 10 ready for each 3 ml."</seg>
<seg id="1021">"any injection • review, whether even at least 12 units of insulin in the cartridge are left, so that a uniform mixture is ensured."</seg>
<seg id="1022">Go to the following way to avoid the injection of air and make a correct dosage: • Hold you Actraphane 10 NovoLet you get a few times with the finger easily against the cartridge.</seg>
<seg id="1023">If air bubbles are present in this way they will keep up above in the cartridge • While you continue to hold the injections in the direction of the pole (figure C) • While the cartridge for a drop in direction (picture D) • Now it has to drop out of the tip of the injections.</seg>
<seg id="1024">• Sailing the closing cap again so on the finishing pen that the number 0 is compared to the Dosiermarke (illustration E) • Enrolment as if the printer is pressed.</seg>
<seg id="1025">"if not, turn the closing flap, until the button knob is pressed, • Hold your Actraphane 10 NovoLet waageress."</seg>
<seg id="1026">"if the pressure knob can not move freely to the outside, insulin is pressed from the injection unit. 0, 2, 4, 6, 8, 12, 16, 16 and 18 units."</seg>
<seg id="1027">"the push-button moves to the outside, while you turn the closing flap • The scale below the button knob shows 20, 40 and 60 units."</seg>
<seg id="1028">"checking the number on the loading cap directly next to the Dosiermarke • Notting the highest number that you can see on the button track record • If you have a wrong dose, turn the closing flap simply forward or backward until you have the right number of units."</seg>
<seg id="1029">"otherwise, insulin from the injections and the chosen dosage will not be correct • If you have mistaken, a dosage of more than 78 units, run the following steps:"</seg>
<seg id="1030">Then take the closing flap and set them back so that the 0 of the Dosiermarke is opposite.</seg>
<seg id="1031">Pay attention to press only during the injection on the push-button. • Keep the push-button after the injection moulding into the skin until the injections made out of the skin.</seg>
<seg id="1032">"if not, turn the closing flap, until the button knob is pressed and then proceed as described before using it." "unfortunately, you can hear when using the button is a clickable sound noise."</seg>
<seg id="1033">It's possibly impossible • you can adjust no dosage which is higher than the number of the cartridge scale units • You can use the residual scale scale to estimate how much insulin still exists.</seg>
<seg id="1034">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1035">"224 If one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1036">"226 on every injection • Check whether or even at least 12 units of insulin in the cartridge are left, so that a uniform mixture is ensured."</seg>
<seg id="1037">Go to the following way to avoid the injection of air and make a correct dosage: • Hold you Actraphane 20 NovoLet you get a few times with the finger easily against the cartridge.</seg>
<seg id="1038">If air bubbles are present in this way they will continue up in the cartridge • While you continue to hold the injections in the direction of the pole (picture C) • While the cartridge for a drop in the direction of the injection (picture D) • Now it has to drop out of the tip of the injections.</seg>
<seg id="1039">"if not, turn the closing flap, until the button knob is pressed, • Hold your Actraphane 20 NovoLet waageress."</seg>
<seg id="1040">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1041">"234 If one of the listed side effects you may not impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1042">236 ahead of any injection • Check whether or at least 12 units of insulin in the cartridge are left to ensure a uniform mixture.</seg>
<seg id="1043">Proceed to avoid the injections of air and make a correct dosage: • Hold you Actraphane 30 NovoLet you get a few times with the finger easily against the cartridge.</seg>
<seg id="1044">If air bubbles are present in this way they will keep up above in the cartridge • During you continue to hold the injections in the direction of the pole (figure C) • While the cartridge for a drop in direction (picture D) • Now it has to drop out of the tip of the injections.</seg>
<seg id="1045">"if not, turn the closing flap, until the button knob is pressed, • Hold your Actraphane 30 NovoLet waageress."</seg>
<seg id="1046">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1047">"244 If one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this use of information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1048">"246 In every injection • Check whether at least 12 units of insulin in the cartridge are left, so that a uniform mixture is ensured."</seg>
<seg id="1049">Go to the following way to avoid the injection of air and make a correct dosage: • Hold you Actraphane 40 NovoLet you get a few times with the finger easily against the cartridge.</seg>
<seg id="1050">If air bubbles are present in this way they will keep up above in the cartridge • During you continue to hold the injections in the direction of the pole (figure C) • While the cartridge for a drop in direction (picture D) • Now it has to drop out of the tip of the injections.</seg>
<seg id="1051">"if not, turn the closing flap, until the button knob is pressed, • Hold your Actraphane 40 NovoLet waageress."</seg>
<seg id="1052">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1053">"254 If one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this use of information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1054">"it is recommended - after having taken from the fridge - the temperature of the Novolet prepens to increase room temperature, before the insulin is charged to the manual for the first use."</seg>
<seg id="1055">"256 at every injection • Check whether at least 12 units of insulin in the cartridge are left, so that a uniform mixture is ensured."</seg>
<seg id="1056">Proceed to avoid the injections of air and make a correct dosage: • Hold you Actraphane 50 NovoLet you get a few times with the finger easily against the cartridge.</seg>
<seg id="1057">If air bubbles are present in this way they will continue up in the cartridge • While you continue to hold the injections in the direction of the pole (picture C) • While the cartridge for a drop in the direction of the arrow (picture D) • Now it has to drop out of the tip of the injections.</seg>
<seg id="1058">"if not, turn the closing flap, until the button knob is pressed, • Hold your Actraphane 50 NovoLet waageress."</seg>
<seg id="1059">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1060">"► in Insulininfusion pumps, if the InnoLet's dropped, damaged or broken, is the danger of running insulin, if it was not properly kept or frozen (see 6 How is Actraphanium?) ► if there is not even incomparatively white and trübe."</seg>
<seg id="1061">"the warning of an undercarriage can suddenly occur, and can be: kold sweat, kold blossom, great hunger, suspicking, sensory, nervousness, nervousness, nervousness, nervousness, confusion, concentration of concentration."</seg>
<seg id="1062">"264 If one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1063">"in use, InnoLet manufacturing and such, which are used shortly or may be managed as a substitute, are not in the fridge."</seg>
<seg id="1064">"it is recommended - after having taken from the refrigerator - the temperature of the Innolet prepens to increase room temperature, before the insulin is supplied in accordance with the instruction manual for the first use."</seg>
<seg id="1065">Let the closing flap of your InnoLet finished always set when InnoLet not in use is to protect the insulin before light.</seg>
<seg id="1066">"how Actraphane looks and content of the packet suspension, white, waking suspension in packs with 1, 5 or 10 Complete to 3 ml each."</seg>
<seg id="1067">"the movement must be repeated until the liquid is equivalent, and tracked • After the Resustion lead you all the steps of the injection without delay."</seg>
<seg id="1068">• disinfect the rubber compounds with a medical tuce • Use always for every injecting a new injections - removing the injections of a NovoFine S injections (picture 1B) • Zipping the large outer injection valve and the inner injection valve board.</seg>
<seg id="1069">• Enrolment always pressed whether the button knob is pressed and the Dosisregler on zero stands • Make the number of units you need injections by turning the Dosislators in clockwise direction (picture 2).</seg>
<seg id="1070">Do not use the residual scale to measure your Insulindosis • You can listen to each individually adjustable unit.</seg>
<seg id="1071">Run the injection technique that has shown your doctor - give yourself the dose by pressing the button into a whole (picture 3).</seg>
<seg id="1072">"the Dosislatency puts himself down to zero and you listen to the injections • The injustices must remain under the skin, to ensure that you press the Dosislators during the injection, as the Dosislators must push down to zero when you press on the push-button • Remove the injections according to the injection."</seg>
<seg id="1073">"medical staff, family members, as well as other supervisors must note general precautions for removal and disposal of injections to avoid unintentional stitches with the injections."</seg>
<seg id="1074">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1075">"► in Insulininfusion pumps ► if the FlexPen was dropped, damaged or broken, is the danger of running insulin. if it was not properly kept or frozen (see 6 How is Actraphanium?) ► if there is not even incomparatively white and trübe."</seg>
<seg id="1076">"if you notice depressions or distortions of your skin at the injection point, report your doctor or your diabetesberacy in this, as these reactions can worsen or influence your intuition if you want to injure in such a place."</seg>
<seg id="1077">"274 If one of the listed side effects you may not impairs or you notice side effects that are not indicated in this use of information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1078">"in use, FlexPen Prepens and those who are used shortly or may be managed as a substitute, are not in the fridge."</seg>
<seg id="1079">"it is recommended - after having taken from the fridge - the temperature of the FlexPen Prepens to increase room temperature, before the insulin is supplied in accordance with the instruction manual for the first use."</seg>
<seg id="1080">Let the closing flap of your FlexPen Prepens always set up when FlexPen is not in use to protect the insulin before light.</seg>
<seg id="1081">"how Actraphane looks and content of the packet suspension, white, waking suspension in packs with 1, 5 or 10 Complete to 3 ml each."</seg>
<seg id="1082">"manufacturer The manufacturer can be identified by the Charge name, which is printed on the flap of the cartons and on the label,"</seg>
<seg id="1083">"275 • Falls on the second and third place of the batch combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B due to the finish line between the positions 1 and 2 twenty times, so that the glass ball moves from one end of the cartridge for another."</seg>
<seg id="1085">Move the finishing pen at least 10 times between positions 1 and 2 and from until the liquid uniform and trübe appears.</seg>
<seg id="1086">"• To reduce the risk of unintentionally needle, you never put the inner shell back onto the injections, after having taken them once again."</seg>
<seg id="1087">279 G Hinkles the FlexPen with the injections up and knock a few times with the finger easily against the cartridge that can collect existing bubbles above in the cartridge.</seg>
<seg id="1088">The dose may be corrected both after the top and downwards by turning the Dosispre-button in the appropriate direction until the correct dose compared to the marking of the ad.</seg>
<seg id="1089">This document is a summary of the European Public Beurances (EPAR) which is discussed as the Committee on Humanities (CHMP) carried out in order to obtain recommendations concerning the application of the drug.</seg>
<seg id="1090">"the arzneial effective ingredient in Actrapide, insulin human (rDNA), is produced with the procedure of the so-called" recombination technology ":"</seg>
<seg id="1091">(44-20) 74 18 84 00 fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / /</seg>
<seg id="1092">Actrapid must not be used in patients who may possibly excessive susceptible to insulin (rDNA) or one of the other components.</seg>
<seg id="1093">"furthermore, the doses of Actrapid may be adjusted if it is given together with a number of other medicines that may affect blood sugar."</seg>
<seg id="1094">"October 2002, the European Commission granted the company Novo Nordisk A / S approval for the Independence of Actrapide in the entire European Union."</seg>
<seg id="1095">"when two kinds of insulin have to be mixed, first the amount of the rapidly acting inulin are to be raised, then the amount of the long acting Insulter."</seg>
<seg id="1096">"3 If the change to Actrapid is required when patients require a dosage adjustment, this may be necessary during the first dosage or in the first few weeks or months after the conversion."</seg>
<seg id="1097">"traveling to travel across multiple times, the patient should be pointed to the Council of his doctor, since such trips can lead to be used or taken at meals at other times."</seg>
<seg id="1098">"5 General diseases and complaints at the end of the agreement - Local oversensitivity reaction to the injection station During the Insulintherapy can occur local oversensitivity actions (redness, swelling, delling, pain and hematom at the injection point)."</seg>
<seg id="1099">"therefore, Diabetics should therefore always have trauma sweets, sweets, biscuits or sugar fruit juice in themselves. • Heavy hypoglycemic injection of glucagon (0.5 to 1,0 mg) is given by an intra-speculators or subkutaneous injection of glucagon (0,5 up to 1.0 mg), given by a fixed help of glucose, which is given intravenous by the doctor."</seg>
<seg id="1100">A clever attempt at an intensive care unit for the treatment of hyperglycemic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed itself greater surgical intervention (blood sugar 4,4 - 6,1 mmol / l) the morality around 42% reduced (8% compared to 4.6%).</seg>
<seg id="1101">"the effect starts within half an hour, the active member is reached within 1.5 to 3,5 hours and the entire active duration is about 7 to 8 hours."</seg>
<seg id="1102">Children and young people The pharmacokinetic profile of Actrapide was examined by a smaller number (s = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1103">"the data is limited, however, however, the assumption that the pharmacocinetic profile in children and young adults are similar to that of adults."</seg>
<seg id="1104">Infusion systems with Actrapide in concentrations 0.05 i.e / ml - 1.3% D-glucose and 10% D- Glucose with 40 mmol / l Calicose-lorid for use of polypropylene in room temperature 24 hours long.</seg>
<seg id="1105">"11 If when changing to Actrapid, when patients require a dosage adjustment, this may be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1106">"traveling to travel across multiple times, the patient should be pointed to the Council of his doctor, since such trips can lead to be used or taken at meals at other times."</seg>
<seg id="1107">13 General diseases and complaints at the Precision Gelderland - Local oversensitivity reaction to the injection station During the Insulintherapy can occur local oversensitivity actions (redness, swelling, delling, pain and hematom at the injection point). "</seg>
<seg id="1108">"therefore, Diabetics should therefore always have trauma sweets, sweets, biscuits or sugar fruit juice in themselves. • Heavy hypoglycemic injection of glucagon (0.5 to 1,0 mg) is given by an intra-speculators or subkutaneous injection of glucagon (0,5 up to 1.0 mg), given by a fixed help of glucose, which is given intravenous by the doctor."</seg>
<seg id="1109">Children and young people The pharmacokinetic profile of Actrapide was examined by a smaller number (s = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1110">"the intravenous application of Actrapid from prepens or cartridges should be an exception and occur only in situations, where no handles are available."</seg>
<seg id="1111">"if the exchange at Actrapid is required when changing to Actrapid, it may be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1112">21 diseases of the skin and the subsistent gel - Lipodystrophy to the injection point can be created when a lipodystrophy can arise if failed to switch to the injectors within the injection range.</seg>
<seg id="1113">Children and young people The pharmacokinetic profile of Actrapide was examined by a smaller number (s = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1114">29 Illnesses of the skin and the shelter - Lipodystrophy to the injection point can be created when a lipodystrophy can arise if failed to switch to the injectors within the injection range.</seg>
<seg id="1115">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="1116">Children and young people The pharmacokinetic profile of Actrapide was examined by a smaller number (s = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1117">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="1118">38 A clan attempt at an intensive care unit for the treatment of hyperglycemic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed itself greater surgical intervention (blood sugar 4,4 - 6,1 mmol / l) the morality around 42% reduced (8% compared to 4.6%).</seg>
<seg id="1119">"diseases of the immune system Gelegingly - Urtikaria, exanthem Very rare - anaphylactic reactions of symptoms, cheating, gastrointestinal disorders, angiogamics, angioidal oils, strips, low blood pressure and helplessness / consciousness."</seg>
<seg id="1120">46 A clan attempt at an intensive care unit for the treatment of hyperglycemic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed itself greater surgical intervention (blood sugar 4,4 - 6,1 mmol / l) the morality around 42% reduced (8% compared to 4.6%).</seg>
<seg id="1121">Keep in the fridge in the fridge (2 ° C - 8 ° C) Non-freezing the carrying bag in carton to protect the content from light to upheaval: not in the fridge or over 25 ° C</seg>
<seg id="1122">Subkutane application Penfill cartridges are intended for use with Novo Nordisk Insulinobjects. Actrapid Penfill may only be used by one person</seg>
<seg id="1123">"store in the fridge (2 ° C - 8 ° C) Non-freezing the cartridge in the envelope, to protect the content from light to upheaval: not in the fridge or over 30 ° C"</seg>
<seg id="1124">Subkutane application for use with Actrapid Novolet are NovoFine injecting packing table and Actrapid NovoLet can only be used by one person</seg>
<seg id="1125">"store in the fridge (2 ° C - 8 ° C) Non-freezing on light, after departure: not in the fridge or over 30 ° C"</seg>
<seg id="1126">Subkutane application for use with Actrapide InnoLet are NovoFine S injecting packing table and Actrapide InnoLet's only be used by one person</seg>
<seg id="1127">This means that about half an hour after you have used it to sink your blood sugar and that the effect will be about 8 hours.</seg>
<seg id="1128">► How to check out the label whether it is about the right inulin type. ► Desinect the rubber compounds with a medical virtualization.</seg>
<seg id="1129">"if this not completely worshipped, if you get the crossroads to your pharmacy, if it had not been kept correctly or frozen (see 6 How is Actrapid to keep?) ► if it does not seem clear like water and colourless."</seg>
<seg id="1130">Use the injection technology that has been recommended to you your doctor or your diabetesberacy in the ► How to ensure the injections of a minimum of 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="1131">83 Searing your relatives, friends and close workmates that they bring you in case of a consciousness of consciousness into the stable page, and immediately need a doctor. "</seg>
<seg id="1132">You may have a very rare severe allergic reaction to Actrapid or one of its components (so called systemic allergic reaction).</seg>
<seg id="1133">"the injection solution is supplied as a clear, colourless solution in packs of 1 or 5 handles each 10 ml or a bunch of 5 ml bottles each 10 ml."</seg>
<seg id="1134">89 Searing your relatives, friends and close workmates that they bring you in case of a state of consciousness into the stable page, and immediately need a doctor. "</seg>
<seg id="1135">► How to check out the label whether it is about the right inulin type; check always the cartridge including the rubber colbens (stops).</seg>
<seg id="1136">► in Insulininfusion pumps ► if the penis fill or the device that has left the penis fill (see 6 How is Actrapid to preserve?) ► if it's not clear how water and colourless looks like.</seg>
<seg id="1137">"if you are treated with Actrapid Penfill and another insulin in Penfill cartridges, you should use two insulinobjects."</seg>
<seg id="1138">"use the injection technology that has been recommended to you your doctor or your diabetesbery in your skin, to ensure that the full dose of injections has been described under your skin, to ensure that the full dose of injections was removed in order to remove the injections of the injections and to dispose and make Actrapid without an apprey injections."</seg>
<seg id="1139">"• Falls on the second and third place of the batch combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerde, Denmark</seg>
<seg id="1140">"• Falls on the second and third place of the batch combination H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1142">► How to check out the label whether it is about the right ink type. ► Benefits always for any injection a new injections to avoid contamination.</seg>
<seg id="1143">"► in Insulininfusion pumps, if the NovoLet's dropped, damaged or broken; there was no danger to store or frozen (see 6 How is Actrapid to preserve?) ► if it's not clear like water and colourless."</seg>
<seg id="1144">This can happen: • If you make too much insulin - if you eat too little or a meal • if you prefer more than otherwise physically</seg>
<seg id="1145">Let the closing flap of your NovoLet finished always set when he is not in use to protect him from light.</seg>
<seg id="1146">Take the closing flap. • Disinfect the rubber compounds with a medical virtue • fixing the injections of a NovoFine injection. • removing the injections of a Novounces Novolet (picture A) • Zipping the large outer cap of the injections and the inner cap of the injections.</seg>
<seg id="1147">"go down to avoid the injection of air and to ensure a correct dosage: • Hold you Actrapide Novolet with the injections in the top • Clicking a few times with the finger easily against the cartridge."</seg>
<seg id="1148">If air bubbles are present in this way they will continue up in the cartridge • While the injections by clicking on top of the path (picture B) • While the cartridge for a drop in the direction (figure C) • Now it must be out of the tip of the injections in a drop of insulin.</seg>
<seg id="1149">• Sailing the closing cap again so on the finishing pen that the number 0 is compared to the Dosiermarke (picture D) • Enrolment as if the printer is pressed.</seg>
<seg id="1150">"if the pressure knob can not move freely, insulin is pressed from the injection cap • 0, 2, 4, 6, 8, 12, 16, 16 and 18 units."</seg>
<seg id="1151">The button knob moves to the outside while you turn the closing flap • The scale under the push button (Druckknopfscala) shows 20, 40 and 60 units. "</seg>
<seg id="1152">"107 • If you can see the highest number you can see on the button track record • If you have the two numbers, if you have a wrong dose, turn the closing arguments forward or backward until you have set the right number of units."</seg>
<seg id="1153">"turn them, until the push knob is completely down and you feel a resistance, then turn the closing date and set them back so that the 0 of the Dosiermarke is opposite."</seg>
<seg id="1154">Make sure to press only during the injection on the push-button • Keep the push-button after the injection moulding into the skin until the injections made out of the skin.</seg>
<seg id="1155">"it's possibly impossible • you can adjust no dosage, which is higher than the number of insulin remaining units. you can use the residual scale, but you can not use it to adjust your dosage or select."</seg>
<seg id="1156">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1157">"► in Insulininfusion pumps, if the InnoLet's dropped, damaged or leashed; there was no danger to store or frozen (see 6 How is Actrapid to preserve?) ► if it's not clear like water and colourless."</seg>
<seg id="1158">"let the closing flap of your InnoLet finished always set, if he is not in use to protect him from light."</seg>
<seg id="1159">• disinfect the rubber compounds with a medical tuce • Use always for every injections of a new injections. • Remove the injections of a NovoFine S injections (picture 1A) • Zipper the large outer cap of the injections and the inner cap of the injections.</seg>
<seg id="1160">"the Dosisregulator turns on zero and you listen to the injections • The injections must remain under the skin after injection, as the Dosislators must be returned to zero, as the Dosislators must push down to zero when you press on the push-button • Remove the injections according to any injection."</seg>
<seg id="1161">"orale Antidiabetika (to take), Monoaminoxide, anabole Steroids, oetylsalicylacid, thyself-enzyme, liasympathomimetika, growth hormone, Danazol, Octopotid or Lanreotid."</seg>
<seg id="1162">"121 ► if it had not been kept correctly or frozen (see 6 How is Actrapid to preserve?) ► if it's not clear like water and colourless."</seg>
<seg id="1163">"if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information, please inform your doctor, your diabetesbery or your pharmacist."</seg>
<seg id="1164">Let the closing flap of your FlexPen Prepens always set up when he is not in use to protect him from light.</seg>
<seg id="1165">"F Hold you get the FlexPen with the injections in up and knock a few times with the finger easily against the cartridge, so that existing bubbles can collect the top of the cartridge above."</seg>
<seg id="1166">The dose may be corrected both after the top and below by turning the Dosispre-button in the appropriate direction until the correct dose opposite the markings of the Dosisindicator.</seg>
<seg id="1167">Adenuric is used in patients who already have signs of crystallotings including arthritis (pain and inflammation in the joints) or gation nodes ("Stones)."</seg>
<seg id="1168">"if the urinary wheel continues after two to four weeks still over 6 mg per Decilite, the dose can be increased at once daily 120 mg once daily."</seg>
<seg id="1169">"during the first treatment months, we are still able to occur under construction cases; for this reason the patients may take at least during the first six months under treatment with Adenuric other medicines for the prevention of gases."</seg>
<seg id="1170">"the medicine is not recommended for children and patients who had an organtransplant, as it was not examined for these groups."</seg>
<seg id="1171">"in the first study, participating in the 1 072 patients, the effectiveness of the various Adenuric dosages (once daily 80, 120 and 240 mg) compared to the placebo (headmedikamp) and by Allopurinol (a different medicine used to treat hyperurikemia)."</seg>
<seg id="1172">In the second study two doses of Adenuric (once daily 80 and 120 mg) compared to 762 patients each with Allopurinol.</seg>
<seg id="1173">In both studies Allopurinol in a dose of once daily 300 mg used; patients with kidney problems received only 100 mg per day.</seg>
<seg id="1174">Main indiator for the effectiveness was the number of patients whose urinary urchin was in the blood among the last three measurements under 6 mg / dl.</seg>
<seg id="1175">"in the first study 48% (126 from 262) of the patients, the Adenuric in a dose of once daily 80 mg, and 65% (175 of 269) the patients who participated once daily 120 mg in the blood of under 6 mg / dl."</seg>
<seg id="1176">"compared to 22%, this was at 22% (60 of 268) patients under Allopurinol and in no one of the 134 patients under placebo of the case."</seg>
<seg id="1177">"the most common side effects of Adenuric (observed at 1 to 10 of 100 patients) are headache, whence (nausea), rash and abnormal liver values."</seg>
<seg id="1178">Especially in patients with cardiac disease may also be a elevated risk of certain side effects that affect the heart and blood vessels.</seg>
<seg id="1179">"the Committee on Humancision (CHMP) is to conclude that Adenuric was more effective in the reduction of the urinary sacks in the blood, but also a higher risk of side effects related to the heart and blood vessels."</seg>
<seg id="1180">"treatment of chronic hyperurikemia in diseases, which have already led to Uratablagings (including one out of the medical story known or currently present, and / or a Gichtarte)."</seg>
<seg id="1181">"if the Serumharnespiegel after 2-4 weeks still &gt; 6 mg / dl (357 µmol / l), can be considered a Dosisincrease at ADENURIC 120 mg 1 x daily."</seg>
<seg id="1182">"in patients with severe kidney functions, the effectiveness and safety were not fully examined (Kreatinin- Clearance &lt; 30 ml / min, see Section 5.2)."</seg>
<seg id="1183">"children and young people There are no experiences in children and young people, the use of Febuxostat is not recommended in this patient group."</seg>
<seg id="1184">"organic transplants receiver Da it received no experiences in transtransplants, the application of Febuxostat is not recommended in this patient group (see Section 5.1)."</seg>
<seg id="1185">Cardiovascular disorders In case of patients with compulsory heart disease (see section 4.8) treatment with Febuxostat is not recommended (see Section 4.8).</seg>
<seg id="1186">"as with other harvesting drugs, it can occur during the treatment start to an acute acute, because by lowering the serumharneiurpiers first urinary urables can be mobilized in the fabric."</seg>
<seg id="1187">"B. with malicious diseases and their treatment, readers - Nyhan-Syndrome) the absolute concentration of Xanthin in rare cases is so far increasing that it comes to a derivative in the urinary tract."</seg>
<seg id="1188">Leberdiseases during the clinical trials of phase 3 were observed by slight overhaul of the liver functioning with Febuxostat treated patients (3.5%).</seg>
<seg id="1189">"it is therefore recommended, prior to the beginning of the Febseostatline treatment and in the further course depending on the small amount of liver functionality (see Section 5.1)."</seg>
<seg id="1190">Theophylline-line has been conducted no exchange studies on Febuxostat but it is known that XO-shirts can lead to an increase in theophyllination by Theophylline was also reported for other XO-Hemmer).</seg>
<seg id="1191">At Probanden was the simultaneous gift of Febuxostat and Naprox250 mg 2 x daily with an increase in Febuxostatexposition (Cmax 28%, AUC 41% and T1 / 2 26%). "</seg>
<seg id="1192">In clinical studies the application of Naproses or other NSAR / Cox-2-shirts are not associated with a clinically significant increase in unwanted events.</seg>
<seg id="1193">Colfosco / Indometacin / Hydrochlorthiazid / Warmbin Febuxostat can be used together with Colfosco or Indometacin, without having a dosage adjustment for Febuxostat or at the same time the other active ingredient is required. "</seg>
<seg id="1194">"in a study with Progangs, 120 mg ADENURIC 1 x daily a medium 22% increase in AUC by Desipramine, a CYP2D6 substrate, which indicates a possible weak inhibitoric effect of Febuxostat on CYP2D6-enzyme in vivo."</seg>
<seg id="1195">"Antazida It could be shown that the simultaneous intake of a Antazidums, the magnesium-hydroxid and aluminium-hydroxid contains, the recording of Febuxostat (about 1 hour) delayed and a decrease of the Cmax by 32%, but not a significant change in the AUC."</seg>
<seg id="1196">Pregnancy data on a very limited number of exposed pregnancies can not be made on side effects of Febuxostat on pregnancy or health of the fetus / newborns.</seg>
<seg id="1197">"experimental studies do not leave direct or indirect impact on pregnancy, embryonic / fetal development or birth (see section 5.3)."</seg>
<seg id="1198">"patients should be cautioned at the taxes of a vehicle, use of machines or in the exercise of hazardous activities, until they may be very well assured that ADENURIC is not influenced their performance."</seg>
<seg id="1199">A numeric higher incidence of the test benches reported in the overall mass group in comparison to the Allopurinol Group (1.4 versus 0.3 events per 100 patient-years) and in long-term - extension studies (1.4 versus 0,7 events per 100 patient years) and found no more statistically significant differences with Febuxostat.</seg>
<seg id="1200">The risk factors in these patients were an arterial erotic disease and / or a myokardincolored or a deadly herbal efficiency in the hospital.</seg>
<seg id="1201">"frequent (≥ 1 / 100 to &lt; 1 / 10), occasional (≥ 1 / 1,000 to &lt; 1 / 100) and rare (≥ 1 / 1,000) and rare (≥ 1 / 1,000), which could be reported in the treatment groups of 80 mg / 120 mg of Feb. treatment groups in total more than once, are listed below."</seg>
<seg id="1202">"waste, nausea, and omiting are more common in patients who are treated at the same time with Colfosco. * * In the clinical studies there were no heavy skin receivers or heavy oversensitivity reactions."</seg>
<seg id="1203">"7 Offered long-term extension studies in the open long-term extension studies, 906 patients were treated up to 1 year long, 322 patients up to 2 years and 53 patients up to 4 years with Febuxostat 80 mg / 120 mg for up to 4 years."</seg>
<seg id="1204">"during the long-term, renewal studies reported that were similar in the studies of the Phase 3 (see chart 1)."</seg>
<seg id="1205">The following treatment related events were reported in all Febuxostat- treatment groups altogether more than once and occurred in patients who received Febuxostat 80 mg / 120 mg in long-term extension period (up to 4 years with an exposure time of &gt; 1.900 patients), according to the data accordingly occasionally. "</seg>
<seg id="1206">The following-related events were reported in the pivotal studies of phase 3 for these doses either not reported or with a lower frequency:</seg>
<seg id="1207">"diabetes, hypereridemia, insomnia, rinsecticide, meatballs, protectionism, protectionery, kidney concentration in the blood, decrease in the blood, decrease in the blood, decrease in the number of white blood cells."</seg>
<seg id="1208">Wirism uric acid is the final product of Purinmetism and arises as part of the reaction skaskade Hypoxanthin → Xanthin → urethic acid.</seg>
<seg id="1209">"Febuxostat is a real, not Purin-selective Inhibitor of the XO (NP-SIXO) with a Ki-value for the in vitro-shirt, which is below the shirt omolar area."</seg>
<seg id="1210">"clinical studies results The effectiveness of ADENURIC was described in two pivotal studies of phase 3 (APEX study and fact study as described below), which were conducted with 1,832 patients with hyperurikemia and gout."</seg>
<seg id="1211">The primary efficacy of the volume was in each study of the percentage of patients with which the last three months had given particular servings &lt; 6.0 mg / dl (357 µmol / l).</seg>
<seg id="1212">"placebo (s = 134), ADENURIC 120 mg 1 x daily (n = 134), ADENURIC 120 mg 1 x daily (n = 134) for patients with a servo Creatininworth to study starts by &gt; 1.5 mg / dl and ≤ 2,0 mg / dl."</seg>
<seg id="1213">The APEX study showed with regard to lowering Serumharneids under 6 mg / dl (357 µmol / l) (see chart 2 and figure 1) the statistically significant doses of Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The fact-study showed with regard to the permanent lowering of the Serumharnespiegels under 6 mg / dl (357 µmol / l) the statistically significant superiority both the treatment with ADENURIC 120 mg 1 x daily compared with the conventional dose of Allopurinol 300 mg.</seg>
<seg id="1215">Patients with SerumCreatininvalues &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were summarized for the analyses. * p &lt; 0,001 versus Allopurinol, # p &lt; 0,001 versus 80 mg "</seg>
<seg id="1216">The reduction of the Serumharneiurespiegels on &lt; 6,0 mg / dl (357 µmol / l) was observed during the arztVisit in week 2 and permanently kept through the entire treatment.</seg>
<seg id="1217">"509 patients received Allopurinol 300 mg 1 x daily; 10 patients with SerumCreatininvalues &gt; 1.5 and &lt; 2,0 mg / dl 100 mg 1 x daily."</seg>
<seg id="1218">"primary end point in the sub-group of patients with kidney functioning, The APEX study was able to assess the effectiveness of 40 patients with kidney's power stations (d.)."</seg>
<seg id="1219">"with ADENURIC the primary active ingredient of 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily)."</seg>
<seg id="1220">"there was no clinically significant differences with regard to the percentage of Serumharnscentration, regardless of its kidney function (58% in group with normal kidney function and 55% in the group with severe kidney functioning)."</seg>
<seg id="1221">Primary final point in the sub-group of patients with Serumharnscentration ≥ 10 mg / dl About 40% of patients (APEX- and fact study) had a servo-concentration of ≥ 10 mg / dl.</seg>
<seg id="1222">The data collected in two years collected data of the open extension stage in the phase 3 showed that the permanent reduction of the incidence of genesis (&lt; 357 µmol / l) require a decrease in the incidence of gases (i.e. less than 3% of patients needed no treatment against a Gichtschub).</seg>
<seg id="1223">"this was also associated with a reduction of the coating depth, which at 54% of patients had a complete disappearance of the gating nodes up to month 24."</seg>
<seg id="1224">Increased TSH- Values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostat (5.5%) and also in patients who received Allopurinol (5.7%) in the open long-term extension studies (see Section 4.4).</seg>
<seg id="1225">In healthy volunteers the maximum plasticonentric period (Cmax) and the surface under the Plasmakonentric period (AUC) of Febuxostat after agreement is easier and multiplers cans of 10 mg to 120 mg doso proportional.</seg>
<seg id="1226">For doses from 120 mg and 300 mg is observed for Febuxostat an increase in AUC that is greater than the dosages disproportionate increase.</seg>
<seg id="1227">After taking a simple or multi-level cans of 80 and 120 mg 1 x daily is the Cmax. 2,8-3.3 µg / ml and 5,0-5.6 µg / ml.</seg>
<seg id="1228">"however, no clinically significant change has been observed in the percentage of Serumharnscentric concentration, provided that this has been tested (multiple doses of 80 mg)."</seg>
<seg id="1229">Distribution The apparent steady-state distribution volumes (vss / F) of Febuxostat is located in the range from 29 to 75 l after intake of doses of 10-300 mg.</seg>
<seg id="1230">The Plasmared connection of Febuxostat is approximately 99,2% (primary binding at Albumin) and is reached via the concentrating width that is reached with cans of 80 and 120 mg.</seg>
<seg id="1231">"in vitro-studies in human Lebriikrosomen showed that these oxidative metabolic mainly formed by CYP1A1, CYP2C8 or CYP2C9, and that Febuxostatglucuronid mainly created by UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">"after taking a 80 mg dose of 14C-marked Febuxostat, approximately 49% of the dose of urine (3%), the known oxidative metabolic (3%), its famous oxidative metabolic and its conjugate (13%) as well as other unknown Metabolites (3%)."</seg>
<seg id="1233">"in addition to the divorce about the urine also found approximately 45% of the dosage in the chair as unchanging Febuxostat (12%), Acylglukuronid of the drug (1%), its famous oxidative metabolic and its conjugate (7%) as well as other unknown Metabolites (7%)."</seg>
<seg id="1234">Special patient-groups Niereninsufficiency. after taking multiple doses of 80 mg ADENURIC in patients with light, moderate or heavy necessiinsufficiency. the Cmax of Febuxostat does not changed in relation to probanden with normal kidney function. "</seg>
<seg id="1235">The middle-AUC of Febuxostat took around about the 1,8-fold of 7.5 μ g. h / ml in group with normal kidney function on 13,2 μ g. h / ml in the group with severe kidney function.</seg>
<seg id="1236">12 liver functionality after taking multiple doses of 80 mg ADENURIC in patients with light (Child- dgh-classification A) or medium-difficult (Child-Pugh-classification A) or medium-difficult (Child-Pugh-classification A) or medium-severe (Child-Pugh-classification A) and its metabolic are not significant compared to probanden with normal liver function.</seg>
<seg id="1237">Age There were no significant changes with regard to the AUC of Febuxostat or its metabolic cans of ADENURIC in older patients compared to younger proportions.</seg>
<seg id="1238">"carcinogenesis, nuts, impairment of the fertilisation In male Ratting was a statistically significant increase in urethic rocks (transitional cell papillome and carcinoms) only in connection with Xanthin-stones used in the high-thin group, at about 11-ply the exposure of people, found."</seg>
<seg id="1239">These findings are seen as a result of a specialised Purinmetallization and urine and for clinical use as not relevant.</seg>
<seg id="1240">It was established that Febuxostat in oral cans of up to 48 mg / kg / day no effect on the fertilisation and reproduction of male and female rats.</seg>
<seg id="1241">"at high doses, which were approximately with 4,3- the humane toxicity, the maternal toxicity, entered into with a reduction in insulating power and a development delay to the descendants of rats."</seg>
<seg id="1242">"teratological studies in supporting rats with expeditions, which are about the 4,3-fold and in supporting rabbits with Expositions that betray the 13-fold of humanitarian extruded exposure, yielded no teratogenic effects."</seg>
<seg id="1243">Colfosco / Indometacin / Hydrochlorthiazid / Warmbin Febuxostat can be used together with Colfosco or Indometacin, without having a dosage adjustment for Febuxostat or at the same time the other active ingredient is required. "</seg>
<seg id="1244">"waste, nausea, and omiting are more common in patients who are treated at the same time with Colfosco. * * In the clinical studies there were no heavy skin receivers or heavy oversensitivity reactions."</seg>
<seg id="1245">"21 Offered long-term extension studies in the open long-term extension studies, 906 patients were treated up to 1 year long, 322 patients up to 2 years and 53 patients up to 4 years with Febuxostat 80 mg / 120 mg for up to 4 years."</seg>
<seg id="1246">The primary efficacy of the volume was in each study of the percentage of patients with which the last three months had given particular servings &lt; 6.0 mg / dl (357 µmol / l).</seg>
<seg id="1247">The data collected in two years collected data of the open extension stage in the phase 3 showed that the permanent reduction of the incidence of genesis (&lt; 357 µmol / l) require a decrease in the incidence of gases (i.e. less than 3% of patients needed no treatment against a Gichtschub).</seg>
<seg id="1248">"26 as unchanging Febuxostat (3%), Acylglucuronid of the drug (30%), its famous oxidative metabolic and its conjugate (13%) as well as other unknown Metabolites (3%)."</seg>
<seg id="1249">Leberer functionaries of 80 mg ADENURIC in patients with lighter (Child- dgh-classification A) or medium-difficult (Child-Pugh-classification A) or medium-difficult (Child-Pugh-classification A) or medium-severe (Child-Pugh-classification A) or medium-severe (Child-Pugh-classification A) changed the Cmax and AUC of Febuxostat and its metabolic function not significantly compared to probanden with normal liver function.</seg>
<seg id="1250">"carcinogenesis, nuts, impairment of the fertilisation In male Ratting was a statistically significant increase in urethic rocks (transitional cell papillome and carcinoms) only in connection with Xanthin-stones used in the high-thin group, at about 11-ply the exposure of people, found."</seg>
<seg id="1251">"the holder of permission for the Insert has to make sure that an Pharmacovigilance system is described as in version 2.0 Module 1.8.1 of the authorisation, ready before the medicine is put into traffic, and so long is available, as the medicine is brought into traffic."</seg>
<seg id="1252">A aktualised RMP is present in accordance with the CHMP guideline for risk management systems for humanity with the next Periodic Safety Update Report (PSUR).</seg>
<seg id="1253">"in addition, an update of the RMP required • if new information is required, which have an effect on the safety issues, the Pharmacovigilance plan or activities for risk management, • within 60 days of reaching important milestones (Pharmacovigilance or risk management) • on request of the EMEA"</seg>
<seg id="1254">"in some people the urethic acid in the blood and can reach concentrations that are so high, that uric acid is insoluble."</seg>
<seg id="1255">"if you keep the urinary concentration by the 1 x daily intake of ADENURIC, the crystals is prevented and this way is achieved with a reduction of complaints."</seg>
<seg id="1256">ADENURIC must not be taken if you are oversensitive (allergic) against the active Febuxostat or one of the other components of ADENURIC.</seg>
<seg id="1257">"inform your doctor before starting with taking this medication. if you suffer a heart attack, or have a rare disease outbreak in a result of a cancer disease or the lesbian-Nyhan-Syndroms (a rare illness, where too much uric acid in the blood is)."</seg>
<seg id="1258">"if you have a shift in the moment (sudden appearance of heavy pain, compressed sensitivity, redness, thermal insulation and jelly swelling), wait until the gation deflection is before you start with the treatment with ADENURIC."</seg>
<seg id="1259">"this does not have to be with each one, but also with you, especially during the first treatment weeks or - months, occur when you take ADENURIC."</seg>
<seg id="1260">Your doctor will prescribe you other medicines to prevent a shift in case or to treat the associated symptoms (such as pains and jelly swelling).</seg>
<seg id="1261">Please inform your doctor or pharmacist if you use other medicines / apply or used especially if it is not prescription drugs.</seg>
<seg id="1262">It is particularly important that you can use your doctor or pharmacist if you use medicines / apply that any of the listed substances may occur as interactions with ADENURIC (for the treatment of cancer) • Azathioprin (for the treatment of asthma) • Warmbin (for the treatment of asthma) • Warmbin (for blood dilution in Hercerties)</seg>
<seg id="1263">No studies have been carried out to the effects of ADENURIC and the ability to use machines.</seg>
<seg id="1264">Please take ADENURIC therefore only after consultation with your doctor if you know is that you suffer from a intolerance toward certain states.</seg>
<seg id="1265">"on the back of the blister packaging are printed, so you can check if you have taken a tablet every day. • The tablets need to be swallowed and can be taken with or without food."</seg>
<seg id="1266">"if you have failed to have a transitional dose, turn to your doctor or to the emergency room at the nearest hospital."</seg>
<seg id="1267">"if you have forgotten the intake of ADENURIC you get these as soon as possible, unless the next intake is short before."</seg>
<seg id="1268">"if you cancel the intake of ADENURIC, your urinary Concentration can be ascending, and your complaints can worsen because new judgment crystals can form in your joints and kidneys as well as their environs."</seg>
<seg id="1269">Frequent side effects (more than 1 of 100 treated; but less than 1 of 10 treated): • conspicuous liver infestation • malache • eving</seg>
<seg id="1270">"rare side effects (more than 1 of 10.000 treated, but less than 1 of 1,000 treated): • weakness • nervousness • Durant • carving"</seg>
<seg id="1271">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="1272">ADENURIC is available in 2 blister packs with 14 tablets (pack with 28 tablets) or in 6 blister packs with 14 tablets (pack with 84 tablets).</seg>
<seg id="1273">"БъWaufour IPSEN Pharma 24 rue Era long F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">"Danmark, Norge, Norge, Suomi / Finland, Sverige Synthèse (IPSEN) AB Kista Sverige / Ruotsi / Puh / Sími: + 46 8 588 370 70</seg>
<seg id="1275">"ADROVANCE is used for treating osteoporosis (a disease, where the bones are used) in women after menopause, where a risk for a low vitamin D mirror is composed of."</seg>
<seg id="1276">"the patient has to take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or disposable other medicines (including Antazida, Calcium- and Vitaminsupplements)."</seg>
<seg id="1277">"to avoid a maturity of the esophagus, the patient is to take place until after the first food intake of the day, the breakfast is 30 minutes after taking the tablet."</seg>
<seg id="1278">"since Alendronat and vitamin D3 already separated from each other in pharmaceuticals that are approved in the European Union, the company presented data from earlier studies and published literature."</seg>
<seg id="1279">The company also led a study with 35 men and 682 postmenopal women with osteoporosis to detect the effectiveness of ADROVANCE in terms of increasing the vitamin D mirror.</seg>
<seg id="1280">"after a 15-week treatment, the proportion of patients with the lowest vitamin D mirror was treated with ADROVANCE (11%) than with those who took exclusively Alendronat (32%)."</seg>
<seg id="1281">"the company also laid data before that, that in ADROVANCE included in ADROVANCE, which is exactly the dose which is needed for preventing a bone loss."</seg>
<seg id="1282">"the most common side effects (observed at 1 to 10 of 100 patients) are headaches, pain of motion apparatus (muscles, bones, or joints) and symptoms of the digestive apparatus, dysphagia (digestion), collarrhea (blows), peprhea (bologation), agarrhea (blowing belly), as well as suction lift."</seg>
<seg id="1283">"in patients with any oversensitivity, vitamin D3 or one of the other components may not be used ADROVANCE."</seg>
<seg id="1284">"it must not be used in diseases of the esophagus, in patients with Hypocalcemia (low calcium mirror) or in patients who can not stand up or sit for at least 30 minutes."</seg>
<seg id="1285">January- 2007 the European Commission hosted the company Merck Sharp & Dohme Ltd. a permission for the Independence of ADROVANCE in the entire European Union.</seg>
<seg id="1286">"chapels, white to broken white tablets, characterized by setting up a button on one side and" 710 "on the other."</seg>
<seg id="1287">ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first meal, beverage or disposable drugs (including Antazida, Calcium- and Vitaminsupplements) for the day. "</seg>
<seg id="1288">The following indications are to be accurate to reduce the risk for malophageal irritation and related side effects (see Section 4.4):</seg>
<seg id="1289">"• ADROVANCE should be swallowed after the advent of the day only with a full glass of water (at least 200 ml), as a risk for oropharyngeale Ulzera. • The patients should not take place before the first food intake of the day, the breakfast is 30 minutes after taking the tablet."</seg>
<seg id="1290">"B. peptic Ulkus, active gastrointestinal bleeding or surgical interventions in the upper Gastrosyinaltrakt except Pyloroplasty, only under special caution (see section 4.3)."</seg>
<seg id="1291">"Ösophageale reactions, such as Ösophagitis, malophageale Ulzera and ösophageale erosion, were reported by patients under the intake of Alendronat (partly these serious and necessary a health instruction)."</seg>
<seg id="1292">"the doctor should therefore draw attention to all signs and symptoms, which should point out upon possible malophonic reactions, and the patients should be pointed out in the appearance of symptoms such as dysphagie, pains while swallow or retrolimmer of soy (see section 4.8)."</seg>
<seg id="1293">3 The risk of severe malicious side effects seems to be increased by patients who do not take correctly and / or after the appearance of symptoms that are on a malophageal irritation.</seg>
<seg id="1294">It is very important that all the analyses to be passed on to the patient and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"while in large clinical studies with Alendronat no elevated risk was detected (according to market launch) Magen- and Duodenalulzera, including some serious and with complications, reported (see section 4.8)."</seg>
<seg id="1296">"Osteonekrose of the Kiefer, usually associated with a tooth extraction and / or a local infection (including Osteomyelitis), was reported in cancer patients whose therapy is predominantly intravenous Bisphosphate."</seg>
<seg id="1297">"there are no data available to indicate whether the deportation of a Bisphosphonattherapy in patients who need a cold surgical procedure, reducing the risk of Osteonekoarthritis of the Kiefer."</seg>
<seg id="1298">The clinical assessment by the doctor treating the doctor is decisive for therapy planning in every patient on the basis of an individual benefit risk.</seg>
<seg id="1299">Patients should be dependent that they should take in the failure of taking a dose of ADROVANCE the tablet in the next morning after they have noticed its failure.</seg>
<seg id="1300">"they should not take two tablets on the same day, but taking one tablet per week as originally planned to continue the weekday."</seg>
<seg id="1301">"other diseases, which affect the mineral metabolism (such as vitamin-D-lack and hypoparathyreoididism), should also be treated before the start of therapy with ADROVANCE."</seg>
<seg id="1302">"Alendronat food and drinks (including mineral water), calcium supplement, Antazida and some orale medicines can affect the remains of alendronat if they are taken at the same time."</seg>
<seg id="1303">"therefore, patients must wait for at least 30 minutes before taking other medicines (see sections 4.2 and 5.2)."</seg>
<seg id="1304">"although specific response studies have not been carried out, Alendronat in clinical studies were taken together with a multitude of usually prescribed medicines, without that clinically relevant interactions."</seg>
<seg id="1305">ADROVANCE is intended only for use in postmenopausal women and therefore does not apply neither during the pregnancy still of breastfeeding women.</seg>
<seg id="1306">Animal studies with alendronage leave no indication of direct compensation effects in terms of pregnancy, the embryonic / fetal or postnatal development. "</seg>
<seg id="1307">"Osteonekrose of the Kiefer was reported in patients among Bisphosphates, but most of the reports come from cancer patients, but was also reported at Osteoporosepatients."</seg>
<seg id="1308">"nevertheless, the serum-calcium up to &lt; 8,0 mg / dl (2,0 mmol / l) and the Serum- Phosphats to ≤ 2.0 mg / dl (0,65 mmol / l) in both treatment groups with similar frequency."</seg>
<seg id="1309">"Alendronat as a result of an oral overdose, hypocalcemie, mortophosphatemie and side effects in the upper Gastrointestinal cord, such as maggiversaries, Sodburn, amplophagitis, Gastritis or Ulzera."</seg>
<seg id="1310">Colecalciferol (vitamin D3) vitamin D3 is produced in the skin through UV-light over the transformation of 7-Dehydrocholesterol to vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-Dihydroxyreis D3 is increasing the intestinal Resorption of calcium and phosphate, the renunciation of calcium and phosphate, the bone of bone and bone resorption."</seg>
<seg id="1312">"in severe cases a lack of secondary hyperparathyreoidized, hypophosphatemia, weakness of the proximal musculature and osteomalazie, and thus to a further increased risk for storms and bone marquarries in osteoporotic persons."</seg>
<seg id="1313">"Bone Mineral Density) to spinal column or bouncing, the 2.5 standard deviation under the mean value for a normal, young people, or regardless of the bone density as this pathological fracture."</seg>
<seg id="1314">The patients received ADROVANCE in the lower thickness (70 mg / 2.800 I.E.) (n = 350) or FOSAMAX (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15-week treatment the mid-level treatment were significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800 I.E.) (56 ng / l]) than in the group under Alendronat alone (46 ng / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 I.U.) lowered significantly after 15 weeks the proportion of patients with vitamin-D-insufficiency (servo-value of 25-hydroxyreis D &lt; 37,5 ng / l [&lt; 15 ng / ml]) around 62.5% compared to Alendronat alone (12% vs.</seg>
<seg id="1317">Studies with Alendronat the therapeutic balance of alendronat once a week 70 mg (n = 519) and Alendronat 10 mg daily (n = 370) was proven in a one-year Multicenter study to postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronat on bone mass and fractional evidence in postmenopausal women were examined in two phase III studies of identities - study (FIT: N = 6.459).</seg>
<seg id="1319">In the Phase III studies of the mid-III studies of the BMD with Alendronat 10 mg / day in proportion to placebo after 3 years 8.8% at the spinal column, 5,9% by the Femurhals and 7,8% on the trochanter. "</seg>
<seg id="1320">"treated with Alendronat treated in comparison to placebo group a reduction around 48% (Alendronat 3,2% compared to placebo 6,2%) in the proportion of patients who suffered one or more spine raktures."</seg>
<seg id="1321">"in the two-year extension of these studies, the ascents of the BMD of spine and Trochanter continue to continue; also the BMD of the Femurhalses and the entire body was maintained."</seg>
<seg id="1322">"fit was made up of two plazebokontroluncontrolled studies, where Alendronat daily (5 mg daily over 2 years and then 10 mg per day continue to be taken either over 1 or 2 years):"</seg>
<seg id="1323">In this study the daily gift of Alendronat the appearance of at least a new spine of 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1324">"resorption related to an intravenous reference point for women amounting to women 0,64% for doses from 5 to 70 mg after night of nights, and two hours before starting a standardized breakfast."</seg>
<seg id="1325">The bioavailability adopted accordingly to approximately 0.46% and 0.39% when Alendronat one or half an hour before a standardized breakfast was taken.</seg>
<seg id="1326">"in Osteoporosestudien was effective, if it was taken at least 30 minutes before the first meal or drinking of the day."</seg>
<seg id="1327">"in healthy volunteers, the gift conducted by oralem prednisone (20 mg three times daily for five days) to none clinically significant change in oral bioavailability of alendronat (rise in average in the range from 20% to 44%)."</seg>
<seg id="1328">"9 distribution studies on rats have surrender to intravenous gift of 1 mg / kg temporarily into soft-divided, but then rapidly redistributed in the bones, or retired with the urine."</seg>
<seg id="1329">Retirement After intravenous gift of a single dose of 14C-Alendronat have been removed about 50% of radioactive substance within 72 hours with the urine and little or no radioactivity was refound in the file.</seg>
<seg id="1330">After intravenous gift of a single dose of 10 mg the renal Clearance of Alendronat 71 ml / min and the systemic Clearance does not break up to 200 ml / min.</seg>
<seg id="1331">"Alendronat will not be avoided at rats not about the saucepre or basal transport system of kidneys, and therefore it is not assumed that it is influenced by humans to use other medicines by these transportation systems."</seg>
<seg id="1332">Resorption For healthy adult probanden (men and men) was after the gift of ADROVANCE after night-time fasting and two hours before recording a meal the middle area under the Serum concentration time (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without considering endogenous vitamin-D3 mirror).</seg>
<seg id="1333">The average maximum concentration in Serum (Cmax) of vitamin D3 was 5.9 ng / ml and the medium-time up to the achievement of the maximum serumconcentration (Tmax) 12 hours.</seg>
<seg id="1334">"biotransformation vitamin D3 is pushed rapidly in the liver quickly to 25-hydroxyory D3 hydroxyand then in the kidney to 1,25-Dihydroxyreis D3, the biologically active form, metabolized."</seg>
<seg id="1335">Retirement of radioactive marker vitamin D3 to healthy probanden was the average rate of radioactivity in urine after 48 hours 2.4%, in the fur after 4 days 4,9%. "</seg>
<seg id="1336">"characteristics in patients preclinical studies have shown that the share of agendronage, which is not exert in bone, quickly over the urine."</seg>
<seg id="1337">"although there are no clinical data about it, nevertheless, that the renal Elimination of Alendronat as in the animal also try to be reduced in patients with reduced kidney function."</seg>
<seg id="1338">"therefore, in patients with reduced kidney function, a slightly increased collation of agendronat in bones (see section 4.2)."</seg>
<seg id="1339">"Alendronat non-clinical data on the conventional studies for safety-harmacology, for chronic toxicity, for the chronic toxicity, for genic toxicity, and to cancerous potential can be seen no particular dangers for man."</seg>
<seg id="1340">Studies in rats showed that the gift of Alendronat to impairments were attributed to the appearance of Dystokie with the appearance of Dystokie that was attributed to a hypocalcemia.</seg>
<seg id="1341">Microcrystine Cellulose (E 460) Lactose-keterses silicon / disperses Silicium dioxide Magyltoluol (Ph.Eurasia) (E 321) Butylhydroxytoluol (Ph.Eurasia) (E 321) Butylhydroxytoluol (E 321) Power natriumsilicat (E 554)</seg>
<seg id="1342">"Etui with sealing aluminium / aluminium eyes packed in cartons to 2 (1 Etui with 2 tablets), 4 (3 Etuis with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 ptuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"rectangular, white to broken white tablets, characterized by setting up a button on one side and" 270 "on the other side."</seg>
<seg id="1345">13. the patients should not lay down at least 30 minutes after the intake of ADROVANCE. • ADROVANCE should not be taken before bedtime or before the first appearance of the day.</seg>
<seg id="1346">"the risk of heavy ophophical side effects seems to be increased in patients who do not take correctly and / or it after the appearance of symptoms, which refer to a malophageal irritation."</seg>
<seg id="1347">"while in large clinical studies with Alendronat no elevated risk was detected (according to market launch) Magen- and Duodenalulzera, including some serious and with complications, reported (see section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) vitamin D3 is produced in the skin by UV-light over the transformation of 7-Dehydrocholesterol to vitamin D3.</seg>
<seg id="1349">The patients received ADROVANCE in the lower thickness (70 mg / 2.800 I.E.) (n = 350) or FOSAMAX (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once a week corresponds to a 24-week extension study with 619 postmenopulose women with osteoporosis.</seg>
<seg id="1351">After 24-week treatment the middle serummirror of 25-hydroxyreis D significantly higher in the 5.600-I.E.-vitamin-D3-Group (= 27.6 ng / l]) than in the 2.800-I.E.-vitamin-D3-Group (64 nmol / l [25,5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between the treatment groups with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">3.8% at the total hips in the group of 70 mg once a week or a day with 10 mg per day.</seg>
<seg id="1354">In this study the daily gift of Alendronat the appearance of at least a new spine of 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1355">The bioavailability adopted accordingly to approximately 0.46% and 0.39% if Alendronat one or half an hour before a standardized breakfast</seg>
<seg id="1356">"distribution studies on rats have result that Alendronate divided itself to intravenous gift of 1 mg / kg temporarily into soft-divided, but then rapidly redistributed in the bones, or retired with the urine."</seg>
<seg id="1357">Resorption For healthy adult probanden (men and men) was after the gift of ADROVANCE (70 mg / 5.600 i.e) after night-concentration of time (AUC0-80 h) for vitamin D3 490,2 ng • h / ml (without considering endogenous vitamin-D3 mirror).</seg>
<seg id="1358">The average maximum concentration in the serum (Cmax) of vitamin D3 was 12.5 ng / ml and the medium-time up to the achievement of the maximum serumconcentration (Tmax) 10,6 hours.</seg>
<seg id="1359">Smaller amounts are spread in fat and muscle tissue and are stored there as vitamin D3 to be released later in the cycle.</seg>
<seg id="1360">"21 vitamin D3 is rapidly used in the liver rapidly to 25-hydroxyory D3 hydroxyand then in the kidney to 1,25-Dihydroxyreis D3, the bioactive form, metabolized."</seg>
<seg id="1361">No evidence has been found on a saturation of the bone's ability to long-term dosage of cumulative doses of up to 35 mg / kg at animals.</seg>
<seg id="1362">"Etui with sealing aluminium / aluminium blister packs in cartons to 2 (1 Etui with 2 tablets), 4 (3 Etui with 4 tablets) or 40 (10 ptuis with 4 tablets) tablets."</seg>
<seg id="1363">"Pharmacovigilance System The holder of permission for the Inleiding system is safe to ensure that an Pharmacovigilance system is described as described in version 2 module 1.8.1 of the application documents, and so long is available, as the marketed medicine is brought into traffic."</seg>
<seg id="1364">"the risk management plan the owner of the approval for the contract is committed to studies and further pharmacovigilance-plan, which are described in the risk management plan (RMP) and its corresponding updates to Version 1 Module 1.8.2 of the authorisation documents are detailed."</seg>
<seg id="1365">A aktualised RMP is in accordance with the CHMP guideline for risk management systems for humancisions with the next periods of Saftey Update Report (PSUR).</seg>
<seg id="1366">"in addition, an update of the RMP required - if new information is required to have an effect on the safety issues, Pharmacovigilance plan or activities for risk management, − within 60 days of reaching important milestones (Pharmacovigilance or risk management) − on request of the EMEA"</seg>
<seg id="1367">Take part in the weekday of a ADROVANCE tablet after getting started as well as before taking the first food and drink and before taking any other medicine by swallow the tablet with a full glass of water (not brew and not lutties).</seg>
<seg id="1368">Perhaps you would like to read this later again. • If you have further questions please contact your doctor or pharmacist. • This medicine was personally committed to you.</seg>
<seg id="1369">"in the menopause, the Eierves do not produce female hormones, oestrogen, more who help the skeleton from women healthy."</seg>
<seg id="1370">"the fraternity usually arise at the hips, the spine or the wrist, and can not only cause pain, but also significant problems such as debued attitude (" Witwenbuckel ") and a loss of mobility."</seg>
<seg id="1371">ADROVANCE prevent not only loss of bone mass but also helps to reduce the bone loss and reduce the risk for spine and hip retractions.</seg>
<seg id="1372">"verification of esophagus or canons (3) if it is not possible to sit at least 30 minutes to stand up or stand, (4) if your doctor has been determined that your calcium content is lower in the blood."</seg>
<seg id="1373">"40 • If you have problems when swallow or using the digestion, • if your calcium levels have received in the blood • if you have cancer, • if you are a chemotherapy or radiation treatment) • if you do not take a chemotherapy or radiation treatment) • if you do not have a chemotherapy or radiation treatment) • if you do not have routinely for dental care."</seg>
<seg id="1374">These complaints can occur in particular if the patients take the ADROVANCE tablet with a full glass of water and / or less before expiry of 30 minutes after taking.</seg>
<seg id="1375">"at intake of ADROVANCE with other medicines, Calciumsupplements, Antazida and some other medicines to involve the effectiveness of ADROVANCE for simultaneous intake."</seg>
<seg id="1376">"certain medicines or food additives can hinder vitamin D in the body, including artificial fatty acids, minerals, orlistat and the cholesterinsenkenden medicine cholestyramin and Colestipol."</seg>
<seg id="1377">"please inform your doctor or pharmacist if you use other medicines / apply or used recently, even if it is not prescription drugs."</seg>
<seg id="1378">Please take this medicine only after consultation with your doctor if you are known that you suffer from a intolerance toward certain states.</seg>
<seg id="1379">"please follow the instructions 2), 3), 4) and 5) to facilitate the transport of the ADROVANCE tablet in the stomach, and to reduce the potential irritation of the esophagus (Ösophagus - the tube, which connects your mouth with the stomach)."</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first appearance and before taking any other medicine only with a full glass (minimum 200 ml) water (not with mineral water). • Not having coffee or tea. • Not having juice or milk.</seg>
<seg id="1381">"(3) Do not go away - stay totally upright (in sitting, standing or toes) - at least 30 minutes long after taking the tablet."</seg>
<seg id="1382">"(5) If you have difficulty or pain during swallow, pain behind the breast-bone, replaceable or worsening sobrides SodCE, set ADROVANCE and search for your doctor."</seg>
<seg id="1383">"(6) Wait according to the swallow of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (magic medicine), Calcium or Vitaminpreparate this day."</seg>
<seg id="1384">"should you accidentally found too many tablets at once, drink a full glass of milk and contact your doctor immediately."</seg>
<seg id="1385">If you missed the intake of a tablet only take one tablet in the next morning after you noticed your failure.</seg>
<seg id="1386">"frequently: • oxygenres harshades; pains of swallow; sizing of the esophagus, sodburn and pain or discomfort in swallow, • bone, muscle and / or joint pain, • abdication; stipation; stipation; flaps, • headache, • headache."</seg>
<seg id="1387">"occasionally: • nausea; exiting, • irritation and inflammation of the esophagus (Ösophagus - the tube, which connects your mouth with your stomach) or the stomach loops, • black or tear similar chair, • skin ash; juckwise."</seg>
<seg id="1388">"after launching the following side effects have been reported (frequency not known): • (swivel) Schwinch, • Yellow, • hair loss, • sound problems (osteonekoarthritis) in connection with delayed wound and infections, often according to the toes of teeth, • swellings of hands or legs."</seg>
<seg id="1389">"43 Dait is helpful if you note, what complaints you had, when they began and how long they stopped."</seg>
<seg id="1390">"the other components are microcrystine Cellulose (E 460), Lactose-sodium, croacarmses silicon / disperses silicon, Magylhydroxytoluol (Ph.Eur.) (E 321), Butylhydroxytoluol (Ph.Eurasia), and aluminum natriumsilicat (E 554)."</seg>
<seg id="1391">The tablets are available in Etuis with sealing aluminium / aluminium blister packs) • 6 tablets (3 Etui with 2 tablets in aluminium blister packaging) • 40 tablets (3 eyelid with 4 tablets in aluminium blister packaging) • 40 tablets (10 ptuis with 4 tablets in aluminium blister packaging).</seg>
<seg id="1392">"in the menopause, the Eierves do not produce female hormones, oestrogen, more who help the skeleton from women healthy."</seg>
<seg id="1393">"48 • If you have allergies, • if you have problems when swallow or using the digestion, • if you have cancer in blood, • if you have cancer, • if you are a chemotherapy or radiation treatment) • if you do not take a chemotherapy or radiation treatment) • if you do not have a chemotherapy or radiation treatment) • if you are not routinely for dental care."</seg>
<seg id="1394">"at intake of ADROVANCE with other medicines, Calciumsupplements, Antazida and some other medicines to involve the effectiveness of ADROVANCE for simultaneous intake."</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first appearance and before taking any other medicine only with a full glass (minimum 200 ml) water (not with mineral water). • Not having coffee or tea. • Not having juice or milk.</seg>
<seg id="1396">3) Do not go - stay totally upright (in the sitting area or toes) - at least 30 minutes long after taking the tablet.</seg>
<seg id="1397">"5) If you have difficulty or pain during swallow, pain behind the breast-bone, replaceable or worsening sobrides SodCE, set ADROVANCE and search for your doctor."</seg>
<seg id="1398">6) Wait according to the swallow of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (magic medicine), Calcium or Vitaminpreparate this day. "</seg>
<seg id="1399">"• (rotary) Schwinch, • Gelenkellings, • fatigue, • hair loss, • pine problems (osteonekoarthritis) in connection with delayed wound and infections, often according to the toes of teeth, • swellings of hands or legs."</seg>
<seg id="1400">"tablets are available as rectangular, white to broken white tablets, characterized by setting up a button on one side and" 270 "on the other side."</seg>
<seg id="1401">Advagraf is administered adult patients to prevent a kidney or liver transplantied to prevent a drainage of the transplanted organ by the immune system.</seg>
<seg id="1402">"since Tacrolimus and prograf are already used in the EU, the company has presented the results from previously performed studies with prograf / prograft and data from the published literature."</seg>
<seg id="1403">"in addition, the results of a clinical study were submitted to 668 patients with kidney transplant, whereby the application of Advagraf with prograf / prograft or in comparison has been compared."</seg>
<seg id="1404">Main indicator of the effectiveness was the number of patients with which the transplantation was terminated after a treatment duration of one year (by example, as often a renewed transplantation or a revival of dialysis was required). "</seg>
<seg id="1405">"in addition, further studies were carried out in 119 patients with kidney transplant and 129 patients with liver transplant and investigates how Advagraf compared to prograf / prograft from the body."</seg>
<seg id="1406">"marble (trembling), headaches, headache, kidney problems, increased blood sugar levels (hyperglycemic), diabetes, more potassium content of blood (hypercalmia), hypertension (hypertension), as well as sleeplessness (insomnie)."</seg>
<seg id="1407">"in patients with any oversensitivity, macro-antibiotics (such as Erythromycin), or one of the other components may not be applied to Advagraf."</seg>
<seg id="1408">Patients and doctors need to be careful when others (especially some herbal) medicines simultaneously be taken at the same time with Advagraf as the Advagraf dose or the dose of the simultaneously active medicine must be adjusted accordingly.</seg>
<seg id="1409">"gestures, retardiert Yellow-orange Gelatinekaptles, printed in red ink with" 0.5 mg "and on the orange capselor with" "647"; they contain white powder. "</seg>
<seg id="1410">Only doctors who are familiar with the immunotherapist therapy and treatment of transplantation patients should be able to arrange this medicine or make changes in the immunohemian therapy.</seg>
<seg id="1411">"based on clinical-relevant differences of the systemic exposure of Tacrolimus, this may lead to transplants or to an increased incidence of side effects, including under- or overimmune soup."</seg>
<seg id="1412">Patients should always keep the same Tacrolimus formulation and the corresponding daily dosage; surveys of the formulation or the regime should only be carried out under the control of an experienced physician (see sections 4.4 and 4.8).</seg>
<seg id="1413">"in consequence of a conversion to an alternative formulation, a therapeutic monitoring and appropriate Dosiscustomizable will be carried out to ensure that the systemic exposure of Tacrolimus will remain."</seg>
<seg id="1414">The dosage of Advagraf should be primarily based on the clinical evaluation of drainage and compatibility in the individual case and on blood cells (see below)</seg>
<seg id="1415">"after switching from Prograf to Advagraf, the Tacrolimus should be controlled before the conversion and over two weeks after conversion."</seg>
<seg id="1416">"on day 4 the systemic exposure, measured as a valley mirror, with both formulations both with kidney and lively patients comparable."</seg>
<seg id="1417">Careful and repeated controls of the Tacrolimus talents are recommended during the first two weeks after transplantation under Advagraf to ensure appropriate substance exposure in the immediate delivery phase.</seg>
<seg id="1418">"since Tacrolimus is a substance with low clearance, can last several days until the steady State is reached."</seg>
<seg id="1419">"if the condition of the patient is not allowed in the first postoperative phase, the Tacrolimus treatment is intravenous (prograf 5 mg / ml concentrating on the manufacture of an infusion solution)."</seg>
<seg id="1420">"the duration of the application to suppression of transplantation must be maintained, the immune soup must not be maintained; therefore a maximum duration of the oral therapy is not indicated."</seg>
<seg id="1421">DosisRecommendations - Niertransplant prophylaxis of transplantation the orale Advagraf therapy should begin with 0.20 - 0.30 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1422">Further derivatives can be later required as the pharmacoinetics of Tacrolimus can change in the course of stabilisation of the patient after the transplantation.</seg>
<seg id="1423">DosisRecommendations - liver transplantation prophylaxis of transplantation the orale Advagraf therapy should begin with 0.10 - 0.20 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1424">"dosage intake - conversion from Prograf on Advagraf must be converted from prograf to a once daily intake of Advagf, so this conversion in relation 1: 1 (mg: mg), related to the entire day dose."</seg>
<seg id="1425">Kidney and liver transplantation after a shift from other immunosressiva on Advagraf once daily needs to begin the treatment with each in kidney and liver transplantation for the prophylaxis of transplantation for the prophylaxis of transplantation.</seg>
<seg id="1426">"transplantation In case of adult patients, which are converted to Advagraf, is a orale initiator of 0.15 mg / kg / day to take daily time in the morning."</seg>
<seg id="1427">Other transplants do not receive clinical experience with Advagraf at Lung, pancreature and dared patients prograf in a oral initiator of 0,2 mg / kg / day and with intestinal initiators from 0,3 mg / kg / day for application. "</seg>
<seg id="1428">Dosages in special patient-groups patients with reduced liver function in the maintenance of blood vessels in the targeted area can be required in patients with severe Leberfunctioning dysfunction.</seg>
<seg id="1429">Patients with reduced kidney function As the kidney function does not exercise any influence on the pharmacoinetics of Tacrolimus cannot be taken into that a dosage adjustment does not require.</seg>
<seg id="1430">"due to the nephrotoxical potential of Tacrolimus, however, is recommended a careful control of the kidney function (including a regular determination of the SerumCreatininspect, a calculation of the creatininka and monitoring of the urevoluminal)."</seg>
<seg id="1431">Conversion of Ciclosporin to advocagraf In the conversion of a Cicrolimus-based therapy is offered to caution (see sections 4.4 and 4.5).</seg>
<seg id="1432">Recommendations about the talent mirror in full flatteries The dose should be based primarily on the clinical evaluation of drainage and compatibility in the case under the help of full bladder Tacrolimus-Talmirror controls.</seg>
<seg id="1433">"it is recommended to conduct frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic controls during accounting therapy."</seg>
<seg id="1434">"blood-talents of Tacrolimus should also change after conversion of prograf at Advagraf, Dosisadaption, changes of immunodepressants therapy or in the current application of substances which could change the Tacrolimus-thoroughties (see Section 4.5)."</seg>
<seg id="1435">"since Advagraf is a medicine with a low clearance, adjustments of the dose may need several days until the steady State has entered."</seg>
<seg id="1436">"the information in clinical trials can be realized that a successful treatment is possible in most cases, when the valley mirror in the blood 20 ng / ml not exceed."</seg>
<seg id="1437">In clinical practice the talent mirror of Tacrolimus lies in the first time after liver transplants usually in the range of 5 - 20 ng / ml and with kidneys - and hearty patients at 10 - 20 ng / ml.</seg>
<seg id="1438">"during the subsequent treatment of liver, kidney and heart transplants were usually used to bleeding in the range of 5 - 15 ng / ml."</seg>
<seg id="1439">"this has led to serious undesirable events, including transplantation or other side effects, which can occur in consequence of Tacrolimus under- or overexposure."</seg>
<seg id="1440">Patients should always keep the same Tacrolimus formulation and the corresponding daily dosage; surveys of the formulation or the regime should only be carried out under the control of an experienced physician (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 For the treatment of adult patients with transplants, who proved to be treated with other immunodepressants than therapies, are still no clinical data for the retardized wording Advagraf."</seg>
<seg id="1442">The prophylaxis of transplantation at adult heart transplants and transplants are not interested in the child-age and no clinical data for the retardized wording Advagraf.</seg>
<seg id="1443">"due to possible interactions that can lead to a reduction of the Tacrolimousehold levels in the blood and a weakening of the clinical effect of Tacrolimus, the intake of the Johannicum perforatum), or other plant breeding may be avoided during a treatment with Advagraf (see Section 4.5)."</seg>
<seg id="1444">"in patients with Diarrhö is a particularly careful control of the Tacrolimoustics concentrations in the blood, since the Tacrolimus blood levels under such circumstances can be subject to significant fluctuations."</seg>
<seg id="1445">"in rare cases, among prograf it was considered a cardiomyopathy, Kammer- or Septumhypertrophy to observe that can therefore occur under Advagraf."</seg>
<seg id="1446">"other factors that increase the risk of such clinic disturbances, are an already existing heart, a treatment with corticians, blood pressure, kidney or liver dysfunctions, infections, liquid and oils."</seg>
<seg id="1447">"as with other immunodepressants, the impact of sunlight or UV light should be restricted due to the possible risk of malignant skin changes due to suitable clothing or use of a solar protection using a high level factor."</seg>
<seg id="1448">"if patients, the Tacrolimus take, symptoms for PRES such as headache, altered consciousness levels, scratches and visual dysfunctions should be a radical investigation (e.g."</seg>
<seg id="1449">"da Advagraf, retardized, Lactose, is in patients with the rare canactose-intolerance, lactase-lack or glucose-malactose-Malmedy special caution."</seg>
<seg id="1450">"simultaneous application of drugs or herbal medicinal products known as inhibites or induction of CYP3A4, can increase the metabolism of Tacrolimus and thus reduce the blood values of Tacrolimus."</seg>
<seg id="1451">"therefore, it is advisable to change the Tacrolimous- blood levels in concurrent gift of substances that can change the CYP3A metabolism and to set the Tacrolimus dose for maintaining even higher concentrations accordingly (see sections 4.2 and 4.4)."</seg>
<seg id="1452">"a strongly affected interaction has been with anti-ykjazol, Fluconazol, Itraconazol and Vorythromycin and HIV proteassigns (z)."</seg>
<seg id="1453">"Pharmacoinetics studies, that the rise of blood levels mainly consists of the increased orbitability of Tacrolimus, caused by the imitation of gastrointestinal temptation, results."</seg>
<seg id="1454">"Hochdosic Prednisolon or Methylprednisolon, as it is used for acute deduction actions, can increase the concentration of Tacrolimus in the blood."</seg>
<seg id="1455">Effect of Tacrolimus on the metabolism of other medicines Tacrolimus is known as CYP3A4-Hemmer; therefore the simultaneous application of Tacrolimus may be metabolized by CYP3A4 metabolized.</seg>
<seg id="1456">"since Tacrolimus increase the clearing of steroid contraceptive and thus able to increase the hormone exposure, is particularly careful with decisions regarding receptive measures."</seg>
<seg id="1457">The results of animal experiments demonstrated that Tacrolimus may reduce the Clearance of Pentobitual and phenazon and extend their half-time.</seg>
<seg id="1458">"the results of a small number of studies in transplants patients deliver no indication that among other immunodepressants, compared to other immunodepressants, there is no risk to unwanted events with regard to the course and the outcome of pregnancy."</seg>
<seg id="1459">"in utero Exposition, a surveillance of newborn on any detrimental effects of Tacrolimus (especially with regard to its effect on the kidneys)."</seg>
<seg id="1460">"it consists of the risk of an early birth (&lt; week 37), and a hyperkalient of the newborn (Inzipped 8 of 111 newborn, i.e.:"</seg>
<seg id="1461">The side-effective profile of immune suppressiva is often not able to determine exactly because of the underlining of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"in the following the side effects are performed after their frequency in descending order: very often (≥ 1 / 1,000, ≤ 1 / 100), occasionally (≥ 1 / 1,000), very rare (≤ 1 / 1,000), very rare (≤ 1 / 10,000, not known (frequency on the basis of the available data is not removable)."</seg>
<seg id="1463">"Ischglic disturbances of the heart disease, tachyarrhythmic and heart breakdown, floorventricular arrhythmia, melraventricular arrhythmia, Palmeratio, Palagatio, Anomatio, Anomatio, Anomatio, Anomalies in EKG, abnorme heart and pulse frequency</seg>
<seg id="1464">"waste, nausea or perforation, bleeding-intestine and perforation, anniversation, anniversation, flatulls, flatulence, flatulence, flatulence, flatulence, distipation, flatulence, signs and symptoms in the stomach-intestinal - range."</seg>
<seg id="1465">"infections and parasitic diseases such as known as other highly effective immunosressiva is treated in patients who are treated with Tacrolimus, the susceptibility for infections (viral, mykotic, protozoal) frequently increases."</seg>
<seg id="1466">Cases of BK-Virus-affiliated Nephropathy and JC-Virus-associated progressive leukoencephalopathy (PML) were reported in patients under immunosressions therapy, including therapy with Advagraf. "</seg>
<seg id="1467">It was reported about benevolent or malicious Neoplasms including EBV- associated lymphoproofs and skin tumors in connection with the treatment with Tacrolimus.</seg>
<seg id="1468">"due to its high molecular weight, its low water solubility and the high binding in Erythrocytes and plasma red can be assumed that Tacrolimus is not dialyzed."</seg>
<seg id="1469">"accounting Mechanism and pharmacodynamic effects on molecular level are likely to be conveyed in the effects of Tacrolimus by its binding to a cytosolish protein (FKBP12), which is responsible for the enrichment of the connection in the cellinners."</seg>
<seg id="1470">This leads to a calcible-dependent shirts from Signaltransducts due to the T-cell and thus prevents the transcription of a certain range of lymphokin genes.</seg>
<seg id="1471">"Tacrolimus oppressed the activation of the T-cells and the proliferation of the B-Helper cells, and the formation of Lympkin 2, Interleukin-3 and the expression of the Interleukin 2 receptors."</seg>
<seg id="1472">"12 confirmed, the first 24 weeks in the Advagraf Group (N = 237) 32,6% and in the Prograf Group (N = 234) 29,3%."</seg>
<seg id="1473">"patients survival rates after 12 months are at 89.2% for Advagraf and 90,8% for prograf; in Advagraf-arm 25 (14 women, 11 men) and in prograf-arm 24 (5 women, 19 men) deaths."</seg>
<seg id="1474">"Niertransplant The effectiveness and safety of Advagraf and Prograf was, each in combination with Mycophenolatmofetil (MMF) and cortikosteroids, compared to 667 de Novo Niery transforms."</seg>
<seg id="1475">"patients survival rates after 12 months are at 96,9% for advocagraf and 97.5% for prograf; in Advagraf-arm 8 (3 women, 7 men) and in prograf-arm 8 (3 women, 5 men) deaths."</seg>
<seg id="1476">"the effectiveness and safety of prograf, Ciclosporin and Advagraf was, each in combination with Basil-antideperinduction, MMF and Cortikosteroids, at 638 de Novo Nierz transforms."</seg>
<seg id="1477">"the incidence of therapy after 12 months (defined as death, transplants, biopsy-confirmed or missing follow-up- data) amounted to 14.0% in the Advagf Group (N = 212) and 17.0% in the Ciclosporin group (N = 212)."</seg>
<seg id="1478">"the treatment difference was -3.0% (Advagraf - Cicrid porin) (95,2%, 4,0%]) for Advagraf vs Ciclosporin and -1,9% (Prograf-Ciclosporin) (5.8.3%, 5.2%]) for prograf vs Ciclosporin."</seg>
<seg id="1479">"in Advagraf-arm 3 (men), in prograf-arm 10 (3 women, 7 men) and in Ciclosporin arm 6 (3 women, 3 men) deaths."</seg>
<seg id="1480">Published results of primary immune soup with Tacrolimus in the form of twice daily used prograf capsules after other primary immorations Prograf has developed into a recognized primary immune soup after pancreas-, lung and intestinal transplants. "</seg>
<seg id="1481">"175 degrees transplantation patients, with 475 patients who had been subjected to a pancredentition and used in 630 cases after a intestinal transplantation as a primary immune soup."</seg>
<seg id="1482">"overall, the security profile of oral prograf published in these published studies the observations of the great studies in which prograf at the liver, kidney and heart transplantation are used to be applied to primary immune soup."</seg>
<seg id="1483">"Lungtransplant in an intermediate analysis over a recently guided, multicentric study with oral prograf was reported about 110 patients who received either Tacrolimus or Ciclosporin."</seg>
<seg id="1484">"also a chronic transplantation, the bronchiolitis obliterans- Syndrome, was less common in the first year after the transplantation less common (2,86% versus 8.57%)."</seg>
<seg id="1485">"the survival rate after one year was 80.8% in the Tacrolimous- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)."</seg>
<seg id="1486">"in the patients treated with Tacrolimus patients, it came in 21,7% of the cases for the creation of a bronchiolitis obliterans in comparison to 38,0% under Ciclosporin (p = 0.025)."</seg>
<seg id="1487">"the number of cases to be changed by Ciclosporin on Tacrolimus (n = 13), was significantly bigger (p = 0.02) than the number of patients who have been converted by Tacrolimus (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">The number of cases in which there came to no acute transplantation was after 6 months (57.7%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%) and after 1 year (Treede et al., J Heart Lung Transplans 2001; 20: 511). "</seg>
<seg id="1489">"in a study, the frequency of the emergence of a bronchiolitis - syndroms was significantly lower in the patients with Tacrolimus patients."</seg>
<seg id="1490">"pancreastfeeding A multicentralized study with oral prograf was carried out at 205 patients who were at the same time a pancrease and kidney transplant, which were after a randomised procedure Tacrolimus (n = 103) or Ciclosporin (n = 102)."</seg>
<seg id="1491">The orale initialdosis (per protocol) of Tacrolimus was 0.2 mg / kg / day and was subsequently to the achievement of the desired talents from 8 to 15 ng / ml at 5.</seg>
<seg id="1492">"intestinal transplantation The published clinical results of a monocentric study associated with oral prograf as a primary immune soup (65 only), 75 liver and Darm and 25 multivisceral transplants) under Tacrolimus and Prednisone a current survival rates of 75% to 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1493">"methods for early detection of epstein-Barr (EBV) - and CMV infections, garantages of the Interleukin 2-Antagists Daclizumab, lower clearance between 10 and 15 ng / ml and newer transplants (Abu-Elmagd et al., Ann Surg 2001; 234: 404)."</seg>
<seg id="1494">"factors such as a low hematopolies and low protein concentration, which will lead to an increase in the unpaved group of Tacrolimus, or by treatment with corticians, the strengthening of metaboism should be responsible for the transplantation of the higher Clearance rates."</seg>
<seg id="1495">"this can be close that Tacrolimus is almost completely metabolized before the separating is almost completely metabolized, whereby the separating mainly takes place via the Galle."</seg>
<seg id="1496">"with stable patients, which were provided by Prograf (twice daily) in relation 1: 1 (mg: mg) in relation to the overall daily dose was the systemic exposure of Tacrolimus (AUC0-24) under Advagraf at approximate 10% lower than under prograf."</seg>
<seg id="1497">"it is recommended to conduct frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic controls during accounting therapy."</seg>
<seg id="1498">21 For the treatment of adult patients with transplants are proven to be treated with other immunodepressants than therapies. there are no clinical data for the retardized wording Advagraf.</seg>
<seg id="1499">"other factors that increase the risk of such clinic disturbances, are an already existing heart, a treatment with corticians, blood pressure, kidney or liver dysfunctions, infections, liquid and oils."</seg>
<seg id="1500">"28 confirmed in the first 24 weeks in the Advagraf Group (N = 237), 32,6% and in the Prograf Group (N = 234) 29,3%."</seg>
<seg id="1501">"the effectiveness and safety of prograf, Ciclosporin and Advagraf was, each in combination with Basil-antideperinduction, MMF and Cortikosteroids, at 638 de Novo Nierz transforms."</seg>
<seg id="1502">"gestures, retardized gray-orange Gelatinekaptles, printed in red ink with" 5 mg "and the orange capselfs with" "687", "they contain white powder."</seg>
<seg id="1503">"it is recommended to conduct frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic controls during accounting therapy."</seg>
<seg id="1504">"37 For the treatment of adult patients with transplants, who proved to be treated with other immunosressiva as therapies, are still no clinical data for the retardized wording Advagraf."</seg>
<seg id="1505">"other factors that increase the risk of such clinic disturbances, are an already existing heart, a treatment with corticians, blood pressure, kidney or liver dysfunctions, infections, liquid and oils."</seg>
<seg id="1506">44 confirmed in the first 24 weeks in the Advagraf Group (N = 237) 32,6% and in the Prograf Group (N = 234) 29,3%.</seg>
<seg id="1507">"the effectiveness and safety of prograf, Ciclosporin and Advagraf was, each in combination with Basil-antideperinduction, MMF and Cortikosteroids, at 638 de Novo Nierz transforms."</seg>
<seg id="1508">"altogether 34 patients received by Ciclosporin on Tacrolimus, while only 6 Tacrolimus patients needed another therapy (Bechstein et al., Transplantation 2004; 77: 1221)."</seg>
<seg id="1509">"intestinal transplantation The published clinical results of a monocentric study associated with oral prograf as a primary immune soup (65 only), 75 liver and Darm and 25 multivisceral transplants) under Tacrolimus and Prednisone a current survival rates of 75% to 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1510">"this can be close that Tacrolimus is almost completely metabolized before the separating is almost completely metabolized, whereby the separating mainly takes place via the Galle."</seg>
<seg id="1511">"risk management plan the owner of the approval for the contract are committed to implement the trials described in the Pharmacovigilance Plan, as described in version 3.2 of the risk management plan (RMP), and all other updates of the RMP, which are approved by CHMP."</seg>
<seg id="1512">"according to the CHMP guideline for medicines to use on human risk management systems, the updated language must be submitted simultaneously with the next periodic security report (Periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">Perhaps you will also get Advagraf also for treatment of your Lebripper; kidney or heart transplants or any other transplantation organ or because the immune response of your body could not be dominated by a predicted treatment.</seg>
<seg id="1514">"taking advantage of Advagraf with other medicines. please inform your doctor or pharmacist if you have other medicines or have recently taken, even if it is not prescription drugs or cures herbal origin."</seg>
<seg id="1515">"amilorid, triamins or Spironolacton), certain paintoidale antiphlogistika as Ibuprofen), antioagulants or medicines for admission to the treatment of diabetes mellitus."</seg>
<seg id="1516">"pregnant and lactation If a pregnancy is planned, or already exists, ask before taking on all medicines to your doctor or pharmacist for advice."</seg>
<seg id="1517">"transport and operation of machines you may not use at the wheel of a vehicle, or use tools or machines, if you feel after taking advantage of Advagraf or sleepy or sunbeds."</seg>
<seg id="1518">"important information on certain other parts of Advagraf Please take Advagraf only after consultation with your doctor, if known, that you suffer from a intolerance toward certain states."</seg>
<seg id="1519">"make sure that you always get the same Tacrolimus medicines if you redeem your prescription, unless your medical specialist has explicitly agreed to a change of the Tacrolimus preparations."</seg>
<seg id="1520">"if you get a medicine whose appearance changes from habitual or the docking instructions, please contact your doctor's doctor or pharmacist, so that you can get the right medicine."</seg>
<seg id="1521">"in order to determine the proper dose and adjust from time to time, he must then perform regular blood tests."</seg>
<seg id="1522">"if you have taken a larger quantity of Advagraf, when you should accidentally taken a bigger amount of Advagraf, look immediately your doctor or the emergency department of the next hospital."</seg>
<seg id="1523">"if you have forgotten the intake of Advagraf If you have forgotten, take the capsules, please take this on the same day at the earliest possible time."</seg>
<seg id="1524">If you cancel the intake of Advagraf at the end of the treatment with Advagraf can increase the risk of reducing your transplantation.</seg>
<seg id="1525">"Advagraf 0,5 mg Hartkapsel, are hard gelatinekaptles, whose brightly yellow Oberpart with" "0.5 mg" and their oranges subpart with "" 647 "each red" "and which are filled with white powder."</seg>
<seg id="1526">"Advagraf 1 mg Hartcapsules, retardized are tungsten carbide, whose white surface are filled with" "1 mg" and their oranges subpart with "" 677 "" and which are filled with white powder. "</seg>
<seg id="1527">"Advagraf 5 mg Hartcapsules, retarardized, are tungsten carbide, whose gray-part with" "5 mg" and their oranges subpart with "" 687 "" and their oranges subpart with "" 687 "" is filled with white powder. "</seg>
<seg id="1528">România Astellas Pharma Boalii de contact pentru România. oseaua Bucureş ti-Ploieşti 1, Parter, 013696-Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská republika Astellas Pharma s.r.o., organizač ná zlož ka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advate is used for the treatment and prevention of bleeding in patients with Hämophilia A (one by the lack of factor VIII conditional blood circulation).</seg>
<seg id="1531">The dosage and frequency of application depends on whether Advate is applied to the treatment of bleeding or to prevent bleeding in surgical intervention.</seg>
<seg id="1532">Patients with Hämophilia A suffer from a factor VIII lack what bleeding problems such as bleeding in the joints, muscles or inner organs. "</seg>
<seg id="1533">"Octocog alfa is not extracted from human plasma, but according to a method that is called" recombinant DNA technology ":"</seg>
<seg id="1534">"it is produced by a cell, in which a gene (DNA) was transferred to the formation of the human eye factor VIII."</seg>
<seg id="1535">"advocates is similar to another in the European Union called Recombinate, however, however, will be different, so the medicine does not contain proteins or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with heavy duty to moderate high tenophilia A, including a study with 53 children under six years, the application of the drug was examined by means of prevention of bleeding as well as in surgical intervention."</seg>
<seg id="1537">"in the main study, the effectiveness of Advate was awarded in the prevention of bleeding in 86% of 510 new blood cisodes with" "excellent" "or with" "good". ""</seg>
<seg id="1538">"the most common side effects of Advate (observed at 1 to 10 of 100 patients) are Schwindel, headaches, Pyrexie (fever) and the formation of antibodies towards factor VIII."</seg>
<seg id="1539">"Advate may not be used in patients, which may possibly be excessive (allergic) against human righteous factor VIII, mouse or hammam protein or one of the other components."</seg>
<seg id="1540">"March 2004, the European Commission granted the Company Baxter AG for approval of Advate in the entire European Union."</seg>
<seg id="1541">Dosage The dosage and duration of the substitution therapy depends on the severity of the factor VIII century, according to the site and the extent of blood and the clinical state of patient. "</seg>
<seg id="1542">In the following hämorrhagic events the factor VIII is not meant to decrease in the corresponding plasmasegel (in% of standard or in i.E. / dl).</seg>
<seg id="1543">Injection all 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeat until the pain and the acute impairment are removed.</seg>
<seg id="1544">Injection all 8-24 hours (6-12 hours in patients under 6 years) repeat until the risk for the patient is over.</seg>
<seg id="1545">"during the treatment process, the control of the injectable dose and frequency of injections is recommended for an appropriate determination of the factor VIII plasma cutting."</seg>
<seg id="1546">"individual patients can differ in their response to factor VIII, different in vivo recovery and have different hemispheres."</seg>
<seg id="1547">3 Prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1548">"if the expected factor VIII-plasma activities will not be achieved or if blood flow is not ruled by a reasonable dose, a test must be carried out if necessary to follow an inhibitor."</seg>
<seg id="1549">"in patients with high inhibitorage it is possible that the factor VIII therapy is not effective, so that other therapeutic action must be wounded."</seg>
<seg id="1550">"the agreement speed should be set up after the patient, with a maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutralising antibodies (inhibitors) against factor VIII is a known compensation in the treatment of patients with hammophilia A.</seg>
<seg id="1552">These inhibitors are always opposed to the procoagulatory activity of factor VIII the IgG immunoglobulins which in Bethesda units (B.E.) per ml plasma by means of modified Bethesda Assay quantified.</seg>
<seg id="1553">"the risk of developing inhibitors, correlation to the extent of the exposure towards the factor VIII, whereas the risk within the first 20 Exposition is dependent on the largest and other factors."</seg>
<seg id="1554">"for pre-treated patients (PTPs) with more than 100 exposition and anamnestable known inhibitorating development, after switching from a recombinant factor VIII product to another, the reoccur of (lowest) inhibitors."</seg>
<seg id="1555">Due to the rare occurrence of the Hämophilia A in women lie about the use of factor VIII during pregnancy and lactation.</seg>
<seg id="1556">"those in the largest number of patients disconnected ADRs were inhibitors against factor VIII (5 patients), which all have previously untreated patients who have a higher risk to the formation of inhibitors, headaches (5 patients), Fieber and Schwinch (each 3 patients)."</seg>
<seg id="1557">"very common (≥ 1 / 10), often (≥ 1 / 100 to &lt; 1 / 10), occasionally (≥ 1 / 1,000 to &lt; 1 / 1,000), very rare &lt; 1 / 10.000), not known (frequency on the basis of the available data is not removable)."</seg>
<seg id="1558">A) The percentage of patients was predicted by the sum of the individual patients (234).</seg>
<seg id="1559">Blood flow was maintained during the whole time and both the factor VIII- mirror in Plasma as well as the Clearance rate showed sufficient value on the 15th of the operating day.</seg>
<seg id="1560">"in clinical studies with ADVATE, 145 children and adults 2 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1561">"in addition, at no one of the 53 paediatric patients with an age of under 6 years and diagnosed with severe Hämophilia A (FVIII ≤ 2%) after previous exposure towards factor VIII- concentrates (≥ 50 days) a FVIII-Inhibitor."</seg>
<seg id="1562">"for previously not treated patients of a ongoing clinical trial formed 5 of 25 (20%) with ADVATE, patients inhibitors against factor VIII."</seg>
<seg id="1563">"the immune response of the patients on traces of contamination proteins have been analysed through the investigation of the antibodies against this proteins, laboratory parameters and painted side effects."</seg>
<seg id="1564">"a patient showed both a statistically significant lifts as well as an ongoing peak of the anti-Cho cell cell, otherwise there is no sign or symptoms shown on an allergic reaction or an oversensitivity."</seg>
<seg id="1565">"in four patients the appearance of Urtikaria, Pruritus, rash and increased number of eosinophiler granulozyten reports on several repeated product compositions in the study reported."</seg>
<seg id="1566">7 As with other intravenous products at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1567">The activated factor VIII works as a Cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.</seg>
<seg id="1568">All Pharmacoinetics studies with ADVATE were conducted at pre-treated patients with severe or moderate philiophilia A (base value of factor VIII-activity ≤ 2%).</seg>
<seg id="1569">The pharmacocinetic parameters come from a cross-Over-study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in the table below 3.</seg>
<seg id="1570">Table 3 summary of the Pharmacoinetic parameters of ADVATE for 100 patients with severe until even Hämophilia A (factor VIII &lt; 2%) PK-parameters (Pharmacokinetics)</seg>
<seg id="1571">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1572">Every single packaged with powder coating with 5 ml solutions (both glass type I with chlorobutyl-rubber-scrapping) and a device for the reconstitution (BAXJECT II).</seg>
<seg id="1573">"if the product is still stored in the fridge, both handle bottles with ADVATE powder and solvent from the refrigerator can be found in room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A significant increase in pulse frequency can be reduced by slowing or timeless disruption of the injection can usually be reduced immediately (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1576">Due to the rare occurrence of the Hämophilia A in women lie about the use of factor VIII during pregnancy and lactation.</seg>
<seg id="1577">"3 newborn (at the age of 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), adults (over 16 years)"</seg>
<seg id="1578">"in clinical studies with ADVATE, 145 children and adults 4 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1579">18 As with other intravenous products at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1580">Table 3 summary of the Pharmacoinetic parameters of ADVATE for 100 patients with severe until even Hämophilia A (factor VIII &lt; 2%) PK-parameters (Pharmacokinetics)</seg>
<seg id="1581">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1582">25 Prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1583">"5 newborn (at the age of 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), adults (over 16 years)"</seg>
<seg id="1584">"in clinical studies with ADVATE, 145 children and adults 6 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1585">29 As with other intravenous products at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1586">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1587">36 Prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1588">"7 newborn (at the age of 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), adults (over 16 years)"</seg>
<seg id="1589">"in clinical studies with ADVATE, 145 children and adults 8 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1590">"40 How in other intravenous products, at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known)."</seg>
<seg id="1591">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1592">47 Prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1593">"9 newborn (at the age of 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), adults (over 16 years)"</seg>
<seg id="1594">"in clinical studies with ADVATE, 145 children and adults 10 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1595">51 As with other intravenous products at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1596">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1597">58 prophylaxis for long-term prophylaxis against patients with severe Hämophilia A should be given doses from 20 to 40 i.e of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1598">"11 newborn (at the age of 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), adults (over 16 years)"</seg>
<seg id="1599">"in clinical studies with ADVATE, 145 children and adults 12 with diagnosed-severe Hämophilia A (FVIII ≤ 2%) and previous exposure towards factor VIII- concentrates (≥ 150 days) showed only a patient after 26 exposition with ADVATE provided a low inhibitortiter (2,4 B.E. in modified Bethesda approach)."</seg>
<seg id="1600">62 As with other intravenous products at ADVATE via oversensitivity type, including anaphysizing / anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1601">"not clinical data, based on studies on safety issues, based, repetitive and local toxicity, and to genotoxicity, show no special risk to the people."</seg>
<seg id="1602">"Pharmacovigilance System The registration holder must ensure that an Pharmacovigilance system, as described in the section 1.1 of the chapter 1.8.1 of drug allowances, and that this system is located throughout the entire period in which the product remains on the market."</seg>
<seg id="1603">"as in the CHMP Directive on the risk-Managment Plan for Human-medicine, this update can be submitted simultaneously with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• when new information is available, the influence on the valid safety precautions, the Pharmacovigilance plan or the measures to reduce the risk of minimization may be considered within 60 days of an important event (as regards the pharmacovigilance, or regarding a measure of risk minimization)"</seg>
<seg id="1605">1 handle bottle with ADVATE 500 I.E Octocog alfa, 1 flow bottle with 5 ml sterilisized water for injecting purposes, 1 BAXJECT II-medical product. "</seg>
<seg id="1606">1 handle bottle with ADVATE 1000 I.E Octocog alfa, 1 flow bottle with 5 ml sterilisized water for injecting purposes, 1 BAXJECT II-medical product "</seg>
<seg id="1607">Special caution when applying ADVATE is required you should inform your doctor if you have recently been treated with factor VIII products especially if you have inhibitors.</seg>
<seg id="1608">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1609">"in taking with other medicines, please inform your doctor if you have other medicines or have been recently taken, even if it is not prescription drugs."</seg>
<seg id="1610">"your doctor will charge your dose of ADVATE (in international units or i.e), depending on your physical body and your body weight, and whether it is used to prevent or treat bleeding."</seg>
<seg id="1611">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1612">"in conjunction with operations Katheterinfection, lower number of red blood cells, thresholds of limbs and joints, extended blood flow after removal of a drainage, diminishing factor and postoperative hematoms."</seg>
<seg id="1613">Rare side effects Since the introduction of the pharmaceutical on the market has been completed over severe and potentially lifelong reactions (Anaphysixie) and other allergic reactions (see above).</seg>
<seg id="1614">"inform your doctor, if one of the listed side effects you impaired considerably, or if you notice side effects that are not listed in this package."</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"information on the production of the solution • Not to be used according to handles and reverson specified shelf date. • The BAXJECT II does not use, if his sterile barrier has damaged, its packaging damaged or signs of a manipulation, as in the symbol"</seg>
<seg id="1617">Important note: • Not to be agreed before you have received the special training from your doctor or your nurse. • To review the product on gravel or discoloration.</seg>
<seg id="1618">"the solution should be slow down with an infusion speed, which is able to access the patient and 10 ml per minute is not enough."</seg>
<seg id="1619">106 In the case of blood results should be the factor VIII mirror within the relevant time period (in% or in i.E. / ml).</seg>
<seg id="1620">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1621">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1622">"occasional side effects Juckreiz, amplify sweating, floods, sensations, sensations, sensations, mulateness, inflammation, inflammation, inflammation, inflammation, ramps, extremes, extremes, extremes, extremes, extremly shwitches,"</seg>
<seg id="1623">116 in the case of blood results should be the factor VIII mirror within the corresponding period of plastic (in% or in i.E. / ml).</seg>
<seg id="1624">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1625">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1626">126 In case of blood results should be the factor VIII mirror within the appropriate time period (in% or in i.E. / ml).</seg>
<seg id="1627">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1628">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1629">136 In case of blood results should be the factor VIII mirror within the corresponding period of plastic (in% or in i.E. / ml).</seg>
<seg id="1630">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1631">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1632">146 In the case of blood results should be the factor VIII mirror within the appropriate time period (in% or in i.E. / ml).</seg>
<seg id="1633">These symptoms can display early signs of an anaphylactic shock which can additionally include the following symptoms can include: extreme scarf, consciousness and extreme respiratory. "</seg>
<seg id="1634">Patients who develop factor-VIII inhibitors in your Plasma with ADVATE cannot be achieved or the bleeding may not be dominated by the development of factor VIII-</seg>
<seg id="1635">"occasional side effects Juckreiz, amplify sweating, floods, sensations, sensations, sensations, mulateness, inflammation, inflammation, inflammation, inflammation, ramps, extremes, extremes, extremes, extremes, extremly shwitches,"</seg>
<seg id="1636">Rare side effects Since the introduction of the pharmaceutical on the market has been completed over severe and potentially lifelong reactions (Anaphysixie) and other allergic reactions (see above).</seg>
<seg id="1637">156 in case of blood results should be the factor VIII mirror within the relevant time period (in% or in i.E. / ml).</seg>
<seg id="1638">"based on the available data available since the original exemption of the CHMP, the CHMP has continued to be assessed as positive, but into consideration that the security profile must be closely monitored in the following reasons:"</seg>
<seg id="1639">"therefore, the CHMP has on the basis of the Security Profils of ADVATE, which makes a submissions of PSURs all 6 months required, decided that the authorisation has to apply for more than 5 years."</seg>
<seg id="1640">December 2008 Gendux Molecular Limited by the Committee on Humanities (CHMP) officially with that the company takes its application for approval of Advexin for the treatment of Li-Fraumeni cancer.</seg>
<seg id="1641">"however, the chest, the brain, the bones, or the softens (tissues, the other structures in the body connects and draws) from it."</seg>
<seg id="1642">"this is a kind of virus that genetically changed so, that it can be gene in the cells of the body."</seg>
<seg id="1643">"in the virus in Advexin, it is a" Adenovirus "which has changed so that there is no copies of himself and thus no infections can trigger people."</seg>
<seg id="1644">Advexin could have been dipped directly into the tumor and thus enable the cancer cells to form the normal p53 protein.</seg>
<seg id="1645">"the p53 protein, which is formed from which not defective in the human body of existing p53 gene, contributes to the restoration of damaged DNA and to kill the cells when the DNA cannot be recovered."</seg>
<seg id="1646">"at Li-Fraumeni cancer, which is defective at Li-Fraumeni-cancer, the p53 protein is not working properly, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"the company presented data from a study with a patient, with the Li-Fraumeni cancer in the field of undermining, in the bones and in the brain."</seg>
<seg id="1648">"after the CHMP checked the answers of the company on the questions asked, there were still some questions unexplained."</seg>
<seg id="1649">"based on the examination of the initial documentation, the CHMP is created on day 120 a list of questions that will be sent to the company."</seg>
<seg id="1650">"according to the CHMP, the CHMP has not been sufficiently proven that the injection of Advexin is in Li-Fraumeni-tumor benefits for the patient."</seg>
<seg id="1651">"the Committee also had concerns about the processing of drug by means of the body, the type of administration and the security of the drug."</seg>
<seg id="1652">"in addition, the company had not sufficiently proven that advocates can be manufactured in a reliable way and that there is neither for the environment nor for people who come in close contact with the patient."</seg>
<seg id="1653">The CHMP does not endorse the CHMP whether the resigning consequences for patients who currently participate in clinical studies or "Com1-Use" programs with Advexin.</seg>
<seg id="1654">"modified drug release, means that the tablets are so assembled that one of the effective components can be released immediately and the other slowly over a few hours."</seg>
<seg id="1655">Aerosze is used to treat the symptoms of seasonal Rhinitis (Heuschnubs, by an allergy against polish-inflated inflammation of the nasal passages) in patients with Rhinoplasty (hidden nose). "</seg>
<seg id="1656">In adults and young children over 12 years the recommended dose of aerosze twice a day a tablet that should be taken completely with a glass of water with or without food.</seg>
<seg id="1657">"the duration of the treatment should be as short as possible and ended as soon as the symptoms, especially the swelling of the nose-sneal (hidden nose), shortened."</seg>
<seg id="1658">A treatment duration of more than 10 days is not recommended because the effects of drug can leave upon the constipation of the nose.</seg>
<seg id="1659">"the main platforms were the changes of gravity of the hay symptoms, which were reported by patients prior to treatment and during the 15-day treatment."</seg>
<seg id="1660">"during the study, patients carried their symptoms every 12 hours into a diary and rated with a standard scale, how difficult the symptoms were in the last 12 hours."</seg>
<seg id="1661">"in viewing of all hops symptoms except the constipation of the nose reported the patients, the aerosze, compared to a decrease of symptoms by 46,0%, compared to 35,9% in patients, the peseudoephedrine alone."</seg>
<seg id="1662">"if only the swelling of the nose-snea was considered, the patients were under aerosze a lination of symptoms by 48.4% compared to 26.7% in patients, the Desloratadin alone took place."</seg>
<seg id="1663">"the most common side effects of aerosze (observed at 1 to 10 of 100 patients) are Tachykarst (heart disease), pomoric hyperactivity (resilience), clamping, fatigue, fatigue, insomnia (sleeplessness), Somnolenz (sleeage), insomnia and nervousness."</seg>
<seg id="1664">"aerosze may be used in patients who may possibly excessive (allergic) against Desloratadine, pseudoephedrine or one of the other components, against adrenown active ingredients or Loratadin (another medicine for the treatment of allergies) are not applied."</seg>
<seg id="1665">"aerosze may also not be used in patients who suffer from a bottwinch (powder painting), Duthyroosis (hypertension of the thyroid), or have already caused an hemorrhic stroke (by brain blood circulation), or have a risk for a hooding stroke."</seg>
<seg id="1666">"on 30 July 2007, the European Commission adopted the European Commission for the Independence of Aerosze in the entire European Union."</seg>
<seg id="1667">"the tablet can be taken with a glass of water, however is to be swallow (i.e. without them to crush, break or walk)."</seg>
<seg id="1668">Aerosze should be applied to children under 12 years due to the missibility and effectiveness (see Section 5.1) for children under 12 years of age.</seg>
<seg id="1669">The duration of the application is as short as possible and should not continue after the symptoms of symptoms.</seg>
<seg id="1670">It is recommended to limit the application duration on 10 days as with long-term application the activity of pseudoephedrine can decrease in time.</seg>
<seg id="1671">"after drop the swelling of the vaulted in the upper breaths, because the treatment can be continued when needed with Desloratadin as Monotherapy."</seg>
<seg id="1672">"since Aerdenze Pseudoephedrine contains, the medicine is also controversial in patients who are treated with a monoaminoxidative (Mao) or within 2 weeks of ending such therapy."</seg>
<seg id="1673">"this is attributable to alphamimetic activity in combination of Pseudoephedrine with other vasoongs, Ergod, Ergodolamin, Ergodolamine, Phenylequin, Phenylephrases in, Ephesians, Oxymetazkaolin, Naphazolin etc.)."</seg>
<seg id="1674">"the safety and the effectiveness of these Combinations were not tested for this patient, and the data are not sufficient to address corresponding recommendations for dosage."</seg>
<seg id="1675">"the safety and the effectiveness of aerosses were not tested in patients with kidney or liver functioning, and the data are not sufficient to address corresponding recommendations for dosage."</seg>
<seg id="1676">"patients must be informed that treatment during a hypertension or a tachykarst or of Palagations, cardiac or etwaists other neurological symptoms (such as headaches or a reinforcement of the headache)."</seg>
<seg id="1677">"in treating the following patients' patients' patients' patients with cardiac disease • patients with cardiac arrhythmia • patients with a myokardincolored in the Anamnese, Diabetes mellitus, brass or bronchospasmus in the Anamnese."</seg>
<seg id="1678">"aerosze is abnormated at least 48 hours before carrying out dermatological testing, since antihistaminika otherwise can prevent positive reactions to indicators for skin campaigns or to reduce their extent."</seg>
<seg id="1679">"in the context of clinical trials with Desloratadin, where Erythromycin or Ketoconazol additionally were given, however, no clinical interaction or changes of the plasma concentration of desloratadin observed."</seg>
<seg id="1680">"in the results of the psychomotor tests, no significant differences could be found between the patients with Desloratadin and with placebo patients regardless of whether desloratadin alone or with alcohol."</seg>
<seg id="1681">"this has not yet been identified for the metaboism of desloratadin responsible enzymes, so that interdependencies with other medicines cannot be completely ruled out."</seg>
<seg id="1682">"Desloratadin inhibits in-vivo CYP3A4 not, and in-vitro-studies have shown that the medicine CYP2D6 does not inhibit and neither a substrate nor an inhibitor of P-Glycopic rotone."</seg>
<seg id="1683">"the unthinkable of the application of aerosze during pregnancy is not secured, experience from a large number of affected pregnancies however no increasing the frequency of abnormalities in comparison to the normal population."</seg>
<seg id="1684">Because reproduction studies on animals do not always be transmitted to humans and are not applied to vokonstriktorical properties of Pseudoephedrine should not be applied in the pregnancy.</seg>
<seg id="1685">"however, patients should be enlightened that it may come in very rare cases to lead to impairment or the ability to use machines."</seg>
<seg id="1686">"symptoms may vary between a ZNS depression (Seal, Apnoe, combustices, coma, cardiovascular collages) and a ZNS stimulation (sleeplessness, hallucinations) with possible letins."</seg>
<seg id="1687">"headaches, anxiety, scourage and increased muscle voltage, eurial, arousal, respiration, respiration, horticulence, horticulence, suspicion, trespass, tails, tachie, oparie or hypotie or hypotony."</seg>
<seg id="1688">"a ZNS stimulation is particularly likely to be particularly likely, as atropin-typical symptoms (mouth drying, puption, puption, hyperthermal and gastrointestinal symptoms)."</seg>
<seg id="1689">These include both the imitation of the release of protalammatoric cytokines like IL-4, IL-8, IL-8 and IL-13 from human mast cells / basophiles P-Selektin on endothelical cells. "</seg>
<seg id="1690">"with an individual dose study with adults, Desloratadin 5 mg no influence on standard measurement sizes, including the strengthening of subjective battles or the tasks that are connected to the flies."</seg>
<seg id="1691">In controlled clinical trials at recommended dosage of 5 mg daily there was no increased frequency of freezing compared to placebo.</seg>
<seg id="1692">"the orale application of Pseudoephedrine in recommended dosage may cause further personomimetic effects, such as an increase in blood pressure, a tachykarst or manifestations of a ZNS arousal."</seg>
<seg id="1693">"there were 1,248 patients aged between 12 and 78 years with seasonal Rhinitis part, with 414 patients Aeraze tablets were received."</seg>
<seg id="1694">"in both studies the histaminantagonistic effectiveness of Aereze tablets, determined by the complete scores for the symptomatic (except nasal sneal cord), significantly higher than under a monotherapy with Pseudoephedrine over the 2-week treatment period."</seg>
<seg id="1695">The effectiveness of aerosze tablets with regard to the abuses effect is determined by the nose-sneal cord, was significantly higher than under a monotherapy with Desloratadin over the 2-week treatment period. "</seg>
<seg id="1696">The effectiveness of aereze tablets showed with regard to gender, age or ethnic affiliation, patients have no significant differences. "</seg>
<seg id="1697">Within a frame of a single dose study of the Pharmacoinetics from Aerosze is desloratadin within 30 minutes after the administration in the Plasma.</seg>
<seg id="1698">"according to the peroral application of aerosze in healthy probances over 14 days the flow of water from desloratadin, 3-Hydroxydesloratadine and Pseudoephedrine is reached on day 10."</seg>
<seg id="1699">"as part of a pharmacocinetic multi-doscope, which was carried out with the formulation as a tablet of healthy adult probances, was noted that four probano-lorloradin poorly impaired."</seg>
<seg id="1700">An components interconnection indicates that the exposure (Cmax and AUC) of Pseudoephedrine according to the sole gift of Pseudoephedrine in biobiquiequivalent was to the exposure to gift of a Aereze tablet.</seg>
<seg id="1701">"based on conventional studies on safety digestology, for toxicity, to toxicity, to genotoxicity, and to reproducifications, the preclinical data with Desloratadin however do not recognise any particular hazards for man."</seg>
<seg id="1702">The combination had no greater toxicity than their individual components and the observed effects were generally related to the ingredient Pseudoephedrine.</seg>
<seg id="1703">The combination of Loratadin / Pseudoephedrine was the combination of Loratadin / Pseudoephedrine in oracle of up to 150 mg / kg / day and at rabbits in a dosage of up to 120 mg / kg / day not teratogenic.</seg>
<seg id="1704">March 2007 and in Module 1.8.1 the authorisation described by the Pharmacovigilance system is established and works before and while the product is on the market.</seg>
<seg id="1705">"antihistaminika wear for the alleviation of allergic symptoms by preventing that Histamin, a body of its own substance, its effect can unfold."</seg>
<seg id="1706">"aerosze tablets liners symptoms, which occur in connection with seasonal Rhinitis (Heuschnubs), such as Niesen, current or jubilty nose and jubilty eyes with the constipation of the nose."</seg>
<seg id="1707">20 sub-specific circumstances can you be particularly sensitive to the Schleife bouncing medicine Pseudoephedrine which is contained in this medicine.</seg>
<seg id="1708">"(Zuckill), a stencil door door (storms), a stencil or the esophagus (intestinal cord), a placement of the stomach or the manoeuvre, bronchospasms in the medical story (respiratory muscles), a cell size or problems with the liver, the kidneys or the bladder."</seg>
<seg id="1709">"inform your doctor if you are using the application of aereze the following symptoms or disorders that occur or diagnosed: • Bluthochpressure • cardiac, cardiac and headache, or a reinforcement of existing headaches."</seg>
<seg id="1710">"at intake of aerosze with other medicines. please inform your doctor or pharmacist, if you have other medicines or have been recently taken, even if it is not prescription medicine."</seg>
<seg id="1711">"transport and operation of machines for use in recommended dosage is not to be reckoned that Aerosze leads to gasoline, leads or pay attention."</seg>
<seg id="1712">If you have taken a larger amount of aerosze than you should check immediately your doctor or pharmacist if you have taken a bigger amount of aerosze than you should.</seg>
<seg id="1713">"if you have forgotten the intake of aerosze, If you have forgotten a dose of time to pick up the application as soon as possible and turn the next dose at the planned time."</seg>
<seg id="1714">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="1715">"cardiac, rainfessness with more physical activity, mess, mess, peninsulence, lupation, sugar, fatigue, fatigue, headache, immunity, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness</seg>
<seg id="1716">"calmations or cardiac arrhythmia, bare physical activity, likeness, nasal infections, nasal infection, nasal infection, nasal infection, nasal wardness, nasal wardness, nasal wardness, nasal wardness, snacking of the scent, crushing, anxiety, anxiety, anxiety and irritability."</seg>
<seg id="1717">"after the launch of Desloratadin was very rare reported on cases of severe allergic reactions (respiratory reactions, juckreiz, Nesselrash and swings) or rackings."</seg>
<seg id="1718">"about cases of heart cloves, cardiac, panacess, instigations, instigations, instigations, insulence, insulence, insulence, insulence, insulence, humilization with more physical activity, over cases of a liver inflammation and about cases of conspicuous liver values were also very rare."</seg>
<seg id="1719">"it is available as 5 mg tablet, 5 mg- Lyophilisat (soluble tablet), 2.5 mgand 5 mg / ml-syrup and as 0,5 mg / ml-solution to deposit."</seg>
<seg id="1720">"for children aged one to five years, the dose is 1,25 mg once daily, in the form of 2,5 ml syrup bzw."</seg>
<seg id="1721">"for children aged 6 to eleven years, the dose is 2.5 mg once daily, either in the form of 5 ml syrup bzw."</seg>
<seg id="1722">Aerius was studied in total eight studies with about 4 800 adults and young people with allergic Rhinitis (including four studies in seasonal Rhinitis and two studies in patients who also studied asthma).</seg>
<seg id="1723">"the effectiveness has been measured by changing the change of symptoms (itch, number and size of the square, impairment of the sleep and the efficiency of the day) before and after six-weekly treatment."</seg>
<seg id="1724">"there were further studies presented to indicate that the body uses the syrup, the solution for taking and the melting tablets in the same way as the tablets and the use of children unthinkable."</seg>
<seg id="1725">"at allergic Rhinitis led, when the results of all studies were taken together, the two-week treatment with 5 mg Aerius became an average acceptance of symptoms (symptoms) around 25 to 32% compared to the decrease of 12 to 26% in patients who received a placebo."</seg>
<seg id="1726">"in the two studies at Urtikaria, the acceptance of symptoms after six-made treatment with Aerius 58 and 67%, compared to 40 and 33% with the patients treated with placebo."</seg>
<seg id="1727">Aerius may not be used in patients who may possibly excessive (allergic) against Desloratadin, Loratadin or one of the other components. "</seg>
<seg id="1728">"January 2001, the European Commission adopted the European Commission for the Independence of Aerius in the entire European Union."</seg>
<seg id="1729">"a tablet once daily, with one or without a meal, to linquate the symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1)."</seg>
<seg id="1730">There are limited experience from clinical studies for effectiveness when applying Desloratadin for young people aged 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of interferrally Rhinitis (occurrence of symptoms for less than 4 days per week or less than 4 weeks) should be carried out according to the previous disease progression and can return after the end of symptoms and resumed upon them.</seg>
<seg id="1732">"in the Persian Rhinitis (occurrence of symptoms in 4 or more days per week, and more than 4 weeks) can be recommended to patients during allergy time."</seg>
<seg id="1733">"clinical-related relevant interactions were not observed in the context of clinical trials with Desloratadin tablets, where Erythromycin or Ketoconazol additionally were given (see below section 5.1)."</seg>
<seg id="1734">"in a clinically-pharmacological study, with the current intake of aserius and alcohol the powerful effect of alcohol is not reinforced (see below section 5.1)."</seg>
<seg id="1735">"however, patients should be enlightened that it can occur in very rare cases, which can lead to a impairment of the transportation or the ability to use machines."</seg>
<seg id="1736">"clinical trials in various indications, including allergic Rhinitis and chronically idiopathic urticaria, were reported at recommended dose of 5 mg daily 3% more side effects in patients with Aerius, when patients were treated with placebo."</seg>
<seg id="1737">"the most frequently recorded side effects that was reported more often than placebo were tiredness (1.2%), oral drying (0,8%) and headache (0,6%)."</seg>
<seg id="1738">"in a clinical study with 578 young patients from 12 to 17 years, the most common side effect of headaches, these stood at 5,9% of the patients were treated with Desloratadin and with 6,9% of the patients, which were treated with placebo."</seg>
<seg id="1739">"in a multidose study, which were administered up to 45 mg of Desloratadin (ninth clinical dose), no clinically relevant effects have been observed."</seg>
<seg id="1740">This includes both the imitation of the release of protalammatoric cytokines like IL-4, IL-8, IL-8 and IL-13 from human mast cells / basophiles P-Selektin on endothelial cells. "</seg>
<seg id="1741">"as part of a clinical study with multiple sclerosis, in the Desloratadin a dosage of up to 20 mg every day over 14 days was given, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1742">"in a clinically-pharmacological study, in the Desloratadin a dosage of 45 mg daily (the Neunfold of the clinical dose) over ten days was given, no extension of the QTc-Intervalls."</seg>
<seg id="1743">"with an individual dosages study with adults, Desloratadin 5 mg no influence on standard measurement sizes, including the strengthening of subjective battles or the tasks that are connected to the flies."</seg>
<seg id="1744">"in patients with allergic Rhinitis was Aerius effective in the alleviation of symptoms such as Niesen, Nasensecretion and Juckreiz of the nose, Juckreiz, tears and redness of the eyes as well as Juckreiz on the palate."</seg>
<seg id="1745">"in addition to the established classification in seasonal and perennial, allergic Rhinitis can also be divided into intermittent Rhinitis and persistible Rhinitis and persistible Rhinitis."</seg>
<seg id="1746">Intermittent Rhinitis is defined as the occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persistiical Rhinitis is defined as the appearance of symptoms of 4 or more days a week and more than 4 weeks.</seg>
<seg id="1748">"as with the outcome of the questionnaire on the quality of life at Rhino-economic tivitis showed, diminished Aerius effectively caused by seasonal Rhinitis ralled strain."</seg>
<seg id="1749">"the chronic idiopathic Urtikaria was investigated for further forms of the priticaria, as the underlying pathology regardless of the etheric pathology regardless of the etheric pathology is similar to and chronic patients can be made easier for spectively."</seg>
<seg id="1750">"because the Histaminites-release is an ordinary factor in all urticarious disorders, is expected that Desloratadin except for the chronic idiopathic urticaria in other forms of the priticaria to an improvement of symptoms. this is confirmed by the recommendations of clinical guidelines."</seg>
<seg id="1751">In two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urticaria was Aerius effective in improving pruritus and the reduction of size and number of squares at the end of the first Dosisintervalls.</seg>
<seg id="1752">"as in other studies with Antihistaminika near chronic idiopathic Urtikaria, the minority of the patients, who are not excluded from the study."</seg>
<seg id="1753">An improvement of the jugs of more than 50% was observed at 55% of patients with Desloratadin treated patients compared to 19% of the patients treated with placebo patients.</seg>
<seg id="1754">"the treatment with Aerius reduced the disturbance of the sleep and of the wax, as is measured by a 4-point scale to assess this variable."</seg>
<seg id="1755">"in a pharmacocinetic study, in which the patients were comparable with the general seasonal Rhinitis population population, was achieved at 4% of patients a higher concentration of desloratadin."</seg>
<seg id="1756">There are no evidence for a clinically relevant Kumulation after once daily use of desloratadin (5- 20 mg) over 14 days before.</seg>
<seg id="1757">"however, this is not identified for the metaboism of desloratadin responsible enzyme, so that interdependencies with other medicines will not be excluded completely."</seg>
<seg id="1758">Desloratadin inhibits in-vivo not CYP3A4 and in-vitro-studies have shown that the medicine CYP2D6 is not inhibit and neither a substrate nor an inhibitor of P-glycopic rotone.</seg>
<seg id="1759">In a single doser study with Desloratadin a dosage of 7.5 mg combined meals (fatty, calorie breakfast) does not affect the availability of desloratadin. "</seg>
<seg id="1760">The clinical trials conducted by Desloratadin and Loratadin conducted in a comparable degree of exposure of desloratadin, no qualitative or quantitative differences with regard to the toxicity of desloratadin and by Loratadin. "</seg>
<seg id="1761">"based on conventional studies on safety issues, toxicity, toxicity, genesis, genotoxicity, and to Reproduction-paricity can be seen the preclinical data with Desloratadin no particular hazards for man."</seg>
<seg id="1762">"colour film (includes Lactose-monohydrate, titanium, Macrogol 400, Indigocarmin (E 132)), Colgocarmin (E 132)), colored Film (includes Hypromess, Macrogol 400), Carnaubaws, blown wwax."</seg>
<seg id="1763">"Aerius can be taken independently of meals, to linquate the symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1)."</seg>
<seg id="1764">The prescription doctor should be aware that most cases of Rhinitis in children under 2 years are caused by an infection (see below 4.4) and that no data are available to support a infective Rhinitis with Aerius.</seg>
<seg id="1765">"in addition to the exclusion of upper breaths or anatomical anomalies should play a role in diagnosis the anamnese, physical investigations and corresponding laboratory tests."</seg>
<seg id="1766">Approximately 6% of adults and children between 2 and 11 years metabolized Desloratadin restricted and find a higher resolution load (see below section 5.2).</seg>
<seg id="1767">"the security of Aerius Sirup in children between 2 and 11 years, which are restricted metabolized, is the same with the children who are normal metabolized."</seg>
<seg id="1768">"this medicine contains Saccharose and sorbitol; therefore patients should not take patients with hereditary problems of a fructose intolerance, glucose-paractose-sorption efficiency of this medicine."</seg>
<seg id="1769">"clinical-relevant interactions with Aerius tablets were not observed when Erythromycin or Ketoconazol additionally were given (see below section 5.1)."</seg>
<seg id="1770">"in a clinically-pharmacological study, with simultaneous intake of aserius tablets and alcohol the powerful effect of alcohol are not reinforced (see below section 5.1)."</seg>
<seg id="1771">The overall stiffness of the side effects of children between 2 and 11 years was similar to the Aerius Sirup group as with the placebo group.</seg>
<seg id="1772">"clinical studies with adults and young people in various indications, including allergic Rhinitis and chronically idiopathic urticaria, were reported at recommended dose 3% more side effects in patients with Aerius, when patients were treated with placebo."</seg>
<seg id="1773">"in a multidose study of adults and young people, with up to 45 mg of Desloratadin (ninth clinical dose), no clinically relevant effects were observed."</seg>
<seg id="1774">"children between 1 and 11 years, who received an anti-histamintherapy in question, received a daily Desloratadinddose of 1,25 mg (aged between 1 and 5 years) or 2,5 mg (aged between 6 and 11 years)."</seg>
<seg id="1775">Because the course of allergic Rhinitis / chronically idiopathic Urtikaria and the profile of Desloratadin with adults and children can be similar in adults to children's population.</seg>
<seg id="1776">"as part of a clinical study with multidisciplinary an adult and young people, in a dosage of up to 20 mg daily over 14 days, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1777">"in a clinically-pharmacological study of adults and young people, in a dosage of 45 mg daily (the Neunfold of the clinical dose) over ten days in adults showed no extension of the QTc Intervalls."</seg>
<seg id="1778">In controlled clinical trials at recommended dosage of 5 mg daily for adults and adolescents no increased frequency of flushing in comparison to placebo.</seg>
<seg id="1779">With an individual daily dose of 7.5 mg of Aerius tablets with adults and young people in clinical studies no impairment of psychomotor.</seg>
<seg id="1780">"in clinical-pharmacological studies of adults, there was neither the simultaneous intake of alcohol neither to a reinforcement of alcohol induced performance impairment even to an increase in the freezing."</seg>
<seg id="1781">"in adult and adolescent patients with allergic Rhinitis were Aerius tablets effective in the alleviation of symptoms like Niesen, Nasensecretion and Juckreiz, tears, and redness of the eyes as well as Juckreiz on the palate."</seg>
<seg id="1782">"as with the outcome of the questionnaire on the quality of life at Rhino-economic tivitis showed, diminishing Aerius tablets effectively replaced by seasonal Rhinitis."</seg>
<seg id="1783">In two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urticaria was Aerius effective in improving pruritus and the reduction of size and number of squares at the end of the first Dosisintervalls.</seg>
<seg id="1784">"the dissemination of this restricted metabolized phenotyps was comparable with adults (6%) and children between 2 and 11 years (6%) and in both populations greater in Black (18% adults, 16% children) than with Kaucasians (2% adults, 3% children)."</seg>
<seg id="1785">Similar pharaoinetic parameters were observed in a pharmacocinetic multidose study with the syupformulation to children between 2 and 11 years with allergic Rhinitis based on metalliances observed.</seg>
<seg id="1786">The load (AUC) by Desloratadin was after 3 to 6 hours approximately 6times higher and the Cmax approximately 3 to 4times higher with a temporal half time of about 120 hours.</seg>
<seg id="1787">There are no responsibility for a clinically relevant active ingredient couulation after once daily use of desloratadin (5- 20 mg) over 14 days with adults and young people.</seg>
<seg id="1788">"12 In different retailers studies, AUC- and Cmax values of desloratadin in paediatric patients were comparable to those of adults, the Desloratadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1789">"however, this is not identified for the metaboism of desloratadin responsible enzyme, so that interdependencies with other medicines cannot be completely ruled out."</seg>
<seg id="1790">"Aerius Sirup is offered in type-III-brainlaser bottles with a safe polypropylene cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with a rigid, clear polystyrene measuring on, kalibriert with 2.5 ml and 5 ml or with a Applications for entries with scaling of 2.5 ml and 5 ml (only for 150 ml bottle)."</seg>
<seg id="1792">A dose of Aerius Lyophilisat once again put into the mouth once daily in the mouth to alleviate the symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1793">Immediately prior to the application the blister has to be opened carefully and the dosage of the lyophilate should be taken from being taken without damage.</seg>
<seg id="1794">"clinical-relevant interactions with Aerius tablets were not observed when Erythromycin or Ketoconazol additionally were used (see below section 5.1)."</seg>
<seg id="1795">"clinical trials in various indications, including allergic Rhinitis and chronically idiopathic urticaria, were reported at recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets, when patients were treated with placebo."</seg>
<seg id="1796">"in a multidose study, which were applied up to 45 mg of Desloratadin (ninth clinical dose), have been observed not clinically relevant effects."</seg>
<seg id="1797">"in two individual dose studies Aerius Lyophilisat was well tolerated; this was documented by clinical laboratory results, medical studies, vitality and ECG-Intervalldata."</seg>
<seg id="1798">"as part of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily over 14 days was applied daily, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1799">"in a clinically-pharmacological study, in the Desloratadin a dosage of 45 mg daily (the Neunfold of the clinical dose) was applied over ten days, no extension of the QTc-Intervalls."</seg>
<seg id="1800">In controlled clinical trials at recommended dosage of 5 mg daily there was no increased frequency of freezing compared to placebo.</seg>
<seg id="1801">"with an 17 single dose study with adults, Desloratadin 5 mg no influence on standard - measurement sizes, including the reinforcement of the flight, or the tasks that are connected to the flies."</seg>
<seg id="1802">"in patients with allergic Rhinitis were Aerius tablets effective in the alleviation of symptoms like Niesen, Nasensecretion and Juckreiz, tears, and redness of the eyes as well as Juckreiz on the palate."</seg>
<seg id="1803">"as with the outcome of the questionnaire on the quality of life at Rhino-economic tivitis showed, diminished Aerius effectively caused by seasonal Rhinitis ralled strain."</seg>
<seg id="1804">18 In a pharmacocinetic study that were comparable with the general seasonal Rhinitis populations with the general seasonal Rhinitis population was achieved at 4% of patients a higher concentration of Desloratadin.</seg>
<seg id="1805">Food has no significant influence on AUC and Cmax by Aerius Lyophilisat to take during food Tmax by Desloratadin between 2.5 to 4 hours and Tmax of 3-OH-Desloratadin 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol Aspartame (E 951) Polacrilin-Kalium paints (III) -oxide (E 172) and Hypromess (E 464)) Aroma Tutti-Frutti Waterfree Citronensäure</seg>
<seg id="1807">A Aerius 2.5 mg melting tray once daily in the mouth, to linquate the symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1). "</seg>
<seg id="1808">Two Aerius 2.5 mg melting coated once daily in the mouth to linquate the symptoms of symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1809">There are limited experience from clinical studies for effectiveness when applying Desloratadin for young people aged 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately before the application, the blister has to be opened carefully and the dose of melting tablets are taken from, without damage."</seg>
<seg id="1811">The effectiveness and irritation of Aerius 2.5 mg melting coated in the treatment of children under 6 years have not been proven.</seg>
<seg id="1812">The overall stiffness of the side effects between the Desloratadine Sirup- and the placebo group was the same and wich is not significant from that in adult patients.</seg>
<seg id="1813">"during the recommended dose, Aerius Schmelzenge as bioequivalent to the Aerius 5 mg of conventional tablets formulate and the erius 5 mg Lyophilisat to the introductory formulation of desloratadin."</seg>
<seg id="1814">"as part of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily over 14 days was applied daily, no statistically signed or clinically</seg>
<seg id="1815">"with an individual dose study with adults, Desloratadin 5 mg. no influence on standard - measuring ranges, including the strengthening of subjective battles or the tasks that are connected to the flies."</seg>
<seg id="1816">"the spread of this poorly metabolized phenotyps was comparable for adult (6%) and pediatric patients between 2 and 11 years (6%), and under Black (adults 18%, children 16%), the safety profile of these patients was not deviating from the general population."</seg>
<seg id="1817">In single-dose-Crossover-studies of Aerius Schmelzenge with Aerius 5 mg of conventional tablets or asterius 5 mg Lyophilisat were the formulations of bioequivalent.</seg>
<seg id="1818">"Aerius 2,5 mg tablets were not examined by paediatric patients, however, in conjunction with the Dosisfins studies in children however support the use of 2.5 mg dosage in children from 6 to 11 years."</seg>
<seg id="1819">Food has no significant influence on AUC and Cmax by Aerius Aerius Lyophilisat to take during food Tmax by Desloratadin between 2.5 to 4 hours and Tmax of 3-OH- Desloratadin 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of preclinical and clinical Irritational tests for the melting tray sets that this formulate a non-probable risk for local irritations.</seg>
<seg id="1821">Micro-crystal cellulose pre-disguised strength Carboxymethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmethylmeth</seg>
<seg id="1822">The Kaltenblister foil consists of polyvinylchlorid (PVC) and laminated to a long-related polyamide (Opa) Film made laminated to a aluminium foil made laminated to a polyvinylchlorid (PVC) film.</seg>
<seg id="1823">A Aerius 5 mg melting tray once daily in the mouth, to linquate the symptoms of allergic rhinitis (including intermittent and persist Rhinitis) and Urtikaria (see below section 5.1). "</seg>
<seg id="1824">At the recommended dose Aerius 5 mg melting tray is considered bioequivalent to the Aerius 5 mg of conventional tablets formulate and the erius 5 mg Lyophilisat to the introductory formulation of desloratadin.</seg>
<seg id="1825">"as part of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily over 14 days was applied daily, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1826">"with an 30 single dose study with adults, Desloratadin 5 mg. no influence on standard - measuring ranges, including the strengthening of subjective battles or the tasks that are connected to the flies."</seg>
<seg id="1827">"in patients with allergic Rhinitis were Aerius tablets effective in the alleviation of symptoms like Niesen, Nasensecretion and Juckreiz, tears, and redness of the eyes as well as Juckreiz on the palate."</seg>
<seg id="1828">In single-dose-Crossover-studies of Aerius 5 mg melting tablets with Aerius 5 mg of conventional tablets or asterius 5 mg Lyophilisat were the formulations of bioequivalent.</seg>
<seg id="1829">The overall analysis of preclinical and clinical Irritational tests for the melting tray sets that this formulate a non-probable risk for local irritations.</seg>
<seg id="1830">"the safety of desloratadin children between 2 and 11 years, which are restricted metabolized, is the same with the children who are normal metabolized."</seg>
<seg id="1831">"this medicine contains sorbitol; therefore patients should not take patients with hereditary problems of a fructose- intolerance, glucose-paractose-sorption efficiency of this medicine."</seg>
<seg id="1832">The overall stiffness of the side effects of children from 2 to 11 years was similar to the Desloratadin group similar to the placebo group.</seg>
<seg id="1833">"in small children between 6 and 23 months, the most frequently recorded side effects were reported on more frequently than placebo (3,7%), fever (2,3%) and sleeplessness (2,3%)."</seg>
<seg id="1834">"in an additional study conducted by 2,5 mg of desloratadin solution, no side effects in patients aged between 6 and 11 years were observed."</seg>
<seg id="1835">At the recommended doses were the plasma concentration of desloratadin (see section 5.2) in the children's and adult population comparable.</seg>
<seg id="1836">In controlled clinical trials at recommended dosage of 5 mg daily for adults and adolescents no increased frequency of flushing in comparison to placebo.</seg>
<seg id="1837">"in addition to the established classification in seasonal and perennial, can allergic Rhinitis depending on the duration of symptoms also in intermittent rhinitis and"</seg>
<seg id="1838">"as with the outcome of the questionnaire on the quality of life at Rhino-economic tivitis showed, diminishing Aerius tablets effectively replaced by seasonal Rhinitis ralled strain."</seg>
<seg id="1839">"the dissemination of this restricted metabolized phenotyps was comparable with adults (6%) and children between 2 and 11 years (6%) and in both populations greater in Black (18% adults, 16% children) than with Kaucasians (2% adults, 3% children)."</seg>
<seg id="1840">"since Aerius solution for taking the same concentration of desloratadin, was not necessary and it is expected to expect the syrup and the tablets."</seg>
<seg id="1841">"in various retailers studies, AUC- and Cmax values of desloratadin in paediatric patients were comparable to those of adults, the Desloratadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1842">"Sorbitol, Propylalose E 955, Hyprombling E 2910, Natriumcitrate 2 H2O, natural and artificial flavors (Bubble-Gum), water and artificial flavors (Bubble), sodium-edetate (Ph.Eur.), rounded water."</seg>
<seg id="1843">"Aerius solution for taking with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III Braunglasflaps with a childbearing polyethylene."</seg>
<seg id="1844">All packaging sizes except the 150 ml packaging size are offered with a measurement spoon with markings for doses of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml packaging size is a measuring poon or a applictance for preparations for entries with scaling of 2.5 ml and 5 ml attached.</seg>
<seg id="1846">"subsequently to the extension of the approval, the regulatory filing will submit regular reports on the unthinkable of a drug by all two years except for it becomes something different from the CHMP."</seg>
<seg id="1847">1 film tablets 2 film tablets 5 film tablets 5 film tablets 15 film tablets 20 film tablets 30 film tablets 90 film tablets 100 film tablets 100 film tablets</seg>
<seg id="1848">1 film tablets 2 film tablets 5 film tablets 5 film tablets 15 film tablets 20 film tablets 30 film tablets 90 film tablets 100 film tablets 100 film tablets</seg>
<seg id="1849">Syrup 30 ml with 1 measuring poons 60 ml with 1 measuring poons 100 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 300 ml with 1 measuring poons</seg>
<seg id="1850">30 ml with 1 measuring poons 50 ml with 1 measuring poons 100 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 300 ml with 1 measuring poons</seg>
<seg id="1851">1 dose of lyophilisat for insertion 3 cans of lyophilisat for insertion 10 cans of lyophilisat for insertion 10 cans of lyophilisat for insertion 10 cans of lyophilisat for insertion 30 cans of lyophilisat for insertion 100 cans of lyophilisat for one-take 100 cans of lyophilisat for one-take 100 cans of lyophilisat.</seg>
<seg id="1852">5 melting coated 6 melting coated 12 melting tablets 18 melting coated 18 melting coated 30 melting coated 60 melting coated 90 melting tablets 100 melting-coated</seg>
<seg id="1853">Solution for taking 30 ml with 1 measuring poons 100 ml with 1 measuring poons 100 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 150 ml with 1 measuring poons 300 ml with 1 measuring poons</seg>
<seg id="1854">Pregnant and lactation questions you during pregnancy and lactation before taking on all medicines to your doctor or pharmacist for advice.</seg>
<seg id="1855">"transport and operation of machines for use in recommended dosage is not to be reckoned that Aerius leads to gasoline, leads or pay attention."</seg>
<seg id="1856">"if you have said by your doctor, you have a intolerance against certain sugar, ask your doctor before you take this medicine."</seg>
<seg id="1857">"regarding the treatment duration your doctor will determine the kind of allergic Rhinitis under which you suffer, and will then define how long you should take Aerius."</seg>
<seg id="1858">If your allergic Rhinitis intermitating is (the symptoms of rare than 4 days per week) or less than 4 weeks last) your doctor will recommend a treatment scheme that depends on your course of course of disease.</seg>
<seg id="1859">"if your allergic Rhinitis persist (the symptoms occur in 4 or more days per week, and more than 4 weeks last), your doctor can advise you a longer continuous treatment."</seg>
<seg id="1860">"if you have forgotten the intake of Aerius If you have forgotten your dose, take them as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1861">"71 After market launch of Aerius, very rarely reported on cases of severe allergic reactions (difficulties in the breathing, pfeifender breathing, jured, usks and rash) and rash."</seg>
<seg id="1862">"about cases of heart cloves, cardiac, panacess, insomness, instigations, insulence, insularities, insulence, bances, irritation, irritation and unusual Leberfunction was also very rare."</seg>
<seg id="1863">"tray is made of colored film (includes Lactose- Monohydratessen, titanium, Macrogol 400, Indigocarmin (E 132)), Colorgocarmin (E 132)), colored movie (includes Hypromess, Macrogol 400), Carnaubaws, curved wax."</seg>
<seg id="1864">"Aerius 5 mg film tablets are individually packed in blister packs with 1, 2, 3, 5, 14, 15, 21, 30, 50, 90, 90 or 100 tablets."</seg>
<seg id="1865">"Aerius Sirup is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older people included."</seg>
<seg id="1866">Important information on certain other parts of Aerius you should not take Aerius Sirups if you are on the dye E 110 allergic.</seg>
<seg id="1867">"if your doctor is informed that you own a intolerance toward some sugars, please contact your doctor before you take this medicine."</seg>
<seg id="1868">"if the syrup has placed a applicationsjection to the preparation with scaling, you can use this alternative to take the appropriate amount of syrup."</seg>
<seg id="1869">"regarding the treatment duration your doctor will determine the kind of allergic Rhinitis under which you suffer, and will then define how long you should take aperius Sirups."</seg>
<seg id="1870">"however, in children under 2 years of waste, fever and sleeplessness common side effects, while with adult tiredness, mouth dry and headaches were reported than with placebo."</seg>
<seg id="1871">"after the launch of Aerius, very rarely reported on cases of severe allergic reactions (difficulties in the breathing, pfeifender breathing, jured, nuts, and rash) and rash."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with a safe sealing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">Aerius Lyophilisat contributes to the symptoms enhances the symptoms of allergic Rhinitis (by an allergy of inflammation of the nasal length, for example hay blowing or house-milk allergy). "</seg>
<seg id="1874">"at intake of Aerius Lyophilisat, together with food and drinks Aerius Lyophilisat, does not need to be taken with water or other fluid."</seg>
<seg id="1875">Regarding the treatment duration your doctor will determine the kind of allergic Rhinitis under which you suffer and will then define how long you should take Aerius Lyophilisat.</seg>
<seg id="1876">"81 If you forgot the intake of Aerius Lyophilisat, If you have forgotten your dose, take them as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1877">"after the launch of Aerius, very rarely reported on cases of severe allergic reactions (difficulties in the breathing, pfeifender breathing, jured, nuts, and rash) and rash."</seg>
<seg id="1878">"Aerius Lyophilisat is individually packed in blister packs with 1, 2, 3, 5, 7, 14, 15, 30, 30, 50 or 100 cans of the lyophilate to the entrance."</seg>
<seg id="1879">"Aerius Schmelzooette improves the symptoms of allergic Rhinitis (by an allergy of inflammation of the nasal length, for example hay blowing or house dust-milk allergy)."</seg>
<seg id="1880">At intake of Aerius Schmelzenge along with food and beverages Aerius Schmelzenge does not need to be taken with water or other fluid.</seg>
<seg id="1881">"regarding the treatment duration your doctor will determine the kind of allergic Rhinitis under which you suffer, and will then define how long you should take Aerius shooters."</seg>
<seg id="1882">"86 If you forgot the intake of Aerius Schmelzooette If you have forgotten your dose, take them as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1883">"Aerius Schmelzooette is individually packed in blister packs with 5, 6, 10, 12, 15, 30, 60, 60, 60, 60, 90 and 100 cans of melting tablets."</seg>
<seg id="1884">At intake of Aerius Schmelzenge along with food and beverages Aerius Schmelzenge does not need to be taken with water or other fluid.</seg>
<seg id="1885">"if you forgot the intake of Aerius Schmelzooette If you have forgotten your dose, take them as soon as possible and then follow the normal treatment plan."</seg>
<seg id="1886">"after the launch of Aerius, very rarely reported on cases of severe allergic reactions (difficulties in the breathing, pfeifender breathing, jured, nuts, and rash) and rash."</seg>
<seg id="1887">"Aerius solution for admission is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older people."</seg>
<seg id="1888">"if the solution for insertion a applicationis attached to inserts with scalations, you can use this alternatively to take the appropriate amount of solution to deposit."</seg>
<seg id="1889">"regarding the treatment duration your doctor will determine the kind of allergic Rhinitis under which you suffer, and will then define how long you should take Aerius solution to take."</seg>
<seg id="1890">"however, in children under 2 years of waste, fever and sleeplessness frequent side effects during an adult redness, oral drying and headache were reported than with placebo."</seg>
<seg id="1891">"97 Aerius solution for disposable is available in bottles with a safe sealing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml packet size is a measuring poon or a applictester diner for entries with scaling of 2.5 ml- and 5 ml cans.</seg>
<seg id="1893">June 2008 divided Novartis Vaccines and Diagnostics S.r.l. the Committee on Humanitarian H5N1-Influenza in adults and older people back.</seg>
<seg id="1894">"Aflunov should be used in adults and older people to protect the flu, which is caused by the trunk (type) H5N1 of the flu-A virus."</seg>
<seg id="1895">"this is a special kind of vaccine which could cause before a trunk of Grippevirus that could cause a future pandemic."</seg>
<seg id="1896">"a Grippepandemic breaks out when a new trunk of influenza, which can easily spread from man to man because people still have no immunity (no protection) against it."</seg>
<seg id="1897">"after making the vaccine the immune system recognises the immune system the parts of the Grippevirus as" "physically" "and forms antibodies against it."</seg>
<seg id="1898">This makes the immune system later in the position to form a contact with a grip virus of this pedigree faster antibodies.</seg>
<seg id="1899">"subsequently, the membrane envelle of the virus with the" surface surface "(proteine on the membrane surface, which recognizes the human body as body-alienation) separated, and used as a component of the vaccine."</seg>
<seg id="1900">"inspection of some of the study centers showed that the study was not conducted according to the" "good clinical practice" (GCP). "</seg>
<seg id="1901">"in this way, the scope of the clinical data base for the evaluation of the vaccine is not made to fulfill the requirements of the EMEA guidelines for prepandemic vaccines."</seg>
<seg id="1902">"should you take part in a clinical trial and need more information on your treatment, please contact your doctor's doctor."</seg>
<seg id="1903">"if you wish further information regarding the basis of the CHMP recommendations, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"it is used in combination with other antiviral medicines for the treatment of adults and children over four years, which are caused by humane immweakest virus of type 1 (HIV-1) which are caused by the acquired Immune Deficiency Syndrome (AIDS)."</seg>
<seg id="1905">"for patients who can't swallow the capsules, Agenerase may not be taken as a solution to deposit, but this cannot be taken together with Ritonavir since the safety of this combination was not examined."</seg>
<seg id="1906">"Agenerase should only be subordinated if the doctor has checked, which antiviral medicines has been taken before, and the likelihood that the virus is addressed to the medicine."</seg>
<seg id="1907">"the recommended dose for patients over twelve years amounts to 600 mg twice daily, which are taken together with twice daily 100 mg of Ritonavir and with other antiviral medicines."</seg>
<seg id="1908">In children between four and twelve years and in patients with a body weight of less than 50 kg the recommended dose of asgenerase depends on the body weight.</seg>
<seg id="1909">Agenerase decreases in combination with other antiviral medicines for HIV quantity in the blood and keeps them at a low level.</seg>
<seg id="1910">"AIDS not to heal, however, however, can delay the immune system and thus also delay the development of with AIDS infections and diseases."</seg>
<seg id="1911">"Agenerase was studied in combination with other antiviral drugs, but without Ritonavir, in two main studies with 736 HIV-infected adults, which were previously not treated with proteascertainties."</seg>
<seg id="1912">"that with low dosage amplified pharmaceuticals Agenerase has been taken with 206 adults, which had previously used proteassigns, with other proteins."</seg>
<seg id="1913">Main Indicator for the effectiveness was the proportion of patients with no subsequent concentrations of HIV in the blood (Viruslast) or the change of the Viruslast after treatment.</seg>
<seg id="1914">"in the studies with patients who previously had not taken proteascertainties, although after 48 weeks under Agenerated, more patients had a virusload under 400 copies / ml than under placebo, but Agenerase was less effective than Indinavir."</seg>
<seg id="1915">"with children lower Ageneric also the Viruslast, whereby however, by the children who had been treated earlier with proteascertainties, only very few of the treatment."</seg>
<seg id="1916">In the study with adults who have been treated earlier with proteascertainties that have been treated with Ritonavir reinforced drug Agenerase after 16-week treatment as effective as other proteins.</seg>
<seg id="1917">"in patients with HIV, which was resistant against four other proteins of proteins, along with Ritonavir to a greater waste of the Viruslast after four weeks than with patients who have continued their previous proteins."</seg>
<seg id="1918">"the most common side effects of Agenerase (observed in more than 1 of 10 patients) are headaches, Diarrhö (perseverity), nausea, rash, rash and Fatigue (tiredness)."</seg>
<seg id="1919">2 / 3 Agenera must not be used in patients who may not be excessive (allergic) against amblown or one of the other components.</seg>
<seg id="1920">"Agenerase may also not be used in patients who are at Johanniskraut (a herbal supplement for treating depression) or drugs, which are just as advertised and harmful in high concentrations in the blood health."</seg>
<seg id="1921">"as with other medicines for patients with patients, Agenerase, the risk of a lipodystrophie (changes in the distribution of the body fat), a oststeonekoarthritis (absorption of bone tissues) or a immune reactivated syndroms (symptoms of a infection which are caused by the recovered immune system)."</seg>
<seg id="1922">The Committee on Humanities (CHMP) to conclude that the advantages of Agenerase in combination with other antiretroviral drugs used to treat with proteins in HIV-1-infected adults and children over four years compared to the risks.</seg>
<seg id="1923">"Agenerase is usually taken together with the pharmacokinetic amplifier Ritonavir, but the committee held that the use of Ageneric in combination with Ritonavir in patients who previously did not have proteins in proteins."</seg>
<seg id="1924">Agenera was originally approved under "exceptional circumstances because at the time of approval for scientific reasons only limited information is required.</seg>
<seg id="1925">"October 2000, the European Commission granted the company Glaxo Group Limited has permission for the Independence of Agenerase in the entire European Union."</seg>
<seg id="1926">Agenerase is available in combination with other antiretroviral medicines for the treatment of HIV 1- 1- infected (PI) -pre-treated adults and children from 4 years of age.</seg>
<seg id="1927">For usually to Agenerase capsules for pharmacocinetic boosts of ampbumps along with low doses of Ritonavir is given (see sections 4.2 and 4.5).</seg>
<seg id="1928">The use of ampblown should take place taking account of the individual viral Resistance and the pre-treatment of the patient (see Section 5.1).</seg>
<seg id="1929">The bioavailability of ampbishops as a solution to one is about 14% less than from ampblown capsules as a capsule; therefore are Agenerase caps and solution to inserts on a milligrams per milligram (see section 5.2).</seg>
<seg id="1930">The recommended dose for Agenerase capsules is 600 mg of ampbumps twice daily with 100 mg Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="1931">"2 If Agenerase capsules are applied without the amplified addition of Ritonavir (booklet), higher doses must be applied to Agenerase (1200 mg twice daily)."</seg>
<seg id="1932">The recommended dose for Agenerated capsules is 20 mg of ampbumps / kg body weight twice daily in combination with other antiretroviral medicines of up to a daily-highest dose of 2400 mg of Ambishops which should not be exceeded (see Section 5.1).</seg>
<seg id="1933">"Pharmacoinetics, effectiveness and safety of Agenerase in combination with low doses of Ritonavir or other proteins in children were not examined."</seg>
<seg id="1934">"Agenerase is not recommended for use in children under 4 years, due to the misregard of data for inconceivable and effectiveness (see section 5.2)."</seg>
<seg id="1935">"based on the pharmacokinetic data, the dose of Agenerase capsules should be reduced to 450 mg twice daily and in patients with severe Leberfunctioning dysfunction at 300 mg twice daily."</seg>
<seg id="1936">"the simultaneous application should be done with patients with slight or even liver functioning with caution, in patients with severe Leberfunction it is controversial (see section 4.3)."</seg>
<seg id="1937">"Agenerase may not be given simultaneously with drugs, which have a small therapeutic width and also represent the substrates of cytochrom P450-Isoenzyme 3A4 (CYP3A4)."</seg>
<seg id="1938">Herbal supplements that contain Johanniskraut (hypericum perforatum) may not be used due to the risk reduction of plasma concentration and a diminished therapeutic effect of ampbishops during the intake of Amblown. (see Section 4.5).</seg>
<seg id="1939">Patients should be pointed out that Agenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="1940">The present antiretroretroviral therapy including treatment with Agenerase does not prevent the risk of transferring HIV to others through sexual contact or contamination with blood.</seg>
<seg id="1941">"for usually, Agenerase caps are to be used together with low doses of Ritonavir and in combination with other antiretroviral medicines (see Section 4.2)."</seg>
<seg id="1942">Patients who suffer from chronic hepatitis B or C and treated with an antiretroviral combination therapy with an antiretrospective treatment of potentially fatal effects.</seg>
<seg id="1943">For the case of simultaneous antiviral treatment of hepatitis B or C please read the relevant information of this medicine.</seg>
<seg id="1944">Patients with pre-existing reduced liver function including a chronic-active hepatitis show an increased frequency of liver dysfunctions under an antiretroviral combination therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">"simultaneous application of Agenerase and Ritonavir with Fluticason or other Glukokortikoids, which is not recommended by CYP3A4, it is not recommended, unless the potential benefits of treatment is the risk of systemic corsore including Morbus Csore and Suppsion of the auxiliary-function. (see Section 4.5)."</seg>
<seg id="1946">"since the material alternation of the HMG-CoA-Reductase-Hemmer Lovastatin and Simvastatin has been dependent on CYP3A4, an simultaneous administration of Agenerative with Lovastatin and Simvastatin due to the increased risk of myopathy, including Rhabdomyolysen not recommended."</seg>
<seg id="1947">"4 For some medicines that can cause serious or life-threatening effects, such as Carbamazepin, Phenytoin, Phenytoin, tricyclic antidepressants and warning in (under monitoring of the International Standardization ratio), are methods of determination of the drug concentration."</seg>
<seg id="1948">"in patients who take this medicine at the same time, Agenerase may be less effective because of decreased plasma pids. (see Section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic interactions with Amuxavir can be altered the effectiveness of hormonal contraceptive pills, however, the information is not sufficient to estimate the type of interactions."</seg>
<seg id="1950">"when methadon is given at the same time with ampblown, the patients should therefore be monitored on Opiatentment symptom, especially if there are also low doses of Ritonavir."</seg>
<seg id="1951">"due to the possible risk of toxicity, due to the high propylation of the Agenerase solution to the entry, this intestinal form of children under a age of four years and should be applied with caution with certain other patients."</seg>
<seg id="1952">Agenerase should be placed on duration 5 if a rash of systemic or allergic symptoms will be accompanied or the vested skins are involved (see section 4.8).</seg>
<seg id="1953">"in patients who received an antiretroviral therapy including proteins, was reported about the appearance of diabetes mellitus, hyperglycemic or an exhilaration of an existing diabetes mellitus."</seg>
<seg id="1954">Many of the patients had other diseases whose therapy is needed to be associated with the development of a diabetes or a hyperglycaemy.</seg>
<seg id="1955">"B. high age, and with drug-dependent factors, such as a longer continuous de antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="1956">"in hämophiles patients (type A and B) that have been treated with proteascertainties, are reports of an increase in bloodation including spontaneous hematoms and heremarthrosen."</seg>
<seg id="1957">"in HIV-infected patients with severely immune defective, at the time the introduction of an anti-retroviral therapy (ART) can develop an inflated reaction to asymptomatic or residuous opportunistic infections that leads to severe clinical trials or deterioration of symptoms."</seg>
<seg id="1958">"although a multifactorial etiology is adopted (including the use of cortikosteroids, alcohol consumption, high Body-Mass index), cases of Osteonekoarthritis in particular were reported in patients with advanced HIV disease and / or long-term application of antiretroviral therapy (ART)."</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width Agenerase may not be used simultaneously with medicines that have a small therapeutic width and also represent the substrates of cytochrom P450-Isoenzyms 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with low therapeutic width Ageneric with Ritonavir must not be changed along with medicines whose active ingredients are being changed via CYP2D6 and are connected to the increased plasma pipers with heavy duty and / or lifelong side effects.</seg>
<seg id="1961">"it was shown that Rifampicin a 82% reduction in the AUC of Ammonavir causes, which can lead to a virological failure and lead to a resident development."</seg>
<seg id="1962">"trying to offset the lowest plasma cutting through a diosisincrease of other proteins in combination with Ritonavir in combination with Ritonavir, have been observed very often unwanted effects on the liver."</seg>
<seg id="1963">Johanniskraut (Hypericum perforatum) The Serummirror of Amblown can be brought down through the simultaneous application of herbal preparations with Johanniskraut (Hypericum perforatum).</seg>
<seg id="1964">"when a patient is already redeemed at Johanniskraut, the amblown mirror, and, if possible to check the Viruslast and shut down the Johanniskraut."</seg>
<seg id="1965">A dosage adjustment for one of the medicine is not required when Nelfinavir is given together with amblown (see also Efavirenz below).</seg>
<seg id="1966">"508% increased, for Cmax against a 30% lower, when Ritonavir (100 mg twice daily) in combination with Amnesty capsules (600 mg twice daily)."</seg>
<seg id="1967">In clinical studies Dosists have been used twice daily and Ritonavir twice daily and Ritonavir 100 mg twice daily used to occupy the effectiveness and thoughtfulness of this therapy.</seg>
<seg id="1968">52% lower when ampblown (750 mg twice daily) in combination with Kaletra (400 mg of Lopinavir + 100 mg Ritonavir twice daily).</seg>
<seg id="1969">"the Cmin values of Ammonavir in Plasma, which were reached in combination of Ammonavir (600 mg twice daily) with Kaletra (400 mg twice daily), are approximately 40 to 50% lower than if Ambumps (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily."</seg>
<seg id="1970">"a dosage recommended for simultaneous administration of ampbishops and Kaletra can not be given, however, there will be a closer monitoring, since the effectiveness and unthinkable of this combination is not known."</seg>
<seg id="1971">"there was no pharmacokinetic study conducted by Ageneric in combination with Didanosin, however, due to the antulent component of Didanosin and Agenerase are at least one hour apart (see Antazida bottom)."</seg>
<seg id="1972">Therefore at gift of Efavirenz (600 mg twice daily) and Ritonavir (100 mg twice daily) and Ritonavir (100 mg twice daily).</seg>
<seg id="1973">"the treatment with Efavirenz in combination with Ammonavir and Saquinavir is not recommended, since the exposure of both proteins would be low."</seg>
<seg id="1974">The effect of Nevirapin to other proteins and available limited data can be suspected that Nevirapin the Serumkoncentration may possibly lowers.</seg>
<seg id="1975">"if this medicine should be used at the same time, caution is offered as delicacy in because of the reduced or possibly subtherapeutic plasma cutting-masegel could be less effective."</seg>
<seg id="1976">"if this medicine is applied together, caution must be performed; a thorough clinical and virological monitoring is to be made, as a precise prediction of the effect of the combination of ampblown and Ritonavir on Delavirdis difficult."</seg>
<seg id="1977">"the simultaneous gift of Ammonavir and Riolutin led to an increase in Plasonentriation (AUC) by Rifaboltin around 193%, and thus a rise in the side effects associated with Rifaboltin."</seg>
<seg id="1978">"if it is necessary for clinical reasons, Riachutin is required along with Agenerase, to be reduced to a reduction in the dosage of Rifaboltin to at least half of the recommended dose, although there are no clinical data."</seg>
<seg id="1979">"pharmacocinetic studies with Agenerase in combination with Erythromycin have not been carried out, however the plasmasal of both medicines could be increased in the case of simultaneous administration."</seg>
<seg id="1980">Simultaneous application of twice daily 700 mg Fosamprenavir and 100 mg Ketoconazol once a daily led to an increase in the Cetoconazol in Plasma by 25% and the AUC (0 members) to the 2,69mm on a daily basis without simultaneous application of Fosamprenavir with Ritonavir.</seg>
<seg id="1981">"other medicines that are listed below, including substrate, inhimer or induction of CYP3A4, if they are used together with Agenerase may possibly lead to interactions."</seg>
<seg id="1982">Patients should therefore be connected to toxicity reactions that are linked to these drugs if they are used in combination with Agenerase.</seg>
<seg id="1983">"based on the data of other proteins, it is advisable that Antazida are not taken at the same time as Agenerase, since it can come to resoratory disorders."</seg>
<seg id="1984">"simultaneous application of antionvolcanic, which are known as encyductors (phenytoin, Phenobyal, carbamazepin), with ampbangavir can lead to a humiliation of plasma cutting of ampbishops."</seg>
<seg id="1985">"the Serum Concentrations of Calciumbers, like Amlodipin, ydipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimpairpin, which increases the activity and toxicity of this medicine is increased."</seg>
<seg id="1986">"simultaneous intake with Agenerase can enhance their plasma-concentration, and with PDE5-inhibitors in connection with side effects including hypotension, tances and Priapism (see section 4.4)."</seg>
<seg id="1987">In a clinical trial where the Ritonavir 100 mg capsules were given twice daily with 50 µg fluticasonpropionat intranasal (4-times daily) over 7 days on probananas (4-times daily) over 7 days to rehearsal cortisol (4 times daily) over 7 days off (90% reduction (90% reduction (90% reduction).</seg>
<seg id="1988">"consequently, the simultaneous gift of Agenerated with Ritonavir is not recommended together with these glucavir along with these glucaviortikoids, unless the potential benefits of treatment is the risk of systemic coritic-effects (see section 4.4)."</seg>
<seg id="1989">"at HMG-CoA-Reductase-Hemmics such as Lovastatin, and Simvastatin, whose distortion has been dependent on CYP3A4, are distinct from plasma cutting with simultaneous administration of Agenerase."</seg>
<seg id="1990">"since plasma cutting increases by this HMG-CoA-Reductase-Hemmics, including a habidomyolysis, the combined application of this medicine is not recommended."</seg>
<seg id="1991">"it is recommended to be a frequent monitoring of therapeutic concentrations up to stabilise the mirror, since the plasticonentriations of Cyet porin, Rapamycin and Tacrolimus can be increased with the current gift of ampbishops (see section 4.4)."</seg>
<seg id="1992">"therefore, Agenerase may not be applied together with oral bidazolam (see Section 4.3), while the current application of Agenerase with parenteralem Midazolam beware."</seg>
<seg id="1993">Data for simultaneous application of parenteric Midazolam with other proteins of proteins point to a possible increase in plasma cutting of Midazolam around the 3- to 4-fold.</seg>
<seg id="1994">"if methadon agreed together with Ammonavir, the patients should therefore be monitored on Opiatentment symptom, especially if there are also low doses of Ritonavir."</seg>
<seg id="1995">"due to the diligence of historical verses of historical comparisons, there cannot be any recommendation as the ampblown dose is given, if Amblown is given at the same time with methadon."</seg>
<seg id="1996">In concurrent gift of warning or other oralen antioagulants along with Agenerase will be an enhanced control of INR (International normalities) because of the possibility of a weakening or reinforcement of the antithrombotic effect (see Section 4.4).</seg>
<seg id="1997">The effect of an additional administration of Ritonavir on hormonal contraceptive is not predictable so as alternative methods are recommended for contraception methods.</seg>
<seg id="1998">Careful monitoring of therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended in concurrent gift of Agenerase (see section 4.4).</seg>
<seg id="1999">"this medicine may only be applied during pregnancy only after careful extraction of possible usage for the mother, compared to the possible risks to the fetus."</seg>
<seg id="2000">"in the milk lapping brewed were proven, Amiravir-related substances were proven, however, it is not known whether Amblown is overflowing with people into the mother's milk."</seg>
<seg id="2001">A reproduction of reproduction that was given to impairment in the uterus until the end of the stagnation of Ammonavir was given during the stagnation time a diminished increase in the 12 body weight in the postage.</seg>
<seg id="2002">The further development of the descendants including fertilisation and reproduction of production was not impaired by the administration of Amuahavir.</seg>
<seg id="2003">The inconceivable of Agenera was studied with adults and children from 4 years in controlled clinical studies in combination with different antiretroviral medicines.</seg>
<seg id="2004">"most of the used effects associated with the Agenerative-treatment effects were slightly to moderate, they appear early on and led rarely to the treatment."</seg>
<seg id="2005">"in many of these events, it is not clarified whether they are related to the intake of Agenerase or another simultaneously on HIV treatment, or whether they are a consequence of the atrocities."</seg>
<seg id="2006">"most of the side-mentioned side effects come from two clinical trials (PROAB3001, PROAB3006), where with Proteascertainties not pre-treated patients 1200 mg of Agenerase twice daily."</seg>
<seg id="2007">"events (degrees 2 to 4) that have been used by the checkers as well as in connection with the study of study, as well as with more than 1% of patients, as well as under the treatment follow-up lab changes (degree 3 to 4) are listed."</seg>
<seg id="2008">The anti-retroviral combination therapy has been associated with a redistribution of the body fat (Lipodystrophy) with HIV patients, including a loss of peripheral and fast underneal tissues, hypertrophy of breasts and dormaler fat collection (boiled). "</seg>
<seg id="2009">"under 113 antiretroviral not pre-treated persons, which had been treated with Ammudin / Zidovudin over a medium duration of 36 weeks, was only a case (Stiernacken) (&lt; 1%)."</seg>
<seg id="2010">"in the study PROAB 3006, at 245 NRTI- pre-treated patients under Ammonavir 7 cases (3%) compared to 27 cases (11%) with 241 patients under Indinavir, in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0,001)."</seg>
<seg id="2011">"skin seals were usually easy to moderate, erythematorial or makulopulous nature, with or without juckreiz, and they usually occurred during the second treatment of treatment and disappeared spontaneously within two weeks, without the treatment with ampbishops had to be broken off."</seg>
<seg id="2012">Cases of Osteonekoarthritis in particular were reported in patients with generally known risk factors, advanced HIV disease or long-term application of an antiretroviral therapy (ART). "</seg>
<seg id="2013">In HIV-infected patients with severely immune defective, at the time the introduction of an antiretroviral Combinational therapy (ART) can develop an inflated reaction to asymptomatic or residual opportunistic infections (see Section 4.4). "</seg>
<seg id="2014">"with PI pre-treated patients, the 600 mg of Agenerase were observed twice daily together with low dosage (degree 3 and 4) which were observed among allergies (degree 2 to 4) and laboratory changes (degree 3 and 4) which were obtained with low dose of triglycavi- and CPK values, which were obtained with low dosage, very often recorded."</seg>
<seg id="2015">"in case of overdose, the patient is to observe signs of an intoxication (see section 4.8) if necessary, are required support measures."</seg>
<seg id="2016">Ammonavir binds to the active center of HIV-1 protein and therefore prevents the processing of viral gag- and gag polarity with the consequence of a formation unripe, not infective Viruspartikel. "</seg>
<seg id="2017">"antiviral activity of Ammonavir in vitro against HIV-1 IIIB was studied both in acute and chronic inymphocytic cell lines (MT-4, CEM-CCRF, H9) as well as in peripheral blood-ymphocytes."</seg>
<seg id="2018">The 50% Hemmeccentric (IC50) of Ammonavir is located in the range of 0.012 to 0.08 µm in infected cells and amounts to 0.41 µm in chronic infected cells</seg>
<seg id="2019">The connection between the activity of Ammony against HIV-1 in vitro and the imitation of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">In the treatment of antiretroviral not pre-treated patients with the currently approved Fosampavir-Dosities - as with other Ritonavir boosterohibitors - the described mutations are rarely observed.</seg>
<seg id="2021">"at sixteen of 434 antiretroviral not pre-treated patients, the 700mg Fosampavir has received twice a day in the ESS100732 study, entered into a virologic distorting up to week 48, with 14 Isolate genotype."</seg>
<seg id="2022">"a genotype analysis of the insect of 13 of 14 children, where a virological failure in the 59 entered into the 59, with proteascertainties did not be pre-treated patients, showed residential pattern that were similar to those in adults."</seg>
<seg id="2023">"L10F / I / V, V11I, I33F, M47V, I47V, I47V, I47V, I47V, I47V, I5V, I85V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V,</seg>
<seg id="2024">"in the study APV30003 and its extension APV30005 (700 mg Fosampavir twice daily: N = 107) to with proteins in patients with virological failure, about 96 weeks, the following protein mutations to:"</seg>
<seg id="2025">Genotype-based analyses Genotype interpretations can be applied to depreciation of the activity of ampblown / Ritonavir or Fosampavir / Ritonavir in patients with proteascertainties.</seg>
<seg id="2026">"the current (July 2006) ANRS-AC-11-algorithm for Fosamprenavir / C / F / V, I54F, I54F, I54F, I84V and L90M in connection with a gestated phoneavir with Ritonavir and a reduced likelihood of a virological response (resistance)."</seg>
<seg id="2027">"the conclusions concerning the relevance of certain mutations or mutationsmuster can be amended by additional data, and it is recommended to always educate the current interpretations to analyse the results of resistance tests."</seg>
<seg id="2028">On phurotype-based analyses clinical analysis-based analysis systems can be used in conjunction with genotype data for depreciation of the activity of ampblown / Ritonavir or Fosampavir or Fosampavir in patients with Proteasformerly isolates isolates.</seg>
<seg id="2029">Companies that sell diagnostic resistance tests, have developed clinically-phänotype-offs (cutting points) for FPV / RTV, which can be applied to the interpretation of results of a resident test tests. "</seg>
<seg id="2030">"each of these four with a reduced sensitivity against Ammonavir associated genetic patterns produces a certain cruise resistant to Ritonavir, the sensitivity against indinavir, Nelfinavir and Saquinavir stays in general."</seg>
<seg id="2031">"there are currently data for cross-resistant difference between ampblown and other proteins of proteins for all 4 Fosamprenavir resident, either alone or in combination with other mutations."</seg>
<seg id="2032">"on the basis of fifth twenty antiretroviral's non-treated patients, with whom a Fosampavir / Ritonavir (three of 25 isolates), Indinavir / Ritonavir (three of 25 isolates), Darinavir / Ritonavir (three of 24 isolates), Saquinavir (three of 24 isolates), Saquinavir (three of 24 isolates) and Tipranavir / Ritonavir (four of 24 isolates)."</seg>
<seg id="2033">"conversely, Amthoravir retains its activity against some other proteins of protein isolates; the receipt of these activity seems to be dependent upon the number and type of Resistence mutations in isolates."</seg>
<seg id="2034">The early departure of a versy therapy is recommended to hold the accumulation of a variety of mutations within limits that may affect the subsequent treatment.</seg>
<seg id="2035">"the cover of the effectiveness of Agenerative in combination with Ritonavir 100 mg twice daily based on the study PRO30017, a randomised open study, in which with PI pre-treated adult (NRTI) or a standard therapy (standard of care, SOC), with a PI, primarily associated with the lowest Ritonavir". ""</seg>
<seg id="2036">"one-time-thirteen (n = 163) patients with proven virus-sensitivity compared to Agenerase, at least another PI and at least one NRTI were included in the part study A by PRO30017."</seg>
<seg id="2037">The primary analysis set the non-sub-legality of APV / Ritonavir compared to the SOC-PI Group in terms of time-adjustable (AAUCMB) in Plasma after 16 weeks of age (AAUCMB) in Plasma after 16 weeks of age of 0,4 log10 copies / ml.</seg>
<seg id="2038">"the cover of the effectiveness of ungeboostertem Agenerase is based on two uncontrolled studies with a total of 288 HIV-infected children aged 2 to 18 years, of which 152 were treated with PI."</seg>
<seg id="2039">"in studies Agenerase solution to take and capsules in doses of 15 mg / kg 3 times daily, 20 mg / kg twice daily and 22,5 mg / kg twice daily, whereby the majority of patients receive 20 mg / kg twice daily."</seg>
<seg id="2040">There was no low dosified Ritonavir at the same time; the majority of the patients treated with PI-treated patients previously had at least one (78%) or two (42%) of the attached NRTIs.</seg>
<seg id="2041">"after 48 weeks, approximately 25% of the patients included a plasma-1-RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml with a medians increase in the CD4 cell number of 26 cells / mm ³ (s = 74) compared to the output value."</seg>
<seg id="2042">19 Basics on this data should be considered with the therapy optimization for the benefit of "Ingeboostertem" Agenerase in consideration.</seg>
<seg id="2043">"according to oral administration, the average duration (tmax) is about 1 to 2 hours for the capsule and about 0.5 to 1 hour for the solution."</seg>
<seg id="2044">"508% increased, for Cmax against about 30%, when Ritonavir (100 mg twice daily) together with Amnesty (600 mg twice daily)."</seg>
<seg id="2045">"administration of Ambishops with a meal leads to a 25% total acceptance of AUC, but has no effect on the concentration of ampblown 12 hours after dosage (C12)."</seg>
<seg id="2046">"therefore, the minimum concentration at steady State (Cmin, ss) remained uninfluenced by the food intake, although the simultaneous food intake is affected by the extent and rate of resorption."</seg>
<seg id="2047">The apparent distribution volume is approximately 430 l (6 l / kg at a body weight of 70 kg) and leaves a large distribution volume as well as an enormous penetration of ampblown from the blood cycle in the tissue.</seg>
<seg id="2048">"this change leads to a decrease of the total concentration of the drug in the plasma, whereby the amount of inadequate Ambishops which represents the active share, probably remains the same."</seg>
<seg id="2049">"while the absolute concentration of inadequate Ambumps remains constant, the percentage of free active components, depending on the total doctor of the steady State of the steady State on the area of Cmax, ss up to Cmin, ss."</seg>
<seg id="2050">"therefore, medicines that CYP3A4 induce or inhibit or a substrate of CYP3A4, with caution can be given once they are given simultaneously with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Agenerase caps, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily amp-up-exposure as with adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">"Amber avir is from the solution 14% less bioverflowing as from the capsules; therefore, Agenerase solution and Agenerase capsules are not interchangeable on a millimetre base."</seg>
<seg id="2053">"even the renal Clearance of Ritonavir is negligible, therefore the effect of a kidney function is likely to be low."</seg>
<seg id="2054">These therapy schemata lead to Ambishops-plasma piers comparable to those who have made to healthy probances after a dosage of 1200 mg of ampbumps twice daily without simultaneous administration of Ritonavir.</seg>
<seg id="2055">"in long-term studies to rabbit in mice and rats, with male animals benign hepatcellular Adenome with doses at dsities with doses at dosing (mice) or 3,8- triple (Ratte) of the exposure to man, according to twice daily gift of 1200 mg of ampblown."</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of hepatocular Adenome and carcinoms has not been enlightened and the relevance of these observed effects for man is unclear.</seg>
<seg id="2057">"from the present exposure data on people, both in clinical studies as well as from therapeutic use, however, however, little evidence of acceptance of a clinical relevance of these findings."</seg>
<seg id="2058">"in a standard battery of In-vivo- and In-vitro-Genotoxical testing, the bacterial strawphoma test, microkernels of rats and Chromosomenerrational test, was ampblown neither mutuous nor genesis."</seg>
<seg id="2059">This liver toxicity can be monitored and proven in clinical everyday life by measuring AST, ALT and the activity of alkaline Phosphatase. "</seg>
<seg id="2060">"until now, in clinical studies there have been observed no significant liver toxicity in patients, neither during administration of Ageneric nor after the end of the treatment."</seg>
<seg id="2061">"studies for toxicity in young animals, which were treated at an age of 4 days, showed both to the control and with the blown animals a high morality."</seg>
<seg id="2062">"at a systemic plasma-position, which lay significant among (edges) or not significantly higher (rats) than the expected exposition under therapeutic dosage, however, have been observed a number of slight changes including Thymuselongation and low skeleton changes that can be found on a consuming developments."</seg>
<seg id="2063">24 If Agenerase capsules are applied without the amplified addition of Ritonavir (booklet) must be used for higher doses of Agenerase (1200 mg twice daily).</seg>
<seg id="2064">The recommended dose for Agenerated capsules is 20 mg of ampbumps / kg body weight twice daily in combination with other antiretroviral medicines of up to a daily-highest dose of 2400 mg of Ambishops which should not be exceeded (see Section 5.1).</seg>
<seg id="2065">"the simultaneous application is to be performed in patients with a vigilance or easier liver functioning with caution, in patients with severe Leberfunction it is controversial (see section 4.3)."</seg>
<seg id="2066">"26 For some medicines that can cause serious or life-threatening effects, such as Carbamazepin, Phenytoin, Phenytoin, tricyclic antidepressants and warning in (under monitoring of the International Standardization ratio), are methods of determination of the drug concentration."</seg>
<seg id="2067">Agenerase should be set to duration 27 if a rash of systemic or allergic symptoms will be accompanied or the vested skins are involved (see section 4.8).</seg>
<seg id="2068">"a elevated risk for a lipodystrophy was associated with individual factors, such as high age, and with drug-dependent factors, such as a longer continuous de antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2069">"it was shown that Rifampicin a 82% reduction in the AUC of Ammonavir causes, which can lead to a virological failure and lead to a resident development."</seg>
<seg id="2070">"508% increased, for Cmax against a 30% lower, when Ritonavir (100 mg twice daily) in combination with Amnesty capsules (600 mg twice daily)."</seg>
<seg id="2071">"the Cmin values of Ammonavir in Plasma, which were reached in combination of Ammonavir (600 mg twice daily) with Kaletra (400 mg twice daily), are approximately 40 to 50% lower than if Ambumps (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily."</seg>
<seg id="2072">"a dosage recommended for simultaneous administration of ampbishops and Kaletra can not be given, however, there will be a closer monitoring, since the effectiveness and unthinkable of this combination is not known."</seg>
<seg id="2073">"the treatment with Efavirenz in combination with Ammonavir and Saquinavir is not recommended, since the exposure of both proteins would be low."</seg>
<seg id="2074">"if this medicine is applied together, caution must be performed; a thorough clinical and virological monitoring is to be made, as a precise prediction of the effect of the combination of ampblown and Ritonavir on Delavirdis difficult."</seg>
<seg id="2075">"if it is necessary for clinical reasons, Riachutin is required along with Agenerase, is to be reduced to a reduction in the dosage of Rifaboltin to at least half of the recommended dose 31, although there are no clinical data."</seg>
<seg id="2076">"the Serum Concentrations of Calciumbers, like Amlodipin, ydipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimodipin, Nimpairpin, Nimodipin, enabling possibly to increase the activity and toxicity of this medicine."</seg>
<seg id="2077">In a clinical trial where the Ritonavir 100 mg capsules were given twice daily with 50 µg fluticasonpropionat intranasal (4-times daily) over 7 days on probananas (4-times daily) over 7 days to rehearsal cortisol (4 times daily) over 7 days off (90% reduction (90% reduction (90% reduction).</seg>
<seg id="2078">In concurrent gift of warning or other oralen antioagulants along with Agenerase will be an enhanced control of INR (International normalities) because of the possibility of a weakening or reinforcement of the antithrombotic effect (see Section 4.4).</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg of Ethinylestradiol plus 1.0 mg Norethindron) led to a decrease of AUC and Cmin from Ambishops by 22% bzw.</seg>
<seg id="2080">"this medicine may only be applied during pregnancy only after careful extraction of possible usage for the mother, compared to the possible risks to the fetus."</seg>
<seg id="2081">A reproduction of reproduction that was given to impairment in the uterus until the end of the stagnation of Ammonavir was given during the stagnation time a diminished increase in the body weight in the postage.</seg>
<seg id="2082">The inconceivable of Agenera was studied with adults and children from 4 years in controlled clinical studies in combination with different antiretroviral medicines.</seg>
<seg id="2083">"in case of overdose, the patient is to observe signs of an intoxication (see section 4.8) if necessary, are required support measures."</seg>
<seg id="2084">"antiviral activity of Ammonavir in vitro against HIV-1 IIIB was studied both in acute and chronic inymphocytic cell lines (MT-4, CEM-CCRF, H9) as well as peripheral blood-ymphocytes."</seg>
<seg id="2085">The 50% Hemmeccentric (IC50) of Ammonavir is located in the range of 0.012 to 0.08 µm in chronic cells and amounts to 0.41 µm in chronically infected cells (1 µm = 0,50 µg / ml).</seg>
<seg id="2086">"conversely, Amthoravir retains its activity against some other proteins of protein isolates; the receipt of these activity seems to be dependent upon the number and type of Resistence mutations in isolates."</seg>
<seg id="2087">"based on these data should be taken into consideration in the therapy with PI-treated children of" "impregnated" "Agenerase". ""</seg>
<seg id="2088">"while the absolute concentration of inadequate Ambumps remains constant, the percentage of free active components, depending on the total doctor of the steady State of the steady State on the area of Cmax, ss up to Cmin, ss.."</seg>
<seg id="2089">"therefore, medicines that CYP3A4 induce or inhibit or a substrate of CYP3A4, with caution can be given once they are given simultaneously with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">"even the renal Clearance of Ritonavir is negligible; therefore, the effect of a kidney function is likely to be low."</seg>
<seg id="2091">In long-term studies to canogens with ampblown up to mice and rats occurred in male animals benepigne hepatcellular Adenome (mice) or 3,8- triple (Ratte) of the exposure to man twice daily from 1200 mg of ampblown.</seg>
<seg id="2092">The underlying mechanism for the emergence of hepatulular Adenome and carcinoms has not been unenlightened and the relevance of these observed effects for man is unclear.</seg>
<seg id="2093">"however, from the present exposure data on people, both clinical studies as well as from therapeutic use, however, little evidence of the acceptance of a clinical relevance of these findings."</seg>
<seg id="2094">"in a standard battery of In-vivo- and In-vitro-Genotoxical testing, the bacterial strawphoma test, microkernels of rats and Chromosomenerrational test, was ammatavid neither mutuous nor genesis."</seg>
<seg id="2095">"studies for toxicity in young animals, which were treated at an age of 4 days, showed both to the control and with the blown animals a high morality."</seg>
<seg id="2096">"these results make sure that in young, the metabolic paths are not fully mature, so that amblown or other critical components of the formulation."</seg>
<seg id="2097">"Agenerase solution to entry is available in combination with other antiretroviral medicines for the treatment of HIV-1-infected, proteasformerly adults and children from 4 years."</seg>
<seg id="2098">"the benefit of with Ritonavir" imoosterter "" Agenerase solution to entry was not covered neither with PI pre-treated patients nor with PI-treated patients. "</seg>
<seg id="2099">The bioavailability of ampbishops as a solution to one is about 14% less than from ampblown capsules as a capsule; therefore are Agenerase caps and solution to inserts on a milligrams per milligram (see section 5.2).</seg>
<seg id="2100">"patients should be able as soon as they are able to swallow the capsules, with the intake of the solution to the entry (see Section 4.4)."</seg>
<seg id="2101">The recommended dose for asgenerase solution is 17 mg (1.1 ml) Ammavir / kg body weight three times daily in combination with other antiretroviral medicines which should not be exceeded (see section 5.1).</seg>
<seg id="2102">"in addition, since there must be no damaging recommendations for simultaneous use of Agenerase solution to inated and low dosill Ritonavir can be avoided, this combination with these patients."</seg>
<seg id="2103">"although a Dosisadaption for Amnesty is not for necessary, an application of Ageneric solution to involve patients with kidney failure (see section 4.3)."</seg>
<seg id="2104">"due to the potential risk of an toxic reaction as a result of the high propylation solution, Agenerase solution is used in small children and children under 4 years, in pregnant women, in patients with reduced liver function or liver detention and in patients with kidney failure."</seg>
<seg id="2105">Simultaneous administration can lead to a petitive inhibiting of this medicine and possibly create serious and / or lifelong side effects as heart rhythmia (z).</seg>
<seg id="2106">Patients should be pointed out that Agenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that it continues to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="2107">The present antiretroretroviral therapy including treatment with Agenerase does not prevent the risk of transferring HIV to others through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that can cause serious or life-threatening effects, such as Carbamazepin, Phenytoin, Phenytoin, tricyclic antidepressants and warfarin (under monitoring of the International standardization ratio), are methods of determination of the drug concentration."</seg>
<seg id="2109">Agenerase should be set on duration if a rash of systemic or allergic symptoms will be accompanied or the vested skins are involved (see section 4.8).</seg>
<seg id="2110">"a elevated risk for a lipodystrophy was associated with individual factors, such as high age, and with pharmaceuticals of 49 dependent factors, such as a longer continuous antiretroviral treatment and associated metabolic disorders."</seg>
<seg id="2111">"in hämophiles patients (type A and B) that have been treated with proteascertainties, are reports of an increase in bloodation including spontaneous hematoms and heremarthrosen."</seg>
<seg id="2112">"it was shown that Rifampicin a 82% reduction in the AUC of Ammonavir causes, which can lead to a virological failure and lead to a resident development."</seg>
<seg id="2113">"508% increased, for Cmax against a 30% lower, when Ritonavir (100 mg twice daily) in combination with Amnesty capsules (600 mg twice daily)."</seg>
<seg id="2114">"simultaneous intake with Agenerase can enhance their plasma-concentration, and with PDE5-inhibitors in connection with side effects including hypotension, tances and Priapism (see section 4.4)."</seg>
<seg id="2115">On the basis of the data on 54 other CYP3A4-Inhibitors will be significantly improved by Midazolon significantly higher plasma concentration of Midazolam.</seg>
<seg id="2116">The potential risk for man is not known. Agenerase solution can not be used due to possible toxicity reactions of the fetus to the Propylenglycol not used during pregnancy (see section 4.3).</seg>
<seg id="2117">"in the milk lapping brewed were proven, Amiravir-related substances were proven, however, it is not known whether Amblown is overflowing with people into the mother's milk."</seg>
<seg id="2118">A reproduction of reproduction that was given to impairment in the uterus until the end of the stagnation of Ammonavir was given during the stagnation time a diminished increase in the 55 body weight in the postage.</seg>
<seg id="2119">The inconceivable of Agenera was studied with adults and children from 4 years in controlled clinical studies in combination with different antiretroviral medicines.</seg>
<seg id="2120">"in many of these events, it is not clarified whether they are related to the intake of Agenerase or another simultaneously on HIV treatment, or whether they are a consequence of the atrocities."</seg>
<seg id="2121">In the treatment of antiretroviral not pre-treated patients with the currently approved Fosampavir-Dosities - as with other Ritonavir boosterohibitors - the described mutations are rarely observed.</seg>
<seg id="2122">"at the early 60 therapy is recommended to hold the accumulation of a variety of mutations in borders, which may affect the subsequent treatment."</seg>
<seg id="2123">62 Basics on this data should be considered with the therapy optimization for the benefit of "ungeboostertem" Agenerase in consideration.</seg>
<seg id="2124">The apparent distribution volume is approximately 430 l (6 l / kg at a body weight of 70 kg) and can be mounted to a large Veteilvolume as well as an enormous penetration of ampblown from the blood cycle in the tissue.</seg>
<seg id="2125">The underlying mechanism for the emergence of hepatocular Adenome and carcinoms has not been enlightened and the relevance of these observed effects for man is unclear.</seg>
<seg id="2126">"at a systemic plasma-position, which lay significant among (edges) or not significantly higher (rats) than the expected exposition under therapeutic dosage, however, have been observed a number of slight changes including Thymuselongation and low skeleton changes that can be found on a consuming developments."</seg>
<seg id="2127">Perhaps you would like to read this later again. − If you have further questions please contact your doctor or pharmacist. − This medicine was personally committed to you.</seg>
<seg id="2128">"it can harm other people, even if these are the same complaints as you. − If one of the listed side effects you may not impairs or you notice effects that are not indicated in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2129">"your doctor will normally inform you, Agenerase capsules, along with low doses of Ritonavir to reinforce the effect of Agenerase."</seg>
<seg id="2130">The use of Agenerase will be based on your doctor for you with individual viral resistance test and your treatment options.</seg>
<seg id="2131">Inform your doctor if you suffer from any of the diseases mentioned above or any of any of the above medicines.</seg>
<seg id="2132">"if your doctor is advised that you take Agenerase capsules, along with low doses of Ritonavir to reinforce the effect (booklet), make sure that you have read carefully before the start of treatment."</seg>
<seg id="2133">"likewise, there are no adequate information to recommend the use of Ageneric capsules, along with rituals for children aged 4 to 12 years or generally with patients under 50 kg body weight."</seg>
<seg id="2134">"therefore, it is important that you read the section" When taking Agenerase with other medicines "" before you begin with the intake of Agenerase. "</seg>
<seg id="2135">"possibly you need additional factor VIII to control the blood pressure. − In case patients, which occur an antiretroviral combination therapy, can occur a redistribution, collection or loss of body fat."</seg>
<seg id="2136">"if you are certain medicines that can lead to serious side effects, like Carbamazepin, Phenytoin, Librycin, cyamycin, tricyclic antidepressants and warning, at the same time as Agenerase, your doctor might perform additional blood tests to minimize possible security problems."</seg>
<seg id="2137">It is recommended that HIV-positive women should not satisfy their children under no circumstances to prevent a transfer of HIV.</seg>
<seg id="2138">"transport and operation of machines There have been no studies regarding the influence of asgeneric, or the ability to use machines."</seg>
<seg id="2139">Please take this medicine only after consultation with your doctor if you are known that you suffer from a intolerance toward certain states.</seg>
<seg id="2140">"Didanosin) take it advisable that you take this more than an hour before or after Agenerase, otherwise, the effects of Agenerase can diminished."</seg>
<seg id="2141">Dosage of Agenerase caps is 600 mg twice daily together with 100 mg Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2142">"if your doctor decides that the intake of Ritonavir is not suitable for you, you will have to take higher doses (1200 mg of blown twice daily)."</seg>
<seg id="2143">"85 Damit Agenerated are a great benefit as possible, it is very important that you take the entire day dose that you take your doctor."</seg>
<seg id="2144">"if you have taken a larger amount of Agenerase, when you should have taken more than the prescribed dose of Agenerase, you should immediately contact your doctor or pharmacist."</seg>
<seg id="2145">"if you have forgotten the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think it and then keep the intake as before."</seg>
<seg id="2146">"with the treatment of an HIV infection, it is not always possible to tell whether to be absorbed side effects by Agenerase, by other medicines that simultaneously be taken at the same time, or by HIV disorder itself."</seg>
<seg id="2147">"headaches, garantness, disease-feeling, copper, blasting, bladder, or juckreiz) - occasionally may force the rash of serious nature and you to break the intake of taking this drug."</seg>
<seg id="2148">"tuning, depression, sleeping disorders, appetite loss tingling in the lips and in the mouth, uncontrolled movements, infertile, soak chairs, increase in certain liver enzymes, the trans, increase in a enzyme of pancrease in the gland called Amylase"</seg>
<seg id="2149">Increased blood values for sugar or cholesterol (a particular blood bed) Elephered blood values of a substance called Bilirubin swelling of the face, the lips and the tongue (angioids). "</seg>
<seg id="2150">"this can include liloss of legs, arms and in the face, a fatty uname in the stomach and in other internal organs, breast enlargement and lipiste in the neck (" "stitching" ")."</seg>
<seg id="2151">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2152">"therefore, it is important that you read the section" When taking Agenerase with other medicines "" before you begin with the intake of Agenerase. "</seg>
<seg id="2153">"in some patients who receive an antiretroviral Combined treatment, one can develop an anti-steonekrose (Abdie of bone tissue as a result of insufficient blood supply of bone)."</seg>
<seg id="2154">"Didanosin) take it advisable that you take this more than an hour before or after Agenerase, otherwise, the effects of Agenerase can diminished."</seg>
<seg id="2155">"94 Damit Agenerated are a great benefit as possible, it is very important that you take the entire day dose that you take your doctor."</seg>
<seg id="2156">"if you have forgotten the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think, and then put it as before."</seg>
<seg id="2157">"headaches, garantness, disease-feeling, copper, blasting, bladder, or juckreiz) - occasionally may force the rash of serious nature and you to break the intake of taking this drug."</seg>
<seg id="2158">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2159">Dosage of Agenerase caps is 600 mg twice daily together with 100 mg Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2160">"so that Agenera brings as possible benefits as possible, it is very important that you take the entire day dose that you take your doctor."</seg>
<seg id="2161">"if you have taken bigger quantities of Agenerase, when you should have taken more than the prescribed dose of Agenerase, you should immediately contact your doctor or pharmacist."</seg>
<seg id="2162">"the benefits of with Ritonavir" imoosterter "" Agenerase solution to entry was not covered neither with proteascertainties to patients still with proteins in the patients. "</seg>
<seg id="2163">"for the application lower doses of Ritonavir (usually used to reinforce the effect [Booklet] of Agenerase capsules, together with Agenerase solution to take no docking recommendations."</seg>
<seg id="2164">Ritonavir solution for one-taking) or additionally Propylenglycol in the intake of Agenerase solution (see also Agenerase may not be taken).</seg>
<seg id="2165">"your doctor will possibly have effects on side effects associated with the Propylenglycolcontent of the Agenerase solution to engage in connection, especially if you have a kidney or liver disease."</seg>
<seg id="2166">"111 If you use certain medicines that can lead to serious side effects, like Carbamazepin, Phenytoin, Librycin, cyamycin, tricyclic antidepressants and warning, at the same time as Agenerase, your doctor might perform additional blood tests to minimize possible security problems."</seg>
<seg id="2167">Ritonavir solution for one-taking) or offered by Propylenglycol in case of intake of Agenerase may not be taken (see Agenerase may not be taken).</seg>
<seg id="2168">Important information on certain other parts of Agenerase solution to entry contains Propylenglycol that can lead in high doses to side effects.</seg>
<seg id="2169">"Propylenglycol can cause a number of side effects including cranes, Benefulness, heart rasen and the reduction of the red blood cells (see also Agenerase may not be taken, special caution in the intake of Agenerase is required precautions)."</seg>
<seg id="2170">"if you have forgotten the intake of Agenerase, If you have forgotten the intake of Agenerase, take it as soon as you think it and then keep the intake as before."</seg>
<seg id="2171">"headaches, garantness, disease-feeling, copper, blasting, bladder, or juckreiz) - occasionally may force the rash of serious nature and you to break the intake of taking this drug."</seg>
<seg id="2172">"this can include liloss of legs, arms and in the face, a fatty uname in the stomach and in other internal organs, breast enlargement and lipiste in the neck (" "stitching" ")."</seg>
<seg id="2173">"the other components are Propylacycol, Macrogol 400 (Polyethylene 400), Acesulum-trauma, Levomenthol, Citrongäure, Citrongäure, sodium-citrate-Dihhydrate, rounded water."</seg>
<seg id="2174">"the applicability and the duration of the treatment with Aldara depend on the treatment of the disease (Aldara for a maximum of 16 weeks a week. • For small basal cell carcinomes, it is possible during one or two four-week treatment cycles, with four weeks of pause between the treatment cycles, three times a week."</seg>
<seg id="2175">"the creams is unlocked in front of sleeping-layered on the affected skin areas, so that they left enough (approximately eight hours) on the skin before it washed."</seg>
<seg id="2176">"in all studies Aldara was compared with a placebo (same cream, but without the active ingredients). • Aldara was tested in four main studies at 923 patients with waiting in the genital area for 16 weeks."</seg>
<seg id="2177">"the main indiator for the effectiveness was the number of patients with complete lowering of the treated warts. • Aldara was also studied at 724 patients with small basal cell carcinoms in two studies, where the patients were treated six weeks and Aldara or the placebo either daily or five times a week."</seg>
<seg id="2178">Main Indicator for the effectiveness was the number of patients with complete lowering of the tumors after twelve weeks. • Aldara was also tested in two studies in total 505 patients with aktine candatants.</seg>
<seg id="2179">"in all studies Aldara was more effective than placebo. • For the treatment of waiting in all four main studies 15% up to 52% of patients treated with their placebo patients, but only 3% to 18% in the patients with Aldara treated patients compared to 0% to 3% in the placebo group."</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the use of the cream (pain or itch).</seg>
<seg id="2181">"clinically typical, not hyperkeratotic, not hypertenderness of candatories (AKS) on the face or on the scalp in immune adults, when the size or number of lesions limit the effectiveness and / or the acceptance of a crotherapy limit and other topographic treatments or less suitable."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before the bed and 6 to 10 hours long on the skin."</seg>
<seg id="2183">The treatment with Imiquimod Creme is so long to continue until all of the visible folds have disappeared in the genital or Perianalrange, or up to a maximum of 16 weeks per treatment period. "</seg>
<seg id="2184">Any interruption in the manner described above should erased when intensive local inflammatory reactions occur (see section 4.4) or when in the treatment area an infection is observed.</seg>
<seg id="2185">"if at follow-up investigation 4 to 8 weeks after the second treatment period the lesions are only uncured, another therapy should be started (see Section 4.4)."</seg>
<seg id="2186">"when a dose was omitted, the patient bear the cream, as soon as he noticed this and then proceed to the usual therapy plan."</seg>
<seg id="2187">Imiquimod-Creme is stored in a thin layer and in the framed ties with foils in infected skin areas until the cream is completely drawn.</seg>
<seg id="2188">It should occur in these patients a breakdown between the benefit of a treatment with Imiquimod and the risks associated with a possible merging of their autoimmune disease.</seg>
<seg id="2189">It should be effected in these patients a breakdown between the benefit of a treatment with Imiquimod and the risk associated with a possible organ transverse or GRAFT-versus-host- reaction.</seg>
<seg id="2190">"in other studies, in which no daily pre-authengids were conducted, two cases of severe phimosis were observed and a case with one to circumcision's leading stripes."</seg>
<seg id="2191">"during an application of Imiquimod cream in higher than recommended doses, a elevated risk for heavy local skin irritation (see section 4.2.) In rare cases the treatment were required and / or lead to a temporary physical impairment."</seg>
<seg id="2192">"in cases where such reactions at the exit of the urethra came up, some women had difficulty in water, which made a emergency catheterisation and treatment of the affected area."</seg>
<seg id="2193">"to use Imiquimod Creme directly following a treatment with other kutan appendiated funds for the treatment of external brackets in the genital and Perianalzone, there are no clinical experience."</seg>
<seg id="2194">"limited data suggest to an increased rate of cargo agents in HIV-positive patients, Imiquimod-Creme has shown a lower effectiveness in this patient group."</seg>
<seg id="2195">"the treatment of Basalcelloms with Imiquimod with Imiquimod within 1 cm to the eyelids, the nose, the lips or the hair-set was not examined."</seg>
<seg id="2196">Local authorities are common but the intensity of these reactions take back in general during therapy or reactions to the treatment with Imiquimod Creme.</seg>
<seg id="2197">"if it is necessary due to the complaints of the patient or due to the severity of local authorities, a treatment period of several days can be done."</seg>
<seg id="2198">The clinical result of therapy can be assessed after the regeneration of the treated skin approximately 12 weeks after the end of the treatment.</seg>
<seg id="2199">"at present, there are no data about long-term healing rates of more than 36 months after the treatment, should be considered to be supervisually other suitable therapy forms."</seg>
<seg id="2200">"in patients with recurrent and pre-treated BCCs are no clinical experience, therefore the application is not recommended during the pre-treated tumors."</seg>
<seg id="2201">Data from an open clinical study point out that at large tumors (&gt; 7.25 cm2) has made a lower probability of response to the Imiquimod Therapy.</seg>
<seg id="2202">"Imiquimod was not examined for the treatment of akic candatants to eyelids, inside the nose or of the ears or in the air area inside the lippenrots."</seg>
<seg id="2203">There are only very limited data on the use of Imiquimod for treatment aktinic Keratants to anatomical places outside the face and the scalp.</seg>
<seg id="2204">"the available data on the acclaimed keratoose of the subpoor and hands support the effectiveness of this application purpose, therefore, such an application is not recommended."</seg>
<seg id="2205">"local Hauling campaigns often appear on, but these reactions usually take back in the course of therapy on intensity or go back after the treatment of therapy with Imiquimod Creme."</seg>
<seg id="2206">"if the local Hauling actions can cause big discomfort or are very strong, the treatment can be suspended for a few days."</seg>
<seg id="2207">"from the data of an open clinical trial, patients with more than 8 AK- Läsions provide a shorter complete healing rate than patients with less than 8 lesions."</seg>
<seg id="2208">"due to the immaculating properties, Imiquimod Cream should be applied with caution in patients who receive an immunotherapist depressed treatment (see 4.4)."</seg>
<seg id="2209">"from animal studies there are no direct or indirect harmful effects on pregnancy, the embryonic / fat development, the discharge or postnatal development (see 5.3)."</seg>
<seg id="2210">"although not according to one time still after multi-storey application, quantified servings levels (&gt; 5ng / ml) can be given no recommendation to apply during lactation time."</seg>
<seg id="2211">The most commonly used shared and may be used as likely or possibly with the application of Imiquimod cream in connection with three times weekly treatment were local reactions at the place of treatment of feigwarts (33.7% of the patients treated with Imiquimod treatment).</seg>
<seg id="2212">"among the most commonly reported cases, as probably or possibly with the application of the Imiquimod Creme in connection-side effects include complaints at the application location with an frequency of 28,1%."</seg>
<seg id="2213">The bases of 185 with Imiquimod-Cream treated in a placebo-controlled clinical trial of phase III reported side effects are listed below.</seg>
<seg id="2214">The most common, as likely or possibly with the application of the Imiquimod Creme in connection-effect were in these studies a reaction to the application location (22% of the patients treated with Imiquimod treatment). "</seg>
<seg id="2215">The side-side-effects that were given by 252 in placebokontrolunanswered clinical trials of the Phase III with Imiquimod-Cream treated patients with aktinic Keratosis are listed below.</seg>
<seg id="2216">"according to the inspection of the clinical evaluation of the clinical trial, it shows that in these placebo-controlled clinical trials with three times of weekly treatment with impiquimod cream, including Erythem (61%), erosion (23%) and the (14%) and the (see section 4.4)."</seg>
<seg id="2217">"according to the inspection of the clinical evaluation of the clinical signs, it shows that in these studies with five times weekly treatment with Imiquimod cream cream very often on heavy duty-themes (13%), heavy erosion (13%), and to heavy duty-training and cabling (19%)."</seg>
<seg id="2218">"clinical trials to investigate the application of Imiquimod for the treatment of aktine keratose, Alopey was observed with an frequency of 0.7% (5 / 1214) at the treatment office or in the surrounding area."</seg>
<seg id="2219">"the irreverly unique absorption of 200 mg of Imiquimod, which corresponds to the content of about 16 bags, could lead to nausea, headaches, mythical and fever."</seg>
<seg id="2220">"the clinically most serious side-effect, which entered into several oral doses of &gt; 200 mg, consisted in hypotony that has been normalized or intravenous fluid."</seg>
<seg id="2221">In a pharmacokinetic investigation were proven according to the topographic application of Imiquimod growing systemic concentrations of the alphabet and other cytokine.</seg>
<seg id="2222">In 3 the relevant phase 3 efficacy studies could be shown that the effectiveness in relation to a complete heat treatment at an imiquimod treatment over 16 weeks of a placebo treatment is significantly superior.</seg>
<seg id="2223">At 60% of the total of 119 with Imiquimod therapists the fetters fully from; this was at 20% of the 105 with placebo diagnosed patients (95% CI):</seg>
<seg id="2224">A complete lowering could be reached at 23% of 157 with Imiquimod treated male patients to 5% of 161 with placebo treated male patients (95% CI):</seg>
<seg id="2225">The effectiveness of Imiquimod at five maliger application per week over 6 weeks was evaluated in two double blinders, placebo-controlled clinical trials. "</seg>
<seg id="2226">The target-cors were histologically confirmed individual primary superfidiplomas with a minimum size of 0.5 cm and a maximum diameter of 2 cm.</seg>
<seg id="2227">"the data from an open, uncontrolled long-term study after four years show that around 79.3% [95% CI (73.7%, 84.9%)] all treated patients clinically been cured and this also stayed for 48 months."</seg>
<seg id="2228">"the effectiveness of Imiquimod with three times of weekly use in one or two treatment periods of 4 weeks, interrupted by a four-week period, treatment-free period, was examined in two double blinders, placebocontrolunanswered clinical studies."</seg>
<seg id="2229">"the patients had clinically typical, visible, discreet, not hyperkeratotic, not hypertropic acid - lesions within one connected 25 cm2 great treatment as on the untreated scalp or on the face."</seg>
<seg id="2230">The prior-year data from two combined observation studies show for patients with clinician exposure to one or two treatment periods of 27% (35 / 128 patients).</seg>
<seg id="2231">The approved indicator of external brackets, AktG Keratose and Superfizielles Basalzinom usually appear in paediatric patients usually not in and were therefore not examined. "</seg>
<seg id="2232">"Aldara Cream was examined in four randomised, double-controlled studies at children aged 2 to 15 years with Molluscum Contagiosum (Imiquimod = 576, placebo n = 313)."</seg>
<seg id="2233">The effectiveness of Imiquimod could not be shown in these studies with the doses examined there (3x / week for a period of ≤ 16 weeks).</seg>
<seg id="2234">A minimum system intake of the 5% of the 5% beiquimod creams by the skin of 58 patients with aktinic Keratosis was observed during three times of weekly usage during 16 weeks.</seg>
<seg id="2235">"the highest drug consumption in the serum at the end of the week 16 were observed between 9 and 12 hours and bets 0,1, 0,2 and 1.6 ng / ml with the use in the face (12.5 mg, 2 bags) and on the hands / poor (75 mg, 6 bags)."</seg>
<seg id="2236">The calculated obvious half-time stood about 10times higher than the 2pcs. after the subutant application in a former study; this refers to an extended retention of drug by means of the skin.</seg>
<seg id="2237">The data on the systematic exposition shown that the Resorption of Imiquimod after topographic application of patients aged 6 - 12 years was low and comparable with which in healthy adults and adults with aktinic Keratzinc-carcinoma.</seg>
<seg id="2238">In a four months study for everyone's toxicity at the Ratte led cans of 0.5 and 2.5 mg / kg KG to significantly lower body weight and elevated milz weight; one also four months long-run study on the dermic application as of the mouse does not have similar effects.</seg>
<seg id="2239">A two-year study related to carcinoity in mice at dermic administration three days a week induced no tumors to the application.</seg>
<seg id="2240">"the corresponding mechanism is not known, but since Imiquimod is only a small systemic absorption of the human skin and not mutiny is a risk to the people due to systematic exposure as very low."</seg>
<seg id="2241">"the tumors occurred in the group of mice, treated with the real-free creams, earlier and in larger number, than in the control group with low UVR."</seg>
<seg id="2242">"it can harm other people, even if these same symptoms have as you. − If one of the listed side effects you have considerably impairs or you notice effects that are not indicated in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2243">● Feigwarzen (Condylomata acuminata) which is formed on the skin in the area of genitalia (sex organs) and the anus (After) have formed a frequent-growing Basalcellular Basket and very low probability of spreading to other parts of the body.</seg>
<seg id="2244">"if it remains untreated, it can lead to deexhibitions, especially in the face - therefore is a fruit detection and - treatment important."</seg>
<seg id="2245">Aktì Keratants are non-smoking areas of the skin that occur during their previous life much of sunlight were exposed.</seg>
<seg id="2246">Aldara should be used only at flat aktine candatants in the face and on the scalp in patients with a healthy immune system where your doctor decided that Aldara for you are the most suitable treatment.</seg>
<seg id="2247">"Aldara Cream supports your body's own immune system in the production of natural substances, which help your body to combat the superficial basal cell carcinoma, the Galactic Keratose, or to fight for the infection with torment responsible virus."</seg>
<seg id="2248">"o if you have already used Aldara Cream or others, similar preparations to inform your doctor if you have problems with your immune system. o Aden Aldara Cream only when you treat problems with your immune system or surgical treatment. o avoid the contact with eyes, lips and nasal grinder."</seg>
<seg id="2249">In case of accidental contact the cream with water removal. o Wend the Cream not innermato. o torn the reactions to the treatment by Aldara Cream not occur with a association or patches. o Falls reactions to the treated place you wash the cream with a mild soap and water.</seg>
<seg id="2250">"once the reactions are shortened, you can continue the treatment. o check your doctor if they have no normal blood image."</seg>
<seg id="2251">"if this daily cleaning is not carried out under the foreskin, can be reckoned with elevated appearance of pre-skin swelling, dots become the skin or difficulties when using the foreskin."</seg>
<seg id="2252">"turn Aldara Cream not in the Urethra (urethra), in the vagina (Scheide), the Zervix (womb) or within the anus (After)."</seg>
<seg id="2253">Taking other medications serious problems with your immune system should use this medication for no more than a treatment cycle.</seg>
<seg id="2254">If you have sexual intercourse during the infection with fetched in the genital area is the treatment with Aldara Cream after sexual intercourse (not previously).</seg>
<seg id="2255">"please inform your doctor or pharmacist if you apply other medicines or have recently applied, even if it is not prescription medicine."</seg>
<seg id="2256">Breastfeeding your baby during the treatment with Aldara Creme not because Imiquimod into the mother's milk.</seg>
<seg id="2257">The frequency and duration of the treatment are different with foils, Basalcell carcinoma and aktinic Keratosis (see specific instructions for each application area). "</seg>
<seg id="2258">"wear a thin layer of Aldara Cream on the clean, dry skin point on the clean, dry skin point on and drag the cream gently upon the skin, until the cream is completely moved."</seg>
<seg id="2259">Men with fats under the foreskin must draw the foreskin each day and to wash the skin area including wash (see section 2 "What must you pay attention to the application of Aldara Creme?).</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">"for 6 weeks minimum 5 days a week, for an adequate amount of Aldara Cream to cover the affected area and 1 cm to cover this area around."</seg>
<seg id="2262">Very common side effects (if more than 1 of 10 patients expect) Frequently side effects (with less than 1 of 100 patients) Very rare side effects (with less than 1 of 10.000 patients)</seg>
<seg id="2263">Tell your doctor / your doctor or your pharmacist / your pharmacist immediately if you do not feel at ease during the application of Aldara Creme.</seg>
<seg id="2264">"if your skin reacts strongly to treatment with Aldara Creme, you should not use the cream area with water and a mild soap, and your doctor or your pharmacist."</seg>
<seg id="2265">A reduced number of blood cells can make you fold more susceptible to infections; they can make that even faster a blast Fleck is created or it can give rise up.</seg>
<seg id="2266">Inform your doctor or pharmacist if one of the listed side effects you explicitly impairs or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2267">"in addition, you can find Juckreiz (32% of the patients), burning (26% of patients) or pain in the areas that you have borne Aldara Cream (8% of the patients)."</seg>
<seg id="2268">"usually it is lighter, that will drop within about 2 weeks after receipt of the treatment."</seg>
<seg id="2269">"occasionally, some patients notice changes in the application location (Wundsecret, inflammation, swelling, bladder, Dermabrasion, drying, dry mouth, gripping-similar symptoms and tiredness."</seg>
<seg id="2270">"occasionally, some patients suffer from changes at the application location (bluff, inflammation, sensitivity, swelling, inflammation, fractures, fractures, diarrhea, redness, credentials, redness, creeks, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness</seg>
<seg id="2271">Aldurazyme is used for the enzymes in patients with secured diagnosis of a Mukopolysaccharid I (MPS I; α -L-Iduronidase lack) to treat the not neurological manifestations of the disease (the symptoms which are not associated with brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (Glykosaminoglykane, gags) will not be dismantled and therefore in most organs in the body, and these compensate."</seg>
<seg id="2273">"the following not neurological symptoms of the MPS I can occur: enlarged liver, rigid joints, the movements are complicity, diminished lung volume, heart and sincerity."</seg>
<seg id="2274">The treatment with Aldurazyme should be monitored by a doctor who has experience in treating patients with MPS I or other hereditary metabolic disorders.</seg>
<seg id="2275">"administration of Aldurazyme should be carried out in a hospital or clinic with reorganization, and the patients may need appropriate medicines to prevent an allergic reaction."</seg>
<seg id="2276">(44-20) 74 18 84 00 fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / /</seg>
<seg id="2277">"the study was primarily examined by the security of the drug, but it has also measured its effectiveness (by examining its effect in terms of reduction in gag concentrations in the urine and in terms of the size of the liver)."</seg>
<seg id="2278">"with children under five years of age Aldurazyme the Gag concentrations in the urine around 60%, and half of the treated children showed a normal large liver at the end of the study."</seg>
<seg id="2279">"the most common side effects of Aldurazyme in patients aged over five years (observed in more than 1 of 10 patients) are headaches, pandemagathy (laughter), Arthropathy (joint pain), Arthropathy (in hands and feet), Hitzegeempathy, fever and reactions to the infusion set."</seg>
<seg id="2280">"very common side effects in patients under five years are increased blood pressure, reduced oxygen saturation (a measurement size of the lung function), tachykardie (accelerated heart rate), fever and contactor."</seg>
<seg id="2281">Aldurazyme may not be highly sensitive (allergic) on Laronidase or one of the other components (anaphylactic reaction).</seg>
<seg id="2282">"the European medicines Agency (EMEA) will each year all new information, which may possibly be known, check and update this summary required."</seg>
<seg id="2283">"the manufacturer of Aldurazyme will receive patients, the Aldurazyme, with regard to the reactions to infusion and the development of antibodies."</seg>
<seg id="2284">June 2003 the European Commission welcomed Genzyme Europe B.V. is a licence for the Indurazyme in the entire European Union.</seg>
<seg id="2285">Laronidase is a recombinant form of humane DNA-Iduronidase and is produced by recombinant DNA technology using Cho-mammalian cell division (Chinese Hamster Ovary, Eierstock of the Chinese Hamsters). "</seg>
<seg id="2286">Aldurazyme is for long-term enzymes in patients with secured diagnosis of a Mukopolysaccharid I (MPS I, α -L-Iduronidase deficiency) to treat the non-neurological manifestations of the disease (see Section 5.1). "</seg>
<seg id="2287">"the treatment with Aldurazyme should take place by a doctor, the experience in treating patients with MPS I or other hereditary metabolism."</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can be tolerated when the patient can tolerated this every 15 minutes in single steps to a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">"the safety and effectiveness of Aldurazyme in adults over 65 years has not been determined, and for these patients there cannot be a docking scheme."</seg>
<seg id="2290">"the safety and effectiveness of Aldurazyme in patients with kidney or liver efficiency has not been determined, and for these patients cannot be recommended any docking scheme."</seg>
<seg id="2291">"with Aldurazyme, patients can develop infusion-related reactions which are defined as any in connection with side effects that occurs during infusion or until the end of the infusion day (see section 4.8)."</seg>
<seg id="2292">"for this reason especially these patients should continue to be monitored, and the infusion of Aldurazyme should only be made available in a reasonable clinical environment in the reorganization facilities for medical emergencies."</seg>
<seg id="2293">"due to the clinical phase 3-study, that almost all patients IgG-antibodies against Laronidase are usually formed within 3 months from treatment."</seg>
<seg id="2294">Patients who develop antibodies or symptoms of infusion in reaction must be treated with caution from Aldurazyme with caution (see sections 4.3 and 4.8).</seg>
<seg id="2295">"since little experience regarding the resumption of treatment after a longer break, has to be done due to the theoretical risk of an oversensitivity reaction after the interruption of the treatment."</seg>
<seg id="2296">60 minutes before the start of infusion with medication (antihistaminika and / or antipyretika) to treat the potential occurrence of infusion reactions.</seg>
<seg id="2297">"in case of mild or moderate-related response to the treatment with antihistaminika and Paracetamol / Ibuprofen and / or a reduction of infusion rate to half the infusion rate, where the reaction occurred."</seg>
<seg id="2298">"in case of a single, heavy infusion in response the infusion must be stopped until the symptoms are brought to decline, a treatment with antihistaminika and Paracetamol / Ibuprofen is to awaken."</seg>
<seg id="2299">Infusion can be performed with a reduction of infusion rate on 1 / 2 - 1 / 4 of infusion rate in which the reaction occurred.</seg>
<seg id="2300">"3 (antihistaminika and Paracetamol / Ibuprofen and / or Corticosteroids), as well as a reduction in infusion rate on 1 / 2 - 1 / 4 of infusion rate, where the required reaction occurred."</seg>
<seg id="2301">Aldurazyme should not be applied simultaneously with chloroquin or Procain because a potential risk of interference with intracellular absorption of Laronidase.</seg>
<seg id="2302">"experimental studies do not leave direct or indirect impact on pregnancy, the embryonic / fetal development, birth and postnatal development (see section 5.3)."</seg>
<seg id="2303">"because no data on newborn, which were exposed to Laronidase over the mother's milk, is recommended, is recommended during the treatment with Aldurazyme not to silent."</seg>
<seg id="2304">The side effects in clinical trials were organized mainly as infusion conditional reactions which have been observed at 53% of patients in the phase 3-3 study (treatment duration up to 4 years) and at 35% of patients in the study with participants under the age of 5 (treatment duration up to 1 year).</seg>
<seg id="2305">"unwanted drugs in connection with Aldurazyme, which were observed during phase 3-3 study and its extension for a total of 45 patients aged 5 years or older in a treatment period of up to 4 years, are common (≥ 1 / 100 to &lt; 1 / 10)."</seg>
<seg id="2306">"in some patients with severe MPS-I-conditional involvement of the upper breaths and gaps in the pre-history, moreover, heavy reactions to, including bronchospasmus, respiratory and facial (see section 4.4)."</seg>
<seg id="2307">"children Unleased drug interactions in connection with Aldurazyme, which were reported during a phase 2-study with a total of 20 patients aged under 5 years, with mainly heavy duty shape and a treatment duration up to 12 months, reported are listed in the table."</seg>
<seg id="2308">"100 E / kg intravenous once a week (recommended dose), 200 E / kg intravenous once a week, 200 E / kg intravenous every 2 weeks or 300 E / kg intravenous every 2 weeks."</seg>
<seg id="2309">"in most patients there was a servo version within 3 months following the treatment of a serokonversion, whereby it came to patients aged under 5 years with a heavy bond form (average after 26 days compared to 45 days with patients aged 5 years and older)."</seg>
<seg id="2310">"until the end of the phase 3-study (or up to a premature pull out of the study), at 13 / 45 patients were not found by radioimmunogeal antibodies (RIP) Assay, including 3 patients, where it has never come to serokonversion."</seg>
<seg id="2311">"patients with errors to the lowest antibodies mirror, a robust reduction in the gag mirror in the Harn, while patients with high antibodies to determine a variable reduction of gag in the Harn."</seg>
<seg id="2312">"four patients (three in the phase 3-study and one in Phase 2-study) showed a marginally to small neutral inhibitoric effect on the enzymatic Laronidas- activity in vitro, which seemed to interfere with the clinical effectiveness and / or the reduction of gag in the Harn."</seg>
<seg id="2313">"the presence of antibodies did not seem to stand in connection with the incidence of unwanted drugs, even if the appearance of unwanted drug interactions typically fell together with the formation of IgG-antibodies."</seg>
<seg id="2314">The reasoning for the enzymes is in one for the hydrolyse of the aculate substate and the prevention of another accumulation of adequate growth of enzymes.</seg>
<seg id="2315">"after intravenous infusion, Laronidase is rapidly taken from the cycle and recorded by cells into the Lysosomes, most likely about Mannose-6-phosphorat- receptors."</seg>
<seg id="2316">"the safety and effectiveness of Aldurazyme were examined in a randomised, double blinders, placebocontrolunloaded phase-3-study at 45 patients aged 6 to 43 years."</seg>
<seg id="2317">"although patients were recruited for the study, which showed the entire disease spectrum, was the majority of patients from the middle phenotype and only a patient pointed to the heavy phenotype."</seg>
<seg id="2318">Patients were recruited if they had a forciated volume (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">The primary endpoints for the effectiveness were the percentage change of the expected FEV and the absolute distance in the 6-minute test test.</seg>
<seg id="2320">All patients were subsequently recruited for an open-label extension where they received more 3.5 years (182 weeks) every week 100 E / kg Aldurazyme.</seg>
<seg id="2321">After 26 weeks of therapy the patients were treated with Aldurazyme patients compared to the placebogas an improvement of the lung function and the capacity that is shown in the following table.</seg>
<seg id="2322">"during open renewal study, an improvement and / or maintenance of these effects of up to 208 weeks in the Aldurazyme / Aldurazyme group and from 182 weeks in placebo / Aldurazyme group, as follows from the following table."</seg>
<seg id="2323">The decrease of the expected percentage of the FEV is not significant over this period of time and the absolute lung volumina increased further proportional to the height of growing children.</seg>
<seg id="2324">"from 26 patients with a Hepatomegalie, before treatment reached 22 (85%) to the end of the study a normal live size."</seg>
<seg id="2325">"within the first 4 weeks, a clear drop of the gag mirror was established in the Harn (µg / mg Kreatinin) which remained constant until the end of the study."</seg>
<seg id="2326">"regarding the heterogeneous stretchers between the patients who taken into account by using a combined end point, the clinically significant changes in the 6-minute test, was generally an improvement in 26 patients (58%), no change in 10 patients (22%) and a deterioration at 9 patients (20%)."</seg>
<seg id="2327">"it was carried out a year-year-2 study conducted by Aldurazyme at 20 patients, who were in the study at 5 years old (16 patients with heavy discontinued form and 4 with the middle course form)."</seg>
<seg id="2328">"for four patients, the dosage was increased due to increased GAGM mirror in the Harn in week 22 in the last 26 weeks to 200 E / kg."</seg>
<seg id="2329">"in a number of patients (s = 7) and a weight increase (s = 3) and a weight increase (s = 3) and all 4 patients with the moderate flow of development (&lt; 2,5 years), and all 4 patients with heavy discontinuous shape, while in the older patients with severe slowing form only limited or no progress in the cognitive development were to be determined."</seg>
<seg id="2330">"in a phase 4 study, studies on pharmacodynamic effects of various aldurazyme-Doystschemata were carried out on the gag mirror in the Harn, the Lebervolume and the 6-minute test test were carried out."</seg>
<seg id="2331">"100 E / kg intravenous once a week (recommended dose), 200 E / kg intravenous once a week, 200 E / kg intravenous every 2 weeks or 300 E / kg intravenous every 2 weeks."</seg>
<seg id="2332">"the Doors scheme with 200 E / kg intravenous every 2 weeks can represent in patients whose difficulties with weekly infusions, but is not proven that the long-term clinical effectiveness of these two docking schemata is equivalent."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will evaluate each new information, which will be available annually, and if necessary, the summary of the features of the drug will be updated."</seg>
<seg id="2334">The pharmacocinetic profile in patients aged under 5 years was similar to older and less strongly affected patients.</seg>
<seg id="2335">"based on conventional studies on safety digestology, toxicity in unique gift, toxicity in repeated gift and reproductionists, let preclinical data do not recognise any particular hazards for man."</seg>
<seg id="2336">"because no compatibility studies were carried out, this medicine may not be mixed with other medicines except with the listed below 6.6."</seg>
<seg id="2337">"when the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution under controlled and validated conditions were carried out."</seg>
<seg id="2338">5 ml concentrates for the production of a solution in carrying bag (type - I-glass) with stopover (silicone-rubber) and sealing (aluminium) with sampling (polypropylene).</seg>
<seg id="2339">10 preparation of the Aldurazyme-Infusion (using aseptic technology) • Je after body weight of the individual patients first determine the number of dilution bottles.</seg>
<seg id="2340">"the holder of the approval for the system has to complete the following program programme, whose results will form the basis for the annual review of the benefit risk."</seg>
<seg id="2341">"this register will be treated as long-term safety and active information on patients who have been treated with Aldurazyme, as well as data on the natural proliferation of the disease in patients without this treatment."</seg>
<seg id="2342">"in patients who suffer from MPS I, lies a enzyme called α -L-Iduronidase, the particular substances in the body (glycosaminoglykane), either in low amount before or this enzyme is missing."</seg>
<seg id="2343">If you allergic (excessive) compared to one of the components of Aldurazyme or if you have a severe allergic reaction to Laronidase.</seg>
<seg id="2344">"infusion in response is each side effect, which occurs during infusion or until the end of the infusion day (see section 4") side effects are possible ")."</seg>
<seg id="2345">"for use of Aldurazyme with other medicines. please inform your doctor if you take medicine, which consists of chloroquin or Procain because a potential risk of a diminished effect of Aldurazyme."</seg>
<seg id="2346">"please inform your doctor or pharmacist if you have taken other medicines or have recently taken recently, including not prescription drugs."</seg>
<seg id="2347">Information for handling - dilution and application The concentration at the production of an infusion solution must be diluted before applying and is intended for intravenous application (see information for doctors or medical professional staff).</seg>
<seg id="2348">The initial infusion rate of 2 E / kg / h can be tolerated when the patient is tolerated this every 15 minutes gradually into a maximum dose of 43 E / kg / h.</seg>
<seg id="2349">"in some patients with severe MPS-ion-conditional involvement of the upper breaths and gaps in the history, but heavy reactions to, including bronchospasmus, respiratory and facial."</seg>
<seg id="2350">"very frequently (incidence with more than 1 of 10 patients): • headache • malaches • Yellow, pain, pain, pain, pains • Scraper • Spoking • Reflammers • less oxygen • less oxygen in the blood • reaction to the infusion set."</seg>
<seg id="2351">"the European medicines-Agency (EMEA) will provide any new information, which will be available annually, and if necessary, the packaging connection will be updated."</seg>
<seg id="2352">"when the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution under controlled and validated conditions were carried out."</seg>
<seg id="2353">Preparation of the Aldurazyme-Infusion (using aseptic technology) • Je after body weight of the individual patients first determine the number of dilution bottles.</seg>
<seg id="2354">"Alimta is applied together with Cisplatin (a other medicine against cancer) if cancer is not removed (drugs against cancer), and" maligne "(e.g. surgery alone can not be removed) and" maligne "(by an operation alone can not be removed) and" maligne "non-national" pneumatic cancer, which does not shed the plate of epithelcells. "</seg>
<seg id="2355">"Alimta is not treated with patients who previously had not been treated in combination with cisplatin and in patients who previously received other chemotherapies, as well as for some therapy."</seg>
<seg id="2356">To reduce side effects should be given patients during treatment with Alimta a Corticosteroid as well as folate (an vitamin) and injections of vitamin B12.</seg>
<seg id="2357">"if Alimta is given together with Cisplatin, should be given before or after the gift of cisplatin in addition an" antiemetikum "(medicines for breaking) and liquids (to bow to a liquid lack)."</seg>
<seg id="2358">"in patients whose blood image changes, or when certain other side effects occur, the treatment should be raised up or the dose should be reduced."</seg>
<seg id="2359">The active form of Pemetrexed slows the formation of DNA and RNA and prevent the cells split.</seg>
<seg id="2360">"the transformation of Pemetrexed into its active form goes more easily than in healthy cells, which leads to higher concentrations of the active form of drug using and a longer lasting effect of cancer."</seg>
<seg id="2361">"for the treatment of malicious Pleuramesothelioms, Alimta was examined in a main study of 456 patients, which previously had not received chemotherapy against their disease."</seg>
<seg id="2362">"in treating non-clinical lung cancer, the effects of Alimta have been treated with local advanced or metastatic illness, which previously had been treated with chemotherapy with the effects of docetaxel (another medicine against cancer)."</seg>
<seg id="2363">"Alimta was also compared with gemcitabin (a further medicine against cancer), and both in combination with cisplatin in a study at 1 725 patients who previously had not received chemotherapy for lung cancer."</seg>
<seg id="2364">"patients who have been treated with Alimta and Cisplatin, survived an average of 12.5 months, compared to 9,3 months at the sole administration of Cisplatin."</seg>
<seg id="2365">"in patients who previously had previously received chemotherapy, the average overlife time with Alimta 8,3 months, compared to 7,9 months at Docetaxel."</seg>
<seg id="2366">"in both studies, patients, where cancer is not the plate of epithelcells in which the administration of Alimta longer overlife than with the comparison of comparison."</seg>
<seg id="2367">September 2004 the European Commission entitled Eli Lilly Nederland B.V. is a permit for the Independence of Alimta throughout the European Union.</seg>
<seg id="2368">Any carrying bag must be recorded with 4.7 ml 0.9% sodium-injection solution (9 mg / ml) - which results a solution of 25 mg / ml.</seg>
<seg id="2369">The corresponding volume of the necessary do- SIS is taken from the carrying bag and with 0.9% sodium-injection solution (9 mg / ml) to 100 ml further diluted (see section 6.6).</seg>
<seg id="2370">ALIMTA is in combination with cisplatin displayed to first-line therapy of patients with locally advanced or metastatic non-clamping bronchiziness except for excessive hard-epithelible Histology (see Section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is indicated in the treatment in zinc-line treatment of patients with lo- Kal advanced or metastatic non-defined bronchial cardiology (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² of surface (KOF) is administered as intravenous infusion over a period of 10 minutes on the first day of every 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of cisplatin is 75 mg / m ² KOF as infusion over a period of 2 hours about 30 minutes after completion of the Pemetrexed- Infusion on the first day every 21-day treatment cycle.</seg>
<seg id="2374">In patients with non-related bronchial carcinoma is the recommended dose of ALIMTA 500 mg / m ² KOF is administered as intravenous infusion over a period of 10 minutes on the first day of every 21-day treatment cycle.</seg>
<seg id="2375">"to reduce the frequency and severity of Hauling actions, on the day before and on the day of the Pemetrexed gift, as well as the day after treatment a cortikosteroid."</seg>
<seg id="2376">During the seven days before the first dose of Pemetrexed must be taken at least 5 cans of folonic acid and the intake must continue during the entire treatment period as well as for another 21 days after the last Pemetrexed- dose.</seg>
<seg id="2377">Patients must also receive an intramuscular injection of vitamin B12 (1000 mcg) in the week before the first pemetrexed dose as well as after each third round cycle.</seg>
<seg id="2378">"in patients who received Pemetrexed, should be created before each gift of a complete blood image - the, including a differentiation of the leukozyten and a Thromanzych."</seg>
<seg id="2379">The alkaline Phosphatase (AP), aspartat-transaminase (AST or SGOT) and alanine-transaminase (ALT or SGPT) should be ≤ 3-fold of the upper limit value. "</seg>
<seg id="2380">At the beginning of a new treatment cycle, a Dosisecond will take place under the reckoning of the blood of blood or the maximum not-hmatological toxicity of the previous therapy cycles. "</seg>
<seg id="2381">"after the recovery, patients must be treated according to the instructions in tables 1, 2 and 3, which are used for ALIMTA as Monotherapy or in combination with cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degrees 2 bleeding.</seg>
<seg id="2383">"should patients not develop-hmatological toxicity ≥ grade 3 (except neurotoxicity), the therapy with ALIMTA must be interrupted by the patient the value before the treatment</seg>
<seg id="2384">The treatment with ALIMTA must be canceled when patients after 2 diosistive toxicity or non-hmatological toxicity degree 3 or 4 occurs or so- fort at the appearance of degree 3 or 4 neurotoxicity.</seg>
<seg id="2385">Clinical trials have no indication that in patients aged 65 years - or in comparison to patients aged 65 years an increased by side-effective risk.</seg>
<seg id="2386">ALIZATA is not recommended for use in children under 18 years of age due to non-sufficient data of inconceivable and effectiveness.</seg>
<seg id="2387">"in clinical studies, patients were not necessary for patients with a creatinin Clearance by ≥ 45 ml / min."</seg>
<seg id="2388">The data base for patients with a creatinin Clearance under 45 ml / min was not sufficient; therefore the application is not recommended (see Section 4.4).</seg>
<seg id="2389">"however, patients were examined with a Leberupset player of &gt; the 1.5-fold of the upper leg (with lowering of the upper limit value) or &gt; 5,0-fold of the upper limit value (in the presence of Lebanetastasen), not specifically investigated in the studies."</seg>
<seg id="2390">Patients must be monitored in terms of bone markings and Pemetrexed must not be given to patients before their absolute neutrality number must be given a value of ≥ 1500 cells / mm ³ and the Thrombo- cylinders again reached a value of ≥ 100,000 cells / mm ³.</seg>
<seg id="2391">A dosage reduction for further cycles is based on the Nadir of the absolute neutroids and maximally non-matological toxicity, as they were observed in the previous treatment cycles - (see section 4.2). "</seg>
<seg id="2392">A lesser toxicity and a reduction of degrees 3 / 4 hämatological toxicity such as neutropenie and infection with degree 3 / 4 Neutropenie was captured when a pre-treatment with folate and vitamin B12 had taken place.</seg>
<seg id="2393">"therefore all patients must be instructed with Pemetrexed patients, folate and vitamin B12 as a prophetic measure for reduction-related toxicity (see section 4.2)."</seg>
<seg id="2394">Patients with easy to medium Niereninsufficiency (NSAIDs) as Ibuprofen and Acetylsali- cylsacid (&gt; 1,3 g daily) for at least 2 days before the therapy and mindset - TENS 2 days after treatment with Pemetrexed (see Section 4.5).</seg>
<seg id="2395">"all patients who are provided for therapy with Pemetrexed, take the intake of NSAIDs with a long half-value for at least 5 days before the therapy, on the day of therapy and at least 2 days after the therapy with Pemetrexed (see Section 4.5)."</seg>
<seg id="2396">"many patients, where these events occurred, appropriate risk factors for the appearance of renal events, including dehydration, the existing hypertension or diabetes."</seg>
<seg id="2397">"therefore, in patients with clinically significant fluid liquid collection - collection in the transcellular space a drainage of the Ergonomy in front of the pemetrexed treatment."</seg>
<seg id="2398">"5 serious cardiovascular events, including myokardincolored, and cerebrovascult events were reported in clinical studies with Pemetrexed occasionally, if this drug was usually given in combination with another cytotetoxic drug."</seg>
<seg id="2399">"for this reason, the simultaneous application of attenuated livelihubs (excluding terrain, this vaccine is not recommended (see section 4.3 and 4.5)."</seg>
<seg id="2400">"since the possibility of an irreversible damage caused by Pemetrexed, men should be pointed out before the treatment - ginn to get advice regarding the sperm level."</seg>
<seg id="2401">"in patients with normal kidney function (NSAIDs, such as Ibuprofen &gt; 1600 mg / day) and Acetylsalicylacid in high dosage (≥ 1,3 g daily) to a reduced pemetrexed outlet with the consequence of a more increasing effect of side effects."</seg>
<seg id="2402">"therefore, caution if in patients with normal kidney function (Kreatinin Clearance ≥ 80 ml / min) high doses of NSAIDs or Actutylsalicylacid can be used in high dosage."</seg>
<seg id="2403">"Ibuprofen) or Acetylsalicylacidity in high dosage for at least 2 days before the therapy, on the day of therapy and mindset - TENS 2 days after treatment with Pemetrexed (see section 4.4)."</seg>
<seg id="2404">"there is no data regarding the interaction potential as with NSAIDs with a long half-value, such as Piroxxicam or Rofecoxib, must be avoided at least 5 days before the therapy, on the day of therapy and at least 2 days after treatment with Pemetre- xed."</seg>
<seg id="2405">The large intra-individual variability of the scent status during the disease and the possibility of interactions between oragulagulants and antine chemotherapy requires increased monitoring frequency of INR (International normalities) if the decision was made to treat the patient with oral antioagulants.</seg>
<seg id="2406">"there are no data for the use of Pemetrexed in pregnant, but as with ande- Antimberolites are expected during an application in the pregnancy of heavy birth."</seg>
<seg id="2407">"Pemetrexed must not be used during pregnancy, except if absolutely - requirements and after careful drafting of the user for the mother and the risk for the fetus (see Section 4.4)."</seg>
<seg id="2408">"since the possibility of an irreversible damage to the reproductive ability by Pemetrexed, men should be pointed out before the treatment commences, advice regarding the sperm count."</seg>
<seg id="2409">It is not known whether Pemetrexed goes into the mother's milk and unwanted effects on tortilled infward cannot be excluded.</seg>
<seg id="2410">"the following table shows the frequency and severity unwanted effects that were reported in &gt; 5% of 168 patients with mesotheliom, and the randomized Cisplatin and Pemetrexed - held as well as 163 patients with mesotheliom, the randomized Cisplatin as Monotherapy received."</seg>
<seg id="2411">"side effects related to frequently (≥ 1 / 10, common (≥ 1 / 100 and &lt; 1 / 10), occasionally (≥ 1 / 1,000 and &lt; 1 / 1,000), very rare (&lt; 1 / 10,000), very rare (&lt; 1 / 10.000), and not known (based on the available data of Spontanreporting no longer)."</seg>
<seg id="2412">"* regard to National Cancer Institute CTC version 2 for each toxicity level, * * which were derived from the term" kidneys / Genital. * * * referred to at National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair loss is to be reported as degrees 1 or 2. "</seg>
<seg id="2413">"for this table a threshold of 5% for the recording of all events, where the doctor reported a connection with Pemetrexed and Cisplatin for possible."</seg>
<seg id="2414">"clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported that randomized Cisplatin and pemetrexed received, embraced arrhythmic and motoric Neuropathy."</seg>
<seg id="2415">"the following table shows the frequency and severity unwanted effects that were reported by &gt; 5% of 265 patients, the randomized Pemetrexed as monotherapy with gifts from folds and vitamin B12 as well as 276 patients who have randomized docetaxel as monotherapy."</seg>
<seg id="2416">* Cover to National Cancer Institute CTC version 2 for each toxicity level. * * relative to National Cancer Institute CTC (v2.0; NCI 1998) is meant to be hair loss only as degrees 1 or 2.</seg>
<seg id="2417">"for this table a threshold of 5% for the recording of all events, where the doctor reported a connection with Pemetrexed for possible."</seg>
<seg id="2418">"clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported, the randomized Pemetrexed received, included supraventricular arrhythmics."</seg>
<seg id="2419">The clinical-relevant laboratory toxicity degree 3 and 4 was compared with the bordered results of three single Pemetrexed-Monotherm (12.5% compared with 5,3%) and an increase in Alanintransase (15.2% compared to 1.9%).</seg>
<seg id="2420">These sub-differences are likely to lead to differences in patient's population as the Pha- se 2 trials both chemonaive as well as clearly pre-treated breast cancer patients with existing Lebleases and / or abnordic output values of the liver functional tests.</seg>
<seg id="2421">"the following table shows the frequency and severity of unwanted effects, which could be reported in connection with the study media; they were received by &gt; 5% of 839 Patients and Pemetrexed, and 830 patients with NSCLC, which were randomized Cisplatin and gemcitabin."</seg>
<seg id="2422">"11 * P-Values &lt; 0,05 comparison of Pemetrexed / Cisplatin, using the" Fisher exactly test ". * * * relative to National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair loss only be reported as degrees 1 or 2."</seg>
<seg id="2423">"for this table, the doctor received a connection with Pemetrexed and Cisplatin for possible, a threshold of 5%."</seg>
<seg id="2424">"clinically relevant toxicity, which were reported to ≥ 1% and ≤ 5% (often) the patients were reported that randomized Cisplatin and pemetrexed, included:"</seg>
<seg id="2425">"clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported that ranised Cisplatin and pemetrexed, included:"</seg>
<seg id="2426">"serious cardiovascular events, including myokardincolored events, including myokardincolored, Angina pectoris, is usually given in combination with another cytotetrexed, which is usually reported in combination with another cytotetoxic drug."</seg>
<seg id="2427">"clinical trials were reported in patients with Pemetrexed treatment occasionally cases of coli- tis (including intestinal and rektal bleeding, sometimes fatal pertory, intestinal perfoal, intestinal Nekrose and Typhlitis)."</seg>
<seg id="2428">From clinical trials were reported in patients with Pemetrexed treatment occasionally cases of sometimes fatal interstitiary pneumatics with respiratory efficiency.</seg>
<seg id="2429">It was reported about cases of akutor kidney failure at Pemetrexed Monotherapy or in combination with other chemotherapeutics (see section 4.4).</seg>
<seg id="2430">They were reported in cases of radiation pneumonia in patients before during or after their pemetrexed therapy (see section 4.4).</seg>
<seg id="2431">ALIMTA (Pemetrexed) is a antine-sculptural antifolate that interrupting its effect by interdependency-dependent metabolic metabolic processes that are necessary for cell replication.</seg>
<seg id="2432">In vitro studies demonstrated that Pemetrexed showed that Pemetrexed as an antifolate with several attacks (DHFR) and Glycinamidribonucleotidforase (GARFT) blocks the folatdependent key enzymes of the de Novo Biosynthesis of Thymidin- and Purinnucleotids are.</seg>
<seg id="2433">"EMPHACIS, a multicentric, randomized phase 3 study of ALITY plus Cisplatin treated patients with malignant Pleuramesotheliom showed that with ALITY and Cisplatin treated patients with malignant Pleuramesotheliom showed that patients had gained a clinically significant advantage over such patients who were only fed with cisplatin."</seg>
<seg id="2434">"primary analysis of this study was made in the population of all patients, which were received in the treatment of treatment (randomized and treated)."</seg>
<seg id="2435">A statistically significant improvement of the clinically relevant symptoms (pain and Dyspnoe) in connection with the malignen Pleuramesotheliom was shown at the use of the Lunar Pleuramesotheliom during the application of the Lunches / Cisplatin-arm (212 patients) compared to the sole cispla- tin-arm (218 patients).</seg>
<seg id="2436">The differences between the two treatments are elaborated by an improvement of the pulmonial parameters in the ALIMTA / Cisplatin-arm and a deceltimidation of the lung function in the course of time in controllarm.</seg>
<seg id="2437">"a multicentric, randomized, open phase III study with ALIMTA at patients with local advanced or metastatic NSCLC after previous chemotherapy patients (Intent to treat Population n = 283) and from 7,9 months at with docetaxel treated patients (ITT n = 288)."</seg>
<seg id="2438">"an analysis of the influence of Histology on the treatment effect fell to favor of ALIZA483 to 0,0; 95% CI = 0.61-1,00 p = 0.047), adapted HR = 0.56; 95% CI = 1,08-2.26, p = 0.018)."</seg>
<seg id="2439">"limited data of a separately randomised, controlled phase 3 study show that active data (survival and progressing free survival) for Pemetrexed between patients with (n = 41) and without (n = 540) pre-treatment by docetaxel are similar."</seg>
<seg id="2440">The efficacy analyses of the PQ Population are consistent with the analyses of the ITT Population and assist the non-basement of the ALIMTA Cisplatin combination compared to the gemcitabin cisplatin combination.</seg>
<seg id="2441">"middle PFS was 4,8 months for the combination ALI15TA Cisplatin compared to 5.6% (95% CI = 0.94 - 1,15), the overall appealing rate amounted to 28.2% (95% CI = 25,0 - 31,4) for the combination of gemcitabin Cisplatin."</seg>
<seg id="2442">The analysis of the influence of the NSCLC Histology on the survival showed clinically relevant subdifferences according to Histology, see below table. "</seg>
<seg id="2443">CI = Confidenzinterval; N = size of the total population a statistically. for non-basement (= Hazard ratio) clearly below the non-basement level of 1,17645 (p &lt; 0,001).</seg>
<seg id="2444">"patients who have been treated with ALIMTA and Cisplatin, needed less transfusions (16.4% versus 28,9%, p &lt; 0,001) and Thrombozytamperes (1.8%, p &lt; 0,001), p = 0,002)."</seg>
<seg id="2445">"in addition, the patients needed the gift of Erythropoetin / Darbopoetin (10,4% versus 18.1%, p &lt; 0,001), G-CSF (4.0%, p = 0,004), and Iron Swap (4,3%, p = 0.021)."</seg>
<seg id="2446">The pharmacocinetic characteristics of Pemetrexed to gift as Monotherapeutics have been examined with 426 cancer patients with different solid tumors in doses from 0,2 to 838 mg / m ² in infusion - over a period of 10 minutes.</seg>
<seg id="2447">Pemetrexed is mainly retired in urine and 70% to 90% of the agreed dose will be re-found within 24 hours following the application unchanged in urine.</seg>
<seg id="2448">Pemetrexed has a total height of 91.8 ml / min and the half-time in plasma is 3.5 hours in patients with normal Nierenfunnel (Kreatinin Clearance 90 ml / min).</seg>
<seg id="2449">"in a study with Beagle-dogs, which had received for 9 months intravenous Bolus injections / Nekrose of the seminiferen epithelbebes)."</seg>
<seg id="2450">"unless required, the storage times and conditions after preparation in the responsibility of the user and should usually not be overwritten 24 hours at 2 to 8 ° C, unless the preparation / dilution has taken place under controlled and validated conditions."</seg>
<seg id="2451">Solve the content of the 100 mg tubes with 4.7% of sodium inchloride (9 mg / ml) without preservatives in this results a solution with a concentration of about 25 mg / ml Pemetrexed.</seg>
<seg id="2452">The preset solution is clear and the coloring ranges from colourless to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2453">Any carrying bag must be recorded with 20 ml 0.9% sodium-injection solution (9 mg / ml) - a solution of 25 mg / ml results.</seg>
<seg id="2454">"23 serious cardio events, including myokardincolored, and cerebrovascult events were reported in clinical studies with Pemetrexed occasionally, if this drug was usually given in combination with another cytotetoxic drug."</seg>
<seg id="2455">"* regard to National Cancer Institute CTC version 2 for each toxicity level, * * which were derived from the term" kidneys / Genital. * * * referred to at National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair loss is to be reported only as degrees 1 or 2. "</seg>
<seg id="2456">"for this table - de a threshold of 5% specified for the recording of all events, where the correct doctor requires a connection with Pemetrexed and Cisplatin for possible."</seg>
<seg id="2457">* Cover to National Cancer Institute CTC version 2 for each toxicity level. * * relative to National Cancer Institute CTC (v2.0; NCI 1998) is meant to be hair loss only as degrees 1 or 2.</seg>
<seg id="2458">29 * P-Values &lt; 0,05 comparison of Pemetrexed / Cisplatin and gemcitabine / cisplatin, using the "Fisher exactly test". * * * relative to National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair loss occurs only as degrees 1 or 2. "</seg>
<seg id="2459">"clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported that ranised Cisplatin and pemetrexed, included:"</seg>
<seg id="2460">"an analysis of the influence of the Histology on the treatment effects fell to favor of ALITY for patients with NSCLC (s = 172, 6.9% CI = 0.61-1,00 p = 0.56; 95% CI = 1,08-2.26, p = 0.018)."</seg>
<seg id="2461">Solve the content of the 500 mg tubes with 20 ml 0.9% reduction in sodium (9 mg / ml) without preservatives in this results a solution with a concentration of about 25 mg / ml Pemetrexed.</seg>
<seg id="2462">The preset solution is clear and the dyeing ranges from colourless to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2463">"Pharmacovigilance System The holder of permission for the Inleigh has been concerned that the pharmaceutical inkovigilance system, as described in version 2.0 contain in Module 1.8.1. permission for the incoming data is ready and when the product is placed in the market, and while the product is located in the market."</seg>
<seg id="2464">"risk management plan the owner of the approval for the contract are committed to the studies and the pharmaceuticals activities according to Pharmacovigilance plan, as agreed in the version 1.2 of the Risk Management Plan (RMP), presented to modules 1.8.2nd of approval for the Internet and all the following updates of the RMP, which have been agreed by CHMP."</seg>
<seg id="2465">"according to" CHMP guideline on Risk Management Systems for Medicinal products for human use "needs to be filed with the next" Periodic Safety Update Report "(PSUR)."</seg>
<seg id="2466">"in addition, a recent review must be submitted • If new information is available, which could have an effect on the current security specifications, the Pharmacovigilance plan or risk minimization) milestones • On request by the EMEA"</seg>
<seg id="2467">"ALIMTA 100 mg of powder for the production of a fuges for the production of an infusionist, ALIMTA 500 mg of powder for the production of a fuges."</seg>
<seg id="2468">"ALIMTA will have received no previous chemotherapy in patients who have not received prior chemotherapy (malicious disease of the Rippenfells) in combination with cisplatin, a different medicine for treating cancers."</seg>
<seg id="2469">"if you have suffered a kidney or earlier, please discuss this with your doctor or hospital purposes, as you may not receive ALITY."</seg>
<seg id="2470">"when you are carried out before every infusion of blood tests, there will be checked whether your kidney and liver function is sufficient and whether you have enough blood cells to receive ALIMTA."</seg>
<seg id="2471">Your doctor may change the dose or break the treatment unless it requires your general state and if your blood values are too low.</seg>
<seg id="2472">"if you also receive Cisplatin, your doctor will ensure that your body contains sufficient water and you get the noteering medicine to avoid leaving before and after the cisplatin gift."</seg>
<seg id="2473">"if you are a liquid collection around the lungs, your doctor can decision - to eliminate these fluid before you get ALITY."</seg>
<seg id="2474">"if you would like to receive a child during the treatment or during the first 6 months after the treatment, please contact your doctor or pharmacist."</seg>
<seg id="2475">"interactions with other medicines. please tell your doctor if you are medicine against pain or inflammation (swellun-) such as such medicines, the" non-steroidale antiphlogistika "(NSAIDs), including medicines that are not prescription-subject (such as Ibuprofen)."</seg>
<seg id="2476">"depending on the planned daimum of your ALIMTA infusion and / or the extent of your kidney function, your doctor will tell you which other medicines you can take, and when."</seg>
<seg id="2477">"please inform your doctor or pharmacist if you have taken other medicines or have recently taken, even if it does not prescription pharmaceuticals."</seg>
<seg id="2478">A nurturing the patient care or a doctor will mix the ALIMTA powder with sterile 0.9% sodium-injection solution (9 mg / ml) before it is applied to you.</seg>
<seg id="2479">Your doctor will prescribe you Kortison tablets (according to 4 mg Dexametha- son two times daily) that you have to take on the day during and on the day after the application of ALIMTA.</seg>
<seg id="2480">"your doctor will include the folate (a vitamin) for disposable or multivitamins, the folate acid included (350 to 1000 micrograms), which you have to take place every day during the application of ALIMTA."</seg>
<seg id="2481">"during the week before the application of ALIMTA and about every 9 weeks (according to 3 cycles of treatment with ALIMTA), you will also receive an injection of Vi- tamin B12 (1000 mcg)."</seg>
<seg id="2482">"is described in this second-term information as" very often "," this means that it was reported by at least 1 of 10 patients. "</seg>
<seg id="2483">"is described by a side effect as" "frequently", "this means that they reported from at least 1 of 100 patients but was reported less than 1 of 10 patients."</seg>
<seg id="2484">"this is described by a side effect as" "occasionally," indicates that they were reported by at least 1 of 1,000 but less than 1 of 100 patients - it implies that they reported from at least 1 of 10,000 but less than 1 of 1,000 patients. "</seg>
<seg id="2485">"fever or infection (frequently): if you have a body temperature of 38 ° C or above, sweat or other signs of an infection (because you might have less white blood cells than normal, which is very common)."</seg>
<seg id="2486">"if you feel tired or weak, swiftly get into respiratory or blass (because you might have less hemoglobin as normal, what is very common)."</seg>
<seg id="2487">"if you find a bluepic of the tooth, the nose or mouth or a different bloodation, which does not come to standstill, or an redly or rosafarisen Urin or un- expected hypertension (because you might have less blood vessels than normal, which is very common)."</seg>
<seg id="2488">"occasionally (occurs at least 1 of 1,000 patients) but less than 1 of 100 patients) increased pulse rate Colitis (inflammation of the inner cladding of colon) interstitielle pneumonitis (verification of water into the body tissues, which leads to swellings)."</seg>
<seg id="2489">"rarely (occurs with more than 1 of 10,000 patients), but less than 1 of 1,000 patients)" radiation Recall "(a rash similar to a heavy sunburn), appearance on the skin, which was previously exposed (a few days to years) of a radiotherapy."</seg>
<seg id="2490">"occasionally, in patients, the ALIMTA, usually joined in combination with other cancers, received a stroke or stroke with low damage."</seg>
<seg id="2491">"in patients, prior to, during or after their ALIMTA treatment can also obtain an radiation treatment, one can occur through radiation caused inflammation of the lung infection (narcation of the lung treatment in connection) occur."</seg>
<seg id="2492">52 Informing your doctor or pharmacist if one of the listed side effects you upliftingly impaired or if you notice side effects that are not led in this package.</seg>
<seg id="2493">"as prescribed prescribed, the chemical and physical stability of the dilution and the infusion solution in the fridge or at 25 ° C for a period of 24 hours been proven."</seg>
<seg id="2494">Tél / Tel: + 32- (0) 2 548 84 84 Бълакикикикикикикикикикикикикикикикикикикикикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикетикикети</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S TLF: + 45 45 26 6100 Eesti Eli Lilly Holly Limited Eesti filiaal Tel: + 3726441100 02 Eesti filiaal Tel: + 3726</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) 1 661 4377 Adsland Icepharma HF.</seg>
<seg id="2497">Tel: + 39- 055 42571 Fabulous? + 357 22 715000 Latviziva Eli Lilly Holyuva Eli Lilly Holdings Limited atstovyb37 Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 România S.R.L. "</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland From Tel: + 46- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Solve the content of the 100 mg tubes with 4.7% of sodium inchloride (9 mg / ml) without preservative solution (9 mg / ml) without preservatives of about 25 mg / ml Pemetrexed.</seg>
<seg id="2501">Solve the content of the 500 mg tubes with 20 ml 0.9% reduction in sodium (9 mg / ml) without preservatives of about 25 mg / ml Pemetrexed.</seg>
<seg id="2502">The preset solution is clear and the coloring ranges from colourless to yellow or green yellow without the progression of the quality.</seg>
<seg id="2503">"it will be used in overweight adults with a body-massdex (Body Mass Index - BMI) of ≥ 28 kg per square meter in combination with a calorie, fatty food."</seg>
<seg id="2504">Patients who take care of Alli and are unable to draw weight after 12 weeks should turn to their physician or pharmacist.</seg>
<seg id="2505">"these enzymes are hated, they can not reduce some fats in food, which happens about a quarter of the nourishment with the food admittedly the intestine."</seg>
<seg id="2506">"in a third study, Alli was compared to 391 overweight patients with an BMI between 25 and 28 kg / m2 with placebo."</seg>
<seg id="2507">"in the two studies of patients with an BMI of ≥ 28 kg / m2 patients, the Alli 60 mg received, after one year an average weight loss of 4.8 kg, compared to 2.3 kg at intake of placebo."</seg>
<seg id="2508">"in the study with Alli in patients with an BMI between 25 and 28 kg / m2 no longer could be observed for patients most relevant weight loss."</seg>
<seg id="2509">"the most common side effects of Alli (observed in more than 1 of 10 patients) are ölige Flags on after, Flatus (Winds) with Stuhldings, fetus / östy chair, Flatbrisk (winch), Flatlock (Winde) and soft chairs."</seg>
<seg id="2510">It must not be used in patients who are treated with Ciclosporin (to prevent the organ transducers in transplantation) or with medicines such as warfarin to prevent blood vessels.</seg>
<seg id="2511">"it may not be applied to patients who are absorbed at a long-term Malabsorpency syndrome (in which not enough nutrients from the digestive tract), or to cholestase (a liver disease), and in pregnant or for breastfeeding mothers."</seg>
<seg id="2512">"July 2007, the European Commission granted the company Glaxo Group limited approval for the transactions of Orlistat GSK in the entire European Union."</seg>
<seg id="2513">Alli is required for weight reduction of adults with overweight (body-Mass BMI ≥ 28 kg / m2) and should be used in conjunction with a slightly hypokaline and fatty diet.</seg>
<seg id="2514">"alli may not be applied to children and young people under 18, because not enough data on the effectiveness and safety."</seg>
<seg id="2515">"however, Orlistat is only minimal resorated, is necessary in elderly and patients with reduced liver and / or kidney function."</seg>
<seg id="2516">• Oversensitivity against the active ingredients or one of the other components • Equal Treatment Syndrome • cholestase • pregnancy (see Section 4.6) • Extensive treatment with warning in or other oralen antioagulants (see sections 4.5 and 4.8)</seg>
<seg id="2517">The likelihood of the advent of gastrointestinal symptoms (see section 4.8) can increase when alli is taken together with a fat-period or fettricher diet.</seg>
<seg id="2518">"as the weight reduction in diabetes can be obtained with improved metabolic control, patients who consult a medicine against diabetes, before the beginning of a therapy with alli a doctor or pharmacist, because the dosage of antidiabetics must be adapted."</seg>
<seg id="2519">Patients who take alli as well as medicines for blood pressure or an increased cholesterol levels or a increased cholesterol levels should consult their doctor or pharmacists whether the dosage of this medicine must be adjusted.</seg>
<seg id="2520">"it is recommended to meet additional fluctuating measures in order to bow to the case of severe Diarrhö possible versus the oral contrasting contraception (see Section 4.5)."</seg>
<seg id="2521">Both in a study on interactions of drugs as well as in several cases with simultaneous application of orlistat and Ciclosporin was observed an absening of Cicing porin plasma cutting.</seg>
<seg id="2522">"when applying Warfarin or other oralen antioagulants in combination with Orlistat could be influenced by Quick values (internationally normalities, INR) (see section 4.8)."</seg>
<seg id="2523">"in most patients who have been treated in clinical studies up to 4 full years with orlistat, the concentrations of vitamins A, D, E and K and the beta carotins in the standardisation area."</seg>
<seg id="2524">"however, the patients should be recommended before bedtime a supplement of the multivitamin supplement to ensure sufficient vitality intake (see section 4.4)."</seg>
<seg id="2525">"after the gift of a single painting Amiodaron was observed in a limited number of volunteers, which at the same time received Orlistat, a slight decrease of Amiodaron-plasma science."</seg>
<seg id="2526">"experimental studies showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see section 5.3)."</seg>
<seg id="2527">The side effects of orlistat are mainly hospitable nature and hang together with the pharmacological effect of drug by means of preventing the absorption of infiltrated fat.</seg>
<seg id="2528">The gastrointestinal side effects were obtained from clinical trials with orlistat 60 mg over a duration of 18 months to 2 years and were generally light and temporary.</seg>
<seg id="2529">"the skins are defined as follows: very often (≥ 1 / 100, &lt; 1 / 10), occasionally (≥ 1 / 1,000, &lt; 1 / 100), rarely (≥ 1 / 1,000), and very rare (&lt; 1 / 10,000), not known (frequency on the basis of the available data is not removable)."</seg>
<seg id="2530">"the frequency of which adverse side effects were determined according to the market launch of Orlistat, is not known because these events were voluntarily reported from a population of a certain size."</seg>
<seg id="2531">+ It is plausible that treatment with alli can lead to infancy in terms of possible or actual gastrointestinal side effects.</seg>
<seg id="2532">"individual doses of 800 mg of Orlistat and multiple sclerosis from up to 400 mg three times daily were given over a period of 15 days to normalgeimportant and overweight probanden, without the significant clinical trials."</seg>
<seg id="2533">With the majority of reported cases reported in the market reported cases of orlistat-overdozation have either been reported to any side effects or similar side effects such as the recommended dose of orlistat.</seg>
<seg id="2534">"based on investigations on people and animals can be attributed by a rapid reformation of systemic effects, which can be attributed to the liabilities of the orlistat."</seg>
<seg id="2535">The therapeutic effect continues in the lumens of the stomach and the upper thin-intestine by kovalente to the active serin-rest of gastric and pancreatic Lipasen.</seg>
<seg id="2536">"clinical trials was derived from clinical trials that 60 mg of Orlistat, three times taken daily, the absorption of about 25% of food is blocked."</seg>
<seg id="2537">"two double blind, randomized-placeable studies of adults with an BMI ≥ 28 kg / m2 occupy the effectiveness of 60 mg of Orlistat, which was taken three times daily in combination with a hypokaline, fatty food."</seg>
<seg id="2538">"primary parameters, the change of body weight compared to the output value (at the time of Randomization), has been rated as follows: as a change in the course of course (table 1) and as a share of the study participants who have lost over 5% or more than 10% of their output weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction has been observed over 12 months, the biggest weight loss occurred in the first 6 months."</seg>
<seg id="2540">The average change in the overall cholesterol was with orlistat 60 mg -2.4% (starting 5.6 mmol / l) and with placebo + 2.8% (output worth 5.4 mmol / l).</seg>
<seg id="2541">The average change of the LDL cholesterol was equivalent to Orlistat 60 mg -3.5% (starting value 3.30 mmol / l) and with placebo + 3.2% (output value 3.41 mmol / l).</seg>
<seg id="2542">The average modification was the average change -4,5 cm with orlistat 60 mg (starting 103.7 cm) and with placebo -3.6 cm (value value 103.5 cm).</seg>
<seg id="2543">Plasma concentration of not metabolized orlistat were 8 hours after the oral gift of 360 mg of orlistat no measurable (&lt; 5 ng / ml).</seg>
<seg id="2544">7 In general in therapeutic dosages not metabolized orlistat in Plasma only sporadically and extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without a sign of a cumulation.</seg>
<seg id="2545">"in a study with adipous patients, which was given minimal systemically resorbious dose, namely M1 (in position 4 hydrolyielded Lactonring) and M3 (M1 according to Absplitting the N-Formyl-Leucin-Gruppe), the approximate 42% of the total plasonentriation."</seg>
<seg id="2546">"based on conventional studies on safety digestology, toxicity, toxicity, genotoxicity, Canadian potential and reproductionsxicity, the preclinical data can be seen no particular risk for man."</seg>
<seg id="2547">"Pharmacovigilance System The holder of permission for the Intranet must ensure that the Pharmacovigilance system is described in accordance with the release of July 2007, as described in Module 1.8.1. the authorisation procedure is applied and works, before and while the product is available on the market."</seg>
<seg id="2548">"risk management planning the owner of the approval for the contract, the studies and additional Pharmacovigilance activities are described as in the Pharmacovigilance plan (RMP) of October 2008 to comply with the Committee of the RMPs, which will be agreed with the Committee on Human Rights (CHMP)."</seg>
<seg id="2549">"according to the CHMP guidelines on risk management systems, the updated RMP must be submitted to the next PSUR (Periodic Safety Update Report)."</seg>
<seg id="2550">"furthermore, a recent review should be submitted: • if new information is available, the current security policies, the Pharmacovigilance plan or risk management, • within 60 days of an important, Pharmacovigilance or risk management, on request of the European drug agency (EMEA)"</seg>
<seg id="2551">"12 PSURs The holder of permission for the incoming decision will submit all 6 months after the Commission decision to submit all 6 months, then for two years and then every three years."</seg>
<seg id="2552">"not use, • if you are under 18, • if you are pregnant or breastfeeding, • if you are suffering in or other blood dilution, • if you suffer from cholestnut, or any other blood dilution, • if you have problems connected to orlistase (disease the liver, when you have problems with the food intake, if you have problems with the food intake (chronic painting)."</seg>
<seg id="2553">"take three times a day with each main mahlp, the fat contains, a capsule with water. • If you should take a day once every day, before bedtime, a multivitamintet (with the vitamins A, D, E and K). • They should not apply for longer than 6 months."</seg>
<seg id="2554">"application: • take three times a day with each main mahltime the fat contains, a capsule with water. • If you should take a day once every day, before bedtime a multivitamintet (with the vitamins A, D, E and K). • They should not apply for longer than 6 months."</seg>
<seg id="2555">Perhaps you would like to read this later again. • If you need more information or a pharmacist if you need further information or a advice. • If you have any further information or a advice if you have any weight loss or a pharmacist for advice.</seg>
<seg id="2556">"possibly you must end the intake of alli. • If one of the listed side effects you may not impairs or you notice effects that are not indicated in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2557">What do you need to be considered before the intake of alli? • allergic should not be used • If ingesting of alli is required • At intake of alli with food and beverages • pregnancy and lactation • transport and operation of machines 3.</seg>
<seg id="2558">How is allergii to assume? • How can you prepare your weight target? o Select your start-time span &gt; How long should I take your account? o adults from 18 years o How long should I take you? o If you have taken alli in too big quantities o If you have forgotten the intake of alli 4.</seg>
<seg id="2559">Which side effects are possible? • serious side effects • Very common side effects • Frequent side effects • impact on blood tests • How can you control nutritional services?</seg>
<seg id="2560">Further information • What alli contains • How it looks and contents of the package • pharmaceutical companies and manufacturers • Further helpful information</seg>
<seg id="2561">Alli serves weight reduction and is used for overweight adults from 18 years with a body mass index (BMI) of 28 or above. alli should be used in conjunction with a fat and calorie diet.</seg>
<seg id="2562">BMI helps to determine whether you have a normal weight in relation to your body size or overweight.</seg>
<seg id="2563">"even though these disorders are initially not able to make you feel uncomfortable, you should nevertheless ask your doctor for an inspection examination."</seg>
<seg id="2564">"for each 2 kg body weight, you can lose within the frame of a diet, you can lose with the help of allergii an additional kilograms."</seg>
<seg id="2565">"please inform your doctor or pharmacist, if you have other medicines or have been recently taken, even if it is not prescription medicine."</seg>
<seg id="2566">Ciclosporin is used according to organ transplants, with severe rheumatoid arthritis and certain severe skin diseases. • Warfarin or other medicines that have a blood thinner effect. "</seg>
<seg id="2567">Orale contraception and alli • The effect of oral calls for tribal prevention (pill) is caused by circumstances weakened or eliminated if you have strong diarrhö (fall).</seg>
<seg id="2568">Please contact your doctor or pharmacist if you use: • Amiodaron for the treatment of cardiac arrhythmia. • Aesthetic used to treat diabetes.</seg>
<seg id="2569">"ask your doctor or pharmacist if you take alli, and if you take medicine against blood pressure since possibly the dosage must be adapted to a high cholesterol levels, since possibly the dosage must be adjusted."</seg>
<seg id="2570">How to define your calorie goals and fetal limits you can find out more about the blue pages in section 6.</seg>
<seg id="2571">"if you leave a meal or contains a meal no fat, take no capsule. allergii can only work when the food contains fat."</seg>
<seg id="2572">"if you take the capsule in connection with a meal that contains too much fat, risky you risk nutritional supplements (see Section 4)."</seg>
<seg id="2573">To get used your body to the new food habits that you already start before the first Kapselections with a calorie and fatty diet.</seg>
<seg id="2574">"nutritional books are effective, as you can comprehend up whatever you eat, how much you eat and it will probably be easier to change your dietary habits."</seg>
<seg id="2575">"to achieve your target weight, you should set two daily goals in advance: one for calories and one for fat."</seg>
<seg id="2576">"• nourish you fatty, to reduce the likelihood for nutritional services (see Section 4). • If you want to move more before you start with taking the capsules."</seg>
<seg id="2577">Remember to ask your doctor if you are not used physical activity. • If you take during intake and after termination of the intake of alli physically active.</seg>
<seg id="2578">• Ei may not be taken longer than 6 months. • If you can determine no reduction of your weight for twelve weeks of application please ask your doctor or pharmacist for advice.</seg>
<seg id="2579">"under certain circumstances, you must end the intake of alli. • With a successful weight loss, it is not about to return the diet and return to the old habits again."</seg>
<seg id="2580">"• If less than an hour passed since the last meal, take the intake of capsule to. • If more than one hour had passed since the last meal, do not take a capsule."</seg>
<seg id="2581">Flowering with and without öligaments, sudden or more busy Stuhldings and softer chair) are attributed to the vorkmechanism (see Section 1). "</seg>
<seg id="2582">"severe allergic reactions • severity allergic reactions identify you to the following changes: heavy breaths, welders, welders, swelling, swelling, swelling, rotary interruption."</seg>
<seg id="2583">"29 Very common side effects These can occur in more than 1 of 10 people, the alli, occur. • Blutations (flatulence) with and without ölign • sudden stool • fetal chair • giving your doctor or pharmacist if one of these side effects will be strengthened or considerably impaired."</seg>
<seg id="2584">"frequent side effects These can occur at 1 of 10 people, the alli, occur. • Mag- (pan-) pain, • incontinence • Beotations • Beotations • Beotations • Beotations, if one of these side effects will be strengthened or considerably impaired."</seg>
<seg id="2585">Effects on blood tests It is not known as often these effects occur. • increasing of specific Leberenzymvalues • effects on blood circulation in patients who take in or other blood thinner (antikoagulating) drugs.</seg>
<seg id="2586">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2587">The most common side effects hang together with the efficacy of the capsules and thus arise that more fat is eliminated from the body.</seg>
<seg id="2588">These side effects usually occur inside the first few weeks after treatment starts since you might not have reduced the fat content in the diet or perhaps not consistently reduced.</seg>
<seg id="2589">"with the following basic rules, you can learn to minimize the nutritional conditionaries: • You already have a few days, or better a week before the first intake of capsules with a fatty food. • learn more about the usual fat content of your favorite dine, and about the size of portions that you usually take."</seg>
<seg id="2590">"if you know exactly how much you eat, sinks the likelihood that you out of seeing your fat is evenly to the daily meals."</seg>
<seg id="2591">"save the amount of calories and fat that you may take per meal, not to take them in the form of an obese story or a secret offense. • Most men can occur in other programs for weight reduction, learning this with time due to customization of their diet."</seg>
<seg id="2592">• pharmaceuticals for children unaccessible. • You may not apply any more than 25 ° C in order to protect the content before humidity. • The bottle contains two white sealed tanks with Silicagel which serve to keep the capsules dry.</seg>
<seg id="2593">Swallow this in no case. • You can guide your daily dose alli in the blue transport box (Shuttle) with you that lies in this package.</seg>
<seg id="2594">"Famar, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom</seg>
<seg id="2595">Overweight has influence on your health and increases the risk for the emergence of various severity diseases • diabetes • Diabetes</seg>
<seg id="2596">"a permanent weight removal, for example by improving the nutrition and more movement, can prevention of serious diseases and has a positive impact on your health."</seg>
<seg id="2597">"select meals, which contain a wide range of nutrients, and learn to nourish yourself permanently."</seg>
<seg id="2598">"energy is also measured in kilojoule, which also gives you as indication of the packaging of foods. • The recommended calorie intake provides how many calories you should take maximum per day."</seg>
<seg id="2599">Notice the table below in this section below. • The recommended fat intake in gramms is the maximum amount of fat that you should take with every meal.</seg>
<seg id="2600">"which amount for you is suitable, refer to the information below to find the number of calories that is suitable for you. • The background of the effect of the capsule is decisive in compliance with the recommended obesity."</seg>
<seg id="2601">"if you take the same amount of fat to feel like so far, this means your body cannot process this amount of fat."</seg>
<seg id="2602">"by adherence to the recommended fat, you can maximize the weight adjustment and at the same time reduce the likelihood for nutritional conditionaries. • You should try to step gradual and continuously."</seg>
<seg id="2603">"34 These reduced calorie intake, it should allow you to gradually lose weight and continuously lose weight about 0.5 kg per week without frustrations and disappointments."</seg>
<seg id="2604">"the more active you are, the higher your recommended calorie activity" means that you can burn every day only little or not to walk stairs, e.g. through motion daily 150 kcal, e.g. through 3 km of walking, 30- to 45-minute garden work or 2 km walk in 15 minutes. "</seg>
<seg id="2605">• For a permanent weight removal it is necessary to set up realistic calorie and lipossessions. • logical is a nutritional book with information on calorie and lipossessions of your meals. • If you're looking for yourself to move more before you begin using the intake of alli.</seg>
<seg id="2606">"the alli programme for supporting weight switching combines the capsules with a dietary plan and a large number of additional information materials, which can help you to be calorie and fatty and give guidelines to be physically active."</seg>
<seg id="2607">"in connection with a tailored program to support the weight output, this information can help you develop a healthier lifestyle and to achieve your target weight."</seg>
<seg id="2608">Aloxi is applied to chemotherapy that are strong peers for nausea and vomiting are (like Cisplatin) as well as for chemotherapy that are graciers for nausea and omiting are (like cyclophosphamide, Doxorubicin or Carboplatin). "</seg>
<seg id="2609">The effectiveness of Aloxi can be enhanced by the additional gift of a Corticosteroids (a medicine that can be used as antiemeticum).</seg>
<seg id="2610">The use of patients under 18 years of age is not recommended because to the effects in this age group does not exist enough information.</seg>
<seg id="2611">"this means that the drug use a chemical substance in the body, 5-Hydroxytryptamin (5HT, also known as serotonin), to the receptors in Darm."</seg>
<seg id="2612">Aloxi was studied in three main studies at 1 842 adults who received chemotherapies which are strong or excessive trigger for nausea and breaking.</seg>
<seg id="2613">"for chemotherapy that have been treated strong peers for exercise and breaking, showed 59% of patients who were treated with Aloxi in the 24 hours after chemotherapy (132 of 223), over 57% of the patients treated with Ondansetron patients (126 of 221)."</seg>
<seg id="2614">"for chemotherapy, the excessive trigger for nausea and breaking, showed 81% of the patients who were treated with Aloxi in the 24 hours after chemotherapy (153 from 189), over 69% of the patients treated with Ondansetron patients (127 of 185)."</seg>
<seg id="2615">"with a comparison with Dolasetron, these values at 63% for Aloxi (119 from 189 patients) and 53% for Dolasetron (101 from 191 patients)."</seg>
<seg id="2616">"March 2005, the European Commission hosted the European Commission of Helsinki n Birex Pharmaceuticals Ltd. a permit for the Independence of Aloxi in the entire European Union."</seg>
<seg id="2617">Aloxi is indigendered: to the prevention of acomiting and exiting at strong emetogenic chemotherapy due to a cancer disease and to the prevention of nausea and vomiting chemotherapy due to a cancer disease.</seg>
<seg id="2618">The effectiveness of Aloxi for prevention of nausea and vomiting that is induced by a strongly emetogenic chemotherapy that can be enhanced by adding one before the chemotherapy given corticosteroids.</seg>
<seg id="2619">Da Palonosetron lengthen the colon-cycle may extend to be patient with anamnestischer Obstipation or signs of a subacute Ileus after injections.</seg>
<seg id="2620">"however, like with other 5HT3-Antagists, however, caution with the current gift of Palonosetron with pharmaceuticals that extend the QT interval or in patients, where the QT interval is extended or which circumcised for such an extension."</seg>
<seg id="2621">"except in connection with another chemical therapy, Aloxi should be used in the days after chemotherapy neither for prevention nor for the treatment of nausea and vomiting."</seg>
<seg id="2622">In preclinical trials Palonosetron the against tumors the activity of the five examined chemotherapists not (Cisplatin, cyclophosphamide, Cycloabin, Doxorubicin and Mitomycin C). "</seg>
<seg id="2623">"in a clinical study, no significant pharmacopolies between a unique intravenous dose of Palonosetron and a steady-state- concentration oroclopramids, an CYP2D6-Inhibitors."</seg>
<seg id="2624">"based on a population based on pharmacokinetic analysis was shown that the simultaneous gift of CYP2D6-Inductidin, Doxorubici, Paroxetine, Vice oxavir, Serenavir, Serpavir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertravir, Sertr</seg>
<seg id="2625">"experiences to the use of Palonosetron in human pregnancies are not before, therefore Palonosetron should not be used in pregnant women, unless it is necessary from the treated doctor than necessary."</seg>
<seg id="2626">"clinical trials were the most common in a dose of 250 micrograms to observed side effects (total 633 patients), which were at least possibly with Aloxi in connection stood, headaches (9%) and Obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10,000) of oversensitivity reactions and reactions at the agreement (burning, curing, complaints and pain) have been reported in post-marketing experiences."</seg>
<seg id="2628">"in the group with the highest dosage, similar frequencies showed themselves from unwanted events such as in the other doses, there were no dose of activity relations."</seg>
<seg id="2629">There were no dialysis studies carried out due to the large distribution volume is a dialysis but probably no effective therapy with a aloxiety.</seg>
<seg id="2630">"in two randomised double-blinded studies were given a total of 1,132 patients, which were a moderemetogenic chemotherapy with ≤ 50 mg / m2 Doxorubicin and 250 microgram or 750 mg Dolasetron (half-time 7,3 hours), which was given on day 1 without Dexamethason intravenous."</seg>
<seg id="2631">"in a randomised double-blindstuds were given a total of 667 patients, which were a strongly emetogenic chemotherapy with ≥ 60 mg / m2 cycloaketron, with patients compared to 32 mg Ondansetron, which were given on day 1 intravenous."</seg>
<seg id="2632">Results of the studies with moderate chemical chemotherapy and the study with strong emetogenic chemotherapy are summarized in the following tables.</seg>
<seg id="2633">"in clinical studies for the indication of chemotherapy and exiting (CINV), the effects of Palonosetron have been comparable to blood pressure, heart rate and ECG parameters including the QTc Intervalls with the corresponding effects of Ondansetron and Dolasetron."</seg>
<seg id="2634">"after the invented pre-clinical trial, Palonosetron has the ability to block the isentarian decentration and Repolarisation involved and extend the duration of the shareholder."</seg>
<seg id="2635">"the aim of the study conducted by 221 healthy Probanden, was the assessment of the EECG Effective Palonosetron in individual doses of 0,25, 0,75 and 2.25 mg."</seg>
<seg id="2636">"resorption After intravenous gift follows the initial acceptance of Plasmakonentriations a slow Elimination of the body with an average weekday period of about 40 hours."</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the surface under the concentrations period (AUC0- 1) are generally proportional to the entire Dosisarea of 0.3- 90 μ g / kg with gestures and cancer patients doso doso.</seg>
<seg id="2638">After intravenous gift of Palonosetron 0.25 mg each second day for a total of 3 cans was at 11 Hodencarcinompatios between day 1 and day 5 measured average (± SD) increase in the Palonosetron-plasma-concentration at 42 ± 34%.</seg>
<seg id="2639">"derived from pharynocinetic simulation, that at once a daily use of 0,25 mg palonosetron has been comparable to 3 consecutive days; however, the Cmax after the single date of 0.75 mg was higher; however, the Cmax after the single-painting of 0.75 mg was higher."</seg>
<seg id="2640">About 40% will be eliminated by the kidneys and about another 50% are converted into two primary metals compared to Palonosetron over less than 1% of the antagonistic effect on 5HT3 receptors.</seg>
<seg id="2641">"in-vitro-studies on the metaboization have shown that CYP2D6 and, in light dimensions, the Isoenzyme CYP3A4 and CYP1A2 at the metaboism of Palonosetron are involved."</seg>
<seg id="2642">"Elijah After a intravenous individual dose of 10 microgram / kg [14C] -Palonosetron have been found approximately 80% of the dose within 144 hours in the urine, Palonosetron as unchanging active ingredients made approximately 40% of the given dosage."</seg>
<seg id="2643">After a unique intravenous Bolusinan object was the total body of 173 ± 73 ml / min and the renal Clearance 53 ± 29 ml / min.</seg>
<seg id="2644">"although patients with severe liver functioning, the terminale Eliminationists and the average systemic exposure with Palonosetron increases, a reduction of dosage is however non-justified."</seg>
<seg id="2645">"in pre-clinical trials, effects were observed only to Expositions which are regarded as sufficient about the maximum human therapeutic exposition, which indicates a low relevance for clinical use."</seg>
<seg id="2646">10 from preclinical trials of evidence that Palonosetron can only block in very high concentrations of Ionenketron in very high concentrations of Ionenketron and extend the promotion of potential duration.</seg>
<seg id="2647">"high doses Palonosetron (each dose corresponded to about 30triple the therapeutic exposure when people), which were given daily over two years, led to a growing frequency of Lebriors, endokrines Neoplasms (in the thyroid, pancreatic) and skin-tumors for rats, but not at mice."</seg>
<seg id="2648">"the underlying mechanisms are not fully known, but due to the high doses of doses and since Aloxi is determined by humans for the unique application, the relevance of these results are low rated as to the human being."</seg>
<seg id="2649">"the holder of this approval for the Internet, the European Commission must inform about the plans for the transactions, in the context of this decision on drug."</seg>
<seg id="2650">"• If one of the listed side effects you can considerably impairs or you notice side effects that are not indicated in this usage information, please inform your doctor."</seg>
<seg id="2651">"• Aloxi is a clear, color injection solution for injections in a Vene. • This can cause the effect of a serotonin recorded chemical substance, which can cause nausea and breaking down, which occur in connection with chemotherapy because of cancer."</seg>
<seg id="2652">21 At the application of Aloxi with other medicines. please inform your doctor if you use other medicines / apply or have recently taken / apply even if it is not prescription medicine.</seg>
<seg id="2653">"pregnancy If you are pregnant or believe pregnant, your doctor will not give you aloxi unless it is definitely required."</seg>
<seg id="2654">Ask your doctor or pharmacist for advice if you are pregnant or believe pregnant.</seg>
<seg id="2655">In some very rare cases it came to allergic reactions to Aloxi or to burning or pains at the intruder.</seg>
<seg id="2656">"as Aloxi looks and content of the pack Aloxi injection solution is a clear, coloured solution and is available in a package with 1 stripes made of glass, which contains 5 ml of the solution."</seg>
<seg id="2657">Бълакиксаораксацикиораорные ораорные ораорные ораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораорные ораораораорные ораораораораораораораораораораораораораораораораораораораораораораораораораораораораораораор</seg>
<seg id="2658">Latvija pharmaceutical Swiss Latvia Sia 54-5 Qruiser members of the Street Riga, LV-1011 Tel: + 37167502185 Lietuva UAB pharmaceutical. "</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd office Village Chester Business Park Chester - 4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"June 2006, the Committee on Humancision (CHMP) adopted a negatives responsible for the approval of approval for the treatment of hepatitis C in the treatment of hpheon 6 million IE / ml injection solution."</seg>
<seg id="2661">"this means that Alpheon is called a biological medicine called Roferon-A with the same cell-effective effective, which is already approved in the EU (" "reference cisions"). "</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long anhalation) hepatitis C (one by a virus infection.</seg>
<seg id="2663">"in a microscopic investigation shows the Lebertissue damage, in addition, the values of the liver enzyme Alanin- Aminotransferase (ALT) is increased in the blood."</seg>
<seg id="2664">It is produced by a yeast into which a gene (DNA) was transferred to the formation of the drug.</seg>
<seg id="2665">"the manufacturer of alpheon recorded data that occupy the comparison of alpheon with Roferon-A (drug structure, composition and purity of the drug, efficacy, safety and effectiveness in hepatitis C)."</seg>
<seg id="2666">"in the study of patients with hepatitis C, the effectiveness of alpheon is compared to the effectiveness of the reference cision by means of 455 patients."</seg>
<seg id="2667">"in the study, how many patients were surveyed after 12 out of 48 treatment weeks as well as 6 months after the treatment of the treatment on the drug (i.e., no indication of the virus in the blood)."</seg>
<seg id="2668">"(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu</seg>
<seg id="2669">"furthermore, concerns were raised concerns that the data on the stability of the material and the market-market is not sufficient."</seg>
<seg id="2670">The number of patients with hepatitis C based on treatment with alpheon and Roferon-A was similar in clinical study.</seg>
<seg id="2671">"after hiring treatment with alpheon, the disease in more patients had more than with the reference cision; in addition, Alpheon had more side effects."</seg>
<seg id="2672">"apart from this, the test used to investigate the question, inwhat extent the medicine is an immune response (i.e., the body forms antibodies - special proteins - against the drug) not sufficiently validated."</seg>
<seg id="2673">It can be used for the treatment of imppetigo (one with crushless skin infection) and small ininfected lazy (rissors or cartwunden), shutters and sewn wound. "</seg>
<seg id="2674">"Altargo should not be used to treat infections that were prophestically or probably due to methyst resistant to stlococcus aureus (MRSA), because Alargo against this kind of infections may not work."</seg>
<seg id="2675">"Altargo can be used in patients from the age of nine months, but with patients under 18 years of age may not exceed 2% of the body surface."</seg>
<seg id="2676">"if the patient is not talking about two to three days, the doctor should examine the patient again and consider alternative treatments."</seg>
<seg id="2677">It works by blocking of the bacterial bosbosomes (the parts of the bacterial cell in which proteins are produced) and inhibit the growth of bacteria.</seg>
<seg id="2678">Main Indicator of the effectiveness was sealed in all five studies of the share of patients whose infection was sealed off after the end of the treatment.</seg>
<seg id="2679">119 (85.6%) of 139 patients under Altargo and 37 (52.1%) of 71 patients under placebo talked to treatment.</seg>
<seg id="2680">"during the treatment of infected Haus, Altargo and Cefalexin similar response: if the results of both studies were taken together in Hautwins, spoke about 90% of the patients of both groups in the treatment."</seg>
<seg id="2681">"however, in these two studies, Altargo was determined that Altargo was caused by the treatment of deportations (sidiary) or infections that have been caused by MRSA, not effective enough."</seg>
<seg id="2682">The most common side effect with Altargo (which was observed in 1 to 10 of 100 patients) is a maturity in the order.</seg>
<seg id="2683">"the Committee on Humancision Science (CHMP) is to conclude that the advantages of Altargo in the curse treatment of the following superficial skin infections against the risks exaggerated: • Impetigo, • infected small lathes, dehydrations or gendered wounds."</seg>
<seg id="2684">"May 2007, the European Commission granted the company Glaxo Group Ltd. a permit for the Independence of Altargo across the European Union."</seg>
<seg id="2685">Patients who have no improvement within two to three days should be examined once again and an alternative therapy is considered (see Section 4.4).</seg>
<seg id="2686">"in the case of a Sensitizing or serious local irritation by the use of Retapamulin Salbe, the treatment should be canceled carefully and an appropriate alternative therapy of the infection."</seg>
<seg id="2687">Retapamulin should not be used to treat infections where MRSA is known or assumed (see Section 5.1).</seg>
<seg id="2688">In clinical studies at secondary wounds was the effectiveness of Retapamulin in patients with infections that were caused by a methicillin-resistant forklihylococcus aureus (MRSA).</seg>
<seg id="2689">An alternative therapy should be considered when after a 2- to 3-day treatment no improvement or deterioration of the infected place occurs.</seg>
<seg id="2690">The effect of the simultaneous application of Retapamulin and other topographic means at the same skin surface has not been examined and the simultaneous application of other topology is not recommended.</seg>
<seg id="2691">"due to the low plasma decentrations, which were achieved by the people after the topuseless skin or infected superficial wounds, is a clinically relevant inhibit in vivo not to be expected (see section 5.2)."</seg>
<seg id="2692">3 After concurrent gift of 2-times daily 200 mg Ketoconazol increased the middle Retapamulin AUC (0-24) and Cmax after topographic application of 1% reapamulin Salbe on the scratched skin of healthy adult men by 81%.</seg>
<seg id="2693">"due to the lower systemic exposure to patients, dosages are not required for patients if topiapamulin is being used during a systemic treatment with CYP3A4 Inhibitors."</seg>
<seg id="2694">Animal studies have shown a reduction of production and are insufficient in regards to a statement on the birth and the killing / postnatal development (see section 5.3).</seg>
<seg id="2695">"Retapamulin Salbe should be used during pregnancy, if an topographic therapy is clearly indexed and the application of reapamulin of the gift of a systemic antibiotic."</seg>
<seg id="2696">"when deciding whether the breastfeeding is continuing / terminated, or the therapy with Altargo should be terminated, is between the benefit of lactation for the baby and the benefit of the Altargo therapy for women."</seg>
<seg id="2697">"in clinical studies to 2150 patients with superficial skin infections, the Altargo was most commonly reported by side-action on the agreement which is about 1% of the patients concerned."</seg>
<seg id="2698">Drug Retapamulin is a semi-synthetic derivative of Pleuromutilin, a substance that is isolated by feritopilus passagerianus (formerly Pleurotus passeckerianus). "</seg>
<seg id="2699">The acts Mechanism of Retapamulin is based on selective shirts of the bacterial protein synthesis by interaction at a specific binding point of the bacterial bosbosses that differs from the ties of other ribosomal interagro-bacterial fabrics.</seg>
<seg id="2700">Data suggest that the ties of ribosomales L3 L3 involved in the region of the ribosomal P attachment and the Peptidyltransferasezcentre.</seg>
<seg id="2701">By binding at this tie-point Pleuromutiline the Peptidyltransfer, block partial P-binding interactions and prevent the normal formation of active 50s ribosomaler subunits. "</seg>
<seg id="2702">"should be based on the local prevalence of the Resistance, the application of Retapamulin in at least some infectious forms should be pursued by experts."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of retapamulin to S.aureus, regardless of whether the insulating or resistant to methicillin."</seg>
<seg id="2704">"in case of non-appealing to the treatment at S.aureus, the presence of tribes with additional virulents (such as PVL = Panton-Valentine Leucocidin) should be considered."</seg>
<seg id="2705">Resorption In a study with healthy adults 1% reapamulin Salbe daily under occlusion on intact and on the gentle skin for up to 7 days.</seg>
<seg id="2706">"from 516 patients (adults and children), 1% reapamulin Salbe received twice daily for 5 days for the topographic treatment of secondary traumatic wounds, were obtained individual plasma robes."</seg>
<seg id="2707">The sampling took place in days 3 or 4 at adult patients each before the mediate and the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual system inclusion in people after topographic application of 1% Salbe on 200 cm2 shielded skin (Cmax = 22 ng / ml) 660-times lower than the retapamulin IC50 for the PGP-shirt."</seg>
<seg id="2709">Metabolism The in vitro oxidative metaboismus by Retapamulin in humane liver liver and CYP2D6 (see Section 4.5).</seg>
<seg id="2710">"in studies for the oratory toxicity of rats (50, 150 or 450 mg / kg) which were conducted over 14 days, there were signs of adaptive liver and thyroid changes."</seg>
<seg id="2711">In-vitro-review on genmutation and / or chromosomal effects in the mouse-Lymphoma test or in cultures of human peripherymphocytes as well as in the rats-microkernel to in-vivo survey chromosomaler effects.</seg>
<seg id="2712">"there was neither at male nor with female bital signs of reduced fertilisation at oral dosages of 50, 150 or 450 mg / kg / day, thus reducing up to 5 times higher exposure to the human being (topographic application to 200 cm2 shopped skin:"</seg>
<seg id="2713">In an embryonic stage of rats have been observed in oral dosages of ≥ 150 mg / kg / day (according to ≥ 3-ply the estimated human exposure (see above)), development stoxicity (see above)), development stoxicity (see above)), development stoxicity (see above)) and maternal toxicity) and maternal toxicity. "</seg>
<seg id="2714">"the holder of permission for the ink has to ensure that a pharmacovigilance system is present, as in the module 1.8.1 of the authorisation presented (version 6.2) is present and works before the product is marketed as long as the marketed product is applied."</seg>
<seg id="2715">"the holder of the approval for the contract is obligated to perform detailed studies in the Pharmacovigilance plan, as described in the version 1 of the Risk Management Plan (RMP), as well as all additional updates of the RMP, which are agreed with CHMP."</seg>
<seg id="2716">"as described in the CHMP" instruction on Risk Management Systems for Medicinal products for human use "," the updated RMP should be submitted simultaneously with the next Periodic Safety Update Report. "</seg>
<seg id="2717">"irritation or other signs and symptoms show at the treated place, you should end the application of Altargo and speak to your doctor."</seg>
<seg id="2718">"do not turn other salons, creams or lotions on the surface that is treated with Altargo if it is not expressly granted by your doctor."</seg>
<seg id="2719">"it may not be applied in the eyes, at the mouth or on the lips, in the nose or in the female genital area."</seg>
<seg id="2720">"if the salads from seeing on one of these surfaces, wash the place with water and ask your doctor for advice if complaints occur."</seg>
<seg id="2721">"after the wear of the salbe you can cover the affected area with a sterilen association or a Gazeverband, unless your doctor has come to uncover the area."</seg>
<seg id="2722">"it is offered in a aluminium tube with a plastic strap, the 5, 10 or 15 gram Salbe, or in a aluminium bag, the 0,5 g salbe."</seg>
<seg id="2723">Ambirix is committed to protecting hepatitis A and hepatitis B (diseases that affect the liver) in children between one and 15 years old that are not immune to these two diseases.</seg>
<seg id="2724">Ambirix is used as part of two cans of existing vaccination and a protection against hepatitis B may only be reached after administration of the second dose.</seg>
<seg id="2725">"for this reason, Ambirix may only be used when immunization is a low risk of hepatitis B infection and is ensured that that can be run from two doses to end existing vaccine plan."</seg>
<seg id="2726">If a refresher dose against hepatitis A or B wants to be Ambirix or another hepatitis B or -B vaccine being given.</seg>
<seg id="2727">Vaccines act by bringing the immune system (the natural defaulting of the body) "as it can invade against a disease.</seg>
<seg id="2728">"after a child has received the vaccine, the immune system recognizes the viruses and surface-surface as" foreign "and produces antibodies against it."</seg>
<seg id="2729">Ambirix contains the same ingredients as the approved vaccine Twinrix Adults and the same since 1997 approved vaccine Twinrix Children.</seg>
<seg id="2730">"the three vaccines are applied to the protection against the same diseases, but Twinrix adults and Twinrix children are administered within three doses of existing vaccination plan."</seg>
<seg id="2731">"because ambitions and Twinrix contain identical ingredients, some of the data which are supported by Twinrix adults, also as proof for the application of Ambirix."</seg>
<seg id="2732">The main indicator for the effectiveness was the proportion of the indictapped children that had developed a month after the last injection of a protective antidecentration.</seg>
<seg id="2733">"in an additional study with 208 children, the effectiveness of the vaccine was compared to a sixsmote and a 12-month distance between the two injections."</seg>
<seg id="2734">Ambirix carried out between 98 and 100% of the indictapped children one month after the last injection of the development of anti-based antibodies against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection of Ambirix was similar between injections - and at a 12-month distance between injections.</seg>
<seg id="2736">"the most common side effects of Ambirix (observed with more than 1 of 10 vaccines) are headache, appetite, pain in the injection point, redness, mating (tiredness) as well as irritability."</seg>
<seg id="2737">Ambirix may react to patients who may possibly excessive (allergic) to active ingredients, one of the other components or Neomycin (an antibiotic) will not be applied. "</seg>
<seg id="2738">August 2002 the European Commission entitled Glaxosclerosis Biologicals. a permit for the Independence of Ambirix throughout the entire world</seg>
<seg id="2739">"the standardization plan for the Grundimmunization with Ambirix consists of two vaccines, whereby the first dose is given at the date of choice and the second dose between six and twelve months after the first dose."</seg>
<seg id="2740">"if a refresher is desired for hepatitis A as well as for hepatitis B, can be vaccinated with the corresponding monovalent vaccines or with a combined empowerment."</seg>
<seg id="2741">The compliant anti-hepatitis C (anti-hepatitis C) - and anti-hepatitis C (anti-HAV) - and anti-hepatitis A virus (anti-HAV) -antibodies (anti-HAV) -antibodies are vaccines in the same size as after vaccination with the respective monovalent vaccines.</seg>
<seg id="2742">"it is not yet completely secured whether immunotherapists who are addressed to a hepatitis-aging vaccination as protection, since they are also protected by immunological antibodies possibly by the immunological memory."</seg>
<seg id="2743">3 As with all injustice they should always be available for the rare laktic reaction after the gift of the vaccine to always be available immediately for medical treatment and supervising.</seg>
<seg id="2744">"if a fast protection against hepatitis B is required, the standardization scheme is recommended by means of combinations, the 360 ELISA units formalininactivated hepatitis-A-Virus and 10 µg recombinable hepatitis B-surface."</seg>
<seg id="2745">In hematalytic and persons with faults of the immune system is not achieved under the priming anti-HAV- and anti-hbs anti-antibodies so that in these cases the gift can be required.</seg>
<seg id="2746">Since a intradermal injection or intra-muscular administration could lead to a suboptimal vaccine success should be avoided.</seg>
<seg id="2747">"in Thrombozytopenie or blood circulation, Ambirix can be injected subkutan injected since it can occur in these cases to intramusculturally gift to bleeding."</seg>
<seg id="2748">If Ambirix is given in the second life year in the form of a separate injection moulds of tetus-, inactivation type b-vaccine (DTPa-IPV / HIB) or with a combined mask - mumps (DTPa-IPV / HIB) or with a combined mask - mumps was given, the immune response was sufficient (see section 5.1). "</seg>
<seg id="2749">"in patients with immunodepressors therapy or in patients with immune defective, it must not be sufficient immune response."</seg>
<seg id="2750">"in a clinical study involving 3 vaccination of this wording in adults, the frequency of pain, redness, swelling, gastroenteritis, headaches and fever comparable with the frequency that has been observed in the former Thiomersal- and preservative vaccine formulating."</seg>
<seg id="2751">In clinical studies 2029 vaccinosen Ambirix received a total of 1027 imperforns at the age of 1 to 15 years.</seg>
<seg id="2752">"in a study with 300 participants aged 12 to 15 years, the compatibility of Ambirix was compared to the 3-doses of Combined-combination."</seg>
<seg id="2753">"only exceptions were the higher frequency of pain and matality on a justification basis per vaccinosis Ambirix, but not on a calculation basis per person."</seg>
<seg id="2754">Pain was observed after the gift of Ambirix at 50,7% of the test compared to 39.1% in the test after the gift of a dosage of 3-cans of combinations.</seg>
<seg id="2755">"after the complete vaccine of 66,4% of the test, the Ambirix had to get enough, about pain, compared to 63,8% at the Probanden, which had been vaccinated with the 3-Dos- Combined."</seg>
<seg id="2756">"however, the frequency of matality was compared to the pro-tape compared to 39,6% of the test, the ambitions received, compared to 318.2% compared to the Probanden, which received the 3-doses of Combinaries."</seg>
<seg id="2757">The frequency pronounced pain and mat was low and comparable to the submissions of the Combined-vaccination with the 3-doses-vaccine has been observed.</seg>
<seg id="2758">"in a comparative study at 1- to 11-year impeers, the appearance of local reactions and general actions was comparable with the 3-doses Combinations with 360 ELISA units formalininactivated Hepatitis-A-Virus and 10 µg recombinable hepatitis B-surface."</seg>
<seg id="2759">"however at the 6- until 11- Jolds, however, after vaccination with ambitions a common incidence of pain (at the injection point) per dose, not per Proband reports."</seg>
<seg id="2760">"the proportion of impairinging, which reported on severe side effects during the 2-cans with Ambirix or during the 3-doses-vaccschemas with the Combinational Hepatitis-A-virus and 10 µg recombination hepatitis-B- surface-surface, was statistically different."</seg>
<seg id="2761">"in clinical studies, the Serokonvertex rates were carried out for anti-HAV 99,1% a month after the first dose and 100% a month after the second, the month 6 adowed dose (d. h. in month 7)."</seg>
<seg id="2762">"the Serokonvertex rates for anti-hbs were 74.7% a month after the first dose and 100% a month after the second, the month 6 adowed dose (d. h. in month 7)."</seg>
<seg id="2763">"7 In a comparative study that was carried out at 12- until including 15-year-old, 142 two cans of Ambirix and 147 received the standard combination simulations with three cans."</seg>
<seg id="2764">"for the 289 people whose immunogenosity was impaired, were the seroprotecection rates (SP in the table below) against hepatitis B in month 2 and 6 according to gift of the 3-procedure is significantly higher than with ambitions."</seg>
<seg id="2765">"the immune response that were taken in a clinical study by 1- to 11-year-olds a month after the end of the complete vaccine series (i.e. in month 7), are listed in the following table."</seg>
<seg id="2766">"in both studies, Impeers received either a 2-cans with Ambirix or a 3-doses-vaccination with an Combinationsimulations with 360 ELISA units formalininactivated Hepatitis-A-Virus and 10µg recombinable hepatitis B-surface."</seg>
<seg id="2767">"in people who were at the time of the Grundimmunzation between 12 and 15 years old, the Persistence of anti-HAV- and anti-hbs anti-antibodies could be proven by at least 24 months after the immunization with Ambirix in the 0-6-month vaccination scheme."</seg>
<seg id="2768">"the immunological action against both antigens was comparable to vaccination, consisting of 360 ELISA units, consisting of 360 ELISA units formalininactivated hepatitis- A-virus and 10 µg recombinable hepatitis B-surface in a dosiscapacity of 0.5 ml."</seg>
<seg id="2769">In a clinical study at 12- until including 15-year-old could be shown that the Persistence of anti-HAV- and anti-hbs anti-antibodies can be compared to immunization in 0-6- months-vaccination scheme.</seg>
<seg id="2770">"if the first dose Ambirix during the second year at the same time with the refresher, Tetrahedron -, inactivated polomyelitis- and 8 Haemophilus (DTPa-IPV / HIB) or with the first dose of a combined mask of vaccines, the immune response was given to all antigens."</seg>
<seg id="2771">A clinical study conducted with 3 cans of the current formulation in adults showed for the current formance of similar servoprotets and serokonversionrates as for previous formulation.</seg>
<seg id="2772">The vaccine is to be inspected both before and after the resustion per eye on etwaist and / or physical-visible changes.</seg>
<seg id="2773">"according to Article 114 of the Directive 2001 / 83 / EC changed version, state batch release is performed by a state laboratory or an authorised laboratory."</seg>
<seg id="2774">14 data on THE cover 1 FERTIGSPRITZE OHNE Nadel 1 FERTIGSPRITZEN OHNE Nadine 10 FERTIGSPRITZEN OHNE Nadine</seg>
<seg id="2775">Suspension for injections 1 ready-splash with Nadel 10 ready-splash without needles 10 ready-splash with needles 50 dsplash without needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 finishing juncing without a needle EU / 1 / 02 / 224 / 004 10 ready-injection moulding with needles EU / 1 / 02 / 224 / 005 50 Finals without needles</seg>
<seg id="2777">"the hepatitis-A virus is usually transferred by viral foods and beverages, but can also be transferred by other ways, such as by Baden in through wastewater waters."</seg>
<seg id="2778">"you can feel very tired, have a darkened urine, a blasses face, yellow skin and / or eyes (laughter) and other symptoms that may possibly make a stationary treatment."</seg>
<seg id="2779">"as with all vaccines, Ambirix cannot protect completely before an infection with hepatitis-A- or hepatitis B virus, even if the total vaccine has been completed with 2 cans."</seg>
<seg id="2780">If you are not infected with hepatitis C or hepatitis B virus if you are not infected with hepatitis C or hepatitis B virus (although you do not feel uncomfortable or sick) a vaccine may not prevent a vaccine to prevent a disease.</seg>
<seg id="2781">"a protection against other infections that cause the liver or symptoms, which are similar to those of a hepatitis or hepatitis B infection cannot be conveyed."</seg>
<seg id="2782">• When your child has already been an allergic reaction to Ambirix or any part of this vaccine including Neomycin (an antibiotic).</seg>
<seg id="2783">An allergic reaction can express itself through juckling skin irritations, respiratory or chastity of the face or the tongue. • If you have already performed an allergic reaction to an earlier vaccine against hepatitis A or hepatitis B. • If you have a severe infection with fever with fever. "</seg>
<seg id="2784">• if you want to quickly have a protection against hepatitis B (i.e. within 6 months and before the planned agreement of the second vaccination).</seg>
<seg id="2785">"with a possible risk of infection with hepatitis B between the first and second vaccine, the doctor will advise you / your child from a vaccine with ambitions."</seg>
<seg id="2786">"instead, he will recommend you / your child 3 injections of a combined Hepatitis C units with a reduced salary of effective components per vaccinosis (360 ELISA units of a formal Hepatitis A-virus and 10 microgram of a recombinable hepatitis B-surface antigens)."</seg>
<seg id="2787">The second vaccination of this vaccination with reduced content of effective components usually occurs one month after the first dose and is likely to give you a vaccination before ending the vaccine.</seg>
<seg id="2788">Sometimes Ambirix is afflicted for individuals who are afflicted on severe blood circulation. • If you are weakened on severe blood circulation. • If you are weakened to your child due to a disease or treatment in your own physical resistance.</seg>
<seg id="2789">"Ambirix may be given in these cases, but the immune response of these individuals may not be sufficient, so that a blood test can be required to see how strong the reaction to vaccine is."</seg>
<seg id="2790">"21 Searing your doctor, if you take / your child further medicines / income (including those who have recently been missing) or if you / your child have recently been mistaken / has been given or immunoglobulins (antibodies) or has been planned in the near future."</seg>
<seg id="2791">"however, it may be that immune response to the vaccine is not sufficient and the person is therefore not protected against one or both hepatitis A and B viruses."</seg>
<seg id="2792">"when another vaccine has to be given simultaneously with Ambirix, should be vaccinated at separate locations and as various limbs."</seg>
<seg id="2793">"if ambitions are given to the same time or shortly before or after an injection of immunoglobulins, it is likely that the reaction to the vaccine is nevertheless enough."</seg>
<seg id="2794">"usually Ambirix or breastfeeding women is not admittedly, except that it is urgent need to be vaccinated both against hepatitis A and hepatitis B."</seg>
<seg id="2795">Important information on certain other components of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"if you miss the agreed date for the second vaccine, talk to your doctor and arrange a new date as soon as possible."</seg>
<seg id="2797">♦ very frequently (more than 1 case per 10 verimpfte cans): • pains or discomfort in the entry point or redness • tenance • headache • appetite • appetite</seg>
<seg id="2798">♦ often (up to 1 case per 10 imminated cans): • swelling at the injection point of fever (over 38 ° C) • Benefulness • Mages-Intestations</seg>
<seg id="2799">"other side effects, the days or weeks after vaccination with comparable combination of hepatitis A and hepatitis B very rarely (less than 1 case per 10,000 verplated cans) have been reported:"</seg>
<seg id="2800">"these include local limited or extended removal, the cheating can or blerning-shaped can be, swelling of the eye-partiality and face, scourly breathing, or swallow, sudden blood pressure and consciousness."</seg>
<seg id="2801">"flu-similar complaints, including Diefffrost, muscle, and joint pain Krampoo, missensitive and" ants, "Multiple Sclerosis, loss of sensory, loss of sensory, loss of feeling, strong headaches and stiffness of the nude, interruption of normal brain functions"</seg>
<seg id="2802">"Ohnut makes inflammation of blood or disease-feeling, appetite and aboutache, liver functional tests Lymphkhuswelling increased inclination to bleeding or to Blutergom (blue Flags), caused by infestation of blood-saturation."</seg>
<seg id="2803">"23 Informing your doctor or pharmacist, if one of the listed side effects you / your child is significantly affected or you notice side effects that are not indicated in this package."</seg>
<seg id="2804">Ambirix is available in packs of 1 and 10 with or without needles and in packs of 50 without needles.</seg>
<seg id="2805">"based on the data, which has become known since the organization of the first approval for the purchase agreement, contracts of CHMP opinion that remains the benefit risk for Ambirix positively."</seg>
<seg id="2806">"since Ambirix is limited only in a member state (in the Netherlands since May 2003), the available safety data for this medicine is limited due to low patient exposure."</seg>
<seg id="2807">Ammonaps can also be used in patients at the age of over a month with invaluable spongiform encephalopathy (brain-compensation as a result of high amorphosis) in the pre-history.</seg>
<seg id="2808">"ammonaps will be summed up to several retailers at meals - swallowed, under the food, or via a Gastroar hose (through the abdominion in the stomach's leading heap) or an nasal Sensor (by the nose in the stomach leading heap)."</seg>
<seg id="2809">"it was not a comparative study, since ammonaps do not be compared with any other treatment or placebo (a hypodrug drug, i.e. without drug)."</seg>
<seg id="2810">"ammonaps can also lead to Appetitions, a abnorly acidity, coaches, impotence, impotence, potency, loss, consticking, suspication, rinsing, suspication, rinsing, inconspicuous body or weight increases."</seg>
<seg id="2811">The Committee on Humancision (CHMP) to the conclusion that ammonaps in patients have been effectively prevented from patients with interference of the urinary cycle.</seg>
<seg id="2812">"ammonaps was approved under" exceptional circumstances, as due to the rarity of the disease at the time of admission only limited information on this medicine. "</seg>
<seg id="2813">The use is indians in all patients with which a complete enzymes already manifested in the newborn old (within the first 28 life-days).</seg>
<seg id="2814">"in patients with a delay of a delay (inconsistency, which is manifested according to the first life force) then there is an indication for the use when in Anamnese a hyperammonary Enzie."</seg>
<seg id="2815">"for infants, for children who are not able to swallow tablets or for patients with gorckdysfunction is AMMONAPS also available in granulatform."</seg>
<seg id="2816">The daily dose is individually calculated with regard to protein intolerance and growth and development of daily protein intake.</seg>
<seg id="2817">"after the recent clinical experience, the normal daily dose of sodium butyrat: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9.0 g / m ² / day in children with a body weight of 20 kg as well as in Herangrowing and adults."</seg>
<seg id="2818">In patients who suffer from a breakfast lack of Carbamylphosphatsynthetase or ornithintranase or Arginine in a dosage of 0.17 g / kg / day or 3.8 g / m ² / day required.</seg>
<seg id="2819">Patients with a Argininosuccinatsynthetase-lack must Arginine in a dosage of 0.1 - 0.7 g / kg / day or 8,8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"AMMONAPS tablets must not be administered patients with gorcktroubles, as a risk to the emergence of Ösophagusulcera consists, if the tablets do not go instantly in the stomach."</seg>
<seg id="2821">"every tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, according to 2.5 g (108 mmol) sodium per 20 g sodium arphenylbutyrat, which corresponds to the maximum daily dose."</seg>
<seg id="2822">"AMMONAPS should therefore be used with patients with counterproductive efficiency, as well as with sodium insufficiency as well as with sodium and odembal clinical clinical trials only with caution."</seg>
<seg id="2823">"since Metabolization and excreases of sodium aryrat over the liver and the kidneys, should be applied only with extreme caution only with extreme caution."</seg>
<seg id="2824">The meaning of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore controversial (see 4.3).</seg>
<seg id="2825">"at subkutaner gift of phenylacetate to young rats in high dosage (190 - 474 mg / kg), it came to a slowdown of neuronal distortion and increased loss of neurons."</seg>
<seg id="2826">"also, there were also a consuming maturation from cerebral synapsen and a diminished number of functional nerves in the brain and thus a disability of brain growth."</seg>
<seg id="2827">"it could not be determined whether Phenylacetate is retired when people turn into the mother's milk, and for this reason the use of AMMONAPS during lactation is contracted (see 4.3)."</seg>
<seg id="2828">"in clinical trials with AMMONAPS, at 56% of patients had at least an undesirable event (AE), and at 78% of these undesirable events that they had not been with AMMONAPS."</seg>
<seg id="2829">"the frequency is defined as follows: very often (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a probable Toxic response to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorektic patient, which developed an metabolic Enzie, periphery Neuropathy and pancreatitis."</seg>
<seg id="2831">A case of overdose came with a 5 month old infant with a free dose of 10 g (1370 mg / kg).</seg>
<seg id="2832">These symptoms go with the accumulation of phenylacetate which showed up to 400 mg / kg / day a dosissive neurotoxicity.</seg>
<seg id="2833">Phenylacetate is a metaboisch active connection that is construed by Acetyelling with Glutamine to phenylacetylglutamine which is eliminated through the kidneys.</seg>
<seg id="2834">"Stnuiometric is seen from phenylacetylglutamine with urea (both compounds included 2 nitrogen atoms); Phenylacetylglutamine is therefore suitable as alternative carriers to the retirement of excess nitrogen."</seg>
<seg id="2835">5 patients with disturbances of the urinary cycle can be accepted that for each grambiased sodium butyrat between 0.12 and 0.15 g phenylacetylglutamine nitrogen produced.</seg>
<seg id="2836">It is of importance that the diagnosis is at an early stage and the treatment will immediately start to improve the survival chances and the clinical outcome.</seg>
<seg id="2837">"the prognosis of the early symptoms of the disease with the appearance of the first symptoms in the newborn old age was almost always infect, and the disease led themselves in treating with Peritonealdialysis and essential amino acids, or with their stickle free analoga within the first year of life to death."</seg>
<seg id="2838">"through hematalysis, utilisation of alternative ways of nitrogen (sodium-phenylacetate), proteinated Kost and possibly substitution of essential amino acids, it was possible to increase the survival rate of Neugeborener on postparties (however within the first life of life) diagnostic disorders within 80%."</seg>
<seg id="2839">"in patients whose disease were diagnosed in the course of pregnancy, the survival rate was 100%, but even with these patients there was time with many to intellectual disabilities or other neurological deficits."</seg>
<seg id="2840">In patients with a delay of the disease (including female patient with the heterogeneous form of the ornithintranscarce-Manaus) which have been treated by a hyperammonic Enzephalopathy and afterwards permanently treated with sodium polyphenylbutyrat and a proteinated diet amounted to the survival rate of 98%.</seg>
<seg id="2841">Already existing neurological deficits are hardly reversible in treatment and in some patients may occur a further deterioration of neurological condition.</seg>
<seg id="2842">"it is known that Phenylbutyrat to phenylacetate oxide is created, which is created in liver and kidney enzymatic with glutamine, with phenylacetylglutamine arises."</seg>
<seg id="2843">The concentrations of phenylbutyrat and its metaboo in plasma and urine were obtained according to gift of a single dose of 5 g sodium-phenylbutyrat in sober-healthy adults and in patients with faults and repeated gifts of oral doses of up to 20 g / day (not controlled studies).</seg>
<seg id="2844">The behaviour of phenylbutyrat and his metabolic was also investigated with cancer patients after intravenous gift from Natriumphenylbutyrat (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">After a oral individual dose of 5 g Natriumphenylbutyrat in tablet form were determined 15 minutes after the intake measurable plasma concentration of phenylbutyrat.</seg>
<seg id="2846">"in the majority of patients with urinary cyclamen or hemoglobinoeopathy, according to various doses of Phenylbutyrat (300-650 mg / kg / day up to 20 g / day) the next morning after night-time fasting no Phenylacetat in Plasma."</seg>
<seg id="2847">"with three of six patients with liver forrpants, which were repeated with sodium-phenylbutyrat (20 g / day oral in three single dots), the middle phenylacetatconcentric presses in the third day five times higher than after the first gifts."</seg>
<seg id="2848">Retirement The medication is avoided within 24 hours to approximately 80 - 100% in the form of conjued product Phenylacetylglutamine on the kidneys.</seg>
<seg id="2849">According to the results of the Micronucleus tests had been treated sodium-phenylbutyrat in with toxicity and non-toxic cans (examination 24 and 48 h after orated administration of a single dose from 878 to 2800 mg / kg).</seg>
<seg id="2850">"AMMONAPS Granulat is either taken by oral (acces and children, who can still not swallow any tablets, or patients with gorckdysfunction) or via a Gastrostompescheme, or a Nasal Sensor."</seg>
<seg id="2851">"after the previous clinical experience the normal daily dose of sodium butyrat: • 450 - 600 mg / kg / day in newborn, infants and children with a body weight of less than 20 kg • 9.0 g / m ² / day in children with a body weight of 20 kg as well as in Herangrowing and adults."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (in particular detectable amino acids), carnitin and Serumlogs one in the plasma should be kept within the normal range."</seg>
<seg id="2853">In patients who suffer from a breakfast lack of Carbamylphosphatsynthetase or ornithintranase or Arginine in a dosage of 0.17 g / kg / day or 3.8 g / m ² / day required.</seg>
<seg id="2854">AMMONAPS Granulat contains 124 mg (5.6 mmol) Natrium per gram Natriumphenylbutyrat per 20 g (108 mmol) sodium per 20 g sodium arphenylbutyrat which corresponds to the maximum daily dose.</seg>
<seg id="2855">When divers were exposed in front of the birth Phenylacetat (active metabolit by Phenylbutyrat) came to lesions in the pyramid cells of the deer.</seg>
<seg id="2856">"a probable Toxic response to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorektic patient, which developed an metabolic Enzie, periphery Neuropathy and pancreatitis."</seg>
<seg id="2857">"Stnuiometric is seen as Phenylacetylglutamine with urea (both compounds included 2 nitrogen atoms); Phenylacetylglutamine is therefore suitable as alternative carriers to the retirement of excess.</seg>
<seg id="2858">Based on investigations on the extraction of phenylacetylglutamine in patients with disorders of the urinary cycle can be assumed that for each grambiased sodium butyrat between 0.12 and 0.15 g phenylacetylglutamine nitrogen produced.</seg>
<seg id="2859">"already existing neurological deficits are also not reversible in treatment, and in some patients can occur a further deterioration of neurological condition."</seg>
<seg id="2860">After a oral individual dose of 5 g Natriumphenylbutyrat in granulatform were determined 15 minutes after taking measurable plasma concentration of phenylbutyrat.</seg>
<seg id="2861">"during the duration of durability, the patient can retain the finished product for a period of 3 months at a temperature of not over 25 ° C."</seg>
<seg id="2862">"with this procedure, the small measuring rangeon 0.95 g, the average measurement of 2,9 g and the large measuring range 8,6 g Natriumphenylbutyrat."</seg>
<seg id="2863">"if a patient has to receive the medication via a probe, AMMONAPS can be dissolved even in water (the solubility of sodium-phenylbutyrat is up to 5 g in 10 ml water)."</seg>
<seg id="2864">"in patients with these rare diseases are missing certain liver enzymes, making them accord the stickery of proteins in the body after consuming proteins in the body."</seg>
<seg id="2865">"if you have performed laboratory examinations, you must notify the doctor that you may take AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory examinations."</seg>
<seg id="2866">"at intake of AMMONAPS, with other medicines. please inform your doctor or pharmacist if you have other medicines or have been recently taken, even if it is not prescription medicine."</seg>
<seg id="2867">During lactation you may not take AMMONAPS as the medicine could go into the mother's milk and harm your baby.</seg>
<seg id="2868">"in rare cases were also turbulence, headaches, flavours, disinfectious, disarmament, disarmament and a deterioration of existing neurological states observed."</seg>
<seg id="2869">If you notice one of these symptoms you will immediately get in touch with your doctor or at the emergency purpose of your hospital for the introduction of a corresponding treatment.</seg>
<seg id="2870">If you have forgotten the intake of AMMONAPS you have the appropriate dose as soon as possible with the next meal.</seg>
<seg id="2871">"changes of blood image (red blood cells, white blood cells, diminishing appetite, depression, irritation, loss, loss, consticking, suspication, suspicks, kidney disease, gain, gain and anomal laboratory values."</seg>
<seg id="2872">Please inform your doctor or pharmacist if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2873">"you may not use AMMONAPS according to the circumstance and the mastery after" "uses" "until the expiration date."</seg>
<seg id="2874">"like AMMONAPS looks and content of the pack AMMONAPS tablets are of white color and oval shape, and they are equipped with the" UCY 500 "." "</seg>
<seg id="2875">"30 If you have performed laboratory examinations, you must notify the doctor that you may take AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory examinations."</seg>
<seg id="2876">"at intake of AMMONAPS, with other medicines. please inform your doctor or pharmacist if you have other medicines or have been recently taken, even if it is not prescription medicine."</seg>
<seg id="2877">"you should take AMMONAPS divided into equal retailers or via a Magenfistel (Hose, which runs through the abdominal wall directly into the stomach) or a Nasal Sensor (Hose, which is guided by the nose in the stomach)."</seg>
<seg id="2878">"31 • can be found out of the tank-poons of granules. • Strange a straight channel, for example a knife over the upper edge of the measuring opening. • See the recommended number of measuring poon granules from the container."</seg>
<seg id="2879">"angiox is used for the treatment of adult patients with" acute Coronarsyndromes "(ACS, decreased blood flow to the heart), for example with instabiler Angina (a form of pain in chest with different thickness) or myokardincolourless (heart attack) without" ST- Hebung "(a anomal measurement value in the electrical cable or ECG)."</seg>
<seg id="2880">"will be used angiox to prevent blood vessels in patients suffering from one PCI, becomes a higher dose and the infusion can be continued by up to four hours after the procedure."</seg>
<seg id="2881">This can contribute to patients with Angina or heart attack to maintain blood flow to the heart and increase the effectiveness of a PCI.</seg>
<seg id="2882">"nearly 14 000 patients participated in the main study of the treatment of ACS, where the effect of angiox at allergic / IIIa-IIb / IIIa-Inhibitor (GPI, a different medicine to prevent blood vessels) with the conventional combined treatment with Hepmarans) and a GPI compared."</seg>
<seg id="2883">"during the PCI the patients frequently became a Stent (a short tubes that remains used in the artery, and they also received other medicines to prevent blood vessels, such as Abciximab and aspirin."</seg>
<seg id="2884">"with the treatment of ACS, Angiox - with or without gift of GPI - in preventing new events (deaths, heart incidents, or Revascularisation) after 30 days or a total of as effectively as traditional treatment."</seg>
<seg id="2885">"in patients who turned into a PCI was Angiox in terms of all indicators just as effective as Heparin, except for heavy bleeding, where it was significantly more effective than hepmarin."</seg>
<seg id="2886">Angiox must not be used in patients who may possibly excessive (allergic) against bivalirudin, other shepherd, or one of the other components. "</seg>
<seg id="2887">"it may not be used by patients who recently had a bloodation, as well as people with strong blood pressure or heavy kidney problems or a heart infection."</seg>
<seg id="2888">The Committee on Humanities (CHMP) to conclude that angiox at the treatment of ACS and during a PCI is an acceptable replacement for hepmarin.</seg>
<seg id="2889">"September 2004, the European Commission granted to The Company The Medicines Company UK Ltd for permission for the Indetox in the entire European Union."</seg>
<seg id="2890">For the treatment of adult patients with acute coronarsyndromes (instabile Angina / non - ST-Heber incoloured (IA / NSTEMI)) at a emergency stop or if an early intervention is planned.</seg>
<seg id="2891">The recommended initiation of angiox from Angiox in patients with ACS is a intravenous bolustion of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if the patient is performed in another episode, an additional bolus should be given by 0,5 mg / kg and the infusion for the duration of the surgery on 1,75 mg / kg / h increases."</seg>
<seg id="2893">"after the PCI requirements, the reduced infusion dose of 0.25 mg / kg / h will be recorded for 4 to 12 hours."</seg>
<seg id="2894">"immediately before the procedure, a Bolustion of 0,5 mg / kg is given to be given, followed by an infusion of 1,75 mg / kg / h for the duration of the surgery."</seg>
<seg id="2895">The recommended dosage of angiox in patients with a PCI consists of 0.7 mg / kg body weight and any subsequent intraint infusion with a dose of 1,75 mg / kg body weight / h at least for the duration of the surgery. "</seg>
<seg id="2896">"the safety and effectiveness of an allergic-gift of angiox has not been studied and is not recommended, even if a brief PCI procedure is planned."</seg>
<seg id="2897">"this value (ACT after 5 minutes) is shortened to under 225 seconds, should be a second pin of 0.7 mg / kg / body weight."</seg>
<seg id="2898">"to reduce the appearance lower ACT values, the reformed and diluted medicine should be carefully mixed before using the application and the Bolusdosis rapidly intravenous."</seg>
<seg id="2899">"once the ACT is worth more than 225 seconds, another surveillance is no longer required, provided that 1,75 mg / kg Infusion dosis is given correctly."</seg>
<seg id="2900">"in case of patients with moderate kidney functionality (GFR 30-59 ml / min), which treated a PCI (whether with bivalirudin against ACS or not), should be used a lower infusion rate of 1,4 mg / kg / h."</seg>
<seg id="2901">"lies the ACT value below 225 seconds, is a second Bolusdosis between 0,3 mg / kg and to check the ACT 5 minutes after the second Bolusdosis."</seg>
<seg id="2902">"in patients with moderate kidney compensation, which were included in the Phase III- PCI study (replace-2), the ACT lay 5 minutes after the gift of the bivalirudin-Bolus at an average 366 ± 89 seconds."</seg>
<seg id="2903">3 In case of patients with severe kidney compensation (GFR &lt; 30 ml / min) and also for dialysis patients (see section 4.3).</seg>
<seg id="2904">The treatment with angiox can be used 30 minutes after the intravenous gift of unfoldable hepmarin or 8 hours after the end of the subdusting gift of lower hepmarin.</seg>
<seg id="2905">• known hypersensitivity against the active ingredients or any other components or against Hirudine • Active bleeding-system and / or irreversible spongiform encephaltis. • severe kidney compensation (GFR &lt; 30 ml / min) and for dialysis patients</seg>
<seg id="2906">Patients are carefully monitored during the treatment with regard to symptoms and signs of blood blood, especially if bivalirudin combination with another antioagulant is given (see Section 4.5). "</seg>
<seg id="2907">"even if in PCI-patients among Bivalirudto occur in most bleeding to arteries, can occur in patients who occur to a perkutant coronary intervention (PCI) during the treatment in principle of bleeding."</seg>
<seg id="2908">"in case of patients who are waiting in and treated with Bivalirudin, should ensure monitoring the INR value (International normalities), should ensure that the value after lowering the treatment with bivalirudin again reached the level before the treatment."</seg>
<seg id="2909">"based on the knowledge about the acts Mechanism of antioagulants (Heparin, Warcolouring, trombolytika or Thrombozytensionists) can be taken from it that these substances can increase the blood circulation."</seg>
<seg id="2910">"in the combination of bivalirudin with Thrombozytensionists, or antioagulants are the clinical and biological hemogic parameters in each case regularly."</seg>
<seg id="2911">"the animal experimental studies are in terms of effects on pregnancy, the embryonic / fetal development, the discharge or the postnatal development of insufficient (see section 5.3)."</seg>
<seg id="2912">4612 were randomised to Bivalirudin alone, 4604 were randomised to Bivalirudin plus GPIIb / IIIa Inhibitor and 4603 were randomized to either unfaded Heparin or Enoxaparin plus GPIIb / IIIa Inhibitor. "</seg>
<seg id="2913">"both in the Bivalirudin group, as well as in the associated with Hepmares, it came to women and patients over 65 years more frequently to unwanted events than with male or younger patients."</seg>
<seg id="2914">Heavy bleeding were defined according to the ACUITY and TIMI measures for heavy bleeding like in the footing of table 2.</seg>
<seg id="2915">Both light and heavy bleeding were significantly lower than in groups with Hepirudin alone than in groups with Heparin plus GPIIb / IIIa- Inhibitor (see table 2).</seg>
<seg id="2916">"an ACUITY heavy blood pressure has been defined as one of the following events: extraction, retrofitting, intraocular blood circulation of ≥ 4 g / dl without obvious blood point, reduction of hemoglobinds of ≥ 3 g / dl with a known blood point, implementation of blood products for transfusion."</seg>
<seg id="2917">"other, less frequently observed blood localization, who entered into more than 0,1% (occasionally), were" "other" "score, retroperitoneal, gastroitinal, ear, nose and neck."</seg>
<seg id="2918">The following information on side effects are based on the data of a clinical study with bivalirudin at 6000 patients who moved to PCI.</seg>
<seg id="2919">"both in the Bivalirudin group, as well as in the associated with Hepmares, it came to women and patients over 65 years more frequently to unwanted events than with male or younger patients."</seg>
<seg id="2920">Both light and heavy bleeding appeared under Bivalirudin significantly less often than in the comparison group among Heparin plus GPIIb / IIIa-Inhibitor.</seg>
<seg id="2921">"the following side effects, which are not listed above, were reported according to comprehensive application in practice and are sorted according to system organs in table 6."</seg>
<seg id="2922">"in case of overdose, the treatment with bivalirudin is to break down immediately and to monitor the patient with regard to signs of blood flow."</seg>
<seg id="2923">"Angiox contains Bivalirudin, a direct and specific Thrombininhibitor, which is located in the catalytic centre as well as in the Aniolympic region of Thrombin binds, regardless of whether Thrombin in the liquid phase or at Gerinnsel."</seg>
<seg id="2924">"the bond of bivalirudin at Thrombin, and thus its effect, is reversible because Thrombin its part the binding of Bivalirudin-Arg3-Pro4 slowly turned into regenerated the function of the active centre of Thrombin regenerates."</seg>
<seg id="2925">"in addition, due to Bivalirudin with serum of patients, in which it was found in the past to heparininduced thyrombh Syndrome (HIT / HITTS) was not induced."</seg>
<seg id="2926">"in healthy volunteers and in patients, Bivalirudin a dosis- and concentric-dependent effects that is covered by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if in the patients below a PCI was conducted, an additional bolus of 0.5mg / kg bivalirudin and the infusion for the duration of the surgery on 1,75mg / kg / h increases."</seg>
<seg id="2928">In the arm A of the ACUITY study was administered at the relevant guidelines for the treatment of akutem coronarsyndrome (ACS) in patients with instabiler Angina / Non-ST-Heber (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to receive a GPIIb / IIIa Inhibitor either before the start of the angiography (at the time of Randomisation) or at PCI.</seg>
<seg id="2930">"in the ACUITY study the characteristics of high-risk factors, which required an angiography within 72 hours, as well as the 3 treatments available."</seg>
<seg id="2931">"approximately 77% of patients had recurrent, 70%, dynamic EKG- changes or increased cardio biomarkers, 28% had diabetes and approximately 99% of all patients underwent up within 72 hours of an angiography."</seg>
<seg id="2932">"primary analysis and the results from the ACUITY study for the 30-Tage- and the 1- yearly point for the total population (ITT) and for the patients who received aspirin and Clopidogrel according to protocol (before the angiography or before the PCI), are shown in tables 7 and 8."</seg>
<seg id="2933">ACUITY study; 30-days and 1-year risk difference for the combined endent end point and its components for patients who received aspirin and Clopidogrel with protocol *</seg>
<seg id="2934">Patients who received aspirin and Clopidogrel with protocol received arm A arm B arm C UFH / Enox Bival B- A C- A Bival + GPIIb / IIIa risk diff.</seg>
<seg id="2935">"the frequency of bleeding both in the ACUITYPE as well as in the TIMI scale up to day 30 for the total population (ITT) and for patients who received aspirin and Clopidogrel according to protocol, is shown in chart 9."</seg>
<seg id="2936">Patients who received aspirin and Clopidogrel Total population (ITT) according to Protocol UFH / Enox Bival Bival (N = 4612)% (N = 4603)% (N = 4601)%%%%</seg>
<seg id="2937">* Clopidogrel before angiography or before PCI 1 A ACUITY heavy blood cell has been defined as one of the following events: extraction, retroperito-neal, intraocular blood pressure of ≥ 4 g / dl without obvious blood point, reintegration of hemogybinds, due to a bloodation, use of blood products to transfusion. "</seg>
<seg id="2938">"the 30-day results, based on four-fold and triple endpoints of one randomised double blind study with over 6,000 patients who are subjected to one PCI (replace-2), are shown in chart 10."</seg>
<seg id="2939">Clinical trials with a small number of patients delivered a limited information on the application of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacokinetic properties of Bivalirudin were evaluated in patients who are underlined up a perkutant coronary intervention (PCI) as well as with patients with ACS.</seg>
<seg id="2941">It is expected that Bivalirudin as Peptid has a catabolism into its amino acids with subsequent revaluation of the amino acids in the body pool.</seg>
<seg id="2942">"primary Metabolit, which is resulting from the split of the Arg3-pro4-binding sequence by Thrombin, is not effective because of the loss of its Affinity to the catalytic centre of Thrombin."</seg>
<seg id="2943">The Elimination takes place in patients with normal kidney function after a process first order with a temporal half time of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on safety issues, toxicity, toxicity, genesis, genotoxicity, or Reproduction stools, the preclinical data can be seen no particular hazards for man."</seg>
<seg id="2945">The toxicity in animals in repetitive or continuous exposure (1 day to 4 weeks at an exposure to 10-ply the clinical steady-state-plasma-concentration) is limited to overthrown pharmacological effects.</seg>
<seg id="2946">Side effects as a result of a longer-term physiological burden as a reaction to a non-homostatic coagulation have been compared to short-homeostatic coagulation compared to short-term exposure compared with very much higher dosage, not observed. "</seg>
<seg id="2947">"if the manufacturing of the ready-made solution 17 is not carried out under the controlled and validated conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox is a freezer powder in individual dose of type-1 glass to 10 ml that is sealed with a butylgummistplate and sealed a cap of preset aluminium.</seg>
<seg id="2949">5 ml steriles water for injecting angiox are given and lightweight until all has been completely dissolved and the solution is clear.</seg>
<seg id="2950">"5 ml are taken from the carrier bag, and further diluted with 5% of glucosm solution for injecting or with 9 mg / ml (0,9%) sodium inchloride solution for injection in a total volume of 50 ml to obtain an end-concentration of 5mg / ml bivalirudin."</seg>
<seg id="2951">"the holder of permission for the office is right to include the studies and Pharmacovigilance activities that are agreed in the Pharmacovigilance plan, as well as in version 4 of the risk management plan (RMP), as well as any subsequent changes of the RMP, which was agreed by CHMP."</seg>
<seg id="2952">"accordingly, the CHMP guideline for the risk management systems for Humancision is to be submitted to the next periods, simultaneously with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast pain due to a heart disease (acute coronary - ACS) • patients who are operated for the treatment of closures in the blood vessels (angioplasty and / or or perkutane Koronarangioplasty - PCI).</seg>
<seg id="2954">• You are pregnant or suspect that you might be pregnant • you intend to get pregnant • you are currently silent.</seg>
<seg id="2955">"there were no studies of the effects on the traffic and the ability to operate machines, but you know that the effects of this drug are only at short notice."</seg>
<seg id="2956">"should perform a bloodation, the treatment with angiox is broken. • At the beginning of the injection or infusion, you will inform your doctor about the possible signs of an allergic reaction."</seg>
<seg id="2957">"such reactions are rarely (they appear in less than 1 of 1000 treated patients). • A particularly careful control is done when you provide a radiotherapy for the vessels that you get the heart with blood (or gamma-brachytherapy). • The dose that you will receive from your body weight, and of the kind of therapy you will receive."</seg>
<seg id="2958">• 0.1 mg / kg body weight as injection followed by an infusion (trough solution) with 0.25 mg / kg body weight means a tenth part of a milligrams of weight; 0,25 mg / kg body weight per hour means a quarter of a milligrams of drug means for each kilograms of the drug per hour).</seg>
<seg id="2959">Probable when angiox is given in combination with other gerinnate or antithrombotic medication is given (see Section 2 "" using Angiox with other medicines ")."</seg>
<seg id="2960">These are occasional side effects (with less than 1 of 100 treated patients). • Thrombose (bloodine) which could lead to serious complications such as a heart attack.</seg>
<seg id="2961">"this is an occasional effect (with less than 1 of 100 treated patients). • pains, blood flow and hypertension at the point of point (after a PCI treatment)."</seg>
<seg id="2962">Please inform your doctor if one of the listed side effects you explicitly affected or you notice side effects that are not indicated in this usage information.</seg>
<seg id="2963">Angiox may not be used on the label on the label and the set-carton after "</seg>
<seg id="2964">Polska The Medicines Company UK Ltd Tel.: + 800 843 633 26 lub + 41 61 564 1320 Properties: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"Apidra is used for treatment of adults, young people and children from six years with diabetes that require a treatment with insulin."</seg>
<seg id="2966">"Apidra is subkutan (under the skin) into the abdominal wall, the thigh or the upper arm or as permanent infusion with an insulin pump."</seg>
<seg id="2967">Diabetes is a disease in which the body does not have sufficient insulin to control the glucosespiegels (sugar) in the blood or the insulin do not work effectively.</seg>
<seg id="2968">"Insulinglulisin differs very low due to humaninsulin, and the change means that it works faster and a shorter act of activity than a short-effective humaninsulin."</seg>
<seg id="2969">"Apidra was produced in the application in combination with a long-effective insulin in patients with type-1 diabetes, where the body is not able to produce a insulin in two studies with a total of 1 million adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">"in type-2 diabetes, which is not effective in type-2 diabetes, Apidra was evaluated in a study with 878 adults."</seg>
<seg id="2971">The main indiator for the effectiveness was the change in concentration of substance glycoylified hemoglobin (HbA1c) in the blood which shows how well the blood sugar is set.</seg>
<seg id="2972">"in the first study with adults with type-1 diabetes, after six months, a reduction of 0.14% (7.4%) compared to a reduction of 0.14% at Insulinlisper."</seg>
<seg id="2973">In adults with type-2 diabetes the reduction of HbA1c concentration amounted to 0.46% after six months with Apidra compared to 0.30% in humanitarian crisis.</seg>
<seg id="2974">"Apidra may not be used in patients, which may possibly be excessive (allergic) against insulinglulisin or one of the other components, or in patients who already suffer from a hypoglycemic."</seg>
<seg id="2975">The doses of Apidra may need to be adjusted if it is administered together with a number of other medicines that may affect blood vessels.</seg>
<seg id="2976">"September 2004, the European Commission entitled Sanofi-Aventis Deutschland GmbH is a licence for the Independence of Apidra in the entire European Union."</seg>
<seg id="2977">Apidra is as subtle injections either in the area of the abdominal ceiling or the Deltamuskels apply or subkutan by continuous infusion in the field of pancreams.</seg>
<seg id="2978">"due to the reduced gluten-dimensioned capacity and the decreased incidence of insulin, the islanders can be set down in patients with a limitation of the liver function."</seg>
<seg id="2979">"any change of its active strength, the brand (Her-), the Insulintyps (normal, NPH, zinkverdelayed etc.), the type of insulin (animal insulin) and / or the manufacturing method can draw a change in the insulin needs."</seg>
<seg id="2980">"3 A insufficient dosage or disruption of treatment, especially in patients with a insulinated diabetes, can lead to a hyperglycemic and a diabetic Ketoazibox; these states are potential life-threatening."</seg>
<seg id="2981">The conversion of a patient to another insulin type or a insulin of another manufacturer should be carried out under strict medical supervision and may make a change of dosage required.</seg>
<seg id="2982">The date of appearance of a hypoglycemic depends on the efficacy profile of the used insulin and can therefore change when changing the treatment schemas.</seg>
<seg id="2983">"to the substances that can increase blood sugar and reinforce the inclination to hypoglycemic, fioxetine, Monoamin-Oxidase, Propoxypha, Propoxypha, Salizylate and Sulphamide antibiotics."</seg>
<seg id="2984">"in addition, under the effect of sympathies such as Betablockers, Clonidin, Guanethidin and reserve the symptoms of adrenagen countering, be weakened or missing."</seg>
<seg id="2985">"experimental studies for reproduction stools showed no differences between Insu- linglulisin and humaninsulin in terms of pregnancy, the embryonic / fetal development, the birth or the postnatal development (see section 5.3)."</seg>
<seg id="2986">"it is not known whether Insulinglulisenters into human breast milk, but generally the insulin occurs neither into the mother's milk, nor will it be resorated to oraler."</seg>
<seg id="2987">"following are the clinical trials listed from clinical trials listed, grouped according to system organs and sorted according to the frequency of their appearance (very often: ≥ 1 / 1,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000); not known (frequency on the basis of availability)."</seg>
<seg id="2988">"cold - welding, cool and blasse skin, fatigue, nervousness or trekking, confusion, concentrations, confusion, concentration of vision, headache, headache, evil and heart cloves."</seg>
<seg id="2989">"Lipodystrophy Wiring to change the injecting position within the injection range, can occur in the result a lipodystrophy to the injection point."</seg>
<seg id="2990">Heavy hypoglycemic bodies with consciousness can be given by means of intra-muscular or substitutes injection of glucagon (0.5 to 1 mg) which is given by a corresponding person or by intravenous gift of glucose by a doctor.</seg>
<seg id="2991">"according to a glucist objects, the patient should be monitored in a hospital to determine the judgment - cause for the heavy hypoglycemic species and to avoid similar episodes."</seg>
<seg id="2992">Insulin insect the blood sugar levels by the stimulation of peripheral glucosity (especially by skeleton muscles and fat) as well as through the imitation of glucosm production in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that at subtle Gatheringlulisin the action occurs faster and the active duration is shorter than at hu- manem Reginsulin.</seg>
<seg id="2994">"in a study with 18 male persons aged 21 to 50 years with type-1 diabetes, TUS showed Insulinglulisin in the therapist range of 0.075 to 0.15 E / kg a disproportionate rise of glucant effect, just as human insulin."</seg>
<seg id="2995">Insulinglulisin has a twice as rapid impact as normal human insulin and achieves the complete glucant effect approximately 2 hours earlier as humaninsulin.</seg>
<seg id="2996">"from the data, it was visible that at an application of Insulingluliscent in 2 minutes before meal a comparable postpale glycemic control is given, 30 minutes before meal is given."</seg>
<seg id="2997">"was given Insulinglulisin 2 minutes before meal, became a better postprandious control than with humane Reginsulin, which was 2 minutes before meal."</seg>
<seg id="2998">"is used Insulinglulisin 15 minutes after the beginning of the meal, a comparable glycemic control such as with humanitarian crisis insulin, which is given 2 rent before meal (see picture 1)."</seg>
<seg id="2999">"Insulinglulisin at Gabe 2 minutes (GLULISIN - previously) before the beginning of the meal, the 30 minutes (NORMAL - 30 min.) before the beginning of the meal (picture 1A), which was given 2 minutes (NORMAL - previously) before a meal (figure 1B)."</seg>
<seg id="3000">"Insulinglulisin at Gabe 15 minutes (GLULISIN - after the beginning of the meal compared to humane nor- malinsulin, which was 2 minutes (NORMAL - previously) before the beginning of the meal (figure 1C)."</seg>
</doc>
</tstset>
